Neuro-Endocrine Activation and Inhibition in Heart Failure by Cleland, John George Franklin
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
NEURO-* ENDOCRINE ACTIVATION AND INHIBITION IN HEART 
FAILURE
JOHN GEORGE FRANKLIN CLELAND M.B.Ch.B., M.R.C.P. (UK) 
VOLUME ONE
(Containing the Historical Introduction and Results) 
THESIS FOR DOCTOR OF MEDICINE
SUBMITTED TO THE UNIVERSITY OF GLASGOW
FROM THE DEPARTMENT OF CARDIOLOGY, WESTERN INFIRMARY 
GLASGOW
SUBMITTED IN MARCH 1991.
COPYRIGHT:- JOHN G.F. CLELAND 1991
intro:1
ProQuest Number: 10987072
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10987072
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
PUBLICATIONS BASED ON MATERIAL WHICH FORMS THIS THESIS
1. Cleland JGF, Dargie HJ, Ball SG, Robertson JIS. The 
use of captopril in the management of cardiac failure. 
Scot Med J. 1984; 29: 129-130
2. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson 
JIS, Morton JJ, East BW, Robertson I, Murray GD, 
Gillen G. Captopril in heart failure. A double blind 
controlled trial. Br Heart J 1984; 52: 530-535.
3. Cleland JGF, Dargie HJ, Roberston JIS, Ball SG, 
Hodsman GP. Renin and Angiotensin responses to posture 
and exercise in elderly patients with heart failure. 
Eur Heart J. 1984; 3: (suppl E) 9-11.
4. Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie 
H: Angiotensin II levels, haemodynamics and 
sympathoadrenal function after low-dose captopril in 
heart failure. Am J Med 1984; 77: 880-886.
5. Cleland JGF, Dargie HJ, Robertson JIS. Angiotensin 
converting enzyme inhibition in heart failure. Br J 
Clin Pharm. 1984; 18: 157s-160s.
6. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP,
Morton JJ, East BW, Robertson I, Ford I, Robertson 
JIS: Effects of enalapril in heart failure: a double
blind study of effects on exercise performance, renal 
function, hormones, and metabolic state. Br Heart J 
1985; 54: 305-312.
7. Cleland JGF, Dargie HJ, East BW, Robertson I, Hodsman 
GP, Ball SG, Gillen G, Robertson JIS, Morton JJ. Total 
body and serum electrolyte composition in heart 
failure: the effects of captopril. Eur Heart J 1985; 
6: 681-688.
8. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton
JJ, Robertson JIS, Ford I: Severe hypotension after
first dose of enalapril in heart failure. Br Med J
1985; 291: 1309-1312.
9. Richards AM, Cleland JGF, Tonolo G, McIntyre GD,
Leckie BJ, Dargie HJ, Ball SG, Robertson JIS: Plasma
atrial natriuretic peptide in cardiac impairment. Br 
Med J 1986; 293: 409-412.
10. Cleland JGF, Dargie HJ, Gillen G, Roberston I, East
BW, Ball SG, Morton JJ, Robertson JIS. Captopril in
heart failure a double-blind study of the effects on 
renal function. J Cardiovasc Pharm. 1986; 8: 700-706.
11. Cleland JGF, Dargie HJ, Henderson E. Arrhythmias in
heart failure: effects of amiodarone. Br J Clin
Practice. 1986; 40: 31-34.
intro:2
12.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Cleland JGF, Pettigrew A, Dargie HJ, Gillen G, East 
BW, Robertson JIS, Robertson I. The effect of 
captopril on serum digoxin and urinary digoxin 
clearance in heart failure. Am Heart J 1986; 112: 130- 
135.
Richards AM, Tonolo G, Cleland JGF, McIntyre GD, 
Leckie BJ, Dargie HJ, Ball SG, Robertson JIS. Plasma 
atrial natriuretic peptide concentrations during 
exercise in sodium replete and deplete normal man. 
Clin Sci 1987; 72: 159-164.
Cleland JGF, Dargie HJ, Robertson I, Robertson JIS, 
East BW: Total body electrolyte composition in
patients with heart failure: a comparison with normal 
subjects and patients with untreated hypertension. Br 
Heart J 1987; 58: 23 0-8.
Cleland JGF, Dargie HJ. Angiotensin converting enzyme 
inhibitors: their current role in thhe management of 
heart failure. Cardiology in Practice 1987; 5: 18-32.
Cleland JGF, Dargie HJ. Ventricular dysrhythmias
during exercise in patients with heart failure: the 
effect of amiodarone. Eur Heart J 1987; 8: 65-69.
Cleland JG, Dargie HJ: Heart failure, renal function
and angiotensin converting enzyme inhibitors. Kidney 
International 1987; 31(Suppl. 20): S-220-S-228.
Dargie HJ, Cleland JGF, Leckie BJ, Inglis CG, East BW, 
Ford I: Relation of arrhythmias and electrolyte
abnormalities to survival in patients with severe
chronic heart failure. Circulation 1987; 75 (Suppl
IV): IV-98.
Cleland JGF, Dargie HJ, Findlay IN, Wilson JT.
Clinical haemodynamic and anti-arrhythmic effects of 
long-term treatment with amiodarone of patients in 
heart failure. J. 1987; 57: 436-445.
Cleland JGF, Dargie HJ, Ford I. Mortality in heart 
failure: clinical variables of prognostic value. Br 
Heart J 1987; 58: 572-582
Cleland JGF, Dargie HJ. Arrhythmias, catecholamines 
and electrolytes. Am J Cardiol 1988; 62: 55-60.
Cleland JGF, Gillen G, Dargie HJ: The effects of
frusemide and angiotensin-converting enzyme inhibitors 
and their combination on cardiac and renal 
haemodynamics in heart failure. Eur Heart J 1988; 9: 
132-141.
Cleland JGF. Neuroendocrine activation in heart 
failure. Curr Opinion in Cardiology 1989; 4: S39-S45.
Cleland JGF. ACE inhibitors in mild heart failure: 
first-line or second line therapy. Eur Heart J 1990; 
11: 51-57.
intro:3
TABLE OF CONTENTS
PART ONE: HISTORICAL INTRODUCTION
CHAPTER ONE PAGE
HISTORICAL PERSPECTIVES
section i) renin and angiotensin 1
section ii) aldosterone 3
section iii) angiotensin-converting
enzyme inhibitors 3
section iv) renin inhibitors 4
section v) summary 5
CHAPTER TWO
PHYSIOLOGICAL CONTROL OF THE COMPONENTS OF THE RENIN- 
ANGIOTENSIN-ALDOSTERONE SYSTEM
section i) renin 6
section ii) angiotensinogen 22
section iii) angiotensin I 22
section iv) angiotensin-converting enzyme 23
section v) angiotensin II 23
section vi) aldosterone 33
section vii) summary 35
CHAPTER THREE
ANIMAL MODELS OF NEUROENDOCRINE ACTIVATION IN HEART 
FAILURE
section i) introduction 36
section ii) renin-angiotensin-aldosterone
system 37
section iii) atrial natriuretic peptide 42
section iv) anti-diuretic hormone 43
section v) sympathetic nervous system 43
section vi) conclusions 45
CHAPTER FOUR
NEUROENDOCRINE ACTIVATION IN HUMAN HEART FAILURE
46
CHAPTER FIVE
CARDIOVASCULAR ADAPTATIONS IN HEART FAILURE
section i) preload 50
section ii) afterload 50
section iii) Frank-Starling principle 52
section iv) extrinsic factors affecting
myocardial contractility 54
section v) heart rate 56
section vi) myocardial hypertrophy 57
section vii) regional blood flow 58
section viii)summary 64
intro:4
CHAPTER SIX
VASCULAR TONE IN HEART FAILURE: THE NEUROENDOCRINE-
THERAPEUTIC INTERFACE
section i) introduction 66
section ii) historical perspectives 67
section iii) "direcf'-acting vasodilators 68
section iv) vasodilators acting through
inhibition or activation
neuroendocrine systems 71
section v) conclusion 76
PART TWO •• METHODS AND RESULTS
CHAPTER SEVEN
METHODS
section i) assessment of symptoms 77
section ii) measurement of blood pressure
and heart rate 78
section iii) 12-lead electrocardiogram 79
section iv) exercise testing in
heart failure 80
section v) assessment of left ventricular
function 82
section vi) ambulatory ECG monitoring 86
section vii) measurement of renal function 87
section viii)plasma volumes 91
section ix) whole body composition 91
section x) testing the autonomic
nervous system 96
section xi) biochemistry 98
CHAPTER EIGHT
THE METABOLIC CONSEQUENCES OF HEART FAILURE AND THE 
INFLUENCE OF NEUROENDOCRINE ACTIVATION
section i) introduction 108
section ii) patients 110
section iii) methods 111
section iv) statistical analysis 111
section v) results 112
CHAPTER NINE
COMPARISON OF AUTONOMIC AND NEUROENDOCRINE FUNCTION IN 
NORMAL SUBJECTS AND PATIENTS TREATED FOR CHRONIC HEART
FAILURE.
section i) introduction 117
section ii) patients 118
section iii) methods 119
section iv) statistical analysis 12 0
section v) results 121
intro:5
CHAPTER TEN
RELATION OF ARRHYTHMIAS, ELECTROLYTES AND 
NEUROENDOCRINE ABNORMALITIES TO SURVIVAL IN PATIENTS 
WITH SEVERE CHRONIC HEART FAILURE
section i) introduction 125
section ii) patients 12 6
section iii) methods 128
section iv) statistical analysis 130
section v) results 131
CHAPTER ELEVEN
HAEMODYNAMICS, ANGIOTENSIN II LEVELS AND 
SYMPATHOADRENAL FUNCTION AFTER LOW-DOSE CAPTOPRIL IN 
PATIENTS WITH SEVERE HEART FAILURE.
section i) introduction 136
section ii) patients 137
section iii) methods 137
section iv) statistical analysis 138
section v) results 139
CHAPTER TWELVE
SEVERE HYPOTENSION AFTER FIRST DOSE OF ENALAPRIL IN 
HEART FAILURE
section i) introduction 142
section ii) patients 142
section iii) methods 142
section iv) statistical analysis 144
section v) results 144
CHAPTER THIRTEEN
OBSERVATIONS ON THE ORAL DOSE OF CAPTOPRIL REQUIRED 
FOR HAEMODYNAMIC EFFECT
section i) introduction 149
section ii) patients 149
section iii) methods 150
section iv) results 150
CHAPTER FOURTEEN
CAPTOPRIL IN HEART FAILURE: 
TRIAL
section i) 
section ii) 
section iii) 
section iv) 
section v)
A DOUBLE-BLIND CONTROLLED
introduction
patients
methods
statistical analysis 
results
152
153 
153 
155 
157
intro:6
CHAPTER FIFTEEN
EFFECTS OF ENALAPRIL IN HEART FAILURE: A DOUBLE-BLIND 
STUDY OF THE EFFECTS ON EXERCISE PERFORMANCE, RENAL 
FUNCTION, HORMONES AND METABOLIC STATE.
section i) introduction 163
section ii) patients 163
section iii) methods 164
section iv) statistical analysis 166
section v) results 167
CHAPTER SIXTEEN
THE EFFECTS OF FRUSEMIDE AND ANGIOTENSIN-CONVERTING 
ENZYME INHIBITORS AND THEIR COMBINATION ON CARDIAC AND 
RENAL HAEMODYNAMICS IN HEART FAILURE.
section i) introduction 176
section ii) patients 177
section iii) study design and methods 179
section iv) statistical analysis 181
section v) results 181
CHAPTER SEVENTEEN
THE EFFECTS OF CAPTOPRIL ON SERUM DIGOXIN AND URINARY 
UREA AND DIGOXIN CLEARANCES IN PATIENTS WITH 
CONGESTIVE HEART FAILURE
section i) introduction 185
section ii) patients 186
section iii) methods 186
section iv) statistical analysis 186
section v) results 187
CHAPTER EIGHTEEN
THE EFFECTS OF SHORT-TERM CONVERTING-ENZYME INHIBITION 
ON RENAL TUBULAR FUNCTION AND ATRIAL NATRIURETIC
PEPTIDE.
section i) introduction 188
section ii) patients 188
section iii) study design and methods 189
section iv) statistical analysis 190
section v) results 191
CHAPTER NINETEEN
THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 
IN PATIENTS WITH HEART FAILURE AND ANGINA PECTORIS
section i) introduction
section ii) patients
section iii) study design and methods
section iv) statistical analysis
section v) results
193
194
195
197
198
intro:7
CHAPTER TWENTY
MORTALITY IN HEART FAILURE: CLINICAL VARIABLES OF
PROGNOSTIC VALUE AND THE IMPACT OF ANGIOTENSIN
CONVERTING INHIBITORS
section i) introduction 2 02
section ii) patients 203
section iii) study design and methods 204
section iv) statistical analysis 206
section v) results 206
PART THREE: DISCUSSION AND CONCLUSIONS
CHAPTER TWENTY ONE
NEUROENDOCRINE ACTIVATION IN HEART FAILURE
section i) renin and angiotensin II 213
section ii) aldosterone 218
section iii) the sympathetic nervous system 219
section iv) anti-diuretic hormone 220
section v) atrial natriuretic peptide 223
section vi) neuroendocrine effects of diuretics
in heart failure 224
section vii) neuroendocrine response
to standing 225
section viii)neuroendocrine response
to exercise 226
CHAPTER TWENTY TWO
THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
ON NEUROENDOCRINE ACTIVATION IN HEART FAILURE.
section
section
section
section
section
section
section
section
section
section
section
i)
ii)
iii)
iv)
v)
vi)
vii)
plasma active renin 
concentration 230
angiotensinogen 230
angiotensin I 231
angiotensin-converting enzyme 231 
angiotensin II 232
aldosterone 232
section x)
section xi)
the sympathetic nervous system 233
viii)anti-diuretic hormone 234
ix) interaction of diuretics and converting 
enzyme inhibitors on neuroendocrine 
systems in heart failure 235
effects of angiotensin converting
enzyme inhibitors on the neuroendocrine 
response to changes in posture 
heart failure 236
effects of angiotensin converting
enzyme inhibitors on the neuroendocrine 
response to exercise 
in heart failure 237
atrial natriuretic peptide 239xii)
xiii)summary
CHAPTER TWENTY THREE
METABOLIC CHANGES IN HEART FAILURE 
section i) serum sodium 
section ii) serum potassium
239
241
243
intro:8
section iii) serum bicarbonate 245
section iv) serum chloride 246
section v) serum calcium and phosphate 246
section vi) blood glucose 246
section vii) serum urate 247
section viii)total body sodium 247
section ix) total body potassium 248
section x) total body nitrogen,
calcium and phosphorus 251
section xi) total body chlorine 252
section xii) total body oxygen 252
section xiii)summary 253
CHAPTER TWENTY FOUR
METABOLIC CHANGES IN HEART FAILURE: THE CONSEQUENCES
OF ANGIOTENSIN-•CONVERTING ENZYME INHIBITION
section i) serum sodium 255
section ii) serum potassium 257
section iii) serum bicarbonate 258
section iv) serum chloride 258
section v) serum calcium and phosphate 259
section vi) blood glucose 259
section vii) serum urate 259
section viii)total body sodium 259
section ix) total body potassium 261
section x) total body nitrogen,
calcium and phosphorus 263
section xi) total body chlorine 264
section xii) total body oxygen 264
section xiii)summary 264
CHAPTER TWENTY FIVE
section
i)
ii)
RENAL FUNCTION IN HEART FAILURE: THE EFFECTS OF
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 
section  the renal haemodynamic consequences of 
cardiac failure 2 66
the effect of angiotensin converting 
enzyme inhibitors on renal function in 
heart failure 2 68
section iii) acute studies on the renal haemodynamic 
effects of angiotensin converting 
enzyme inhibitors 2 68
medium-term studies on the effects of 
ACE inhibitors on renal function in 
heart failure 2 69
chronic effects of angiotensin 
converting enzyme inhibitors on renal 
haemodynamics in heart failure 272 
interaction of angiotensin converting 
enzyme inhibitors and diuretics on 
renal haemodynamics 
in heart failure 275
long-term effects of angiotensin 
converting enzyme inhibition on 
renal sodium handling 
in heart failure 278
section iv)
section v)
section vi)
section vii)
intro:9
section viii influence of angiotensin converting 
enzyme inhibitors on renal tubular
function in heart failure 279
section ix) effects of angiotensin converting
enzyme inhibition on 
renal digoxin handling 282
section x) effects of angiotensin converting
enzyme inhibitors on the distribution 
of intra-renal blood flow in patients 
with heart failure 283
section xi) summary 284
CHAPTER TWENTY SIX
AUTONOMIC FUNCTION IN HEART FAILURE: THE EFFECTS OF 
ANGIOTENSIN CONVERTING ENZYME INHIBITION
section i) autonomic dysfunction 
in heart failure 286
section ii) tests reflecting 
parasympathetic activity 289
section iii) tests reflecting 
sympathetic activity 291
section iv) effects of enalapril therapy 293
section v) effects of enalapril on QTc 298
section vi) summary 299
CHAPTER TWENTY SEVEN
SYMPTOMS
section i) symptoms in heart failure 300
section ii) the effect of angiotensin converting
enzyme inhibitors in 
patients with heart failure 306
CHAPTER TWENTY EIGHT
EXERCISE PERFORMANCE 311
CHAPTER TWENTY NINE
ARRHYTHMIAS, HEART FAILURE AND ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS
section i) introduction 319
section ii) survival in heart failure: the 
death
mode of 
320
section iii) prognosis in heart failure 322
section iv) factors predicting prognosis in heart
failure 323
section v) effect of angiotensin converting enzyme
inhibitors on arrhythmias 328
section vi) effect of treatment on 
prognosis 330
section vii) summary 333
intro:10
CHAPTER THIRTY
ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ISCHAEMIC
HEART DISEASE
section i) chronic heart failure 335
section ii) angina 335
section iii) unstable angina 340
section iv) acute myocardial infarction 340
section v) cardiogenic shock 344
section vi) conclusions 344
CHAPTER 31
CONCLUSION 346
intro:11
LIST OF TABLES
TABLES CHAPTER 7
7.1 New York Heart Association Functional Classification
7.2 Visual Analogue Scores
7.3 Treadmill Protocols
7.4 Reactions Examined During In-Vivo Neutron Activation 
Analysis
TABLES CHAPTER 8
8.1 Comparison of Total Body Potassium in Normal Subjects 
and in Patients with Hypertension and Heart Failure
8.2 Comparison of Measurements in Patients with 
Hypertension and Heart Failure
8.3 Total Body Oxygen in Patients with Hypertension and 
Heart Failure
8.4 Comparison of Measurements in Patients with Heart 
Failure and with Normal or High Renin Concentrations
TABLES CHAPTER 9
9.1 Neuro-endocrine Effects of Dynamic Exercise. Resting 
Values Before and After Diuretic. Comparison to Normal 
Subjects
9.2 Neuro-endocrine Effects of Dynamic Exercise. Light 
Exercise. Comparison to Normal Subjects
9.3 Neuro-endocrine Effects of Dynamic Exercise. Strenuous 
Exercise. Comparison to Normal Subjects
TABLES CHAPTER 10
10.1 Pre-Treatment Comparison of Patients Subsequently 
Receiving Amiodarone or Not
10.2 Pre-Treatment Comparison of Patients Subsequently 
Receiving ACE Inhibitors or Not
10.3 Univariate Analysis of Factors Related to Survival
TABLES CHAPTER 11
11.1 Clinical Characteristics
11.2 Haemodynamic Data
TABLES CHAPTER 12
12.1 Comparison of Patients With and Without Hypotension on 
First Administration of Enalapril
intro:12
12.2 Plasma Hormone Concentrations in Case 2 Before and 
After Enalapril
TABLES CHAPTER 13
13.1 Haemodynamic and Neuro-endocrine Effects of Captopril 
in a Patient (1) Developing Syncope after 3mg of 
Captopril
13.2 Haemodynamic and Neuro-endocrine Effects of Captopril 
in a Patient (2) Developing Syncope after 3mg of 
Captopril
TABLES CHAPTER 14
14.1 Clinical Effects of Captopril Compared to Placebo
14.2 The Effects of Captopril on Cardiac Function
14.3 Biochemistry and Total Body composition. Captopril v 
Placebo
14.4 Renal function - The Effects of Captopril
TABLES CHAPTER 15
15.1 Clinical Effects of Enalapril v Placebo.
15.2 Effects of Enalapril on Cardiac Function
15.3 Autonomic Function Tests. Enalapril v Placebo.
15.4 Serum Biochemistry. Enalapril v Placebo.
15.5 Neuro-endocrine Effects of Enalapril Before and After 
Treatment with Diuretic and Digoxin.
15.6 Neuro-endocrine Effects of Enalapril During Standing 
and Exercise
15.7 Effects of Enalapril on Total Body Elemental 
Composition
15.8 Effects of Chronic Enalapril Therapy on Renal Function
15.9 Comparative Effects of Short- and Long-Term
Administration of Enalapril on Renal Function in 
Patients with Heart Failure
TABLES CHAPTER 16
16.1 Comparison of the Effects of Frusemide, Enalapril and 
their Combination on Neuroendocrine Variables.
TABLES CHAPTER 17
17.1 Effects of Captopril on Urinary Digoxin Clearance
intro:13
TABLES CHAPTER 18
18.1 Effects of Short Term Enalapril on Serum electrolytes.
18.2 Effects of Short Term Enalapril on Urine Composition.
TABLES CHAPTER 19
19.1 Treadmill Exercise Testing. Captopril v Placebo
19.2 Supine Bicycle Exercise. Captopril v Placebo
19.3 Serum Biochemistry and Neuro-endocrine Effects of 
Captopril in Patients with Heart failure and Angina
19.4 Ambulatory ECG Monitoring
TABLES CHAPTER 2 0
20.1 Comparison of Amiodarone and Non-Amiodarone Treated 
Groups
20.2 Comparison of ACE Inhibitor and Non-ACE Inhibitor 
Treated Groups
20.3 Comparison of Digoxin and Non-Digoxin Treated Groups
20.4 Predictors of Prognosis on Univariate Analysis
intro:14
LIST OF FIGURES
FIGURES CHAPTER 8
8.1 Relation Between Plasma Active Renin Concentration and 
Total Body Potassium in Patients with Heart Failure
8.2 Relation Between Plasma Active Renin Concentration and 
Mean Blood Pressure in Patients with Heart Failure
8.3 Relation Between Plasma Active Renin Concentration and 
Serum Sodium in Patients with Heart Failure
8.4 Relation Between Plasma Active Renin Concentration and 
Serum Potassium in Patients with Heart Failure
8.5 Relation Between Total Body Potassium and Serum 
Potassium in Patients with Heart Failure
FIGURES CHAPTER 9
9.1 Tests of Parasympathetic Reflex Function, Comparison 
of Normal Subjects and Patients with Heart Failure
FIGURES CHAPTER 10
10.1 Cumulative Proportion Surviving. Ventricular 
Extrasystoles
10.2 Cumulative Proportion Surviving. Exercise Time
10.3 Cumulative Proportion Surviving. Serum Sodium
10.4 Cumulative Proportion Surviving. Plasma Noradrenaline
10.5 Cumulative Proportion Surviving. Amiodarone Treatment
10.6 Cumulative Proportion Surviving. Plasma Active Renin 
Concentration
10.7 Cumulative Proportion Surviving. Fractional Shortening
10.8 Cumulative Proportion Surviving. Serum Potassium
10.9 Correlations Between Ventricular Extrasystole 
Frequency and Measures of Neuro-endocrine Activity, 
Arterial Pressure, Exercise Time, and Serum 
Electrolytes.
10.10 Relationship Between Plasma Active Renin Concentration 
and Plasma Noradrenaline
10.11 Correlations Between Plasma Active Renin Concentration 
and Plasma Noradrenaline against Serum Electrolytes, 
Arterial Pressure and Exercise Time.
10.12 Correlations Between Serum Electrolytes and Arterial 
Pressure and Total Body Electrolytes
intro:15
10.13 Relationship Between Plasma Active Renin Concentration 
and Total Body Potassium
10.14 Relationship Between Ventricular Extrasystoles and 
Total Body Potassium
10.15 Cumulative Proportion Surviving. ACE Inhibitor 
Treatment
FIGURES CHAPTER 11
11.1 Individual Responses of Mean Arterial Pressure, 
Pulmonary Artery Diastolic Pressure and Heart Rate to 
Acute Administration of Captopril
11.2 Acute Haemodynamic Response to Captopril in Patient 3.
11.3 Individual Responses in Plasma Concentrations of 
Angiotensin II, Renin, Plasma Noradrenaline and 
Adrenaline to Acute Administration of Captopril
11.4 Plasma Concentrations of Angiotensin II, Renin, Plasma 
Noradrenaline and Adrenaline to Acute Administration 
of Captopril in Patient 3
FIGURES CHAPTER 12
12.1 Relationship Between Log Plasma Angiotensin II and 
Fall in Mean Blood Pressure after Enalapril
12.2 Relationship Between Fall in Mean Blood Pressure and 
fall in heart rate after Enalapril
12.3 Relationship Between Initial Mean Blood Pressure 
Change in Mean Blood Pressure after Enalapril
12.4 Relationship Between Serum Sodium and Change in Mean 
Blood Pressure after Enalapril
12.5 Relationship Between Frusemide Dose and Change in Mean 
Blood Pressure after Enalapril
12.6 Relationship Between Creatinine/Urea Ratio and Change 
in Mean Blood Pressure after Enalapril
12.7 (Case 3) Changes in Systolic and Diastolic Blood 
Pressure and Heart Rate after 5mg of Enalapril
FIGURES CHAPTER 14
14.1 Individual and Mean Changes in Glomerular Filtration 
Rate, Effective Renal Plasma Flow, Renal Blood Flow 
and Mean Blood Pressure with Captopril Therapy.
14.2 Individual and Mean Changes in Serum Creatinine and 
Urea, Filtration Fraction and Reno-vascular Resistance
intro:16
with Captopril Therapy.
14.3 Poor Relationship Between Percentage Change in Mean 
Blood Pressure and Percentage Change in Glomerular 
Filtration Rate with Captopril Therapy.
14.4 Relationship Between Percentage Change in Effective 
Renal Plasma Flow and Percentage Change in Glomerular 
Filtration Rate During Treatment with Captopril 
Therapy.
FIGURES CHAPTER 15
15.1 New York Heart Association Functional Class at 
Baseline and After Enalapril or Placebo.
15.2 Relationship Between the Increase in Serum Potassium 
on Enalapril and the Baseline Plasma Renin 
Concentration
15.3 Relationship Between the Increase in Total Body 
Potassium on Enalapril and the Baseline Plasma Renin 
Concentration
15.4 Relationship of the Percentage Change in Mean Blood 
Pressure and the Percentage Fall in Glomerular 
Filtration Rate During Treatment with Enalapril
15.5 Relationship of the Decline in Glomerular Filtration 
Rate on Enalapril to the Initial Plasma Angiotensin II 
concentration
15.6 Effects of Enalapril on Renal Function
FIGURES CHAPTER 16
16.1 Diagrammatic Outline of the Study.
16.2 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Systemic Haemodynamics.
16.3 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Renal Function.
16.4 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Haematocrit and Blood Volume.
16.5 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Serum Biochemistry.
16.6 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Urine Volume and Biochemistry.
FIGURES CHAPTER 17
17.1 Correlation of Creatinine Clearance and Digoxin 
Clearance Before and After Captopril
intro:17
FIGURES CHAPTER 19
19.1 Visual Analogue Scores for Breathlessness, Tiredness 
and Angina
19.2 Glyceryltrinitrate consumption. Captopril v Placebo 
FIGURES CHAPTER 2 0
20.1 Cumulative Proportion Surviving. Amiodarone
20.2 Cumulative Proportion Surviving. ACE Inhibitors
20.3 Cumulative Proportion Surviving. Effect of Digoxin
20.4 Estimated Survival Function. Effect of Amiodarone
20.5 Estimated Survival Function. Effect of ACE Inhibitors
20.6 Estimated Survival Function. Ventricular Extrasystoles
20.7 Estimated Survival Function. Coronary Artery Disease
20.8 Estimated Survival Function. Mean Arterial Pressure
20.9 Estimated Survival Function. Exercise Time 
20.lOEstimated Survival Function. Potassium
intro:18
ACKNOWLEDGMENTS
I wish to thank the following without whose help the 
studies presented herein could not have been 
completed.
Dr Henry J Dargie and Dr JIS Robertson who provided 
valuable guidance and advice. Dr Iain Morton, Dr 
Brenda Leckie and Professor Stephen Ball who gave 
generous technical assistance with the biochemical 
assays. Mr Gerry Gillan for his help with radio­
isotopic measures of renal and cardiac function. Dr 
Ian Roberston and Dr Bill East for performing the 
measurements of whole body composition. Ms Esther 
Henderson and Sister Kay Mcleod for their technical 
assistance and help in organising the studies. Dr Iain 
Ford for his statistical advice and Ms Elaine 
Lipscombe for her secretarial help.
DEDICATION
To My Mother and My Wife without who waited patiently 
for the completion of this work.
intro:19
SUMMARY
The idea of vasodilator therapy for heart failure has been 
toyed with for almost one hundred years, possibly more. In 
the mid-twentieth century nitrates attained a definite role 
in the management of acute pulmonary oedema. There is 
little doubt that vasodilators can improve central
haemodynamics acutely. However, during the 1970's 
investigators started to apply physiological principles of 
preload and afterload reduction to the management of 
chronic heart failure. The results were largely 
disappointing, either because tolerance occurred to the 
vasodilator actions of the drugs, or because vasodilatation 
is an ineffective mode of treatment for chronic heart 
failure. When work on this thesis started disillusionment 
was setting in regarding the efficacy of chronic
vasodilator therapy for patients with heart failure.
Although increases in plasma renin were first demonstrated 
in heart failure almost 50 years ago, there are few studies 
which have investigated the haemodynamic and metabolic 
correlates of renin-angiotensin-aldosterone system
activation in detail. The present work indicates that 
patients with heart failure have a depletion of total body 
potassium and an excess of total body sodium when compared 
to normal subjects or patients with mild untreated 
hypertension. This depletion in potassium is not related to 
a reduction in lean body mass. Within the group of patients 
with heart failure elevated plasma concentrations of active 
renin were associated with a lower arterial pressure, lower 
serum concentrations of sodium and potassium and more
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marked depletion of total body potassium. Arterial pressure 
appears to be an important determinant of renin secretion 
in heart failure. Although the electrolyte disturbances are 
probably largely a consequence of increased plasma 
concentrations of renin and angiotensin II, mediated 
through aldosterone and antidiuretic hormone, depletion of 
serum sodium and potassium may further stimulate renin 
secretion.
The renin-angiotensin, sympathetic and parasympathetic 
nervous systems are closely integrated. Angiotensin II can 
stimulate sympathetic activity in several ways, but can 
also reduce parasympathetic activity. The present work 
confirms that patients with heart failure have elevated 
sympathetic activity at rest, but reduced parasympathetic 
and sympathetic reflex activity as has been previously 
shown. This thesis also shows that at maximal exertion 
patients with heart failure have evidence of reduced 
sympathetic activity compared to normal subjects, and that 
this is related to the intensity rather than duration of 
exercise.
In view of the disturbances in haemodynamic function, 
autonomic activity and cellular metabolism in heart failure 
it is not surprising to find a high frequency of 
arrhythmias. These arrhythmias are directly related to 
plasma concentrations of renin and noradrenaline, though 
whether this is a causal relationship or by association 
with the severity of ventricular dysfunction is 
controversial. The present study found a poor relationship
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between the severity of ventricular dysfunction and the 
frequency of arrhythmias in a group of patients with 
generally poor ventricular function.
Using two double-blind cross-over studies the angiotensin- 
converting enzyme inhibitors captopril and enalapril were 
shown to improve symptoms and exercise performance over a 
6-8 week period. The study on captopril constituted one of 
the first placebo-controlled investigations in the 
literature to establish the efficacy of angiotensin- 
converting enzyme inhibitors in chronic heart failure. The 
paper on enalapril established that this was a class 
effect. These studies demonstrated that angiotensin- 
converting enzyme inhibitors could correct hypokalaemia and 
total body potassium depletion, but did not have a major 
impact on serum or total body sodium. Angiotensin- 
converting enzyme inhibitors also reduced plasma levels of 
noradrenaline, suggesting reduced sympathetic activity, and 
improved parasympathetic reflex responsiveness. Not 
surprisingly angiotensin-converting enzyme inhibitors also 
reduced the frequency of ventricular arrhythmias.
Studies were performed to investigate the effects of 
angiotensin-converting enzyme inhibitors on renal function 
in greater detail, and their interaction with frusemide. 
These indicated that introduction of angiotensin-converting 
enzyme inhibitor led to a reduced diuresis, plasma volume 
expansion and a fall in serum sodium. Urinary potassium 
losses were reduced and serum potassium unaltered in the 
short term. Renal blood flow tended to increase and
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glomerular filtration rate to fall; these effects were 
enhanced by concomitant administration of frusemide. 
Studies on renal tubular function indicated increased 
proximal tubular water and sodium reabsorption as the 
likely cause for the reduced diuresis in response to 
frusemide. Longer term studies indicate that angiotensin- 
converting enzyme inhibitors cause a consistent fall in 
glomerular filtration rate and increase in renal blood flow 
while the filtration fraction is reduced towards normal. 
Withdrawal of the angiotensin-converting enzyme inhibitor 
leads to a rapid return of glomerular filtration to 
baseline levels, but renal blood flow appears elevated for 
some time after withdrawal, suggesting structural change in 
the vasculature or prolonged tissue enzyme inhibition.
Heart failure and angina pectoris commonly co-exist but the 
effects of angiotensin converting enzyme inhibitors had not 
been studied previously in such patients. The present study 
indicates that captopril may reduce the angina threshold. 
The reduction in coronary perfusion pressure appears to 
offset the potential beneficial effects on myocardial 
oxygen consumption of the reduction in preload and 
afterload. However, the frequency of ventricular 
arrhythmias was also reduced in this study.
Finally an attempt was made to determine if angiotensin- 
converting enzyme inhibitors had had a beneficial effect on 
prognosis in patients with heart failure. This was an open 
non-randomised evaluation. Computer modelling was used to 
try and correct for differences in the distribution of
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adverse prognostic factors between those receiving an 
angiotensin-converting enzyme inhibitor and those not. A 
non-significant trend to improved prognosis in those 
receiving captopril or enalapril was noted. However, there 
was an excess of vascular deaths in the group treated with 
an angiotensin-converting enzyme inhibitor, but small 
numbers make these findings of uncertain significance.
Angiotensin-converting enzyme inhibitors are a new modality 
for the treatment of chronic heart failure. The work 
presented in this thesis has helped establish their 
usefulness and limitations, and demonstrated that they are 
more than mere vasodilator agents. The reason for their 
efficacy remains to be established. Perhaps it is because 
they induce haemodynamic tolerance infrequently. However, 
correction of intra-cellular electrolyte disturbances and 
autonomic dysfunction could be at least as important.
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PART ONE HISTORICAL INTRODUCTION
CHAPTER Is HISTORICAL PERSPECTIVES 
RENIN AND ANGIOTENSIN
The hormone renin was first discovered by Tigerstedt and 
Bergman in 1898.1 They showed that extracts of rabbit renal 
cortex caused marked and prolonged increases in blood 
pressure. Little further progress was made for 3 0 years. 
In the 1930's Goldblatt's experiments2 demonstrating that 
renal artery constriction could lead to sustained 
hypertension stimulated a further search for a pressor * 
substance secreted by the kidney, which finally led to the 
re-discovery of renin.3 However, it was soon realised that 
renin was not inherently a vasoactive substance. Friedman4 
found that in an isolated dog's tail preparation renin did i 
not cause vasoconstriction directly and that an 
intermediate substance must be responsible. Kohlstaedt et 
al 5 and Munoz et al 6 suggested that and subsequently 
Braun-Menendez7 and Page and Helmer8 showed that renin acted 
as an enzyme to produce a substance that had a short-lived 
but powerful vasoconstrictor effect. They called it 
hypertensin or angiotonin but subsequently it became known 
as angiotensin. It was around this time that Merril first 
noted that there was an increased concentration of renin 
in the renal veins of patients with heart failure.83 
Later, it was shown that if renin was incubated with plasma
1
in the absence of chloride ions, a decapeptide was formed, 
which was named angiotensin I.9 Chloride ions activated a 
dipeptidyl carboxypeptidase, which subsequently became 
known as the angiotensin-converting enzyme, that removed 2 
amino acids from the C-terminal to produce angiotensin II, 
the most powerful component of the renin-angiotensin 
cascade.10,11,12 The story was completed by the identification 
of a large alpha-globulin protein synthesised in the liver 
which was called the renin substrate or angiotensinogen.13
Originally, the plasma was thought to be the main site of 
formation of angiotensin II, but subsequently the kidney 
and lung were found to be major sites of conversion.14,15 It 
is now realised that many, if not all, tissues have the 
ability to convert angiotensin I t:o angiotensin II. The 
converting enzyme appears to be bound to the vascular
endothelium of many tissues, and is probably the major
source of plasma converting enzyme.16
Angiotensin II is extracted across the kidney, the limbs, 
and the splanchnic circulation, though the proportions due 
to receptor binding and metabolism are unknown.
Aminopeptidase enzymes are largely responsible for 
angiotensin II degradation. One heptapeptide fragment,
angiotensin III, may retain some biological activity.17
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ALDOSTERONE
As early as 1941, Raab reported that the blood level of 
adrencortical hormones was elevated in heart failure18 while 
in patients with heart failure the concentration of sodium 
was noted to be lower in faeces, sweat and saliva.19'22
In 1950, Deming and Leutscher23 noted that urine extracts 
from patients with congestive cardiac failure contained a 
substance with potent sodium-retaining activity which they 
identified as an adrenal steroid. This was later isolated 
and characterised as aldosterone.24,25
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Though it has been possible to interfere with the effects 
of angiotensin II by the use of "inactive" structural 
analogues for 3 0 years, progress in understanding the 
consequences of such an intervention was hampered by the 
need for intravenous infusions and the partial agonist 
activity of the analogues.26,27 Ferreira in 1965 discovered 
a bradykinin-potentiating factor in the venom of the 
Brazilian pit viper, Bothrops jararaca.28 Later the venom 
was also shown to inhibit the angiotensin-converting 
enzyme.29 Isolation, purification, sequencing and synthesis 
led to the first potent specific angiotensin-converting 
(ACE) inhibitor, teprotide.30 Unfortunately, this was 
inactive orally, but a programme of drug development 
subsequently led to the discovery of captopril. The number 
of ACE inhibitors now given to man runs into two figures.
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All these compounds depend in part for their activity on 
the formation of ligands wit:h the tightly-bound zinc ion of 
the enzyme.31 However, it appears that these compounds do 
not have the ability to chelate free zinc ions or to remove 
the ion from metaloproteins.
RENIN INHIBITORS
Renin's only known effect is to catalyse the production of 
angiotensin I from its precursor32. This is the
rate-controlling step in the production of angiotensin II.33 
In contrast, the angiotensin-converting enzyme has a number 
of other substrates including bradykinin, enkephalin and 
perhaps neurotensin and substance P.34 Inhibition of 
angiotensin-converting enzyme is therefore less specific. 
Also, the angiotensin-converting enzyme is not the
rate-limiting step in the production of angiotensin II, 
therefore almost complete inhibition is needed to reduce 
plasma levels of angiotensin II. Moreover, other enzymes 
such as cathepsin G and tonin may act upon angiotensin I 
to produce angiotensin II.35'36 However, despite some 
promising work in normal volunteers,37 no renin inhibitor is 
generally available for study in patients with heart 
failure at present.
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SUMMARY
Development of orally effective ACE inhibitors has 
permitted a much better understanding of the role of the 
renin-angiotensin-aldosterone system in heart failure. The 
introduction of new inhibitors of renin and angiotensin II 
receptor antagonists will help to elucidate more precisely 
which action(s) of the ACE (angiotensin-converting enzyme 
inhibitors) is (are) most important in mediating their 
beneficial as well as adverse effects.
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CHAPTER 2: PHYSIOLOGICAL CONTROL OP THE COMPONENTS OF THE 
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
A) RENIN
Renin is first synthesised as a high molecular weight 
protein, preprorenin. This is metabolised to inactive 
prorenin (molecular weight 55,000 Daltons), which may then, 
in certain tissues, be converted to active renin (molecular 
weight 44,000 Daltons).38 Many tissues have the capacity to 
process this into the active compound (eg;human chorionic 
cells) ,39
Circulating renin originates largely from the kidney where 
it is synthesised and stored in the juxtaglomerular cells 
of the afferent glomerular arteriole of the kidney.40'42
Five basic mechanisms controlling renin release have been 
described. They are:
1) an intrarenal baroreceptor
2) the amount of sodium (or possibly chloride) ion sensed 
by the macula densa segment of the distal tubule
3) the sympathetic innervation of the kidney and 
humorally released catecholamines
4) hormonal factors, including angiotensin II,
prostaglandins and atrial natriuretic peptide
5) plasma potassium and calcium.
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Intrarenal Baroreceptors
That renin could be released by a reduction in renal 
perfusion pressure was first alluded to by Kohlstaedt et al 
in 1940,43 though this was originally attributed to a 
reduction in pulse pressure rather than mean perfusion 
pressure. Tobian et al in 1959 were the first to suggest 
the existence of an intrarenal baroreceptor that increased 
renin secretion in response to a reduction in mean 
perfusion pressure,44 which was later confirmed by Skinner 
et al.45 Tobian also noted that juxtaglomerular cell 
granulation decreased with an increase in renal perfusion 
pressure.44
Renin release in response to hypotension was found still to 
occur, despite removal of the influence of the macula 
densa, sympathetic nerves and adrenal hormones.46,47 But 
papaverine, which blocks renal auto-regulation at the 
afferent arteriole, was shown to prevent 
haemorrhage-induced renin secretion from denervated, 
non-filtering kidneys in anaesthetised dogs, suggesting a 
role for the afferent arteriole in renin secretion.48
The theory formulated was that high renal perfusion 
pressure or afferent renal arteriolar vasodilatation would 
stretch the vascular wall, leading to stretch of the 
juxtaglomerular cells located in the media of the afferent 
arteriole49 and that this would lead to a decrease in renin
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release. However, several investigators noted that 
experimental models of renal (and systemic) hypotension led 
to renal vasodilatation, sufficient to maintain blood flow, 
concurrent with increased renal renin secretion.50,51 This 
renal auto-regulation in response to hypotension still 
occurred in the presence of renal vasoconstriction produced 
by intrarenal infusion of angiotensin II, or noradrenaline 
or an increase in sympathetic nerve discharge.52,53 In the 
light of these experiments, Vander54 proposed that a 
decrease in transmural pressure, a decrease in intramural 
tension, or a reduction in intravascular pressure was the 
stimulus to renin secretion. Kaloyanides et al demonstrated 
that clamping the ureter, a manoeuvre that increases renal 
interstitial pressure, caused a rise in renin secretion 
that could be reversed by increasing the renal perfusion 
pressure.55 This supports the notion that transmural 
pressure gradients rather than changes in afferent 
arteriolar diameter regulate renin release. Of note, 
maximal renin secretion appeared to occur at the time of 
maximal afferent arteriolar vasodilatation, whether induced 
by ureteric occlusion or hypotension.56 However, other 
experiments 57 showed that at a fixed perfusion pressure and 
at an assumed constant interstitial pressure, 
vasodilatation with papaverine reduces renin secretion and 
vasoconstriction with phenylephrine increases it. This 
suggests that changes in afferent arteriolar radius may 
after all be important in the release of renin.
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Initial reports of an effect of indomethacin on 
auto-regulation have not been confirmed.58,59 However, renin 
release in response to hypotension within the 
auto-regulatory range is inhibited by indomethacin, 
suggesting an important role for prostaglandin- mediated 
renin release.60 Renin release in response to more profound 
hypotension is not inhibited by indomethacin.
A rise in interstitial pressure induced by ureteric 
occlusion also induces prostaglandin E2 production, while 
indomethacin can prevent the associated renal 
vasodilatation and renin release.61,62
Autonomic Nervous System
In 1952, De Muylder identified nerves travelling to the 
afferent renal arterioles and the juxtaglomerular cells.63 
These were later identified as sympathetic in origin.64,65 A 
cholinergic nerve supply to the kidney is more 
controversial.66 Vander first noted that stimulation of 
renal nerves could release renin.67 It was later 
demonstrated that this could be blocked by propranolol.68 It 
was not clear whether these effects were due to changes in 
afferent arteriolar tone, changes in sodium content at the 
macula densa or direct. However, using the non-filtering, 
papaverine-treated kidney, it was shown that renin release 
occurred independent of changes in haemodynamics and sodium 
metabolism.69 Alpha-adrenergic inhibition in contrast caused 
an increase in renin secretion by haemodynamic mechanisms.68
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The afferent signals and central control of renal 
sympathetic nervous activity have also been intensively 
investigated. Studies on the brainstem in dogs and cats 
suggest that the sympathetic nervous system has a "tonic" 
stimulatory effect on renal renin secretion.70,71 Renal 
sympathetic nervous activity has been shown to be inversely 
related to carotid sinus pressure,72,73, and a reduction in 
carotid sinus pressure may lead to a rise in renin.74 
Vagally-innervated cardiopulmonary receptors have also been 
identified that inhibit renin release.75 Interpretation of 
early studies showing an inverse relationship between 
changes in atrial pressure and renin release are hampered 
by a lack of knowledge of atrial natriuretic peptide, but 
suggest a neural component mediated by vagal afferent s.76,77 
It thus appears that:
1) cardiopulmonary receptors with vagal afferent
pathways tonically inhibit renal release and can
respond to a decrease in central blood volume that 
does not activate baroreceptors.
2) these reflexes may be modified by tonic inhibition
from carotid baroreceptors.78,79
3) the efferent limb of these reflexes is via
sympathetic innervation.79,80
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Circulating Catecholamines
Infusion of both noradrenaline and adrenaline may stimulate 
renin release,67,81 though intravenous infusions of
noradrenaline may actually reduce renin as a result of the 
increase in arterial pressure. The stimulation of renin 
secretion persists in the non-filtering kidney model, even 
when papaverine is used to reverse renal vasoconstriction.69 
Propranolol but not alpha-adrenergic receptor blockade 
prevents renin release by sympathetic stimuli82 and renin 
release appears to be predominantly mediated through the 
beta-1 receptor.83'85 Stimulation of alpha receptors may 
cause renal vasoconstriction and indirectly induce renin 
release.86 However, others have found that alpha-adrenergic 
stimulation may inhibit renin release,87,88 while 
alpha-adrenergic receptor antagonists may increase 
circulating renin.89 Low dose infusions of noradrenaline in 
one experiment were found to inhibit renin release while 
higher doses stimulated renin secretion.90 This could be due 
to stimulation of pre-synaptic alpha-receptors which reduce 
noradrenaline and hence renin release, while at higher 
doses post-synaptic beta,, receptors are stimulated.91,92 
In-vitro studies confirm that beta-adrenergic stimuli lead 
to renin secretion, but an effect mediated through 
alpha-receptors is controversial.93,94
Dopamine also stimulates renal renin release,95'98 which can 
be blocked by haloperidol but not propranolol. However, 
changes in renal blood flow may override this effect.
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Parasympathetic Nervous System
Acetylcholinesterase-containing fibres have been identified 
within the kidney," but renal sympathetic nerves have been 
shown to contain acetylcholinesterase.66 Atropine can 
prevent the increase in renal plasma flow, urine volume, 
and sodium and potassium excretion caused by 
acetylcholine.100 However, no change in renal renin secretion 
has been noted with infusions of acetylcholine101 or when 
incubated with rat renal slices in-vitro.102
The Macula Densa and Sodium Metabolism
The macula densa region of the distal tubule, at the 
boundary of the ascending limb of the loop of Henle and the 
distal tubule, is in close contact with the juxtaglomerular 
cells of the afferent arteriole. 103,104 This intimate 
relationship has suggested that renin may in some way 
control individual nephron glomerular filtration rate.105
In 1963, Brown et al noted that sodium depletion could 
cause renin release in man.106 Sodium deprivation leads to 
an increase in proximal tubular sodium reabsorption107,108 and 
a decrease in the sodium load (the product of sodium 
concentration and tubular flow rate) to the macula densa. 
Osmotic diuretics, by restoring the distal tubular sodium 
load, can override the effects of hypotension on renal 
renin release.109 Volume expansion by hypotonic saline
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results in a reduced fractional excretion of sodium and an 
increase in renin, which can be reversed if isotonic saline 
is infused into the renal artery but only in the kidney 
ipsi-lateral to the infusion,110 indicating that the filtered 
sodium load or the sodium concentration at the afferent 
arteriole is important in controlling renin. In 
micropuncture studies in rats, diuresis induced by saline 
or mannitol has been shown to suppress renin secretion and 
increase the distal tubular sodium load, but the distal 
tubular sodium concentration was increased by saline and 
reduced by mannitol, indicating that sodium load rather 
than concentration may be more important.111 Studies with 
non-filtering kidneys have suggested that hypertonic saline 
does not suppress renin release by non-tubular mechanisms,112 
and some studies on rat renal cortical slices have failed 
to show an increase in renin release if osmolality is kept 
constant,113 though others have noted an increase in renin 
release with increasing sodium concentration in the 
perfusate.114,115
In the intact kidney, increased plasma osmolality and 
oncotic pressure may both increase plasma renin, though the 
mechanisms may be different. The former may alter 
juxtaglomerular cell volume116 and the latter glomerulo- 
tubular balance to reduce the delivery of sodium to the 
distal tubule.117
Volume expansion alone does not appear to reverse the
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activation of the renin-angiotensin system caused by sodium 
depletion.118'120 Saline suppression of renin release is due 
primarily to increased tubular sodium transport, rather 
than volume expansion.
However, Kotchen has suggested that the chloride ion rather 
than sodium may be more important in renal renin control,121 
at least in the rat, though this could not be confirmed in 
dogs.122
Potassium
Potassium chloride infused into the renal artery suppresses 
renin secretion, with an increase in potassium ion 
concentration as small as 0.5 mmol/1,123 but this also caused 
increased sodium excretion. This effect is not seen in 
non-filtering kidneys.112 Potassium also does not appear to 
increase renin secretion in-vitro.113 Dietary potassium 
depletion in dogs has been shown to cause hypokalaemia and 
stimulate plasma renin in the absence of a change in plasma 
sodium.124 Others have reported similar results and an 
increase in renal prostaglandin synthesis.125 A high dietary 
potassium has also been shown to block the rise in renin 
associated with sodium depletion in rats.126 However, studies 
with potassium bicarbonate rather than chloride have not 
reproduced these results,127 perhaps because the increase in 
potassium is attenuated by the alkalosis. Potassium given 
with lactate or sulphate as the anion does appear to 
suppress renin.122
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Dietary potassium supplementation also reduces plasma renin 
in salt-deprived normal human subjects128 and in patients 
with hypertension on a normal sodium diet,129 generally 
accompanied by increases in plasma potassium. However, an 
acute infusion of potassium to achieve similar in creases 
in plasma potassium does not suppress renin in 
sodium-deplete subjects, although it does appear to enhance 
the ability of sodium repletion to suppress renin.130,131. 
Others have suggested that adrenal steroids may be 
necessary for the effects of potassium on renin secretion,132 
but as potassium loading induces a marked natriuresis in 
Addisonian patients,133 it is difficult to test in man.
Calcium
Calcium can inhibit sodium reabsorption,134 alter blood 
pressure135 and catecholamine release.136 Therefore, it is 
difficult to assess the role of calcium on renin release. 
In-vitro, calcium suppresses renin secretion, while the 
suppression of renin by angiotensin II does not occur in 
the absence of calcium137, in contrast to sympathetically- 
mediated renin release.138 Acute and chronic hypocalcaemia 
does not appear to affect plasma renin in man,139 though 
intravenous injections of calcium chloride can reduce 
renin.140 Verapamil infused intrarenally reduces renin 
release in the intact kidney; the reverse is seen in the 
papaverine-treated, non-filtering kidney,141 suggesting that 
haemodynamic effects reverse an inhibitory effect of 
verapamil.
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Magnesium
Magnesium chloride infused into the renal arteries of dogs 
causes renin release.142 However, the intravenous infusion 
of magnesium sulphate to salt-deplete human subjects did 
not alter plasma renin.140 In-vitro experiments have also 
failed to show an effect of magnesium on renin release.143
Angiotensin II
Vandel and Geelhoed144 first demonstrated that angiotensin 
II could suppress renin secretion in the absence of a 
change in renal perfusion pressure in dogs. DeChamplain 
subsequently noted that subpressor doses of angiotensin II 
could suppress renin in normal and hypertensive humans.145
There are two mechanisms by which angiotensin II can reduce 
renin. Firstly, a "short" feedback loop, by a direct effect 
on the juxtaglomerular cells146 and, secondly, by a "long" 
loop through stimulation of aldosterone and volume 
expansion. The direct effects appear calcium-dependent, at 
least in part.137 Angiotensin II powerfully reduces the 
effects of sympa thetic activation and frusemide on renin 
secretion. 147,148 Reducing angiotensin II formation by 
inhibiting the converting enzyme leads to a prompt rise in 
renin.
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Anti-diuretic Hormone
Anti-diuretic hormone (ADH) suppresses renin secretion in 
animal models,149 even in non-filtering kidneys.150 Plasma 
renin is elevated in diabetes insipidus151 and can be 
suppressed by infusions of ADH in both normal subjects and 
patients. 152,153 However, these effects are probably mediated 
through indirect effects on plasma volume.
Prostaglandins
Early studies in dogs and man failed to show consistent 
effects of prostaglandins of the E series on renin 
release154,155 and in-vitro studies failed to show a direct 
effect on renin production.156 However, later in-vitro 
studies on prostacyclin did show direct stimulation of 
renin.158 Subsequent studies in dogs showed that renin was 
also released by prostaglandin E158 and that this was not 
mediated by the sympathetic nervous system or the macula 
densa.159 Moreover, indomethacin administered to the 
salt-deplete, renally denervated, dog model induced a fall 
in renal blood flow, glomerular filtration rate and renin 
secretion.160 Prostacyclin has also been shown to stimulate 
renin release in intact animal models and man.161,162 Other 
prostaglandins like prostaglandin F2alpha may inhibit renin 
release in-vitro.163
An alternative mechanism by which prostaglandins could 
stimulate renin release is by elevating renal interstitial 
pressure.164,165
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Atrial Natriuretic Peptide
Atrial natriuretic peptide is directly related to atrial 
pressure (or perhaps transmural tension), and serves as a 
further mechanism linking atrial pressures to renin 
secretion. 166,167 The direct effect of atrial natriuretic 
peptide is to inhibit the release of renin,168-170 
aldosterone,170-171 and anti-diuretic hormone.172 The 
associated natriuresis, by increasing the distal tubular 
sodium load, should also favour renin suppression by an 
effect on the macula densa.
However, some clinical studies have failed to demonstrate 
an effect of atrial natriuretic peptide on renin release. 
Vasodilatation, hypotension and a relative reduction in 
plasma volume might stimulate renin, while increased 
transudate of solutes into the renal parenchyma could raise 
tissue pressures, resulting in renin stimulation.
Cardiac Glycosides
Digoxin is widely prescribed in heart failure. Several 
studies have reported that it may reduce plasma renin173 and 
inhibit renal renin release by frusemide.174 The mechanism 
is obscure but Thames suggested that acetylstrophanthidin 
caused a reflex reduction in renal sympathetic activity via 
vagal afferents.175 However, others have suggested that 
glycosides may alter the intracellular sodium content of 
the macula densa,176 thereby inhibiting renin release.
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DIURETICS 
"Loop11 diuretics
Loop diuretics inhibit the active co-transport of chloride 
in the thick ascending limb of the loop of Henle; sodium 
reabsorption appears to follow the ionic gradient 
passively.177"180 This effect may also occur at the macula 
densa.181 These agents also cause in increase in renal blood 
flow, specifically to the renal cortex, and can override 
renal auto-regulation. 182-184 The haemodynamic effects appear 
to be prostaglandin-mediated.185,186
Frusemide increases plasma renin in man, 187,188 though the 
mechanism is disputed. Reduction in plasma volume may 
increase renin, but when the frusemide-induced volume loss 
is replaced, plasma renin still rises. 189,190 Others have 
shown a bi-phasic release of renin by frusemide, the late, 
but not the early, in crease can be prevented by fluid 
replacement.190,191 In animal studies, the early rise in renin 
is not blocked by propranolol or enhanced by 
aminophylline,192 but the late increase may be reduced by 
sympathetic denervation and propranolol.191,193. However, in 
studies of unilateral renal sympathetic denervation, the 
stimulatory effect of small (0.5 mg/kg), but not large (6 
mg/kg), intravenous doses of frusemide on renin was reduced 
in the denervated kidney.194 The effects of the smaller dose 
could be mediated by venodilatation de-activating cardiac 
vagal afferents and increasing renal sympathetic activity,195 
while larger doses had a direct renal effect. In man,
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propranolol and metoprolol can both inhibit the 
diuretic-induced increase in renin. 196,197 But, renin release 
under these circumstances may be accompanied by and due to 
a concomitant increase in sympathetic activity.198 Fru semide 
causes renal vasodilatation which could activate intrarenal 
baroreceptors. In non-filtering kidneys, renal 
vasodilatation with papaverine blocks the effects of 
frusemide on renin secretion,199 though renin release still 
occurs through macula densa mechanisms in filtering 
kidneys. Prostaglandins probably mediate frusemide-induced 
vasodilatation and also play a role in frusemide-stimulated 
renin release.200,186 Frusemide releases renin from rat renal 
cortical slices but this does not appear to be inhibited by 
indomethacin.201,202 In man, the natriuresis, hypotension, 
increase in renal blood flow, and increase in renin release 
caused by frusemide, may all be attenuated by 
indomethacin.203,204 The early response is most profoundly 
affected,205 while the later, volume-dependent, response is 
partially attenuated, perhaps because of the impaired 
diuresis.
Frusemide causes a rise in plasma arachidonic acid,206 
inhibits the conversion of prostaglandin E2 to prostaglandin 
F2alpha208 and also probably enhances prostacyclin 
production.208 However, loop diuretics increase renal 
intracapsular pressure, which may also stimulate pros­
taglandin production, though this can also be an effect of 
the prostaglandins themselves.
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The increase in renin after frusemide is limited by the 
"negative feedback" of angiotensin II.144 Angiotensin- 
converting enzyme inhibitors will release renin from this.
Osmotic diuretics
Osmotic diuretics appear to have a tri-phasic effect on 
renin release. Initial activation may be due to changes in 
juxtaglomerular cell volume;209 renin suppression then 
occurs, probably as the sodium load increases at the macula 
densa,210 then renin rises as the plasma volume contracts.
Thiazide diuretics
Prolonged treatment with thiazide diuretics leads to an 
increase in plasma renin,211 which may be attenuated by 
propranolol and atenolol.212,213 This is probably an effect of 
sodium and volume depletion.
Potassium-sparing diuretics
Amiloride increases plasma renin,214 as does 
spironolactone,215 despite increasing plasma potassium.
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B) ANGIOTENSINOGEN
Otherwise known as renin substrate, it is a heterogeneously 
glycosylated alpha2-globulin, with a molecular weight 
between 60,000-65,000 Daltons.216 It is synthesised in the 
liver,217 but more recent studies have indicated that mRNA 
is expressed in a variety of tissues,218'219 suggesting that 
local angiotensin production may take place. Alterations in 
plasma angiotensinogen as well as renin concentrations may 
affect the rate of angiotensin I formation.220 This reaction 
is the rate-limiting step in angiotensin II production. 
Pregnancy and oral contraceptives may elevate, and 
nephrotic syndrome depress, substrate concentrations.221*224 
Angiotensin II also stimulates increased hepatic synthesis 
of its own precursor, while other angiotensinogen fragments 
may inhibit production.225,226 Severe parenchymal liver 
disease may reduce angiotensinogen production.226
C) ANGIOTENSIN I
Angiotensin I is largely devoid of activity, and it is 
always difficult to be sure that preparations are 
uncontaminated by some angiotensin II. Intrinsic effects on 
prostaglandins and adrenal catecholamines have been 
postulated.227,228 Levels on the arterial side of the 
circulation are considerably lower than in the pulmonary 
artery due to conversion to angiotensin II in the pulmonary 
circulation.229
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D) ANGIOTENSIN-CONVERTING ENZYME
This is identical to kininase II which degrades bradykinin 
but is not particularly specific for either. It can also 
hydrolyse enkephalins and the beta-chain of insulin. It is 
present in plasma but also widely distributed in the lungs, 
kidney and other tissues, largely bound to the 
endothelium.230,231
The angiotensin-converting enzyme is present in excess and 
is not the rate-limiting step in angiotensin II production.
E) ANGIOTENSIN II
This is the major active component of the renin- 
angiotensin cascade, and it has diverse effects. It has a 
half-life in the circulation of less than one minute.232 It 
is largely degraded by enzymatic processes during transit 
through the capillary bed, and more slowly by 
angiotensinases in the circulation.233,234 The effects of 
angiotensin II are generally considered to be mediated by 
a single receptor subtype, but in some tissues at least 
there is evidence for heterogeneity.235,236
Effects on blood pressure 
Immediate Pressor Effect
Angiotensin II has very powerful direct arterial 
constricting effects.237 This effect is receptor- mediated, 
and can be antagonised by saralasin, though it should be 
recognised that saralasin has partial agonist activity.238,239
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Sustained high dosage results in tachyphylaxis.240 The 
pressor effect is diminished by sodium depletion.241 This may 
also represent receptor down-regulation, but could be due 
to a reduction in plasma volume, or a reduction in smooth 
muscle responsiveness.242,243
Slow Pressor Effect
If angiotensin II is infused over many days at doses which 
are initially subpressor, blood pressure will gradually 
rise.244'246 This may be due to decreased vascular compliance, 
sympathetic activation, resetting of baroreceptors, 
enhanced aldosterone secretion, and sodium retention.247"251. 
It is difficult to reproduce this with other pressor 
agents.246
Venoconstriction
A direct effect of angiotensin II on limb veins is 
controversial, but only probably occurs at high 
concentrations which produce rapid tolerance.252"256 However, 
it has been shown that local infusions of angiotensin II 
may facilitate reflex neurogenic venoconstriction that 
appear to be mediated through sympathetic presynaptic 
mechanisms.252,257 Interestingly, although the direct 
venoconstrictor effects undergo rapid tachyphylaxis,256 
reflex venoconstriction does not appear to do so.257
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Stimulation of Aldosterone Secretion
Angiotensin II increases plasma levels of aldosterone258,259 
by increasing adrenal secretion260 and possibly by decreasing 
hepatic blood flow and hence aldosterone degradation.261 
However, a number of factors help modulate the stimulatory 
effects of angiotensin II, including dopamine and 
potassium.259,262 In contrast to its pressor effects, sodium 
depletion enhances the ability of angiotensin II to 
stimulate aldosterone secretion, possibly by upregulating 
receptors.263'266 During prolonged infusions, tolerance may 
appear, but this may be indirect due to potassium 
depletion269 and is incomplete.
Inhibition of Corticotrophin Secretion
At high doses, infusion of angiotensin II can cause a rise 
in ACTH,268 though the reverse has also been noted.269 When 
administered into the cerebral ventricle it stimulates 
corticotrophin release, an effect also noted when applied 
to cultured anterior pituitary cells.270,271 This may be part 
of a physiological local control system or be mediated 
through anti-diuretic hormone.271
Stimulation of Anti-diuretic Hormone Secretion
Concentrations of angiotensin II that are found in many 
patients with heart failure are capable of stimulating the 
production of anti-diuretic hormone.272,273 The 
paraventricular nucleus contains a high quantity of 
angiotensin II receptors274 and excitation at this level
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appears responsible for anti-diuretic hormone release.275 
Central injections of angiotensin II can also stimulate 
oxytocin release.276
Sympathetic Transmission
There is evidence that angiotensin II may enhance 
sympathetic activity, both centrally and by peripheral pre- 
and post-synaptic mechanisms. Angiotensin II can produce a 
pressor response mediated through the area prostrema or 
periventricular nuclei (depending on species) which can be 
blocked by beta-adrenergic antagonists.277'280 Tolerance does 
not develop to this pressor response and the effects may be 
seen with low dose carotid intra-arterial infusions.281
Acting on peripheral sympathetic fibres, angiotensin II may 
enhance tyrosine hydroxylase activity and hence 
noradrenaline synthesis.282 Angiotensin II may also enhance 
noradrenaline release at sympathetic nerve terminals283*284 
and reduce re-uptake,285 thereby increasing the concentration 
of noradrenaline in the synaptic junction. Angiotensin II 
may also potentiate the post-synaptic effects of 
noradrenaline.287 However, responses to sympathetic 
stimulation are increased to a much greater degree than the 
responses to exogeneously administered noradrenaline.287,288 
Angiotensin II may also release catecholamines from the 
adrenal medulla.289,290
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Parasympathetic Transmission
Angiotensin II has been shown to reduce vagal tone in 
animal experiments and in man, while captopril appears to 
enhance parasympathetic reflexes.291"295 This is centrally 
mediated.296
Central Nervous System
Angiotensin II is not thought to cross the blood-brain 
barrier. However, some periventricular nuclei (eg, the 
subfornical organ, organum vasculosum laminae terminalis) 
and area postrema lie outside this and are thus susceptible 
to circulating angiotensin n . 297»298 All the components of 
the renin-angiotensin system, including angiotensin II 
receptors, are present within the brain itself.299 Centrally 
administered angiotensin II also has a pressor effect.300
Direct Myocardial Effects
Direct postive inotropic effects of angiotensin II on the 
myocardium have been shown in both animal experiments and 
in man.301"303 If the increase in blood pressure is prevented, 
there is also evidence of a direct chronotropic effect.304, 
305 The inotropic effect appears to be a calcium-mediated 
phenomenon.305 However, the inotropic and chronotropic 
effects of angiotensin II are normally obscured by the 
responses to the increased arterial pressure.304 In animal 
models angiotensin II administered to produce high 
"physiological" circulating levels may also induce focal 
myocardial cell necrosis.306/307
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Effects on the Renal Circulation
Angiotensin II causes preferential constriction at the 
efferent arteriole, thus maintaining glomerular hydrostatic 
pressure, despite a reduction in the renal perfusion 
pressure during hypotension.308"310 Increases in afferent 
arteriolar tone with angiotensin may occur in intact 
animals, but probably represent auto-regulation in response 
to the rise in perfusion pressure.311 Angiotensin II may 
also cause a change in the intrarenal distribution of blood 
flow, diverting blood away from the outer cortical nephrons 
to the juxtamedullary nephrons.312
Glomerular Effects
Apart from hydrostatic pressure, glomerular filtration 
depends on the area available for filtration and the 
hydraulic conductivity of the glomerular wall. The product 
of the latter two is the ultrafiltration coefficient. 
Agents which reduce ultrafiltration coefficient cause 
glomerular contraction but have not been shown to alter 
glomerular ultrastructure.313'314 Therefore, it has been 
assumed that changes in glomerular surface area are of more 
importance. Mesangial cells contain contractile
myofilaments and possess receptors for angiotensin II, 
stimulation of which does appear to cause contraction.315'319 
Similar properties may exist in glomerular endothelial 
cells.320 Angiotensin may therefore reduce glomerular 
filtration rate by causing mesangial cell contraction and
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an increase in ultrafiltration coefficient. This will have 
the opposite effect on glomerular filtration rate to the 
effects of angiotensin II on the efferent arteriole.
Intrarenal Distribution of Blood Flow
It remains unclear what the importance of angiotensin II is 
to the distribution of intrarenal blood flow, although 
circumstantial evidence abounds. Firstly, superficial 
cortical nephrons contain more renin than the 
juxtamedullary321 However, this gradient may be lost during 
sodium depletion and low renal perfusion pressure.322,323 
There is evidence that angiotensin II preferentially 
constricts cortical vessels.324 Sodium deprivation in 
animals, which activates the renin- angiotensin system, 
diverts blood to the deeper, juxtamedullary nephrons.325 In 
human heart failure, there is evidence of reduced cortical 
blood flow, which can be reversed by frusemide.326 In rats 
and hypertensive man, there is some evidence that it can 
also be reversed by captopril.327,328 Thus, angiotensin II 
diverts blood to the juxtamedullary nephrons which direct 
blood to the vasa vasorum of the long loops of Henle that 
reach down into the renal medulla. These changes in 
intrarenal blood flow may contribute to sodium retention in 
heart failure.326
Proximal Renal Tubule
Sodium is actively reabsorbed at this site by a variety of 
mechanisms. Sodium is exchanged for potassium at or near
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the basement membrane, which leads to an electrochemical 
gradient for sodium reabsorption from the tubular lumen. 
This is greatly enhanced by a number of co- and 
counter-transport systems with other ions and solutes.329,330 
Water follows the osmotic gradient freely.
Angiotensin II causes the resistance at the efferent 
arteriole to increase, which produces a rise in glomerular 
filtration fraction. The oncotic pressure of plasma 
reaching the vasa vasora at the proximal tubule increases 
and the hydrostatic pressure falls. These peritubular 
capillary forces were long thought to contribute to 
proximal tubular reabsorption. However, both angiotensin II 
and sympathetic activation can lead to proximal tubular 
reabsorption in the absence of changes in oncotic or 
hydraulic pressure.331'333 In- vitro experiments also suggest 
that noradrenaline and angiotensin II can stimulate 
proximal tubular sodium reabsorption directly.334,355 
However, at high concentrations angiotensin II may inhibit 
proximal tubular sodium reabsorption.332,336
Distal Tubule
The major effect of angiotensin II is mediated through 
aldosterone, which stimulates active sodium transport in 
exchange for sodium and potassium.337 Aldosterone stimulates 
the production of a protein which mediates its effects on 
ion exchange. This leads to several hours delay in onset 
and offset of its effects.338
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Stimulation of Drinking
Angiotensin II stimulates drinking in animals, an effect 
which is seen most powerfully when administered directly to 
the central nervous system.267,269,339,340 There is some evidence 
that this may also be true in man.341,342 Central 
administration of angiotensin II has also been reported to 
stimulate salt appetite.343
Internal Distribution of Electrolytes
Angiotensin II increases the infux of sodium into smooth 
muscle cells in exchange for potassium.344,345 This may effect 
smooth muscle tone and vascular resistance.
Prostaglandins
Angiotensin II may stimulate the renal production of 
prostaglandins of the E series.346,347 This effect of 
angiotensin II may be organ-specific since it has been 
shown not to occur at other sites.348 The renal release of 
prostacyclin and prostaglandin E2 tend to occur in 
situations which also provoke renin release,349,351 and their 
production leads to afferent arteriolar vasodilatation.352
Indomethacin can attenuate the renal vasodilator effects of 
converting enzyme inhibition353,354 Some studies have 
suggested that converting enzyme inhibitors may actually 
stimulate prostaglandin synthesis, though this may be a 
bradykinin-dependent pathway.355,356
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Renin
Angiotensin II appears to directly inhibit renin production 
(vide supra).
Biochemical Mediation of the Effects of Angiotensin II
Occupation the angiotensin II receptor stimulates the 
hydrolysis of the phosphatidylinositol 4,5-biphosphate and 
inhibits the production of cyclic AMP (adenosine 
monophosphate) ,357*358 in turn this increases intracellular 
free calcium, enhancing contraction.359
Angiotensin II as a Growth Factor
Angiotensin II has recently been implicated as a proto­
oncogene. Thus, angiotensin II may induce hypertrophy of 
cardiac and vascular myocytes.360'361
Tissue Renin-Angiotensin Systems
The capacity to produce renin and angiotensinogen is of 
course present in the DNA of all cells. Messenger RNA for 
renin and angiotensinogen has been found in many tissues, 
indicating likely local synthesis,362,363 though a 
physiological action is not clearly established. Cells also 
appear to have the ability to take up components of the
system from other cells and the circulation. Locally
synthesised angiotensin II may have effects on the cell in 
which it was synthesised (autocrine effect) or on adjacent 
cells (paracrine effect). However, nephrectomy causes a
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rapid disappearance of renin activity from vascular 
tissues, suggesting that local synthesis of renin is of 
lesser importance,364 though plasma inactive renin is little 
affected.
F) ALDOSTERONE
Aldosterone secretion is stimulated by angiotensin II, 
corticotrophin and a fall in plasma potassium.258'266, 365-368 
Aldosterone secretion is inhibited by atrial natriuretic 
peptide and dopamine,262,369,370 the apparent degree of
inhibition increasing as angiotensin II stimulation 
increases. This competitive action does not seem to be
mediated through angiotensin II receptors. Sodium depletion 
and potassium loading enhance the sensitivity of 
aldosterone secretion to angiotensin II, 258*259 while 
aldosterone secretion may be controlled, at least in part, 
by locally formed angiotensin II.371
A 25% increase in plasma aldosterone may occur with an 
infusion of as little as 10 mmol potassium,366 an amount 
which does not alter plasma potassium concentration. 
Aldosterone also varies as the dietary intake of
potassium.365 The effects of potassium on aldosterone
secretion probably out-weigh those of angiotensin II.367 
Dietary sodium restriction stimulates renin-angiotensin 
activity, and thereby aldosterone. Only large changes in 
plasma sodium concentration appear to affect aldosterone 
secretion directly.372
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Corticotrophin is a powerful aldosterone secretagogue but 
tachyphylaxis to its effects occur within 6 hours.368 
Anti-diuretic hormone has also been observed to stimulate 
aldosterone secretion, at least in-vitro, through 
stimulation of V2 receptors, though again tachyphylaxis is 
seen.373 The granulosa cells are richly innervated, and 
beta-receptor stimulation could also enhance steroid 
synthesis.374
Atrial natriuretic peptide inhibits aldosterone secretion 
in response to the above stimuli in animals and in-vitro. 
In man, infusions of atrial natriuretic peptide also cause 
a fall in aldosterone, but this may not be observed if 
baseline levels are low.370
Dopamine probably inhibits aldosterone secretion through D- 
2-receptors.262,375 . Bromocripitine can attenuate 
frusemide-induced aldosterone release, while metoclopramide 
raises plasma levels of aldosterone.376,377
Actions
Aldosterone stimulates sodium uptake and potassium loss in 
the renal tubule, and the salivary and sweat glands378 The 
site of action is the distal tubule and collecting duct, 
where sodium uptake is coupled to potassium and hydrogen 
ion excretion.378 With continued administration, normal 
subjects will eventually "escape" from the sodium-retaining
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effects of aldosterone. This is largely due to a reduction 
in proximal tubular reabsorption and may be an effect of 
atrial natriuretic peptide.379 Patients with heart failure 
do not "escape" from the sodium-retaining effects of 
aldosterone.380
SUMMARY
There are therefore many reasons for the renin- 
angiotensin-aldosterone system to be stimulated in patients 
with heart failure. Many of the actions of angiotensin II 
and aldosterone could be deleterious. However, angiotensin 
II and aldosterone may have a central role in supporting 
the blood pressure in heart failure while angiotensin II 
may help maintain glomerular filtration rate. Therefore, 
interference with these systems cannot automatically be 
assumed to be beneficial.
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CHAPTER 3 * ANIMAL MODELS OF NEUROENDOCRINE ACTIVATION IN 
HEART FAILURE
Probably the first "model" investigating neuroendocrine 
activation in heart failure was in man, when an increased 
concentration of renin was noted in renal vein blood of 
patients with chronic heart failure.381
Few studies of neuroendocrine function exist on animals 
with heart failure due to left ventricular damage, and thus 
it is difficult to equate animal models with human disease. 
Ertl and others have suggested that ACE inhibitors improve 
ventricular function and reduce ventricular arrhythmias 
after myocardial infarction in animal models, though some 
have speculated that this may be a specific property of the 
captopril molecule rather than an effect of ACE inhibition. 
382,383,384 rpj^ effects of ACE inhibitors on survival have also 
been studied in rats with left ventricular dysfunction due 
to myocardial infarction.385 However, the neuroendocrine 
effects of such cardiac insults have been studied only 
rarely, and often indirectly,386,387 and do not generally 
provide sufficient information to understand, in detail, 
neuroendocrine activation under such circumstances.
A low cardiac output has been induced in animal models by 
vena caval constriction, but in this model atrial pressure 
is reduced, unlike common forms of human disease. Pulmonary 
banding and tricuspid avulsion results in a low cardiac 
output and raised right atrial pressure, but the left
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atrium and ventricle are only secondarily affected. High 
output failure has been induced by arteriovenous fistulae, 
but again these models do not closely parallel the common 
human condition. Riegger developed an interesting dog model 
of heart failure by rapid ventricular pacing, but, again, 
this is not an accurate simulation of common human forms of 
heart failure. Nonetheless, valuable insights and analogies 
may be drawn from these less representative models from 
which we have a large amount of data.
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Despite the fact that renin381 and angiotensin n 388 were 
shown to be elevated in early studies of patients with 
heart failure, early animal studies failed to show a 
consistent increase in renin or aldosterone, despite marked 
sodium retention.389'392 Transient increases in renin and 
aldosterone were noted after tricuspid avulsion or vena 
cava constriction, which were dismissed by some and studied 
by others.389'392
When normal humans and dogs are administered aldosterone, 
they retain water only transiently.393'394 After retaining 
sodium for a few days they "escape" from the 
sodium-retaining properties of the steroid. In a series of 
experiments, Davis et al, using a low cardiac output (vena 
cava constriction) dog model, showed that dogs with heart 
failure did not undergo "escape" from a 
mineralocorticoid.395,396 This had previously been shown in
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man397 This was not due to increased renal vein pressure and 
was unaffected by hypophysectomy, adrenalectomy and renal 
denervation. Davis was also able to induce the same effect 
in a high output model with an arteriovenous shunt398 and 
showed that sodium retention varied according to the 
administered dose of steroid and noted de Wardener's 
suggestion that a natriuretic factor may be at play.399 We 
now know that this model of heart failure, by reducing 
atrial stretch, may well reduce secretion of atrial 
natriuretic peptide, thus enhancing the sodium-retaining 
effects of aldosterone. An increase in atrial natriuretic 
peptide may well have been the much sought after mechanism 
of the "escape" phenomenon.400
In dogs with an arteriovenous fistula, which usually only 
develop features of heart failure when given additional 
aldosterone, it was noted that angiotensin II could induce 
further secretion of aldosterone, heart failure and 
ascites.401 This could be prevented by adrenalectomy. These 
investigators also noted a reduced pressor response to 
angiotensin II, though whether this was due to contraction 
of plasma volume, prior receptor occupation or 
down-regulation, or a fall in cardiac output, was not 
investigated.
Despite Davis' claims that an effective excess of 
aldosterone was necessary for the production of the signs 
of congestive heart failure, this was not confirmed by the
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advent of specific aldosterone antagonists. In human 
studies, spironolactone was found to elicit a diuresis in 
only 40% of patients. Moreover, the diuresis had a poor 
relationship to the measured level of aldosterone.402
Additional studies of inferior and superior vena cava 
constriction around this time demonstrated that the rise in 
renal venous pressure was not the cause of sodium 
retention, but did show that sodium retention could be 
blocked by hexamethonium or phenoxybenzamine.403,404
In one of the most elegant experiments to date, Watkins et 
al showed that heart failure induced either by inferior 
vena cava or pulmonary artery constriction was followed by 
a fall in arterial pressure, intense activation of renin 
and aldosterone and marked sodium retention.405 After one or 
two days, plasma volume expansion became obvious, arterial 
pressure rose, urinary sodium returned to control, and 
activity of the renin-angiotensin-aldosterone system waned, 
at least in dogs subjected to moderate constriction. 
Initially, single doses of an ACE inhibitor produced 
further marked falls in arterial pressure. If these dogs 
received further single doses of an ACE inhibitor on 
subsequent days the resultant fall in pressure diminished 
progressively and was lost after 10 days. At this time, 
renin had returned to normal.
In dogs subjected to more severe constriction, the fall in
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arterial pressure was greater, activation of renin and 
aldosterone persisted, sodium retention was progressive and 
plasma volume was not expanded. Prolonged treatment with an 
ACE inhibitor prevented the rise in aldosterone, but 
exacerbated the fall in arterial pressure, did not reverse 
sodium retention and prevented mildly affected dogs from 
regaining haemodynamic equilibrium. A similar important 
role for angiotensin II in maintaining blood pressure under 
these circumstances has been suggested from studies with 
saralasin.
In the studies by Watkins et al, they also noted that the 
major cause of water "retention" was increased consumption. 
They attributed this to a dipsogenic effect of angiotensin 
II, though they did not comment if thirst was affected in 
the dogs treated with an ACE inhibitor. Sodium retention, 
rather than angiotensin II, could have accounted for the 
increase in thirst. They also noted that the increase in 
renin was greater in dogs put into heart failure by vena 
cava constriction compared to pulmonary artery 
constriction. Though this could be explained by low atrial 
pressure stimulating vagal afferents and hence increased 
sympathetic outflow to the kidney, an increase in atrial 
natriuretic peptide with right atrial distension leading to 
inhibition of renin release is equally plausible.
In contrast to the above, Freeman et al, using a similar 
animal model, noted that ACE inhibition resulted in a
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suppression of aldosterone and a natriuresis.406 However, the 
data are not so inconsistent on more detailed examination. 
Only those dogs that had a well maintained arterial 
pressure and glomerular filtration rate during 
angiotensin-converting enzyme inhibition had a marked 
natriuresis. Sodium retention occurred in those dogs where 
arterial pressure fell to any great extent after an ACE 
inhibitor.
Riegger et al have used rapid ventricular pacing as a model 
of heart failure.407 In this model, induction of heart 
failure is accompanied by activation of the renin- 
angiotensin-aldosterone and sympathetic nervous systems, 
and anti-diuretic hormone (ADH). Levels of ADH were 
inappropriately elevated in relation to plasma osmolality. 
In a subsequent series of experiments, inhibiting each of 
these systems using captopril, prazosin or an anti-diuretic 
hormone ( V.,) receptor antagonist, they showed that the 
latter had little effect on the elevated peripheral 
vascular resistance of heart failure.408,409 Prazosin had a 
transitory effect only which may have been reversed by 
activation of renin. Only captopril produced sustained 
beneficial haemodynamic effects. They also suggested that 
captopril prevented fluid retention. However, the effects 
of ACE inhibition on sodium excretion in animal models is 
highly variable. One explanation may be variations in 
sodium loading. It has been shown in rats that ACE 
inhibitors actually induce sodium retention in salt-deplete
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animals and the reverse in sodium- loaded.410 Animals with 
heart failure may be more likely to behave as 
sodium-deplete, or, expressed in another way, have 
increased renal sodium avidity. Studies with renin 
inhibitors suggest that they too may have beneficial 
haemodynamic effects in heart failure but also fail to 
increase sodium excretion.411
Activation of the renin-angiotensin system may precipitate 
worsening heart failure and hence further activation of 
neuroendocrine systems in at least 2 ways. Firstly, the 
increase in vascular tone may cause a further increase in 
atrial pressure and a decline in cardiac output. More 
subtly, angiotensin II may cause focal myocardial necrosis 
in supra-physiological doses, leading to deterioration in 
intrinsic myocardial function
ATRIAL NATRIURETIC PEPTIDE
Atrial natriuretic peptide (ANP) is also elevated in heart 
failure, with increased atrial turnover and depleted atrial 
stores.387 That the natriuretic response to ANP is impaired 
in heart failure is well described.412,413 In animal models, 
restoration of renal artery perfusion pressure has been 
shown to restore the natriuretic response,414 while the 
effects of angiotensin II, aldosterone and sympathetic 
nervous system activation may all impair ANP's natriuretic 
effects.415 Administration of anti-ANP antibodies in animals 
with heart failure elicits further sodium retention,
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suggesting that the increased levels of ANP in heart 
failure are not inert .416Administration of an atriopeptidase 
inhibitor to elevate plasma levels of ANP are also 
associated with a diuresis.417 There are reports that ANP 
receptors may be reduced in heart failure, at least on 
platelets.418
ANTI-DIURETIC HORMONE
Further studies on hypophysectomy before and after the 
induction of heart failure suggested that increases in 
plasma levels of ADH had little impact on sodium and water 
retention in heart failure.419,420 Some animal models have 
suggested an important role for ADH-induced 
vasoconstriction, which may be enhanced by the baroreceptor 
impairment which occurs in heart failure.421,422 However, 
marked haemodynamic effects from ADH-V1 receptor inhibition 
are uncommon.423
SYMPATHETIC NERVOUS SYSTEM
In addition to an increase in circulating catecholamines 
which reflect increased sympathetic nerve traffic, cardiac 
stores of noradrenaline are reduced in animal models of 
heart failure.424 There appears to be a reduction in cardiac 
synthetic capacity and decreased neuronal re-uptake of 
noradrenaline.425,426 Reduction in activity of tyrosine 
hydroxylase activity, the rate- limiting step in 
noradrenaline synthesis, has been noted.427,428 It is now 
generally agreed that cardiac beta,, receptors are
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down-regulated in heart failure, leading to a reduction in 
sensitivity to adrenergic stimuli,429'431 while beta2 and 
alpha-receptors are relatively less affected.
Increased cardiac sympathetic activity may be beneficial 
initially, increasing the force of cardiac contraction and 
heart rate. However, sustained high levels of sympathetic 
activity may lead to focal myocardial necrosis432,433 and/or 
progressive ventricular dysfunction and arrhythmias. 
Increased peripheral sympathetic activity leads to 
increased arterial and venous tone and renal sodium 
retention.434-441
Inhibition of alpha,, receptor-mediated increases in vascular 
tone in animal models leads to transient beneficial 
haemodynamic effects only.407,408 The reasons for this are not 
clear. As non-specific alpha2 receptor blockade may also 
have taken place, this could have led to heightened 
sympathetic activity and a reversal of the initial 
beneficial effect. Alternatively, Zelis has suggested that 
heightened peripheral sympathetic activity may actually 
have a beneficial effect in heart failure, directing blood 
flow during exercise to the most metabolically active 
muscle fibres.442'443
Activation of the renin-angiotensin system commonly occurs 
during prazosin therapy and may be responsible for 
haemodynamic tolerance, though such activation could also
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represent a response to overall haemodynamic deterioration 
or to heightened renal sympathetic activity.
CONCLUSIONS
Animal models offer valuable insights into the dynamic 
responses of neuroendocrine systems in heart failure. These 
models must be treated with caution due to the time course 
and character of the haemodynamic perturbation. Important 
differences between species may occur, and this is 
especially likely when extrapolating to humans, the only 
bipeds so far studied, whose cardiovascular system has been 
specifically adapted for the upright posture.
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CHAPTER 4: NEUROENDOCRINE ACTIVATION IN HUMAN HEART FAILURE
Relatively few studies exist of the development of heart 
failure in man. McAlpine et al444 demonstrated an increase 
in activation of the sympathetic nervous and 
renin-angiotensin systems and arginine vasopressin after 
myocardial infarction. Those patients who went on to 
develop clinical evidence of heart failure demonstrated 
sustained neuroendocrine activation. In contrast, in those 
patients who recovered without developing evidence of heart 
failure neuroendocrine activation declined.
In contrast, Bayliss et al445 studied patients with untreated 
compensated heart failure during rest and exercise, 
demonstrating excessive activation of the sympathetic 
nervous system but that the renin- angiotensin system 
appeared suppressed. However, it should be noted that there 
were no healthy controls in this study and the authors only 
compared their results with a reference range. Milder 
degrees of neuroendocrine activation therefore may have 
been missed. However, in a series of patients presenting 
with acute left ventricular failure, Broqvist et al446 
suggested again that whereas the sympathetic nervous system 
was activated, there was little evidence of activity within 
the renin-angiotensin system. They also demonstrated that 
plasma levels of atrial natriuretic peptide were high and 
fell with diuretic therapy. However, it should be noted 
that the patients presenting with acute left ventricular
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failure in this study appeared to be hypertensive. A series 
of case reports447,448 has suggested that the arterial 
pressure may have a major impact upon renin-angiotensin 
system activation in untreated heart failure. This may 
explain the heterogeneity of neuroendocrine activation in 
untreated heart failure.449,450
These findings are all consistent with animal models of 
heart failure in which initial activation of the 
sympathetic nervous and renin-angiotensin systems results 
in fluid retention and vasoconstriction. Arterial pressure 
returns to normal or may even be raised when blood volume 
is expanded, resulting in a waning of neuroendocrine 
activation. However, if the cardiac insult is severe and 
acute, then failure to maintain stroke output and pressure 
may lead to shock; or the very high filling pressure 
resulting from failure of ventricular emptying may result 
in pulmonary oedema, even though it may be required to 
maintain cardiac output. Under these circumstances, when 
haemodynamic equilibrium cannot be achieved, neuroendocrine 
activation may be intense. The majority of patients with 
chronic heart failure are already receiving diuretics 
which maintain activation of the neuroendocrine 
systems.446,451 Conversely, diuretics may also reduce the 
intrinsic neuroendocrine activation of acute heart failure. 
446'449 This is probably due to withdrawal of acute sympathetic 
activation with the resolution of pulmonary oedema. A 
reduction in atrial pressure will also cause a decline in
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plasma atrial natriuretic peptide.452
While recent interest has concentrated on vasoconstrictor 
mechanisms in heart failure, the failure of vasodilator 
mechanisms such as atrial natriuretic peptide, bradykinin, 
and the vasodilator prostaglandins may be important.453 
Patients with heart failure demonstrate simultaneous 
activation of both vasoconstrictor and vasodilator systems; 
plasma levels of noradrenaline, renin, angiotensin II, 
aldosterone, arginine vasopressin and atrial natriuretic 
peptide all being elevated, in contrast to the reciprocal 
relationships seen in normal subjects.454
Neuroendocrine activation becomes more intense as the 
diuretic dose is increased. Exercise causes further 
stimulation of the sympathetic nervous system455'457 and 
renin-angiotensin system,458 and arginine vasopressin and 
atrial natriuretic peptide.459 However, there is marked 
individual variation in the intensity of activation. Low 
serum sodium, potassium and arterial pressure levels are 
more accurate clinical markers of intense neuroendocrine 
activation than symptom class or level of ventricular 
dysfunction.460
Plasma concentrations of renin, angiotensin II, 
noradrenaline and atrial natriuretic peptide are inversely 
related to prognosis.461,462 High levels of catecholamines and 
angiotensin II may be directly cardiotoxic and add to a
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downward spiral of increasing vascular resistance, 
neuroendocrine activation and deteriorating haemodynamic 
function.
However, it remains uncertain whether neuroendocrine 
activation itself makes a contribution to increasing 
mortality or is just a marker of severity. The 
demonstration that low levels of renin-angiotensin system 
activity with high sympathetic activity may be exchanged 
for the converse by diuretics illustrates the absence of 
any simple relation between neuroendocrine activation and 
prognosis. Though diuretics are central to the management 
of severe heart failure, it is possible that they may 
adversely affect prognosis in mild heart failure because of 
unfavourable changes in haemodynamic, metabolic or 
neuroendocrine factors. This is especially likely if 
excessive doses result in reduction in body fluid 
compartments below normal.
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CHAPTER 5: CARDIOVASCULAR ADAPTATIONS IN HEART FAILURE
PRELOAD
Preload, the resting myocardial tension, is determined by 
the degree of actin/myosin overlap of the contractile units 
of the myocytes. Due to slippage between myocytes in 
chronically distended ventricles, actin/myosin overlap may 
be similar in diseased and normal hearts 463 so it cannot 
easily be predicted where the patient "is" on the 
Frank-Starling curve. The effects of a reduction in preload 
are also difficult to predict. A small increase in venous 
capacity may lead to an effective reduction in ventricular 
volume without affecting cardiac output. Larger falls in 
volume will result in a fall in output. It is likely that 
patients die before reaching the descending limb of the 
Starling curve and therefore unlikely that reduction in 
preload alone will ever cause a rise in cardiac output. 
Reducing blood volume by venesection or diuresis is 
effective in lowering ventricular filling pressures 464»465 
but since many of the haemodynamic, autonomic and endocrine 
consequences of heart failure appear similar to those of 
blood loss, further stimulation of these adaptive 
mechanisms appears undesirable.
AFTERLOAD
Afterload, the resistance which the ventricle has to 
overcome ion order to eject its contents, depends on the 
radius of the chamber, the energy required to deform the
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myocardium, the systolic pressure that it generates and the 
aortic impedance (a synthesis of arterial compliance and 
arteriolar resistance) .465 The normal, but not the failing, 
ventricle, compensates for rises in afterload by an 
increase in contractile force so that the stroke output 
remains unchanged. This law of the heart, less well known 
than Starling's, was described by Sarnoff, and is equally 
important.466 It follows that reduction of after load by 
arteriolar dilators allows the ejection fraction and stroke 
output to rise, with little effect on filling pressures 
unless more complete ventricular emptying reduces cardiac 
volumes so that both preload and afterload fall. Diuretics 
may also reduce afterload, either by reducing external 
arterial compression by oedema 467 or by altering the 
composition of the vessel wall (ie reducing sodium 
content) .468
CARDIAC ADAPTATION TO HEART FAILURE
Four basic processes are recognised by which the heart may 
attempt to compensate for declining function. Myocardial 
contractility may be increased by activating intrinsic 
myocardial mechanisms according to the Frank- Starling 
principle or by exogenous neuroendocrine factors. In 
addition, cardiac output may be maintained by increasing 
heart rate, and myocardial hypertrophy may occur in order 
to cope with the altered loading conditions of the 
ventricles.
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The Frank-Starling Principle
Both atrial and ventricular muscles behave according to 
Starling's law that "The mechanical energy set free on 
passage from the resting to the contracted state is a 
function of the length of the muscle fibre11.469
In the normal heart, an increase in venous return on 
exercise or due to a rise in intravascular volume distends 
the cardiac chambers (ie increases preload). A concomitant 
change in actin-myosin overlap enhances the myocardial 
contractile state, stroke volume rises and diastolic 
chamber volume tends to return to normal. Sarnoff and 
Mitchell466 examined ventricular stroke work over a range of 
end-diastolic pressures and termed the resulting relation 
the Ventricular Function Curve. Movement along a single 
curve represents operation of the Frank-Starling principle. 
Displacement of the curve reflects a change in inotropic 
state of the ventricle.
In heart failure, the Frank-Starling principle still 
operates but the curve on which the heart functions has 
changed, ie, there is a change in the inotropic state of 
the myocardium. This has its sub-cellular correlate. 
Actin-myosin overlap and sarcomere length seem to be the 
same in a chronically dilated and normal heart. In the 
canine left ventricle, sarcomere length is similar, with 
end-diastolic pressures from normal up to 60 mm Hg. Further 
rises in preload up to 100 mm Hg reduced developed pressure
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by only 7.5%463,470 However, length/tens ion relationships are 
not the same as pressure/volume relationships. According to 
Laplace's law, afterload also increases as the cardiac 
chamber dilates and if there is a decreased cardiac
reserve, reduced myocardial wall shortening in systole will 
occur. The development of mitral regurgitation during 
ventricular dilation may also decrease forward stroke 
volume and result in an apparent depression of ven tricular 
performance as preload is elevated. These two mechanisms 
probably account for the observed depression of cardiac
function at high preloads. It is doubtful if the human
myocardium ever reaches the descending limb of the
Frank-Starling curve. However, chronic ventricular 
dilatation presumably puts the myocyte at a disadvantage 
whenever a further acute increase in loading occurs, as 
during exercise. In the management of heart failure with 
venodilators, the Frank-Starling principle could have more 
adverse consequences: reduced preload may cause an apparent 
decline in cardiac contractility. However, a reduction in 
end-diastolic volume will reduce afterload according to 
Laplace's law. Of course, the reduction in contractility 
due to the reduction in end- diastolic sarcomere length may 
only be temporary, just as ventricular distension leads to 
myocyte slippage, rather than sarcomere lengthening in the 
chronically dilated heart, reduction of dilatation may 
reverse this process.
In summary, the Frank-Starling principle seems designed to
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deal with short term events only, ie, exercise, acute 
volume loading, etc. However, there are advantages in 
reducing ventricular filling pressure and therefore atrial 
and intra-pulmonary pressures. Reducing chamber size will 
also reduce ventricular afterload.
Extrinsic Factors affecting Myocardial Contractility
As we have already observed, the Frank-Starling principle 
is one mechanism by which myocardial contractility can be 
altered to cope with short term changes in volume loading. 
An alternative mechanism of increasing contractility to 
maintain cardiac output and ventricular filling pressures 
is to introduce an inotropic substance. Chief among the 
naturally occurring mechanisms must be cellular handling of 
calcium ions471'473 and the sympathetic nervous system,474-475 
though it should be noted that the latter may mediate its 
effect through changes in cytosolic calcium. There may be 
lesser contributions from glucagon, angiotensin II, 
histamine and sodium.476-480
Intracellular calcium ions and adenosine triphosphate may 
well be the final determinates of the contractile state of 
the myocyte, and are also essential for relaxation. Though 
extra-cellular calcium ions can have a pronounced inotropic 
effect, perhaps most clearly seen in man when 
electromechanical disassociation may result from the 
intravenous use of verapamil,481 cellular calcium ion 
overload could eventually result in cell death.482
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Hypoph°sph°taeinic cardiomyopathy is poorly understood but 
may be due to impairment of glycolytic pathways,483 or 
changes in calcium ion flux across cell membranes.484
A rise in sympathetic nervous system activity appears an 
almost constant accompaniment to cardiovascular stress. In 
untreated heart failure a rise in plasma noradrenaline has 
been shown, even prior to the introduction of diuretic 
therapy. In acutely decompensated heart failure, 
tachycardia, resulting from this increase in sympathetic
nerve activity is common; in chronic heart failure
sympathetic nervous system activity and tachycardia may be 
less marked. This may be due in part to impaired
intracardiac conduction but changes in receptor density or 
function and/or defects in myocardial catecholamine 
synthesis may occur. Bristow and others485 have shown 
evidence of beta-receptor down- regulation on the
myocardium. Down-regulation of beta,,- receptors appears more 
pronounced than for beta2. Although there are many technical 
explanations for down-regulation of beta receptors, the 
observation that in-vitor myocardial tissue also 
demonstrates reduced cardiac sympathetic responsiveness 
strongly suggests a functional as well as a numerical 
reduction in receptor sites. However, evidence also exists 
for a reduction in activity of such enzymes as tyrosine 
hydroxylase, the rate-limiting step in noradrenaline 
synthesis in sympathetic nerve terminals.
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Although several authors have indicated that the 
concentration of contractile proteins within the myocyte 
may be reduced in heart failure, there is no universal 
agreement on this subject. Indeed, some have argued that 
individual myocyte contractile function in heart failure is 
normal, and that no intracellular defect to 
receptor-mediated stimuli exists.
Some of the recent evidence suggesting that individual 
myocyte function in heart failure is normal may seem 
surprising. However, a defect in the collagen matrix in 
which the myocytes exist may be the fundamental problem in 
such conditions as dilated cardiomyopathy. If the collagen 
matrix becomes rigid, then it would become difficult for 
myocytes to either contract or relax. There are limitations 
to the interpretation of the data; in particular, studies 
on isolated myocytes are technically complicated. The 
myocytes that survive the harvesting process may well be 
the "fittest" and cells are generally studied in unloaded 
conditions. It is also possible that myocyte function is 
rapidly restored once the cell is removed from its adverse 
environment.
The Heart Rate
The most obvious means by which the heart compensates with 
increased metabolic demand (ie exercise) is by increasing 
the heart rate. The rise in stroke volume during stress 
makes relatively little contribution to the rise in cardiac
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output. In heart failure the rise in sympathetic drive and 
fall in parasympathetic activity results in a rise in 
resting heart rate to help maintain cardiac output, at 
least in the absence of conducting system disease. This 
phenomenon is much more obvious in acute rather than 
chronic heart failure, and may be related to receptor 
down-regulation or a depletion in cardiac noradrenaline 
stores due to a defect in synthesis, as discussed above. 
Digoxin therapy may also further suppress the heart rate.
There would appear to be no intrinsic harm in raising heart 
rate to maintain cardiac output but if myocardial 
compliance is depressed and ventricular distensibility 
reduced, ventricular filling may be impaired and cardiac 
output compromised. Additionally, most of the coronary 
blood flow occurs in diastole: in heart failure, where
myocardial oxyen supply may be already precarious,488 this 
may further derange myocyte metabolism and cardiac 
contractility.
Myocardial Hypertrophy
In heart failure, afterload is increased both due a rise in 
systemic vascular resistance and due to the dilatation of 
the cardiac chambers, according to Laplace's law. The 
decline in cardiac output is generally proportionally 
greater than the rise in systemic vascular resistance, 
hence, patients with heart failure, as a population, have 
a lower blood pressure than subjects without heart failure
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The stimulus to left ventricular hypertrophy in heart 
failure is, as yet, unknown, but might include alterations 
in sympathetic nerve activity, angiotensin II, local tissue 
messengers, or change in cell function as a direct 
consequence of a change in loading conditions.489,490 In 
patients with hypertension there is some evidence that 
agents that block the sympathetic nervous system or 
angiotensin II production may cause more regression of left 
ventricular hypertrophy than agents such as hydralazine 
that do not.491'493 This suggests that mechanical stress alone 
is not the sole determinant of left ventricular 
hypertrophy. Left ventricular hypertrophy tends to 
normalise the stress imposed on each sarcomere in diastole 
and systole as cardiac volume rises. Of course, this 
normalisation of wall stress requires more energy to deform 
the myocardium itself and may reduce diastolic filling and 
also systolic function. This adaptive process is therefore 
not a perfect answer to the change in loading conditions 
and could be conceived as contributing to the problem in 
some patients.
REGIONAL BLOOD FLOW
The increase in systemic vascular resistance is not uniform 
among the vascular beds. Renal, skin and splanchnic 
vascular resistance are often markedly increased while 
cerebral and coronary vascular resistance are little 
altered. Skeletal muscle blood flow is only slightly
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reduced at rest until heart failure is far advanced, but 
fails to rise normally on exercise even at an early stage. 
Interventions that increase cardiac output may fail to 
increase the blood supply to those organs where it is 
required. Even if the blood flow to an organ does increase, 
it may still be nutritionally ineffective if it bypasses 
metabolically active areas.
CUTANEOUS BLOOD FLOW IN HEART FAILURE
Cutaneous blood flow is reduced at rest only in very severe 
heart failure 494«495. in mild-to-moderate congestive cardiac 
failure, cutaneous blood flow is not significantly reduced 
at rest. However, during exercise, sympathetically-mediated 
cutaneous vasoconstriction becomes marked,495 and is 
sustained throughout the entire period of exercise. In 
addition, as the absolute amount of work done during 
exercise may be less, the thermal stress on the cutaneous 
circulation is reduced.
THE SPLANCHNIC CIRCULATION
In severe cardiac failure the splanchnic blood flow is 
often severely reduced. In milder heart failure splanchnic 
blood flow may be reduced only during exercise.494 The 
splanchnic blood flow seems more under the influence of 
the sympathetic nervous system, with little contribution 
from angiotensin n . 496*497
59
CEREBRAL BLOOD FLOW
In heart failure cerebral blood flow appears to be 
decreased.498,499 Although studies in animals and man have 
shown that cerebral circulation can auto-regulate despite 
a wide variation in perfusion pressure,500 in heart failure 
the cerebral blood flow seems unable to compensate for the 
fall in perfusion pressure. This may be due to increased 
sympathetic activity.501,502 There is as yet no direct 
evidence that angiotensin II or anti-diuretic hormone 
influence cerebral blood flow.
In patients with heart failure, in contrast to normal 
subjects, cerebral blood flow probably declines during 
exercise.
RENAL BLOOD FLOW
As cardiac output falls, so too does renal blood flow.503-505 
In early heart failure this is evident only during 
exercise506 while at rest, renal blood flow, glomerular 
filtration rate, and filtration fraction are normal. With 
worsening cardiac function, the haemodynamics become rela­
tively fixed. Renal blood flow may be further upset by 
arrhythmias commonly seen in this condition.507 In 
experimental heart failure in animals there is also 
redistribution of blood flow, with a relative reduction of 
cortical, compared to medullary, flow. This results in 
diversion of blood to the juxta- medullary nephrons, whose 
loops of Henle and associated vasorecta descend deep into
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the medulla and are re sponsible for counter-current 
exchange, and may be important in maintaining the 
production of a concentrated urea-rich but sodium-poor 
urine that is characteristic of heart failure. Such data as 
exists suggest that re-distribution of renal blood flow in 
favour of the medulla also occurs in heart failure in 
humans, though most studies of renal function have been 
carried out on patients treated with diuretics.508"511
In addition to the fall of cardiac output, other factors 
affecting renal blood flow in heart failure include 
increased sympathetic nerve activity, leading to afferent 
arteriolar constriction, and a fall in renal blood 
flow.512,513 In the early stages of heart failure, the fall in 
renal blood flow may not be accompanied by a corresponding 
fall in glomerular filtration rate because glomerular 
hydrostatic pressure is maintained by efferent arteriolar 
constriction, thought to be mediated by angiotensin n . 514*516 
This leads to an increased filtration fraction, though 
probably a further reduction in renal blood flow. Even 
greater levels of angiotensin II cause, in addition, 
afferent arteriolar constriction, leading to a further fall 
in renal blood flow and glomerular filtration rate.
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SKELETAL MUSCLE BLOOD FLOW
Skeletal muscle blood flow is altered little at rest in 
patients with heart failure until the evidence of cardiac 
dysfunction is severe.517 However, exercise- induced 
vasodilatation is markedly impaired, even in milder degrees 
of heart failure.518'521 Additionally, blood flow to the 
non-exercising limb is considerably reduced, suggesting 
generalised neurendocrine activation with vasoconstriction 
limited in the exercising limb by metabolic factors.
When patients with congestive heart failure exercise, 
freguently the blood pressure shows little or no increase, 
and occasionally exercise-induced hypotension results.521 If 
the resistance vessels in active skeletal muscle dilated 
normally and there were not excessive arteriolar 
constriction elsewhere, syncope would occur more commonly 
during exercise, assuming that the cardiac output could not 
respond adequately.
The origin of the increased vascular stiffness has not yet 
been fully elucidated. Although sympathetic activity is 
heightened during exercise, nerve blockade of the forearm 
or intra-arterial injections of phentolamine into the 
exercising limb fail to normalise arteriolar responses.520 
Infusion of noradrenaline to produce circulating levels 
normally seen during exercise in patients with heart 
failure did not reduce the reactive hyperaemia response. 
However, infusion of noradrenaline in this way is certainly
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not physiological and may represent only a small fraction 
of the sympathetic activity mediated physiologically 
through nerve terminals. However, these studies have really 
only considered the hyperaemic response to a maximal 
metabolic stimulation, whereas alpha-adrenergic tone 
probably only plays a regulatory role during sub-maximal 
stimulation. It generally appears that no vasodilator so 
far tested has been able to substantially alter the 
reactive hyperaemia during limb ischaemia or exercise. One 
factor that might contribute to the arteriolar stiffness 
seen in congestive heart failure is an increased sodium and 
water content of the resistance vessels.522,523 Initially it 
was noted that after diuresis there was some restoration of 
the reactive hyperaemia response towards normal. It was 
also demonstrated that the sodium content of large and 
small arteries is increased. When mineralocorticoids and 
salt are administered to normal volunteers, this may also 
attenuate the peak reactive hyperaemic response.524 Another 
explanation for the altered hyperaemia after ischaemia or 
exercise is increased tissue pressure in patients with 
heart failure.525 Thus, vasodilators per se may have a 
limited role in improving skeletal muscle blood flow during 
exercise. Diuretics or other substances which are able to 
alter the sodium-potassium homeostasis may be more 
effective. Although it has been demonstrated that 
alpha,,-adrenergic receptor antagonists may increase skeletal 
muscle blood flow during sub- maximal exercise, it has also 
been noted that the oxygen consumption of the limb does not
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undergo corresponding improvement. This suggests that the 
increased skeletal muscle blood flow is diverted away from 
the metabolically active muscle.
Changes in skeletal muscle blood flow during exercise in 
heart failure are further complicated by the abnormalities 
of skeletal muscle mass and function. Thus, the reduction 
in limb blood flow could reflect a reduction in oxygen 
requirements of the exercising limb. However, during 
exercise femoral venous oxygen saturation is uniformly 
lower in patients with heart failure, suggesting that 
decreased oxygen requirement is not the cause of reduced 
exercise limb blood flow. Moreover, lactate production 
during exercise is greater in patients with heart failure,526 
suggesting that the metabolic stimulus during exercise to 
reduce arterial dilatation is greater in heart failure 
sub j ects.527*529
SUMMARY
The cardiovascular adaptations to chronic heart failure are 
complex. They involve not only the heart but also the 
peripheral circulation. These are closely integrated, but 
the relationship between the two is markedly different 
during exercise.
Although heart failure is characterised by markedly 
elevated vascular resistance, this varies considerably 
among the regional circulations. Non-specific
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vasodilatation may reduce vascular resistance. However, if 
this diverts blood from the renal circulation at rest, or 
the cerebral or skeletal muscle circulations during 
exercise, it could be deleterious.
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CHAPTER 6: VASCULAR TONE IN HEART FAILURE: THE
NEUROENDOCRINE-THERAPEUTIC INTERFACE 
INTRODUCTION
Impaired cardiac function is of course the primary problem 
in heart failure, but it is also the primary stimulus to 
activation of several integrated neuroendocrine systems. 
This results not only in a general increase in vascular 
tone but also changes in regional arterial resistance. 
Activation of these neuroendocrine systems at first appears 
to have important beneficial effects for the failing 
circulation, maintaining cardiac output, blood pressure and 
blood flow to essential organs. However, prolonged or 
extreme neuroendocrine activation may prove deleterious.
The advent of effective diuretics had tremendous impact on 
the management of patients with heart failure, but then, in 
the absence of a cure for the primary problem, thoughts 
turned to altering vascular tone and it soon became 
apparent that the body countered this with heightened 
autonomic and humoral activity. The success of 
angiotensin-converting enzyme inhibitors has highlighted 
the benefits of damping down this neuroendocrine 
activation.
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HISTORICAL PERSPECTIVES
Before the 1940's, theories on the nature of the 
circulatory disorder in heart failure abounded but the 
means of treating the condition were limited. The advent of 
cardiac catheterisation, methods of measuring regional 
blood flow and, finally, non-invasive measures of 
cardiovascular function, have contributed to better 
understanding of the interplay between the failing heart 
and the abnormal circulation that it still supports.
While Sharpey-Schafer 530 and McMichael 531 described the 
relationship between cardiac output and venous pressure in 
heart failure in the 1940's, Wood 532 recognised the 
importance of systemic vasoconstriction in the maintenance 
of blood pressure. These observations were brought together 
in the 1960's and integrated the concepts of altered 
preload, after load and myocardial contractility.533'535
As understanding of the pathophysiology of heart failure 
grew, so did the therapeutic armamentarium. Although the 
efficacy of digoxin for patients in sinus rhythm has 
remained controversial,536,537 no other inotropic agent has 
yet been more effective or safe.538
Mercurial diuretics, introduced in the 1920's, thiazides in 
the 1950's and loop diuretics in the 1960's all made 
substantial contributions to the alleviation of symptoms 
although they may indirectly have had deleterious
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haemodynamics and neuroendocrine effects.
The concept of reducing vascular tone in heart failure is 
remarkably old. Osier (1892) used nitroglycerine539 and 
Savill (1936) suggested sympathectomy as a treatment for 
intractable heart failure540. These ideas gained substance 
in the 1950's, with the use of ganglion- blocking 
agents541,542 and nitrates.543 Since then, nitrates have 
achieved a lasting place in the management of pulmonary 
oedema. The use of phentolamine in the 1970's ushered in 
the "modern" era of vasodilator therapy.544 However, until 
the appearance of angiotensin-converting enzyme inhibitors 
in the 1980's, vasodilators had achieved no firm role in 
the management of chronic heart failure. In contrast to 
preceding agents, ACE inhibitors suppress the 
neuroendocrine consequences of heart failure, but, like 
them, tend to cause a further fall in arterial pressure.
"DIRECT"-ACTING VASODILATORS
Arteriolar Vasodilators
Daly has shown that in contrast to ACE inhibitors, the 
combination of nitrates and hydralazine leads to an 
increase in transmyocardial noradrenaline release which 
contributes to a rise in arterial noradrenaline, adrenaline 
and renin.553 The increase in renin may also be 
prostaglandin-mediated in part, 554 but is generally not 
paralleled by an increase in aldosterone, which may reflect 
effects on hepatic clearance or adrenal release.
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Calcium antagonists cause a natriuresis and diuresis when 
used in very low doses in hypertensive patients, but this 
effect may be reversed by higher (hypotensive) doses. 
Whether the same is true in heart failure is unknown. 
Carefully controlled studies of sodium and water balance 
after hydralazine are lacking but what evidence there is 
suggests that fluid retention may occur,555 whereas minoxidil 
causes such gross fluid retention that it may be difficult 
to control with diuretics.556
Thus, activation of vasoconstrictor mechanisms, plus salt 
and water retention, may attenuate the haemodynamic 
benefits of many arterial vasodilators, and explain the 
apparent development of tolerance. Despite this, the 
combination of isosorbide dinitrate with hydralazine 
appears to favourably affect the prognosis in heart 
failure.557 Newer arterial vasodilators such as flosequinan 
may not activate neuroendocrine systems and initial reports 
on therapeutic efficacy are encouraging.559
Organic and Inorganic Nitrates
These compounds reduce both arteriolar resistance and 
venous tone. The reduction in preload may limit the 
increase in cardiac output or even cause it to fall. 
Tolerance to nitrates is common and appears largely 
mediated through endothelium-dependent mechanisms. However, 
activation of the renin-angiotensin system559 and plasma
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volume expansion560 may also contribute to nitrate tolerance 
in heart failure. At present, it is uncertain whether 
intermittent dosing or concomitant administration of 
N-acetylcysteine can prevent tolerance to nitrates.
Although stimulation of the renin-angiotensin and 
sympathetic nervous system by sodium nitroprusside is 
attenuated in heart failure, a rebound increase in vascular 
resistance may occur after sudden cessation.561 This may be 
prevented by phentolamine562 and is probably mediated through 
neuroendocrine activation. A reduction in atrial pressure 
and consequently in plasma atrial natriuretic peptide could 
also lead to a rise in plasma renin.
There is no convincing evidence that nitrates are effective 
in reducing symptoms or increasing exercise performance in 
chronic heart failure, though they are highly effective in 
acute heart failure by reducing atrial pressure. Studies 
that purport to show benefit in chronic heart failure are 
hampered by small numbers, poor study design and variations 
in diuretic dose.563,564
Inodilators
This is a recently-coined phrase for phosphodiesterase 
inhibitors and dopamine analogues which, although 
originally thought to act mainly as inotropes, exert many 
of their effects through vasodilatation.565 These drugs all 
tend to reduce vascular resistance and atrial pressure
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while increasing cardiac output. Limb blood flow is most 
strikingly increased, with little efect on renal or 
hepatomesenteric blood flow.
Phosphodiesterase inhibitors have shown conflicting effects 
on plasma noradrenaline and arginine vasopressin, though 
plasma renin increases and atrial natriuretic peptide 
falls.566,567 The significance of these findings is as yet 
unclear.
Clinical studies have generally not shown much benefit 
during long-term treatment with amrinone or milrinone and 
survival may even be impaired.568 Recent studies with 
enoximone are more promising.569
VASODILATORS ACTING THROUGH INHIBITION OR ACTIVATION OF 
NEUROENDOCRINE SYSTEMS
Aloha-adrenergic Receptor Antagonists
Phentolamine, the first drug of this class to be used in 
heart failure, inhibits both post-(alpha,,) and pre- (alpha2) 
synaptic alpha-receptors. Tachycardia and postural 
hypotension were common and led to the development of 
selective alpha-l-receptor antagonists such as prazosin, 
trimazosin and doxazosin.
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Alpha-l-receptor Antagonists
These agents reduce both arterial and venous tone. Limb 
blood flow is increased, particularly during sub-maximal 
exercise570 when sympathetic tone usually limits 
exercise-induced vasodilatation. However, oxygen extraction 
does not appear to change.571 Tolerance is common. Increased 
sympathetic activity during exercise may be beneficial, at 
least in mild heart failure, by directing the limited 
cardiac output to the metabolically most active muscles.572
Prazosin is not very selective (about 10:1) and inhibition 
of the alpha2-receptor may intensify sympathetic and 
renin-angiotensin system activity.573,574 This activation, 
combined with a reduction in atrial natriuretic peptide and 
renal perfusion pressure may excacerbate sodium retention, 
reversing the beneficial direct effects of prazosin- 
induced vasodilatation. Unfortunately, trimazosin, which is 
more selective, does not appear more effective or less 
likely to give rise to tolerance. Spironolactone575 and 
captopril576 have both been used to try and prevent fluid 
accumulation with prazosin, without success.
Clinical experience with these agents again suggests no 
benefit from vasodilator therapy,577,578 while some studies 
demonstrate an adverse outcome.574,576
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Alpha-2-Receptor Antagonists
Clonidine, a centrally-acting alpha2-receptor agonist, may 
reduce sympathetic activity. No clinical benefit has been 
noted.579 Methyldopa has also been used to reduce central 
sympathetic activation in heart failure but without 
objective evidence of benefit.580
Drugs acting on Beta-adrenergic Receptors
Beta-1 Receptors
Pure agonists are vasoconstrictive, arrhythmogenic, 
activate the renin-angiotensin-aldosterone system and, in 
excess, may cause myocardial necrosis. Antagonists reduce 
myocardial oxygen consumption and arrhythmias but their 
negative inotropic qualities sometimes exacerbate failure. 
Partial agonists such as xamoterol are promising but, as 
their effects are more on the myocardium than on the 
periphery, will not be discussed further.
Beta-2-Receptors
Beta-2 agonists have proved disappointing in clinical use. 
Dopexamine may activate both the sympathetic and 
renin-angiotensin systems,581 while rapid tolerance has been 
demonstrated in some studies.582 This could be due to 
neuroendocrine excitation but receptor down- regulation or 
uncoupling seems just as likely.583
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Dopamine Analogues
Fenoldopam (a DA,, agonist) also produces vasodilatation but 
may activate both the sympathetic and renin- angiotensin 
systems.584 Dopamine (DA2) receptor stimulation by orally 
active analogues such as bromocriptine may cause a decline 
in sympathetic nervous activity with consequent 
vasodilatation.585 Levodopa and ibopamine may have additional 
direct inotropic effects.586,587 However, withdrawal of 
sympathetic support from the failing heart may 
counterbalance the benefit of peripheral sympathetic 
inhibition. Proof that dopamine and its analogues are 
effective in the management of chronic heart failure is 
still awaited.
Anti-diuretic Hormone
Arginine vasopressin,, -receptor antagonists have little 
haemodynamic effect in heart failure unless arginine 
vasopressin is markedly elevated, when a marked reduction 
in atrial and arterial pressures and an increase in cardiac 
output may be observed.588
Atrial Natriuretic Peptide
Infusion of pharmacological doses of atrial natriuretic 
peptide in heart failure results in peripheral 
vasodilatation, an increase in cardiac output and a 
reduction in atrial pressures. Compared to normal subjects, 
such patients have a diminished (though not absent)
74
diuresis and natiuresis, with little change in glomerular 
filtration rate.589 Although aldosterone is suppressed and 
plasma noradrenaline tends to fall, plasma levels of 
arginine vasopressin are generally unaffected.590 Plasma 
levels of renin are also unchanged, suggesting that the 
stimulus to renin secretion caused by the vasodilatation is 
balanced by a direct inhibition of renin secretion. 
Atriopeptidase inhibitors are an alternative method of 
increasing atrial natriuretic peptide and have been shown 
to have natriuretic effects in heart failure.591
Prostaglandins
Prostacyclin is a powerful vasodilator but has little 
effect on sympathetic or renin-angiotensin system 
activity.592 Infusion of prostaglandin E has similar effects 
but may also cause renin release.593
Bradvkinin
Bradykinin degradation is inhibited by captopril and could 
be responsible for the venodilating effect of captopril. 
Studies on aprotinin, which inhibits the formation of 
bradykinin, have failed to demonstrate any attenuation of 
captopril's effects in heart failure.594
Serotonin
Preliminary studies on ketanserin, which selectively blocks 
5-HT2 receptors, indicate that it may cause vasodilatation 
and an increase in cardiac output.595 Plasma catecholamines
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increase, perhaps due to inhibition of neuronal re-uptake.
Renin-Anaiotensin-Aldosterone System
Inhibition of the enzyme renin may prove to be the most 
specific way of preventing angiotensin II formation. Human 
studies in heart failure are awaited.
Saralasin, a competitive inhibitor of angiotensin II at its 
receptor, has partial agonist activity, but again 
experience of its use in heart failure is limited.
CONCLUSION
Although direct acting vasodilators might be expected to 
improve symptoms and exercise performance in heart failure, 
they have proved disappointing. Most vasodilators appear to 
increase blood flow to skeletal muscle but there is no 
evidence that this leads to increased oxygen utilisation 
during exercise. There is compelling evidence that 
administration of vasodilators to patients with chronic 
heart failure will generally lead to further neuroendocrine 
activation which may limit their therapeutic efficacy. 
Angiotensin- converting enzyme inhibitors may circumvent 
this problem by prevention of angiotensin II formation 
which in turn will lead to reduced sympathetic activity and 
aldosterone production.
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PART TWOS METHODS AND RESULTS
CHAPTER 7S METHODS
THE ASSESSMENT OF SYMPTOMS
Symptoms were assessed according to the New York Heart 
Association classification, as outlined in Table 7.1. This 
is a fairly crude estimate of the severity of heart 
failure, yet appears meaningful, at least in studies on 
prognosis in heart failure. New York Heart Association 
class was also used as a guide to alteration in symptoms 
after therapeutic intervention but as it was felt that such 
a division would fail to demonstrate subtle changes, 
symptoms were also assessed by direct questioning and by 
visual analogue scores.
Direct Questioning
In some studies, the assessment of changes in symptoms was 
also made by direct questioning while both doctor and 
patient were kept "double-blind". In this way, observer and 
inappropriate patient bias was eliminated. Patients were 
asked at the end of each part of the study to say whether 
or not they felt improved. At the end of the trial the 
patients were then asked to state which period of "therapy" 
had benefited them most.
This form of symptom assessment is probably the most 
sensitive index of change but is difficult to quantify.
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TABLE 7.1
Criteria for New York Heart Association Functional
Classification
I Patients without limitation of physical activity.
Ordinary activity does not cause undue fatigue, 
palpitation, dyspnoea or anginal pain.
II Patients with slight limitation of physical
activity. They are comfortable at rest. 
Ordinary physical activity results in fatigue, 
palpitation, dyspnoea or anginal pain.
Ill Patients with moderate limitation of physical
activity. They are comfortable at rest. Less 
than ordinary physical activity causes fatigue, 
palpitation, dyspnoea, or anginal pain.
IV Patients with inability to carry on any physical
activity without discomfort. Symptoms of cardiac 
insufficiency or anginal syndrome may be present 
even when the patient is at rest.
Visual Analogue Scores
Visual analogue scores were applied "double-blind", the 
patient being asked to mark a point on a 10 cm ungraduated 
line (see examples) corresponding to their symptoms. At the 
end of each study period the patient was asked to score 
himself/herself again, but without referring back to the 
previous scores. The possibility of systematic errors of 
such a method of assessing symptoms has been suggested. In 
order to investigate this possibility we studied 20 
patients during the open run-in phase of the study on 
enalapril. Visual analogue scores were applied before and 
four weeks later, at the end of this run-in period. The 
results are outlined in Table 7.2. No significant change in 
mean scores was noted, although there was considerable 
individual variation. Further evidence for a lack of any 
systematic drift of scores came from a study on amiodarone 
in heart failure where a similar scoring system was used.596 
During this double-blind placebo- controlled study of a 
drug which did not alter symptoms of breathlessness, 
fatigue or ankle swelling by direct questioning, no change 
in mean visual analogue scores was noted over a 6-month 
period.
THE MEASUREMENT OF BLOOD PRESSURE AND HEART RATE
Blood pressure was measured with a Hawksley random zero 
sphygmomanometer unless measured directly, intra- 
arterially (vide infra). Pressure readings were taken using 
a standard forearm cuff with phase I Korotkoff sounds taken
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TABLE 7.2
Breathlessness
mean
median
range
Tiredness (mm)
VISUAL ANALOGUE SCORES
n=20
Run-in period 
Pre- Post-
(mm)
58 55
64 61
16-98 15-92
mean
median
range
49
61
2-100
51
58
0-100
as systolic and phase V as diastolic. Mean arterial 
pressures for this method were calculated as the diastolic 
pressure plus one-third of the pulse pressure. Heart rate 
was derived from the apex beat for patients in atrial 
fibrillation and from the radial pulse in those in sinus 
rhythm. During exercise testing and tests of autonomic 
function, heart rate was derived from the 
electrocardiogram.
THE 12-LEAD ELECTROCARDIOGRAM
The 12-lead electrocardiogram was recorded in the standard 
manner. QT intervals were measured from the same lead on 
each occasion; the lead in which the QT interval could most 
clearly be defined being chosen. The QT was defined by 
extrapolating the maximal downslope of the T wave to the 
isoelectric line and measuring the distance to the 
preceding Q wave.597 Difficulties arose in the interpretation 
of the QT interval as many subjects had intra-ventricular 
conduction defects. The JT interval was therefore also 
recorded by subtracting the QRS width from the QT interval. 
QT and JT intervals were also corrected using Bazett's 
formula.
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EXERCISE TESTING IN PATIENTS WITH HEART FAILURE
Exercise using a motorised treadmill was used in preference 
to a bicycle ergometer as this was thought more closely to 
simulate the ordinary activity of our patients.
Heart rate was monitored by a 12-lead electrocardiogram, 
with ST segment monitoring to detect evidence of serious 
ischaemia or arrhythmias. Blood pressure was monitored with 
a sphygmomanometer, (vide supra).
Patients were all familiarised with walking on a treadmill 
on at least one occasion before entering a study. Patients 
were taught to use a surrounding bar for balance, and 
taught not to perform isometric exercise (the "wheel-barrow 
effect") which might have altered oxygen consumption, blood 
pressure, and exercise performance.
The effects of test familiarisation and the effects of 
placebo on treadmill exercise performance were assessed 
separately in 20 patients undergoing exercise (see appended 
abstract A). In short, exercise time may double from the 
time of initial exercise to the end of a trial of placebo. 
Approximately half of the improvement appears to be due to 
the learning process and half to be due to the introduction 
of placebo.
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Abstract
In patients with chronic heart failure undergoing exercise 
testing for the assessment of new therapies the relative 
contributions of familiarisation with the procedure and the 
so-called placebo effect are uncertain.
Accordingly we assessed the exercise responses in 20 patients 
with heart failure, mean age 57+9years. The aetiology was 
ischaemic heart disease in 11, cardiomyopathy in 7 and persisting /
heart failure after succesful valvar surgery in two. Patients 
were exercised twice before and once after an open run-in period, 
prior to randomisation to placebo or a cardioactive drug. The 
placebo response was then estimated only in those 20 patients 
randomised to placebo first. This ensured that both the doctor 
and patient were kept double-blind to prevent a bias towards no 
response. Four patients who died and 18 patients who received 
active therapy first were excluded from the final analysis. The 
active therapies being considered were enalapril and amiodarone.
The treatment periods were 2 months and 3 months respectively.
All patients were exercised using a modified Bruce Protocol with 
heart rate and blood pressure monitoring. Breathlessness or 
tiredness was the end-point in 76 of the 80 tests performed and 
sustained ventricular arrhythmias in four. Values are mean £ 
standard deviation. Analysis of variance was used to test for 
differences between each test period. When a statistical 
difference was found student’s t-test was used to confirm likely 
differences.
The initial exercise time Was 5.3±3,1 minutes and increased to 
7.9+4.6mins (p<0.01) at the start of the run-in phase. Exercise 
increased insignificantly during the run-in phase to 
8.4±2.3mins., but after placebo increased further to 
10.1±3.9mins.(p<0.01). Despite the increase in exercise 
performance, peak exercise heart rate and blood pressure were not 
statistically significantly different at each time point.
The contribution of the placebo effect seems similar to that of 
familiarisation with the exercise protocol in this study where 
placebo was administered double-blind.
As patients with heart failure have a considerably reduced 
exercise performance compared to healthy controls, 
protocols were modified accordingly (Table 7-3). Initially, 
a modified Balke protocol was used in the study on
captopril. This was subsequently felt not to be an optimal
form of exercise for patients with heart failure and was 
substituted with a modified Bruce protocol for the study on 
enalapril. Although both the patients, the exercise
protocol, and the benefits of therapy were robust enough to 
show changes, it became clear that some patients were 
stopping due to fatigue and others due to breathlessness. 
This prompted an investigation into differing exercise 
protocols and their relationship to the symptom terminating 
exercise in patients with heart failure598,599 and also their 
effects on maximal achieved oxygen consumption. In summary, 
exercise protocols involving very gradual stages were 
usually terminated by fatigue, whereas protocols which 
increased speed or inclination rapidly were usually
terminated with breathlessness. In the study on angina, 2 
"arithmetic" exercise protocols were applied to the 
patients, one with very gradual increases in workload, the 
other with much more rapid increments.598
In the study of angina and heart failure, cardio­
respiratory performance was also assessed by measuring the 
volume and partial pressures of exhaled gases using a 
Horizon Mobile Metabolic Cart (Sensormedics). Gas volumes 
were calculated from the speed of rotation of a finely
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TABLE 7.3
MODIFIED
BALKE
MODIFIED
BRUCE
Stage Time Speed 
(min) (mph)
1 3 2
2 3 2.5
3 3 3
4 3 3
5 3 3
1 3 1.7
2 3 1.7
3 3 1.7
4 3 2.5
5 3 3.4
6 3 4.2
Gradient Predicted
(%) oxygen con
sumption 
(ml/min)
0 7
4 14
8 21
12 28
16 33
0
5
10
12
14
16
tuned turbine, carbon dioxide using infra-red spectroscopy, 
and oxygen by a polarographic method. In this way oxygen 
consumption was determined. Maximal oxygen consumption is 
an index of peak cardiac output during exercise, and
appears to be a more reproducible measure of
cardiopulmonary performance than exercise time alone.599*600 
Measurement of minute ventilation and carbon dioxide 
production allows an assessment of the anaerobic threshold.
ASSESSMENT OF LEFT VENTRICULAR FUNCTION 
Systolic Time Intervals
Systolic time intervals were calculated from the standard 
lead II of the electrocardiogram and high quality M-mode 
echocardiograms of the aortic valve. All recordings were 
made at a paper speed of 100 mm/sec. Only patients in sinus 
rhythm were studied thus. The pre-ejection period was 
measured from the onset of the QRS to the time of opening 
of the aortic valve. The left ventricular ejection time was 
measured as the duration of opening of the aortic valve.
Electro-mechanical systole was taken as the sum of
pre-ejection period (PEP) and the left ventricular ejection 
time (LVET) . Appropriate corrections were made for heart 
rate for each of these intervals.601'604
Changes in pre-ejection period mainly reflect changes in 
left ventricular preload, assuming that the intrinsic
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ventricular function remains constant, a fall in preload 
leading to a prolongation of the PEP. An increase in 
afterload may also prolong the PEP. Although left bundle 
branch block prolongs the PEP, this is of little relevance 
when within-patients comparisons are made.
The LVET may be prolonged by a fall in afterload or an 
increase in preload. The reduction in LVET in heart failure 
is due to a reduction in overall myocardial fibre 
shortening. The duration of electromechanical systole 
shortens as the inotropic state of the ventricle increases. 
The ratio of the pre-ejection period to left ventricular 
ejection time correlates with angiographically-derived left 
ventricular ejection fraction.604
M-Mode Echocardiography
M-mode echocardiograms were taken with simultaneous two- 
dimensional echocardiography (IREX) to ensure correct and 
reproducible orientation. M-mode echocardiograms were 
analyzed on a dedicated digitising board (KONTRON), with 
the results of at least 6 cardiac cycles averaged.
The criteria for quantification of the M-mode 
echocardiogram were those proposed by Sahn605 and accepted 
by the American Society of Echocardiography in 1978. These 
methods have been found to be reproducible by several 
authors, even when used for repeat measurements over 
considerable periods of time.606
83
Left ventricular end-diastolic dimensions were timed at the 
onset of the R-wave and were taken at the level of the tips 
of the mitral valve leaflets. End-systolic dimension was 
taken as the smallest perpendicular systolic dimension. 
Fractional shortening was calculated as left ventricular 
end-diastolic dimension minus left ventricular
end-systolic dimension, divided by the end-diastolic left 
ventricular dimension.
The use of M-mode echocardiography in patients with heart 
failure due to ischaemic heart disease has been criticised 
as regional rather than uniform, global dysfunction is the 
rule. However, we were making within-patient comparisons, 
therefore such objections are less important. Incorporation 
of an infarcted segment in the region measured by M-mode 
echocardiography could fail to identify improvement in 
ventricular function at other sites, thus leading to an 
under-estimate of any improvement with angiotensin- 
converting enzyme inhibitors.
Doppler Echocardiography
Continuous wave Doppler signals were recorded from the 
cardiac apex (DOPTEK). Only patients with high quality 
Doppler signals were chosen for this study. The area under 
the curve (the velocity-time index) was measured by 
planimetry and the average of 10 cycles obtained. The 
outflow tract radius was taken as the aortic valve orifice,
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according to the method of Ihlen.607 Stroke volume was 
calculated as the square of the outflow tract radius x ii 
x the velocity-time index. Cardiac output was then 
calculated as heart rate x stroke volume. Doppler-derived 
cardiac outputs have been compared with cardiac outputs 
using the thermodilution technique. The largest error in 
measuring cardiac output appears to be the calculation of 
the left ventricular outflow tract dimensions. As this 
probably varies little within a subject over a period of 
months, the outflow tract dimension was calculated only 
once, and used repeatedly for serial comparisons.
The reproducibility of this technique in our hands, given 
suitable subjects, is illustrated in Figure 7.1. For 
within-patient comparisons, this technique appears 
satisfactory.
Monitoring Pulmonary and Systemic Arterial Pressure 
directly
All pressures were recorded with 23Db Stratham transducers 
placed at mid-chest height, and a multi- channel pen 
recorder (Mingograph, Elema Siemens). Patients were studied 
in the supine position, and at least 6 hours after the last 
meal and last routine medication. Pulmonary arterial 
pressures were measured by a size 7 Swan-Ganz flow-directed 
thermodilution catheter inserted via an antecubital vein 
into the pulmonary artery. Cardiac output was measured from
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3-5 sequential injections of 10 ml of chilled 0.15M saline 
solution. Output was calculated from a model 9520A Ed wards 
computer. Arterial pressures were measured via a radial 
artery cannula and recorded by a Gould P23 ID transducer. 
Mean pressures were obtained by electronic integration.
Radionuclide Ventriculography
Patients were injected with 1-3 mg of stannous 
pyrophosphate, 15 minutes prior to injection with 550 MBq 
of "m-Technetiurn to label the patients' own red blood cells.
Rest and exercise ejection fractions were assessed by 
multiple uptake gated acquisition, triggered from the R- 
wave of a simultaneous ECG recording, and a multi- crystal 
gamma camera. Images were acquired in the supine position, 
with bicycle exercise also supine, starting at a 25 Watt 
load and increasing by 25 Watts every 2 minutes.
Resting images were acquired over 600 cardiac cycles and 
exercise images over 300 cardiac cycles.
AMBULATORY ELECTROCARDIOGRAPHIC MONITORING
Ambulatory electrocardiographs were recorded for 48 hours 
using a Medilog I system (Oxford). Electrodes were placed 
in the modified VI or V5 positions and checked for 
satisfactory impedance values before connection to the 
recorder. Tapes were analyzed using a semi- automated
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playback system at 60 times normal speed, with expert 
visual supervision and without knowledge of the patients' 
cardiac or treatment status. The frequency of ventricular 
extra-systoles and couplets were counted, while more 
complex arrhythmias were printed for later consideration. 
Ventricular salvoes were defined as 3 or more consecutive 
beats at any rate and ventricular tachycardia as 3 or more 
consecutive beats at more than 120 beats per minute.
THE MEASUREMENT OP RENAL FUNCTION
Several measures of renal function will be reported in this 
thesis. At its most simple, serum urea and creatinine are 
a useful reflection of renal function; monitoring these 
proved a useful guide to the glomerular filtration rate in 
this study. Serum urea and creatinine will reflect the
cumulative effects of several days of renal function, and
thereby may be markers of changes in renal function to a 
variety of stimuli, eg, exercise, etc, which will not be 
observed under the more controlled conditions outlined 
below.
However, both compounds are incompletely filtered at the 
glomerulus and both show variable reabsorption and
excretion in the renal tubule. That angiotensin converting 
enzyme inhibitors can alter tubular function as well as 
glomerular filtration seems certain, therefore more
detailed and precise methods of measuring renal function
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are warranted. However, measurement of glomerular 
filtration rate by the other methods in this study reflect 
renal status over relatively short periods of time.
Clearance of substances by the kidney with measurements in 
blood and urine constitutes the second method of 
measurement. We have measured renal clearance of digoxin as 
well as sodium, potassium, magnesium, phosphate, urea and 
creatinine. For the determination of the clearance of urea 
and creatinine, 24 hour urine collections with paired sera, 
from the beginning to the end of the collection period, 
were used. In those studies using digoxin and phosphate 
clearance, 6 hour urine collections were made. This shorter 
collection period allowed us to study patients with heart 
failure before and after they received their required daily 
treatment with diuretics. This is important as diuretics 
such as frusemide necessarily affect renal tubular function 
and are therefore likely to alter drugs which undergo 
tubular excretion or reabsorption. Clearance was calculated 
by calculating the mean serum level over the six hours from 
timed samples at the start of the urine collection, at 3 
hours and at 6 hours. Digoxin was always given at least 6 
hours before starting urine collections to ensure that the 
peak drug concentration occurred before sampling and that 
a relatively simple decay curve was being observed.
Thirdly, single radio-isotope injection techniques were 
used to measure glomerular filtration rate (40 MBq 99m'
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Technetium-DTPA or 51Cr-EDTA) and effective renal plasma 
flow (1 MBq of chromatographically pure 131i- hippuran or 
1251-hippuran) .608-610 The volumes used were 4 ml and were 
accurately measured. Patients were kept on strict bed rest 
for the period of study and were always given exactly the 
same treatment apart from the drug under scrutiny (ie, 
captopril, enalapril or frusemide), and were always studied 
at the same time of day and with the same relationship to 
meals. Six ml plasma samples were taken from the opposite 
arm into lithium-heparin tubes at baseline (for a 
background count) 20 minutes, 45 minutes, 2, 3, 4 and 6
hours after injection. Analysis of over 100 studies 
revealed that the background, 45 minute and 2 and 4 hour 
samples carried all the useful information and subsequently 
analysis was performed using only these samples. Renal 
blood flow was calculated from the following formula: renal 
blood flow = effective renal plasma flow x 1- haematocrit. 
As not all the blood flowing to the kidney passes through 
a glomerulus (ie blood flow to the renal papillae) and 
since 131I-hippuran is not 100% extracted in the glomerular 
filtrate, measurement of renal blood flow may be 
underestimated. Angiotensin converting enzyme inhibitors 
may decrease the efficiency of renal hippuran extraction. 
The measurements of renal blood flow that I have used may 
have underestimated the increase in renal blood flow during 
ACE inhibition to a proportionally greater extent.
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Renal vascular resistance was calculated as: 80 (mean
arterial pressure (mm Hg) x (renal blood flow (1/min)).
The filtration fraction was taken as the ratio of the 
glomerular filtration rate to the effective renal plasma 
flow, as by convention.
Using data obtained from baseline and placebo phases of the 
clinical trials we have performed, the standard error of 
the estimate was 3 ml/minute for the glomerular filtration 
rate and 32 ml/minute for effective renal plasma flow. The 
difference in accuracy between the two measures may 
reflect some inferiority in the techniques for measuring 
plasma flow. However, physiological control of glomerular 
filtration is tightly held while renal blood flow is much 
more variable, which could also account for the observed 
difference.
Tubular Function
Tubular function was assessed from the fractional excretion 
of sodium, potassium and phosphate. For these studies, 
patients were admitted to the ward and commenced on diet 
with 100 mmol sodium, 40 mmol potassium and 2,500 ml fluid, 
48 hours prior to the study. The amount of electrolyte 
filtered at the glomerulus was calculated by multiplying 
the creatinine clearance by the mean plasma concentration 
of the electrolyte obtained from 3 samples over the 6-hour 
study period. Urine volumes were measured over 6 hours and
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the urinary concentration of electrolytes calculated. The 
fractional excretion of electrolyte was expressed as that 
percentage of the electrolyte filtered at the glomerulus 
that was actually found in the urine. Whereas sodium is 
absorbed by a variety of mechanisms throughout the length 
of the renal tubule, phosphate is largely reabsorbed in the 
proximal tubule.611 Potassium may be reabsorbed at several 
sites along the renal tubule but may be exchanged for 
sodium in the distal tubule under the influence of 
aldosterone. (See Chapter 2).
PLASMA VOLUMES
Plasma volumes were estimated by measuring plasma 
radioactivity before and 10 minutes after the injection of 
125I-human serum albumin. Blood volume was calculated using 
the haematocrit. It was assumed that the red cell mass was 
constant over periods of less than 3 days, allowing short 
term serial follow up of plasma volume.
THE ANALYSIS OF WHOLE BODY COMPOSITION 
The Measurement of Total Body Potassium
Total body potassium was derived from endogenous 40 K using 
a sodium iodide detector with both the patient and detector 
shielded by 10 cm of lead. The patient passed the detector 
at a uniform speed on a motorised couch, first supine, then 
prone in the reverse direction. The estimated coefficient
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of variation is +3.9% for a subject with 3,600 mmol of 
potassium.612 This method has been validated using phantoms 
containing a known quantity of potassium (40K) in solution 
by Lye et al, who found a similar level of accuracy.613
Total Body in-vivo Neutron Activation Analysis
Total body sodium, chlorine, calcium, phosphorus, nitrogen 
and oxygen were measured simultaneously by total body 
in-vivo neutron activation analysis using two sealed tube 
14 MeV generators.614'627 Subjects lay on a motorised couch 
which passed between the neutron tubes at a constant speed 
of 52 mm/second and received a simultaneous bilateral 
scanning irradiation. The radiation dose received was one 
REM (10 MsV) at the body surface.
i
Induced radioactivity was then measured in a high 
sensitivity shadow shielded whole body counter using 2 
large sodium iodide detectors by repeated counting scans 
for up to 30 minutes after irradiation. The following 
reactions were examined and from calculation of the induced 
radioactivity the total amount of each element shown was 
calculated.
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Table 7.4
Element Reaction t/2 %S.D.*
(minutes)
Sodium 23Na-24Na 901.80 2.9
Chlorine 37C1-38C1 37.18 4.0
Calcium 48Ca-49Ca 8.72 3.5
Phosphorus 31P -28A1 2.24 2.1
Nitrogen 14N -13N 9.97 2.2
Oxygen 16N -14N 0.12 2.9
*Derived from variance in repeated measurements on phantoms 
of known consistency.614,615
This technique has been extensively validated against 
"phantoms" of varying size with known chemical composition 
and shown to be highly accurate and reproducible. 
Measurements have also been made in animals which were 
subsequently cremated and then analyzed for body 
composition. These have also substantiated the validity of 
the technique. Limited data are available on repro­
ducibility in man due to the relatively high radiation
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exposure required for repeat studies. Patients with heart 
failure have a poor prognosis, therefore repeat studies 
were ethically permissible.
Total body sodium is made of 2 main components. A "rapidly 
exchangeable" component is present largely in the
extracellular space though intracellular sodium may 
increase in heart failure. A second, "slowly exchangeable" 
component, comprising about 25% of all sodium, is present 
largely in bone.619
Chloride is mostly present in the extracellular space and 
is almost entirely exchangeable.622 Total body chlorine 
correlates well with bromide space and extracellular fluid 
volume may be calculated by dividing total body chlorine by 
serum chloride concentration with a 10% reduction to allow 
for intracellular chloride.
Calcium and phosphorus are largely present in bone and show 
little change except over long periods of time. However, 
they form a useful standard for studies performed weeks 
apart.
Nitrogen is an index of protein mass: muscle, collagen and 
the viscera being the major sites of this element. 
Therefore, nitrogen is a useful index of lean body mass.
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Most of the element oxygen is present as water. This 
measurement is an index of total body water.
Values are expressed in millimole for sodium, potassium and 
chlorine, in grams for calcium, phosphorus and nitrogen, 
and kilograms for oxygen. Results for whole body elements 
were also compared with and expressed as a percentage of 
predicted values for healthy subjects matched for height, 
weight, age and sex. The normal values for total body 
potassium were predicted from those obtained by Boddy et 
al.612 Potassium was also expressed as mmol/g of nitrogen, 
as suggested by Burkinshaw and Morgan.623
Normal values for sodium and calcium were derived from 
measurements by Ellis et al.620 Equations for the prediction 
of chlorine were based on measurements of extracellular 
fluid space using radioactive bromine. "Dry" weight was 
estimated in the heart failure group by correcting their 
extracellular fluid weight to that of controls. Predicted 
values for total body nitrogen were derived from the 
formula N (g) = 322 x height3 + 81.624
Phosphorus and oxygen have not been measured in normal 
subjects. No correction is possible for oxygen. However, 
phosphorus and calcium are closely related so this ratio 
may be used to '’normalise" phosphorus measurements.
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TESTING THE AUTONOMIC NERVOUS SYSTEM
A) Parasympathetic Function
1) The Valsalva Ratio
In normal subjects, during the strain period of the 
Valsalva manoeuvre, the blood pressure drops and the heart 
rate rises. After the release, the blood pressure rises, 
overshooting its resting value as the heart slows. The 
heart rate changes can be abolished by atropine but are 
unaffected by popranolol, suggesting that the responses are 
mediated via the parasympathetic nervous system.628 In 
patients with autonomic damage, heart rate changes little.629
For the present experiments, the patient was asked to blow 
into a modified mercury sphygmomanometer for 15 seconds 
while maintaining a pressure of 40 mm Hg. The heart rate 
response was measured by continuously monitoring the 
electrocardiogram. The result was expressed as a ratio of 
the longest R-R interval after the manoeuvre to the 
shortest R-R interval during the manoeuvre. A mean from 
three tests was used.
2) The R-R Interval during deep breathing
Heart rate varies continually in normal subjects. This 
"high frequency" variation is abolished by atropine but 
uninfluenced by popranolol.630 Patients were requested to 
breathe in and out deeply at 5 second intervals while 
continuously recording the electrocardiogram for one
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minute.631 The mean change in heart rate over 6 cycles, from 
the largest R-R interval (expiration) to the shortest 
(inspiration) was calculated.
3) The immediate Heart Rate Response to Standing
On standing upright, an immediate rapid increase in heart 
rate occurs which is maximal around the 15th beat and then 
a relative overshoot bradycardia occurs, maximal about 30th 
beat.632 This is also mediated by the vagus nerve.633 The 
longest R-R interval around the 30th beat was expressed as 
a ratio of the shortest R-R interval around the 15th beat.
B) Sympathetic Function
1) Posture
On standing, pooling of blood in the legs causes a fall in 
blood pressure which is normally rapidly corrected by 
peripheral vasoconstriction. This is dependent upon many 
mechanisms and appears to involve important sympathetic 
reflexes. The blood pressure and heart rate were recorded 
after 15 minutes rest in the supine position and after 2 
minutes standing. In addition, changes in plasma 
noradrenaline were measured.
2) Exercise Testing refs 628,630
Exercise is associated with an increase in heart rate, 
cardiac output and arterial blood pressure, associated with 
a reduction in systemic vascular resistance. The
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tachycardia associated with exercise can be markedly 
reduced with a beta-blocker. Circulating catecholamines 
rise during exercise. The blood pressure and heart rate 
response during dynamic exercise therefore appeared at 
least partially mediated through the sympathetic nervous 
system, though the initial increase in heart rate during 
exercise is mediated through parasympathetic withdrawal.
Exercise capacity was determined using a modified Bruce 
protocol with 3 minute stages. Blood pressure and heart 
rate were compared at the last fully completed stage of the 
shortest exercise test for intra-subject comparisons at 
different time points.
BIOCHEMISTRY
The Timing and Method of Sampling
All samples were withdrawn from forearm veins, apart from 
one study when samples for catecholamines, renin and 
angiotensin II were withdrawn from an in-dwelling arterial 
cannula.
For most studies a rigid standardisation of the timing and 
circumstances of sampling was adopted.
Unless otherwise stated, venous blood was drawn between 8 
am and 9 am from an in-dwelling cannula, the patient having
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fasted, apart from water, and remained supine overnight. 
All drugs, including investigational drugs, were withheld 
until samples had been taken.
Sampling times and circumstances varied in individual 
studies but in each case rigid criteria were set and 
adhered to so that comparisons could be made both between 
and within individual patients or volunteers.
Electrolytes, Urea and Creatinine
These were measured on a multi-channel analyzer, using an 
ion-selective electrode.
Digoxin
Serum digoxin was measured using a fluorescent polarisation 
immunoassay. Urine digoxin was measured by diluting urine 
with "blank” (non-digoxin containing) serum. This assay is 
specific for digoxin and its metabolites digoxigenin and 
mono-and bis-digitoxside.634
Urinary digoxin clearance was calculated from the urinary 
digoxin concentration multiplied by the volume passed over 
6 hours. The mean serum digoxin over the sampling period 
was calculated from the mean of three plasma samples. All 
studies were commenced 6 hours after the last dose of 
digoxin. The fractional excretion of digoxin was calculated 
from the amount excreted in the urine divided by the amount 
filtered at the glomerulus (mean serum digoxin
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concentration multiplied by the creatinine clearance).
SPECIAL BIOCHEMISTRY
Plasma Active Renin Concentration refs: 635-637 
(Normal range for the laboratory 10-50 U/ml)
The assay was based on an antibody-trapping method. Blood 
samples (5 ml) were collected into chilled containers 
containing EDTA as anticoagulant. Centrifugation and 
separation of plasma was completed within 1 hour. Plasma 
was stored at -20 °C until assayed.
Tubes for incubation contained 35 U1 of plasma, ox renin 
substrate (40 Ul) , buffer "3" (10 Ul) , and angiotensin I
antiserum at appropriate dilution (5 Ul) . The last 3 
constituents were pre-mixed in the ratio 8:2:1 and 55 Ul of 
the mixture was added to each tube. Tubes were incubated at 
37°C for 3 0 minutes. This period of incubation usually 
generated sufficient angiotensin I to read against the 
sensitive portion of the standard curve. Unusually low and 
high renin samples were incubated for longer, or in 
dilution. The renin reaction was terminated by addition of 
buffer "1" (1.4 ml at 4 0 C) , followed by angiotensin I125(50 
Ul;20 pg) . For radio-immunoassay of angiotensin I, the 
tubes were then incubated at 4 °C for a further 48 hours. 
Free and antibody-bound radioactivity were separated using 
Dextran-coated charcoal (150 Ul) , and the pellet was 
counted in a spectrometer. Plasma renin concentration was 
derived from the reaction velocity (ng/ml/hour) by
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interpolation of a calibration curve, prepared with varying 
concentrations of the International Standard Renin 
contained in buffer "2" (35 Ul).
Angiotensin II refs: 638-640
(Normal range for the laboratory 5-35 pmol/1)
Twenty mis of blood were taken directly into tubes con­
taining an inhibitor solution to prevent generation of 
angiotensin II from angiotensin I and to prevent the 
degradation of angiotensin II to the octapeptide and 
smaller peptide fragments. The inhibitor solution contained 
0.125 M EDTA and 0.025 M o- phenanthroline in distilled and 
freshly boiled water, containing 0.2% neomycin sulphate. 
Angiotensin in the supernatant was absorbed onto Dowex-H+ in 
a batch extraction and subsequently eluted with ammonia. 
The eluate was dried at 37 °C under an air stream: half of 
the residue was used for the anti-serum incubation.
Antibodies against As^-Va^-angiotensin II were raised in 
rabbits using a minor modification of a method described by 
Goodfriend et al.640
Incubation was carried out in 0.5 ml Tris buffer at 4 °C for 
2 days. The concentrations of anti-serum and of label (125I- 
Asn1-Val5-angiotensin II) were varied depending upon the 
assay range. Twenty picograms/ml of label and a 1:16,000 
dilution of anti-serum were usually used.
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The recovery of angiotensin II from blood was 83% + 11% 
(SD) . The within assay coefficient of variation was 8.9% 
and the between assay coefficient of variation 12.3%.
During inhibition of the converting enzyme, angiotensin I 
levels rise, although the angiotensin II and antiserum used 
in our analysis has a low cross-reaction (less than 1%) 
with angiotensin I. With the low levels of angiotensin II 
and high levels of angiotensin I under these circumstances 
falsely high values for angiotensin II may be obtained. 
Accordingly, a correction factor was introduced.642
Aldosterone ref: 641
(Normal range for the laboratory 150-500 nmol/1) 
Aldosterone was measured by radio-immunoassay. Neutral 
extracts of 2 ml of plasma, containing 25,000 cpm of 3H- 
labelled aldosterone (50 Ci/mmol) were chromatographed on 
a Bouche B5 type chromatography system. The aldosterone 
region was located by means of isotope scanning equipment 
and was diluted drop wise with methanol (5 ml) . Portions of 
the eluate were assayed for 3H recovery, and by using this 
information duplicate samples containing 5,000 cpm of 3H 
were removed for radio-immunoassay. Ethylene glycol (5% 
V/V;.l ml) was added to the samples and standards at this 
point.
The samples, together with standards ranging from 0 -
200pcg of aldosterone, each containing 5,000 cpm of 3H-
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labelled aldosterone, were evaporated to dryness at 30°C in 
a vacuum oven. The residues were then dissolved in
anti-serum solution (0.5 ml;1:500,000 in 0.05 mmol/litre of 
borate buffer, Ph 7.5, containing 2% (V/V) methanol and
0.5% (W/V) bovine gamma globulin), and incubated at room 
temperature for one hour, and then at 4°C for at least one 
hour. Free steroid was absorbed by means of a
Dextran-coated charcoal solution. After centrifugation at 
4°C, 0.5 ml of the supernatant was assayed for 3H content by 
accumulating 10,000 counts.
Anti-diuretic Hormone refs: 644,645
(Normal range for the laboratory: 0.3-0.7 pg/ml)
Blood samples for anti-diuretic hormone measurement were 
stored in iced water until centrifuged at 4°C when the 
plasma was separated and stored at -20°C. In view of the 
observations that ADH binds to platelets,644 care was taken 
not to remove the plasma immediately above the red cells. 
Anti-diuretic hormone was extracted from plasma using
pre-packed C18 reverse phase cartridges (SEP-PAK, Waters
Associates, Milford, Massachusetts, USA). Cartridges were 
initially washed with methanol (5 ml), followed by 
distilled water (5 ml) . Three to five ml of plasma was 
applied to the cartridge under gentle vacuum, followed by 
washing with 15% acetic acid (5 ml) . Anti-diuretic hormone 
was eluted from the column by washing with methanol (2 ml) . 
The methanol extracts were dried under a stream of air and 
the dried extracts dissolved in 50 mmol/litre Tris with a
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pH of 7.4 for assay.
A sensitive and specific anti-diuretic hormone anti- serum 
(72/IV) was used.645 This anti-serum was raised in New 
Zealand white rabbits by immunisation with anti- diuretic 
hormone conjugated to bovine thyroglobulin.645 Standard ADH 
(0 - 4 peg) or unknown extract was incubated with ADH 
anti-serum at a final dilution of 1:75,000 and 125I- ADH (0.5 
peg, New England Nuclear, Dreich, West Germany) for 48 
hours at 5°C. Bound and free anti-diuretic hormone were 
separated using Dextran- coated charcoal.
The within-assay coefficient of variation was 6.1% and the 
between assay coefficient of variation was 10.8%.
Catecholamines refs: 647,648
(Normal range (resting) for the laboratory: 0.8-1.2 nmol/1) 
Blood samples were taken into chilled tubes, and kept at 
4°C, immediately centrifuged, deproteinated by adding 1 
molar perchloric acid in a ratio of 1:4 and plasma stored 
at -20°C for analysis. Samples were measured by the 
radio-enzymatic method of Da Prada and Zurcher.647 Briefly, 
the catecholamines are converted into their 3- methoxy 
derivatives in the presence of crude catechol-O- methyl 
transferase and S-adenosyl-L (methyl3H) methionine. The 
following modifications were included:
1) Ethylene glycol bis-amino ethyl ether tetracetate (3 
mmol/litre) was added to the plasma samples.
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2) Tris (1 mol/litre), magnesium chloride (75 mmol/litre), 
benzyloxamine (a dopa-D-carboxylase inhibitor, 0.5 
mmol/litre), 20 Ul of catechol-O-methyl-transferase
solution and 3.6 UCi of S-adenosyl-L-(methyl-3H) methionine 
(5-15 Ci/mmol; Amersham, Bucks). The total incubation 
volume was 150 Ul, and pH 8.43.
3) The 3 methoxy derivatives were extracted into 1 ml of 
ether, in the presence of tetra-phenylboron and back 
extracted into 50 Ul of hydrochloric acid (0.1 mmol/1) . 
This was applied directly to thin layer chromatography. 
Noradrenaline and adrenaline derivatives were extracted 
into 1 mmol of ammonium hydroxide (0.05 mol/1) and 
converted into vanillin by the addition of 50 Ulof 4% (W/V) 
sodium periodate. After 5 minutes, 1 ml of acetic acid (0.1 
mmol/1) was added, and the vanillin extracted into toluene 
containing 0.6% 5-(bi-phenyl-4-yl)-2-(4-butylphenyl) 
-L-oxa-3,4,diazole. The limit of detection calculated as 
twice the blank value was 0.1 nmol/1 for noradrenaline and 
adrenaline. The inter-assay coefficient of variation for 
noradrenaline was 8.6, and adrenaline 11.2%.
As mentioned above, venous sampling was generally employed 
which does appear to reflect overall sympathetic 
activity.648'649 However, some observers suggest that a large 
contribution to the measured level of catecholamines may 
derive from the capillary bed which is subserved by the 
vein used for sampling. In one study, where changes in 
catecholamine levels were being sought over a short period,
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arterial sampling was used by preference to overcome this 
possible criticism.
Atrial Natriuretic Peptide refs: 651-651 
(Normal range for the laboratory: undetectable-80 pg/ml) 
Blood was collected in chilled plastic tubes containing 
EDTA as an anticoagulant and sufficient Trasylol to give a 
final concentration of 50 klU/ml. Each sample was 
transported on ice and centrifuged at lOOOg for 10 minutes 
at 4°C. Atrial natriuretic peptide was extracted from 1-3 ml 
of plasma on C18 reverse phase columns (Sep-pak, Waters 
Associates). Sep-paks were pre-activated with 5 ml of 
methanol and washed with 5 ml of distilled water before 
application of acidified plasma (0.25 ml 2N hydrochloric 
acid/ml plasma). The cartridges were then washed three 
times with 5 ml 0.1% vol/vol trifluoroacetic acid, and the 
absorbed peptide was eluted with 2 ml 60% acetonitrile/0.1% 
wt/vol into plastic tubes. The extracts were dried down 
under compressed air and reconstituted in 0. 5 ml buffer 
(100 mM sodium phosphate, pH 7.4 Triton X-100, and 50 kMU 
Trasylol/ml). Antibodies to human atrial natriuretic 
peptide were raised in New Zealand white rabbits. The 
antibody used for the radio-immunoassay gave 50% binding of 
2 g 1251-human atrial natriuretic peptide (Amersham 
International) at a dilution of 1/ 33,000. Cross reaction 
of the antibody with a variety of synthetic atrial 
natriuretic peptide sequences (5-28 human atrial 
natriuretic peptide, 7-28 human atrial natriuretic peptide,
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atriopeptins I, II and II, and rat atrial natriuretic 
peptide) was greater than 90%. No significant-cross 
reactions with cardiodilatin, bradykinin, arginine 
vasopressin, angiotensins I or II or adrenocorticotrophic 
hormone were seen. For the assay set up in duplicate, 100 
Ul antibody at a dilution of 1/10,000, and 2 pg labelled 
human atrial natriuretic peptide in 50 Ul buffer were 
incubated at 4 oC for 24 hours. Free and bound ligands were 
separated by adding 1 ml charcoal-coated dextran. The 
mixture was immediately centrifuged for 10 minutes (1000 g 
at 4 oC) and the free label counted. Non-specific binding 
of human atrial natriuretic peptide, estimated by adding 
excess synthetic human atrial natriuretic peptide (5 
ng/tube) was consistently 3-4% both in standard solutions 
and in reconstituted plasma extracts; hence, no correction 
for binding was required.
Radio-labelled synthetic alpha human atrial natriuretic 
peptide (20 pg) added to 3 ml plasma before extraction was 
recovered at a mean rate of 91 +6%. Recovery rates of cold 
synthetic human atrial natriuretic peptide added to 3 ml of 
plasma at concentrations of 100 pg/ml and 500 pg/ml were 86 
+9% and 91 ±8% respectively. Inter-assay and intra-assay 
coefficients of variation were 7.8% and 7.5% respectively.
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CHAPTER 8: THE METABOLIC CONSEQUENCES OF HEART FAILURE AND 
THE INFLUENCE OF NEUROENDOCRINE ACTIVATION
INTRODUCTION
After many years of debate, there is still controversy 
about the prevalence, extent, and relevance of potassium 
depletion in patients treated with diuretics for heart 
failure.652”657 While some investigators have documented 
reduced body potassium levels in such patients, this has 
been attributed to lack of good con trol data or to muscle 
wasting as a manifestation of "cardiac cachexia".652 Some of 
the difficulties may have arisen due to the absence of a 
definitive diagnosis of heart failure which the advent of 
modern diagnostic techniques, in particular echocardi­
ography, has largely resolved. Also, the measurement of 
total exchangeable potassium requires a prolonged 
equilibration time after the administration of radioactive 
tracers which can introduce inaccuracies.656,658 Measurement 
of total body potassium using the endogenous 4OK isotope 
avoids this difficulty. Other problems are presented in 
defining adequate control groups for comparison. Body 
elemental composition is highly dependent on body mass, 
adiposity, age, and sex.659 Control groups have rarely been 
adequately matched with patients in heart failure, nor have 
the appropriate corrections usually been made.
Patients with severe heart failure have a poor prognosis, 
the one year survival for a patient with New York Heart
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Association Class III heart failure being approximately 
50%.660,661 Interest in potassium depletion in heart failure 
has renewed since the obser vation that potassium depletion 
can be corrected, arrhythmias reduced, and possibly 
prognosis improved with the use of angiotensin-converting 
enzyme inhibitors.662,663
The technique of in-vivo total body neutron activation 
analysis performed on the same day also has allowed us to 
measure total body sodium, chlorine, phosphorus, calcium, 
and nitrogen. Nitrogen is an index of protein mass,664 
muscle, collagen, and the viscera being the major sites of 
this element.665 Measurement of body nitrogen allows a 
correction for leanness. The element oxygen is mainly 
present in the body as water and is therefore an index of 
this constituent.
In-vivo neutron activation analysis requires a fairly large 
dose of radiation and is not permitted in normal subjects. 
However, endogenous 4OK measurements followed by activation 
analysis to assess body composition have been employed in 
untreated patients with essential hypertension,666 and do not 
differ from normal values. In addition, we have measured 
total body potassium in a large series of normal subjects 
and found no difference from the mean value in untreated 
essential hypertensives matched for age and sex.667,668 We 
have therefore compared patients treated for heart failure 
with diuretics and digoxin to patients with untreated
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essential hypertension and to normal subjects matched for 
height, weight, age and sex.
PATIENTS
Forty patients referred to the cardiac department for 
further investigation and treatment of heart failure were 
compared with 20 subjects without evidence of cardiac or 
other pathology, and 20 patients with untreated essential 
hypertension. Heart failure was confirmed by measurement of 
a raised left ventricular end-diastolic pressure (>16 mm 
Hg) and poor stroke volume on left ventricular 
cine-angiography, and a fractional shortening on M mode 
echocardiography of less than 20% (14+3%;mean +SEM) with 
end-diastolic dimension greater than 6 cm (6.4+0.2 cm). The 
aetiology of cardiac failure was ischaemic heart disease in 
20, idiopathic (dilated) cardiomyopathy in 17, and severe 
residual left ventricular function after successful valve 
replacement in 3 (2 aortic, one mitral and aortic). Nine
were in early NYHA Class IV heart failure but did not 
suffer undue orthopnoea, 18 in NYHA Class III and 13 in 
NYHA Class II. All patients had received at least 80 mg/day 
frusemide (mean 147+13 mg/day) for more than 3 months (mean 
duration 11+5 months). In addition to frusemide, 5 were 
taking bendrofluazide 5-10 mg/day. Twelve subjects were 
taking potassium chloride in a mean daily dose of 2.1+0.1g, 
but none was receiving potassium-sparing diuretics.
All the hypertensive group were asymptomatic and also
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without clinical, biochemical or radiological features of 
heart failure, aortic coarctation, Cushing's syndrome, 
primary hyperaldosteronism, renal disease or 
phaeochromocytoma. Any previous treatment had been 
withdrawn at least 4 weeks before measurements were made.
METHODS
In each subject nude weight and height were measured. Blood 
pressure was recorded with the patient supine.
Total body potassium, sodium, chlorine, oxygen, nitrogen, 
calcium and phosphorus were measured in the hypertensive 
subjects. Elements other than potassium alone were not 
measured in normal subjects due to the ethical issues noted 
above. Blood was drawn from patients who were fasting and 
supine overnight at 9 am, and again at 4 pm, after 30 
minutes supine after usual therapy; sodium, potassium, 
chloride, urea, creatinine and phosphate were measured and 
results expressed as the mean of the two values. In 
addition, plasma concentrations of active renin, 
angiotensin II and aldosterone were determined from the 9 
am sample, using methods previously determined.
STATISTICAL METHODS
Between-group analysis was made using students t-test or 
the Wilcoxon rank sum test for non-parametrically 
distributed variables. Results of body elemental 
composition for patients with heart failure and
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hypertension were expressed as the ratio of calculated to 
predicted normal, 100% representing no difference between 
calculated and predicted values. Values are expressed as 
mean +standard error of the mean for normally distributed 
data, or mean, median and range where the data is not 
normally distributed. A single parameter t-test was used to 
test for systematic deviation from predicted normal values. 
Significance was taken at the 5% level. Correlations were 
performed using the method of least squares for variables 
with bivariate normal distribution and Spearman's rank 
correlation for non-parametrically distributed data.
RESULTS
Anthropomorphic Measurements (Table 8.1)
The normal subjects and patients with hypertension and 
heart failure were similar in respect to height, weight, 
age and sex. Sub-groups of heart failure patients with 
normal and elevated renin were similar, and each did not 
differ from the normal or hypertensive group. The 
similarity in weight persisted even when the heart failure 
group's weight was corrected for their higher extracellular 
fluid volume (Table 8.2).
Blood Pressure
Though the blood pressure in the hypertensive group was not 
greatly elevated (170+3/105+3 mm Hg) , mean blood pressure 
was significantly greater than in those with heart failure
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Table 8.2 Comparison o f  measurements in patien ts w ith hypertension and heart fa ilure
Hypertension H eart failure P
Weight (kg) 69(3) 68 (2) 67 (3)
(corrected for ECF) NS
Mean blood pressure (mm Hg) 126 (3) 94 (3) < 0-001
Serum sodium (mmol/1) 141 (1) 138 (1) < 0-05
Serum potassium (mmol/I) 4-2 (01) 3-6 (0 1) < 0 005
Serum chloride (mmol/1) 102(1) 98(1) ' < 0-05
Serum bicarbonate (mmol/1) 27-5 (0-5) 29-3 (0 4) ■ < 0 02
Serum urea (mmol/1) 4-7 (0-3) 6-6 (0-4) < 0-005
Serum creatinine (/imol/I) 90 (3) 102 (4) < 0-05
Ureaxreatinine ratio 51-7(0-2) 64-4 (2-7) < 0-005
PARC (/iU/ml) 24(5) 215 (46) < 0 005
Plasma angiotensin II (pmol/1) 23(1) 64(9) < 0-005
Plasma aldosterone (pmol/1) 331 (32) 729 (117) < 0 005
Total body potassium (mmol) 3250 (171) 2831 (93) < 0 05
Total body potassium (°0) 103 (89-110) 95 (67-117)* < 0 01 .
Total body nitrogen (g) 1640(59) 1688 (49) NS ’
Total body nitrogen (°0) 100 (92-117) 106 (86-133)t NS
Total body potassiummitrogen (mmol:g) 1-97 (0-05) 1-68 (0-03) < 0-0001
Total body potassiummitrogen (°0) 103 (97-108) 91 (74-106)+ < 0-001
Total body sodium (mmol) 3160(113) 3473 (88) < 0-05
Total body sodium (%) 98 (89-104) 108 (92-129) < 0-001
Total body chlorine (mmol) # 1697 (70) 1748 (55) NS
Total body chlorine (%) 96 (86-110) 104 (87-142) NS
Extracellular fluid volume (ml) 16-7 (0-6) 17 9 (0-5) NS
Extracellular fluid volume (ml/kg) 242 (9) 266 (6) < 0-02
Total body calcium (g) 960 (37) 998 (23) NS
Total body calcium (%) 98 (89-112) 106 (83—121 )t NS
Total body phosphorus (g) 534 (20) 542 (13) NS
Total body phosphorus-.calcium (g:g) 0-56 (0-0*) 0-54 (0-01) < 0. 02
ECF, extracellular fluid volume; °0, percentage of normal predcted; PARC, plasma active renin concentration. 
•*p <0 05, tp < 0 001, Jp < 0 001 compared with predicted normal (see text).
Values are mean (SEM) for absolute values and mean and range for percentage values.
Table 8.3 T ota l body oxygen in patien ts w ith  hypertension and patien ts w ith  heart failure
Hypertension H eart failure P
No 7 32
Total body oxygen (kg) 42-9 (3 0) 36-0 (2-3) < 0 05
Total body oxygen (0,0) 104 (89-112) 93 (76-109) < 0 01
Total body oxygen (kg/kg body weight) 0-59 (0 05) 0-54 (0-07) < 001
TBK/TBO (mmol/kg) 80 (5) 79 (9) NS
TBNa/TBO (mmol/kg) 79 (8) 95 (9) < 0 001
TBO, total body oxygen; TBK, total body potassium; TBNa, total body sodium; "•„> percentage of predicted normal. 
Values are mean (SEM) for absolute values and mean (range) for percentage values.
(132±2/78±1).
Serum Electrolytes (Table 8.2)
Serum sodium, potassium and chloride were significantly 
higher in those patients with hypertension, while serum 
bicarbonate, urea and creatinine were higher in those with 
heart failure.
Hormones (Table 8.2)
Plasma concentrations of active renin, angiotensin II and 
aldosterone were considerably higher in subjects with heart 
failure. Only 2 subjects with hypertension had plasma 
active renin concentration above the normal range compared 
to 26 patients with heart failure.
Total Body Composition (Tables 8,1-8.3)
Total body potassium was depleted in subjects with heart 
failure, compared to normal subjects, the hypertensive 
group and to predicted normal values. Total body potassium 
was normal in the hypertensive group, as previously 
reported. Mean total body sodium was normal in the 
hypertensive group but elevated in the group with heart 
failure, again either by comparison with the hypertensive 
group or with predicted normal values. Total body chlorine 
was not significantly different between the 2 groups and 
did not deviate significantly from predicted. Although 
total extracellular fluid volumes was similar in 
hypertensives and patients with heart failure when results
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were corrected for body weight, patients with heart failure 
had a significantly expanded volume, despite being free 
from clinically apparent oedema. The increase in 
extracellular fluid volume could account in a large part 
for the increase in total body sodium in the patients with 
heart failure.
Total body calcium tended to be higher in patients with 
heart failure but phosphorus was similar in both groups of 
patients. The ratio of phosphorus to calcium was 
consequently lower in the patients with heart failure.
Absolute values for total body nitrogen were similar in the 
heart failure group compared to normals and hypertensives. 
When expressed as a percentage of predicted normal, 
nitrogen values were increased only in the heart failure 
group. The difference in potassium expressed in mmol/g of 
nitrogen was thus highly signif icant, levels being much 
lower in those with heart failure. Subjects with heart 
failure were approximately 12% deplete of potassium 
compared to hypertensives, when correctd for nitrogen 
values.
Total body oxygen was reduced in heart failure. (Table 8.3) 
In the context of an expanded extracellular fluid volume, 
this suggests intracellular dehydration. The ratio of 
sodium to oxygen was increased in patients with heart 
failure, but the ratio of potassium to oxygen was similar
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when compared to patients with hypertension.
COMPARISON OF SUB-GROUPS OF CARDIAC FAILURE PATIENTS WITH 
LOW OR NORMAL RENIN LEVELS AND THOSE WITH ELEVATED LEVELS 
(Table 8.4)
A cut-off point of 50 uU/ml for plasma active renin 
concentration was used, the upper limit of normal for the 
laboratory. Subjects in each group were well matched for 
anthropomorphic measurements, though the high renin group 
had an excess of males. The patients with high plasma renin 
(n=26) had correspondingly high plasma levels of 
angiotensin II and aldosterone. There was no difference in 
severity of heart failure or diuretic requirements between 
the groups. Total body and serum potassium, serum sodium 
and mean blood pressure were all inversely related to 
plasma renin. (Figures 8.1-8.4) Potassium supplements were 
significantly greater in those subjects with low serum 
potassium and elevated plasma renin. Extracellular fluid 
volume was not contracted in those with a high plasma 
renin.
Similar sub-setting for hypertensive patients was not 
carried out due to the small group (2 patients) with 
elevated plasma renin.
CORRELATIONS BETWEEN SERUM AND TOTAL BODY ELECTROLYTES
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Serum and total body potassium (expressed as a percentage 
of predicted normal) were significantly correlated in 
patients with heart failure (r=0.74;p<0.001) (Figure 8.5), 
and this relationship was maintained after correcting total 
body potassium for total body nitrogen (r=0.75;p<0.001). 
The relationship appeared linear over the measured range. 
A similar relationship was not observed in the group with 
hypertension (r=0.1;ns and r=0.3;ns). Serum sodium (r=0.1 
heart failure and r=0.36 hypertension) was not 
significantly related to total body sodium (percentage of 
predicted normal) but serum chloride was related to total 
body chlorine (percentage of predicted normal) 
(r=0.34;p<0.05 heart failure and r=0.59;p<0.01 
hypertension).
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CHAPTER 9 S COMPARISON OF AUTONOMIC AND NEUROENDOCRINE 
FUNCTION IN NORMAL SUBJECTS AND PATIENTS TREATED FOR 
CHRONIC HEART FAILURE
INTRODUCTION
Peripheral circulatory control in heart failure is under 
the influence of both the autonomic nervous system and 
circulating hormones. The role of locally produced hormones 
and of substances such as endothelin and 
endothelium-dependent relaxing factor in heart failure is 
yet to be determined.
Although many studies have measured hormone levels and 
noradrenaline in the plasma, many have used historical 
controls or normal laboratory values from which to draw 
conclusions. The number of studies which have incorported 
an age- and sex-matched healthy control group are few. 
Also, there is little published information on the acute 
effects of diuretics on neuroendocrine activation in heart 
failure. While there is more information on the effects of 
exercise on neuroendocrine activation, there are major 
problems in interpreting the information as normal subjects 
can exercise for longer and to higher workloads. It is not 
clear to what extent neuroendocrine activation is dependent 
on duration or on the intensity of exercise.
Autonomic reflexes have been intensively investigated in
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heart failure but the interpretation of the tests is open 
to question.
This chapter seeks to fill some of the gaps in the 
information on this topic and also to reassess some of the 
established information in preparation for later studies on 
the effects of angiotensin-converting enzyme inhibitors on 
these systems.
PATIENT SELECTION
Twenty patients with chronic heart failure due to ischaemic 
heart disease (9) , congestive (dilated) cardiomyopathy (8) 
or severe left ventricular dysfunction subsequent to 
successful valve replacement (3) and who were in New York 
Heart Association Class III or IV were included. The mean 
age was 58+4 years and duration of symptoms at entry was 18 
+13 months. All had had symptoms for more than 3 months. 
Patients with serious concomitant disease or significant 
valvar regurgitation were excluded.
All vasodilators were withdrawn at least one month before 
investigation and doses of frusemide (mean daily dose 
124+57 mg/day), and digoxin (mean daily dose 0.22 +0.06 
mg/day) were held constant. One patient refused frusemide 
and continued on bumetanide 3 mg/day. Four patients also 
received amiloride 10-15 mg/day, 5 potassium chloride 
(1.8-2.4 g/day), one hydrochlorthiazide 100 mg/day. Two 
patients were in atrial fibrillation, one had a ventricular
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demand pacemaker, and one had been on amiodarone 400 mg/day 
for the previous 2 years; this continued unchanged 
throughout. The latter 4 patients underwent testing of 
neuroendocrine function but were excluded from tests of 
autonomic function.
Ethical supervisory committee permission was obtained for 
the study and written informed consent from each patient.
NORMAL SUBJECTS
Twelve age-matched normal subjects were chosen, who were on 
no therapy, led a sedentary life-style and who had no 
abnormalities detected clinically or on a 12-lead 
electrocardiogram. All had normal levels of serum 
electrolytes, urea and creatinine. Their mean age was 56+9 
years, and 9 were men.
METHODS
Patients had heart rate and blood pressure measured, and 
blood samples taken for the concentration of sodium, 
potassium, active renin, angiotensin II, aldosterone, 
anti-diuretic hormone, noradrenaline, and adrenaline. (See 
Methods) All samples were taken via an in-dwelling cannula 
at the following times:
1) Fasting and supine for 30 minutes between 8 and 9am.
2) Four hours after usual medication with 30 minutes supine
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rest prior to sampling.
3) After 5 minutes in the upright position.
4) Immediately after exercise. Patients underwent a maximal 
exercise test. Normal subjects underwent 2 tests. The first 
test exercised them to the same level as the patients with 
heart failure achieved at maximal exercise. The second test 
was a maximal stress test but very steeply "ramped" so that 
exercise intensity rather than duration increased.
5) Five minutes after exercise (potassium and 
catecholamines only).
TESTS OF AUTONOMIC FUNCTION
Parasympathetic reflexes were tested using the Valsalva 
ratio, the R-R interval during deep breathing, and the 
15:30 ratio immediately after standing. (See Methods)
Sympathetic reflexes were assessed using the blood pressure 
response to 2 minutes standing and an exercise test. (See 
Methods)
STATISTICAL ANALYSIS
Values were expressed as mean, median, and range where they 
were not normally distributed, otherwise as mean and 
standard deviation. Statistical evaluation was carried out 
in 3 ways:
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1) Unpaired t-tests were used to compare actual values for 
patients with heart failure and normal subjects. A value 
p<0.05 is taken as significant.
2) A within-group comparison for the effects of physio­
logical manoeuvres on clinical and neuroendocrine variables 
was used. For patients with heart failure a comparison was 
carried out for the effects of usual daily therapy on 
neuroendocrine and clinical variables. Non-fasting, and in 
the case of heart failure, post-treatment supine values 
were compared with values taken after 5 minutes in the 
upright posture. Values immediately after exercise were 
then compared with those obtained during upright posture. 
Finally, immediate post-exercise values were compared with 
values for potassium, noradrenaline, and adrenaline 5 
minutes after exercise.
3) A between-group comparison of the magnitude of 
neuroendocrine and clinical changes during each of the 
above physiological manoeuvres was carried out.
RESULTS
Resting values for heart rate, blood pressure and 
neuroendocrine variables in patients with heart failure, 
before and after diuretic administration, and in normal 
subjects, are shown in Table 9.1.
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At baseline, patients had a significantly lower blood 
pressure and higher heart rate than normal controls and 
exhibited marked neuroendocrine activation, with lower 
values for plasma sodium and potassium concentration.
In response to diuretic therapy, there was no significant 
change in heart rate or blood pressure. However, further 
marked neuroendocrine activation was observed with 
increases, not only in renin-angiotensin system activity, 
but also plasma noradrenaline. Both plasma sodium and 
potassium concentrations fell after diuretic therapy.
Heart rate variability during each of the tests of 
parasympathetic function was reduced in patients with heart 
failure. (Figure 9.1)
In response to standing, there were no marked changes in 
neuroendocrine activity in patients with heart failure. 
However, in response to standing, plasma noradrenaline rose 
in normal subjects. Thus, the rise in plasma noradrenaline 
was blunted in heart failure (p<0.01). (Table 9.2)
Blood pressure did not change significantly in either group 
but heart rate rose only in normal subjects, emphasizing 
the loss of the reflex increase in sympathetic activity 
with upright posture in patients with heart failure.
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TABLE 9.1
NEUROENDOCRINE EFFECTS OF DYNAMIC EXERCISE
, Patients with Normal
Heart Failure Subjects
' n = 20 n = 12
Supine
Fasting Pre-diuretic Non-fasting
Heart Rate (bpm) 79(10) p<0.05 74(5)
Sys BP (mmHg) 119(26) p<0.01 138(9)
Dia BP (mmHg) 72(11) p<0.001 88(5)
Plasma Sodium
(mmol/L) 139 (3) p<0.01 143(2)
Plasma Potassium 3.8(0.3) p<0.001 4.4(0.3)
(mmol/L)
P.A.R.C. (uU/ml) 81:47:3-352 p<0.001 14:14:6-27
P.Ang.II (pmol/L) 39:31:1-160 p<0.001 6: 6:1-17
P.Aldo. (pmol/L) 505:361:217-1336 p<0.01 224:212:36-61;
P.A.D.H (pg/ml) 1.9:1.6:0.3-5.1 p<0.01 0.8:0.6:0.4-2
P.N.Adr (nmol/L) 3.2(1.4) p<0.01 2.0(0.8)
P.Adr (nmol/L) 0.3(0.1) ns 0.2(0.1)
Non-fasting Post-diuretic
significance significant
V . pre-diuretic v. normals
Heart Rate (bpm) 83(12) ns p<0.01
Sys BP (mmHg) 122(24) ns p<0.01
Dia BP (mmHg) 77(18) ns p<0.01
Plasma Sodium 138(3) p<0.01 p<0.001
(mmol/L)
Plasma Potassium 3.5(0.3) p<0.001 p<0.001
(mmol/L)
P.A.R.C. (uU/ml) 152:91:3-972 p<0.001 p<0.001
P.Angll (pmol/L) 55:46:0.5-134 p<0.01 p<0.001
P.Aldo. (pmol/L) 650:469:108-1949 p<0.01 p<0.001
P.A.D.H. (pg/ml) 2.2:1.9:0.3-5.9 ns p<0.001
P.Noradr.(nmol/L) 3.9(1.4) p<0.001 p<0.001
P.Adr. (nmol/L) 0.4(0.2) ns p<0.05
Figures are given as mean (S.D.) or mean:median:range 
P. = plasma. SYS = systolic. DIA = diastolic 
A.R.C. = active renin concentration. Aldo = aldosterone. 
Ang II = angiotensin II. A.D.H. = anti-diuretic hormone. 
Adr = adrenaline
TABLE 9.2
NEUROENDOCRINE EFFECTS OF DYNAMIC EXERCISE
Patients with Normal
Heart Failure Subjects
n = 20 n = 12
Upright Pre-exercise
Heart Rate (bpm) 82(14) ns * 80(6)
Sys BP (mmHg) • 116 (20) p<0.005 138(12)
Plasma Potassium 3.5(0.3) p<0.001 4.6(0.5)
(mmol/L)
Plasma Sodium 138(3) p<0.001 143 (3)
(mmol/L)
P.A.R.C. (uU/ml) 183:103:4-1356 p<0.001 18:18:6-38
P.Ang.II (pmol/L) 54: 40:7-156 p<0.001 9: 7:3-20
P.Aldo. (pmol/L) 686:505:108-2527 p<0.001 291:289:72-694
P.A.D.H (pg/ml) 2.2:2.1:0.3-6.5 p<0.001 1.1:0.9:0.4-2.6
P.N.Adr (nmol/L) 4.1(1.5) p<0.001 ** 2.8(0.8)
P.Adr (nmol/L) 0.3(0.3) ns 0.3(0.1)
@0
Upright Immediate Post*-exercise (Light Exercise)
Time (minutes) 6.5(3.2) ns 6.5
Heart Rate (bpm) ** 121(17) p<0.01 * * 107(12) 00
Sys BP (mmHg) ** 145 (27) p<0.01 ** 165(23)
Plasma !Potassium ** 3.9(0.3) p<0.01 ** 4.9(0.8)
(mmol/L)
Plasma Sodium * 139(3) p<0.001 143(5)
(mmol/L)
P.A.R.C . (uU/ml) * * 219:183:4-1443 p<0.001 21: 18:6-50 00
P.Angll (pmol/L) ** 81: 57:10-183 p<0.001 10: 9:2-26 00
P.Aldo. (pmol/L) ** 975:578:289-3032 p<0.001 357:288:36-1152 00
P.A.D.H . (pg/ml) ** 7.5:3.4:0.5-57 pco.ooi 1.4:1.4:0.4-2.8 00
P.N.Adr (nmol/L) •k ie 8.4(4.0) p<0.02 * 6.1(3.2)
P. Adr (nmol/L) * 0.5(0.5) ns * 0.5(0.3)
Five Minutes Post--exercise
Plasma :Potassium ** 3.2 (0.5) p<0.001 4.5(0.7) 00
(mmol/L)
P.N.Adr (nmol/L) 7.4(4.6) p<0.001 * 3.6(1.1) 00
P. Adr (nmol/L) 0.7(0.6) p<0.05 0.3(0.2) 0
Comparisons have been made in three ways (see text for details):-
1) The actual values of normal subjects and patients with heart failure 
These values are given in the central column
2) * indicates a within group comparison of the effects of physiol- 
gical manouevres. * = p<0.05, ** = p<0.01.
3) @ indicates between group comparisons. 0 = p<0.05, @0 = p<0.01 
For abbreviations see table 9.1
During exercise, further marked increases in neuroendocrine 
activation were observed in patients with heart failure. 
At the same work intensity, patients with heart failure had 
a similar blood pressure response but an exaggerated heart 
rate response compared to normal subjects. In normal 
subjects the renin- angiotensin-aldosterone system and 
anti-diuretic hormone showed little evidence of activation 
at this workload. Plasma noradrenaline was less in normal 
subjects in absolute terms compared to patients with heart 
failure during this form of exercise, but the magnitude of 
increase was similar. (Table 9.2)
In contrast, normal subjects had marked increases in 
anti-diuretic hormone and catecholamines during maximal 
exertion, several times that seen in patients with heart 
failure. (Table 9.3) The plasma levels of renin, 
angiotensin II and aldosterone achieved at maximal exertion 
were still significantly less in patients with heart 
failure. Although the magnitude of the change from the 
resting state was similar in patients with heart failure 
compared to normal subjects, when considered as a 
percentage of the basal levels, then the increases in 
renin-angiotensin system activity during maximal exertion 
was greater in normal subjects than in patients with heart 
failure.
Potassium rose during exercise in each group of subjects.
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TABLE 9.3
NEUROENDOCRINE EFFECTS OF DYNAMIC EXERCISE
Patients with 
Heart Failure
n = 20
Normal
Subjects
n = 12
Upright Immediate Post-exercise (Strenuous Exercise)
Time (minutes) 6.5(3.2) ns
Heart Rate (bpm) ** 121(17) p<0.001 **
Sys BP (mmHg) ** 145(27) p<0.001 kk
Plasma Potassium ** 3.9(0.3) p<0.001 **
(mmol/L)
P.A.R.C. (uU/ml) ** 219:183:4-1443 p<0.01 * *
P.Angll (pmol/L) * * 81: 57:10-183 p<0.01 * *
P.Aldo. (pmol/L) ** 975:578:289-3032 p<0.05 **
P.A.D.H. (pg/ml) ** 7.5:3.4:0.5-57 p<0.01 * *
P.N.Adr (nmol/L) ** 8.4(4.0) p<0.001 •k k
P.Adr (nmol/L) * 0.5(0.5) p<0.01 k k
Five Minutes Post-exercise
Plasma Potassium ** 3.2(0.5) p<0.001 kk
(mmol/L)
P.N.Adr (nmol/L) 7.4(4.6) p<0.001 kk
P.Adr (nmol/L) 0.7(0.7) P<0.05
6.7(1.2) 
174(15) 
194(17) 
5.7(0.9)
00
00
00
64:52:9-161 0
29: 21:2-67 
690:478:128-1764 
1:16.3:1.1-62.9 00
30.4(12.9) 
2.5(1.3)
4.1(0.8)
5.9 (2.7)
0.4(0.9)
Comparisons are made in three ways (see text for details):-
1) The actual values of normal subjects and patients (p values given 
in central column)
2) * indicates a within group comparison of the effects of physiol- 
gical manoeuvres (in this case a comparison between the the supine 
non-fasting state and immediate post-exercise values or immediate 
and 5 minute post-exercise values). * = p<0.05, ** = p<0.01.
3) @ indicates between group comparisons. 0 = p<0.05, 00 = p<0.01.
For abbreviations see table 9.1
00
00
00
00
00
The rise in potassium in patients with heart failure was 
similar to that seen during light exercise in normal 
subjects. The rise in potassium during strenuous exercise 
was considerably greater in normal subjects compared to 
maximal exercise in patients with heart failure. (Tables 
9.2 & 9.3)
Five minutes after exertion, plasma noradrenaline and 
adrenaline remained markedly elevated in the heart failure 
group while plasma potassium had fallen below resting 
baseline levels (p<0.05). In contrast, in normal subjects, 
plasma noradrenaline had fallen to near baseline levels 5 
minutes after light exercise, while plasma potassium had 
also returned to normal. Five minutes after strenuous 
exercise in normal subjects, plasma noradrenaline levels 
had dropped considerably but not to normal levels. 
Post-exercise serum potassium was still within the normal 
range but was significantly (p<0.05) lower than resting 
baseline levels.
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CHAPTER 10S RELATION OF ARRHYTHMIAS, ELECTROLYTE AND 
NEUROENDOCRINE ABNORMALITIES TO SURVIVAL IN PATIENTS WITH 
SEVERE CHRONIC HEART FAILURE
INTRODUCTION
Although the conventional treatment of heart failure with 
potent diuretic drugs has improved the symptoms and the 
short-term outlook of patients with congestive heart 
failure, the long-term prognosis in patients with severe 
left ventricular dysfunction referred to tertiary care 
centres remains extremely poor.669'673 Diuretics act to 
correct the abnormal sodium retention seen in patients with 
heart failure,674,675 but they also stimulate the 
renin-angiotensin system, which is already activated in 
these patients as a result of compromised renal 
perfusion.676,677 Unfortunately, such neurohormonal activation 
may lead to important electrolyte abnormalities, 
particularly hyponatraemia and hypokalaemia.These adverse 
metabolic effects may have their own prognostic conse­
quences678 or may be associated with an increased frequency 
of serious ventricular arrhythmias.679'682
The arrhythmogenic potential of diuretic therapy in 
patients with congestive heart failure may have important 
clinical implications. When evaluated by the physician, 
most patients with congestive heart failure show a high 
frequency of ventricular ectopic activity on ambulatory 
electrocardiographic monitoring,671,673,683,684 and many die
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suddenly during long-term follow-up. 669-671
It has been demonstrated in previous chapters that there 
are serious electrolyte abnormalities in patients with 
heart failure, and that this may be related to
neuroendocrine activation. Therefore, we evaluated the 
relative importance of a number of potential prognostic 
factors (including hyponatraemia and hypokalaemia) in a 
prospective study of patients with congestive heart failure 
secondary to left ventricular dysfunction, in whom we 
investigated the relationship among electrolyte 
abnormalities, ventricular function, ventricular
arrhythmias, and neuroendocrine activation.
PATIENTS
The study population comprised 84 consecutive patients in 
whom a diagnosis of heart failure of greater than 3 months' 
duration was established and in whom measurements of plasma 
active renin and noradrenaline concentrations were made. In 
each patient the diagnosis of congestive heart failure was 
confirmed by a typical clinical presentation, supported by 
objective evidence of left ventricular dysfunction by 
echocardiography.All patients had a left ventricular
end-diastolic dimension greater than 58 mm and a
cardiothoracic ratio (on a posteroanterior chest X-ray) 
greater than 0.52.All patients had symptoms of dyspnoea or 
fatigue at rest or on exertion but were symptomatically 
stable. The functional status (New York Heart Association
12 6
Class) of these patients was Class II in 27 patients, Class 
III in 31 patients, and Class IV in 26 patients. There were 
66 men and 18 women, ranging in age from 22 to 78 years 
(mean 59) . The median duration of heart failure was 20 
months (range 12-82).
The cause of heart failure in these patients was ischaemic 
heart disease in 48 patients, idiopathic dilated 
cardiomyopathy in 20, residual left ventricular dysfunction 
after successful valve replacement in 10, previous 
hypertension in 2, and alcohol-related cardiomyopathy in 4. 
Patients in whom angina was a significant complaint at rest 
or during exercise were excluded from this study. Coronary 
artery disease was diagnosed either by coronary angiography 
or by a typical history of myocardial infarction supported 
by appropriate electrocardiographic and enzymatic 
changes.Idiopathic dilated cardiomyopathy was diagnosed on 
the basis of angiographically normal coronary arteries and 
the absence of any specific heart muscle disease as 
determined by endomyocardial biopsy. All patients were 
stabilised on diuretics (frusemide 40-750 mg/day;mean 143) , 
and in most cases (68 patients) digoxin for at least one 
month before entry into this study. No patient was taking 
a potassium-sparing diuretic, but 23 patients were taking 
potassium chloride supplements (median dose 1800 mg/day; 
range 600-2400). All patients were evaluated at a time of 
clinical compensation, and were not receiving vasodilator 
or anti-arrhythmic therapy.
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METHODS
BASELINE EVALUATION
All patients underwent the following tests within one week:
1) Vital signs, including heart rate and blood pressure. 
These measurements were made on at least 3 occasions and at 
different times of the day, and an average of 3 values was 
used for analysis.
2) Treadmill exercise test, using a modified Bruce 
protocol. All patients had had at least one previous 
exercise test with the same protocol, and all tests were 
carried out by the same cardiologist and technician. All 
tests were symptom-limited and were stopped in all cases 
because of breathlessness or fatigue.
3) Ambulatory electrocardiographic monitoring using a 
Medilog I system, with subsequent analysis using a 
Pathfinder Analyzer under constant visual monitoring. The 
median duration of ambulatory monitoring was 72 hours 
(range 48-120).
4) M-mode echocardiography under 2-dimensional control with 
each patient in the left lateral position.
5) Serum sodium and serum potassium concentrations, 
analysed from venous blood samples taken on at least 2 
occasions at different times of the day (average value used
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for analysis); the median number of samples was 5 (range 
2-10). Potassium-sparing diuretics had been withdrawn for 
at least 2 weeks before these measurements, but potassium 
supplements were continued if the patient had been 
receiving these previously.
6) Serum digoxin concentration, analysed from blood drawn 
at least 6 hours after the last dose of the drug.
7) Total body sodium (measured by activation analysis) and 
total body potassium (measured by endogenous levels of 40K); 
values for both variables were expressed as a percentage of 
predicted normal on the basis of age, sex, height and 
weight.685,686
8) Plasma active renin (by radio-immunoassay) and plasma 
noradrenaline (by radio-enzymatic assay) ,687'688
DRUG TREATMENT
After the completion of these baseline evaluations, 51 
patients were treated with an angiotensin-converting enzyme 
inhibitor, either captopril or enalapril. The median 
maintenance dose of captopril was 75 mg/day (range 
37.5-150) and that of enalapril was 10 mg/day (range 5-40). 
Twenty-nine patients were treated with amiodarone, 
initially at a dose of 200 mg, 3 times/day, followed by a 
mean daily maintenance dose of 183+54 mg (range 100-400).
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Patients were allocated to treatment with converting-enzyme 
inhibitors or amiodarone either for clinical reasons 
according to the preference of the attending physician, or 
in the context of a clinical trial. Patients received no 
other vasodilator drugs or anti-arrhythmic agents unless 
otherwise stated.
DATA ANALYSIS
The mode of death was ascertained from the patient's 
relatives, the patient's physician, or the hospital staff. 
When death was believed to be due to cardiac causes, it was 
classified as sudden or the result of pulmonary oedema or 
cardiogenic shock. Sudden death was defined as death 
occurring without a marked change in symptoms in the 
preceding 24 hours. In those patients who died suddenly, 
further inquiries were made to determine whether they 
experienced some gradual deterioration in their symptoms of 
heart failure in the month before death.
The log-rank test was used to compare the survival rates 
among designated therapeutic subgroups. Predictors of 
mortality were determined by a Cox proportional hazards 
model, which identifies and corrects for important co- 
variates.689 Both forward and backward elimination procedures 
were carried out to protect against the omission of 
important predictors.690 Kaplan-Meier survival curves were 
constructed, where appropriate. Pearson's product-moment 
correlation coefficients were calculated to investigate
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potential inter-relationships among prognostic variables. 
Group means are presented as mean+SD unless stated 
otherwise.
RESULTS
Baseline Characteristics of Patients
The initial mean arterial pressure in our patients was 
91+14 mm Hg (range 66-130). The mean serum sodium 
concentration was 137+6 mmol/1 (range 124-148), and the 
mean serum potassium concentration was 3.7+0.4 mmol/1 
(range 3.0-4.6). Total body potassium was reduced at 96+10% 
of predicted normal (p<0.05), and total body sodium was 
increased at 107+9% of predicted normal (p<.01). The mean 
plasma concentrations of active renin and noradrenaline 
were elevated, 227+357 U/l (range 4- 1705) and 4.8+3.1 
nmol/1 (range 1.0-18.4), respectively. The mean 
end-diastolic and end-systolic left ventricular dimensions 
were 68+8 and 58+10 mm, respectively; the mean percent 
fractional shortening was 15.0+6.8%.
The mean frequency of ventricular extrasystoles was 5181/24 
hours (median=1837;range:0-24,299). Couplets or salvoes of 
ventricular extrasystoles were found in 82% of patients 
during the course of ambulatory monitoring (mean 17/24 
hours;median=ll;range 0-768). Ventricular tachycardia was 
seen in 61% of patients, with a mean overall frequency of 
8 events/24 hours (median=2:range:0-201). The frequency of 
ventricular extrasystoles and ventricular tachycardia was
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related (r=0.67;p<.001).
Patients treated with amiodarone were similar to those who 
did not receive the drug with respect to all pre- treatment 
variables. (Table 10.1) Patients treated with 
converting-enzyme inhibitors were similar to those who were 
not, except that patients who received captopril or 
enalapril received larger doses of frusemide (165+16 
mg/day) and had higher plasma active renin concentrations 
(275+385 U/ml) than those who did not (108+52 
mg/day;p<.01;153+300 U/ml;p<0.05, respectively).(Table
10.2).
PROGNOSTIC VARIABLES
The mean duration of follow-up was 31 months (range 12- 
52) , during which time 49 patients (58%) died. Of these 
deaths, 35 were sudden (71%), and although clinical 
deterioration had occurred in 8 patients in the preceding 
months, death in these patients was nonetheless unexpected. 
Five patients died in cardiogenic shock after a recurrent 
myocardial infarction, and 2 died after a cerebrovascular 
accident.One patient died after a mesenteric artery 
occlusion, one postoperatively after peripheral vascular 
surgery, one from chronic lymphatic leukaemia and asso­
ciated respiratory infections, and one from rectal 
carcinoma.Only 3 deaths were considered to be the result of 
intractable heart failure. Four patients who died suddenly 
had developed symptomatic sustained ventricular tachycardia
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Table 10.1
Pretreatment clinical, biochemical, and hemodynamic variables in patients grouped according to treatment with 
amiodarone
Amiodarone 
(n -  29)
No Amiodarone 
(n =  55) p value
Ag'e (yr) 59 ± 8 58 ± 7 NS
(39-75) (31-72)
Cause o f heart failure
Coronary artery disease 20 28 NS
Idiopathic cardiomyopathy 27 9 NS
Duration o f heart failure (mo) 21 ± 2 0 19 ±  18 NS
(3-84) (3-72)
Mean arterial pressure (mm Hg) 93 ±  13 89 ±  15 NS
(67-126) (66-124)
Fractional shortening (%) 14.5 ± 6 .0 I 5 .0 ± 7 .0 NS
(6 .4-30 .0) (4 .0 -30 .0)
Exercise time (min) 7.4 ± 5 .0 6.5 ± 5 .0 NS
(0.4-14) (0.4-16)
Furosemide dose (mg/day) 130 ± 6 0 150 ± 1 1 3 NS
(40-250) (40-750)
Ventricular extrasystoles (per 24 hr) 1705 1860 NS
(10-16742) (56-24299)
Plasma active renin concentration (ptU/ml) 272 ± 3 9 0 203 ± 3 4 0 NS
(14-1705) (4-1467)
Plasma norepinephrine (nmol/I) 4.9 ± 3 .5 4.6  ± 2 .9 NS
(1 .7 -13.7) (1 .0 -18 .0)
Serum sodium concentration (mmol/l) 1 3 6 .6 ± 4 .0 136.7 ± 6 .2 NS
(128-143) (124-148)
Serum potassium concentration (mmol/l) 3.7 ± 0 .3 3.8 ± 0 .4 NS
(3 .2 -4 .3 ) (3 .0 -4 .6 )
Total body sodium 105 ± 9 108 ± 9 NS
(percent predicted normal) (95-125) (95-129)
Total body potassium 98 ± 9 95 ± 1 3 NS
(percent predicted normal) (74-117) (67-113)
Values shown represent m ean, SD, and range within each group.
Table 10.2
Pretreatment clinical, biochemical, and hemodynamic variables in patients grouped according to treatment with convert- 
ing-enzyme inhibitors
Converting- 
enzyme inhibitor 
(n =  51)
No converting- 
enzyme inhibitor 
(n =  33) p value
Age (yr) 58 ± 8 58 ±  8 NS
(31-75) (39-73)
Cause o f heart failure
Coronary artery disease 27 21 NS
Idiopathic cardiomyopathy 24 12 NS
Duration o f heart failure (mo) 18 ±  18 22 ± 2 2 NS
(3-72) (3-84)
Mean arterial pressure (mm Hg) 8 8 ±  13 94 ±  15 NS
(67-122) (67-126)
Fractional shortening (%) 14.7 ± 6 .5 15.3 ± 7 .0 NS
* (5 .0 -32 .8 ) (4 .0 -30 .0 )
Exercise time (min) 6 .6 4 :4 .0 7 .0 ± 4 .0 NS
(0.4-16) (0 .4-16)
Furosemide dose (mg/day) 165± 113 108 ± 5 3 <  .01
(40-750) (40-200)
Ventricular extrasystoles (per 24 hr) 2106 1420 NS
(13-24299) (10-16742)
Plasma active renin concentration (/xU/ml) 275 ± 3 8 5 153 ± 3 0 0 <  .05
(4-1467) (5-1705)
Plasma norepinephrine (nmol/1) 4.9 ± 3 .2 4 .6 ± 3 .0 NS
(1.0 -18 .4 ) (1 .0 -13 .7)
Serum sodium concentration (mmol/1) 1 3 5 .9 ± 5 .8 1 3 7 .9 ± 4 .8 NS
(124-138) (128-138)
Serum potassium concentration (mmol/1) 3 .6 ± 0 .3 3 .9 ± 0 .4 NS
(3 .0-4 .3 ) (3 .2 -4 .6 )
Total body sodium 107 ±  10 106 ± 7 NS
(percent predicted normal) (95-129) (100-120)
Total body potassium 96 ± 1 2 98 ± 1 3 NS
(percent predicted normal),. (67-113) (74-117)
Values shown represent mean, SD, and range within each group.
Table 10.3
Univariate analysis of factors related to survival
Variable X2 p value
Ventricular extrasystoles 20.9 .00001
Exercise time 17.8 .00001
Mean arterial pressure 13.0 .001
Serum sodium concentration 12.1 .001
Plasma norepinephrine 12.0 .001
Amiodarone 9.9 .01
Plasma active renin concentration 9.6 .01
Fractional shortening 8.3 .01
Serum potassium concentration 7.6 .01
during follow-up. None had been on anti- arrhythmic therapy 
at the time, although each subsequently received treatment 
with procainamide (2 patients), tocainide (one patient), or 
amiodarone (one patient).
Using a Cox proportional hazards model and taking each 
variable separately, several variables were found to be of 
prognostic value (in order of importance): ventricular
extrasystoles, exercise time, mean arterial pressure, serum 
sodium concentration, plasma noradrenaline concentration, 
therapy with amiodarone, plasma active renin concentration, 
fractional shortening, and serum potassium concentration. 
(Table 10.3 and Figures 10.1-10.8)Using stepwise regression 
analysis, 5 variables had independent prognostic signifi­
cance: ventricular extrasytoles, fractional shortening, a 
diagnosis of coronary heart disease, exercise time, and 
treatment with amiodarone. (Figures 10.1-10.8) No 
predictive value of ventricular tachycardia independent of 
ventricular extrasystoles was observed.
RELATIONSHIPS AMONG PROGNOSTIC VARIABLES
The frequency of ventricular extrasystoles varied directly 
with plasma concentrations of active renin (r=0.45) and 
noradrenaline (r=0.52) and inversely with exercise time 
(r=-0.46), mean arterial pressure (r=-.46), serum sodium 
concentration (r=-.44), and serum potassium concentration 
(r=-0.44); all pc.001). (Fig 10.9) No association was seen 
with either the use of digoxin or with serum digoxin levels
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Figure 1 0 . 9 Correlation plots showing relationship 
between ventricular ectopic activity (VES/24 hr) and 
jTJretreatient "“values for plasma active renin 
i; concentration, plasma norepinephrine, mean arterial 
pressure, exercise time, serum sodium (Na+) 
‘concentration, and serum potassium (K+) concentration in 
patients with congestive heart failure.
(range 0.8-2.3 nmol/1). Of the associations noted above, 
only plasma noradrenaline and exercise time were inde­
pendently related to the frequency of ventricular 
extrasystoles, but these two variables explained only 35% 
of the observed variability (R2 value).
The percent fractional shortening was weakly and inversely 
related to mean arterial pressure (r=- 0.23;p<.05) but was 
not significantly related to any other variable, including 
the frequency of ventricular extrasystoles.
Exercise time was linearly and inversely related to plasma 
active renin concentration 0(r=-.35;p<.01) and plasma 
noradrenaline (r=-0.51;p<.001) but was linearly and 
directly related to mean arterial pressure (r=0.48;p<.001).
Plasma active renin concentration varied linearly and 
directly with plasma noradrenaline (r=-0.71). (Figure
10.10) Plasma renin and noradrenaline were inversely 
related to serum potassium concentration (r=-0.53 and 
-0.47, respectively), serum sodium concentration (both 
r=-0.62), mean arterial pressure (r=-0.50 and -0.52, 
respectively) and exercise time (r=-0.35 and -0.53).(Figure
10.11)By multiple regression analysis, the combination of 
serum potassium concentration, plasma noradrenaline, age, 
and mean arterial pressure carried independent information 
accounting for 75% (R2 value) of the observed variation in 
log plasma active renin.The severity of heart failure (as
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Figure 10.11 Correlation plots showing relationship 
between'circulating neurohormones (plasma active renin 
concentration (left) and plasma norepinephrine (NE, 
right) and serum sodium (Na+) concentration, serum 
potassium (K ), mean arterial pressure, . and exercise 
time in patients with congestive heart failure.
assessed by New York Heart Association functional 
classification) and the plasma active renin concentration 
accounted for 58% of the observed variation in plasma 
noradrenaline. If plasma active renin concentration was 
excluded, then mean arterial pressure was the best 
predictor, accounting for 46% of the observed variation in 
plasma noradrenaline.
In addition to the relationships noted above, serum sodium 
concentration and serum potassium concentration varied 
linearly and directly with values for mean arterial 
pressure (r=0.65 and 0.45, respectively). Serum and total 
body potassium were directly and linearly related (r=0.52), 
but total body sodium was unrelated to any other variable. 
(Figure 10.12) Forty-three percent of the variability in 
total body potassium was predicted by the log of plasma 
active renin concentration. (Figure 10.13) Total body 
potassium depletion was associated with a greater frequency 
of ventricular ectopics.(Figure 10.14)
EFFECTS OF THERAPY IN DESIGNATED SUBGROUPS
During long-term follow-up, patients treated with 
amiodarone fared better than those who were not 
(p<.01),(Figure 10.5) but neither treatment with 
converting-enzyme inhibitors nor digoxin was related to 
survival. (Figure 10.14)These effects persisted after 
correction for any differences in prognostic variables 
between the therapeutic subgroups.
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CHAPTER 11:HAEMODYNAMICS, ANGIOTENSIN II LEVELS AND 
SYMPATHOADRENAL FUNCTION AFTER LOW-DOSE CAPTOPRIL IN 
PATIENTS WITH HEART FAILURE
INTRODUCTION
This study was undertaken to assess the haemodynamic 
efficacy, likely mode of action, and safety of giving 
captopril to patients with severe heart failure.
Though several studies have monitored the haemodynamic 
effects of captopril, many are flawed in their study design 
(ie comparing basal haemodynamic effects with peak 
"apparent” effect, instead of some preselected time point), 
and little attention was paid to the sequence of events at 
the onset of the drug's action. Most studies agree that the 
effects of captopril on the venous side of the circulation 
are equal to or greater than its effects on the systemic 
side. Therein lies a paradox. Angiotensin II appears to be 
a predominant arteriolar constrictor with little effect on 
the venous circulation. If reduction in angiotensin II is 
indeed the mode of action of angiotensin converting enzyme 
inhibitors, why the pronounced venous effects? Several 
investigators have shown that angiotensin II can have 
effects on the sympathetic nervous system. Perhaps a 
reduction in sympathetic activity could account for the 
venodilatation? By giving a low dose of captopril (6.25 mg) 
and by close haemodynamic and biochemical monitoring it was 
hoped to throw more light on the mechanisms by which
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captopril acted on the circulation. Several authors have 
noted severe initial adverse responses to these agents, 
including profound hypotension, renal failure, and 
death.691'693 It was therefore felt necessary to study a small 
population in detail to assess if this was an appropriate 
initial dose of captopril and how closely the initiation of 
therapy required to be monitored.
PATIENTS AND METHODS
Ten patients with New York Heart Association functional 
class III or IV heart failure were studied; the clinical 
details are shown in Table 11.1. All had symptoms for more 
than 6 months and were receiving digoxin (mean daily dose 
0.2 mg) and frusemide (mean daily dose 196 mg) . Vasodilator 
drugs were discontinued at least one week before the study. 
The aetiology was idiopathic congestive (dilated) 
cardiomyopathy in 5 patients, ischaemic heart disease in 
two patients, and alcoholic cardiomyopathy, chronic aortic 
regurgitation and chronic mitral regurgitation in one 
patient each. Eight patients were in sinus rhythm, and two 
had ventricular rhythm with a controlled ventricular 
response.
STUDY DESIGN
Patients were studied supine six hours after the last 
medication and six hours after food. Pulmonary and systemic 
pressures and cardiac output were measured invasively. 
Fifteen minutes after final placement of catheters, two
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sets of haemodynamic measurements were made, fifteen 
minutes apart; these varied by less than 5%. Measurements 
of systolic, diastolic, mean arterial and pulmonary 
arterial diastolic pressures were then made every 2.5 
minutes over a period of 60 minutes, after the patients had 
been given 6.25 mg captopril by mouth. Cardiac output was 
measured at baseline, 30 minutes and 60 minutes. The plasma 
concentrations of active renin, angiotensin II, 
noradrenaline and adrenaline were measured in arterial 
blood samples taken every 5 minutes. Serum sodium was also 
measured prior to giving captopril.
STATISTICAL METHODS
Results are expressed as mean + standard deviation. 
Correlations were calculated by the method of least 
squares. For pressures, heart rate and hormonal 
measurements, correlations were calculated for each 
variable with time. Statistical significance was derived 
from a two-way sign test on the slopes of the correlations. 
Paired t-tests with Bonferroni's correction were used to 
analyse changes in cardiac index and systemic vascular 
resistance. The same method was used to assess changes in 
plasma concentrations of angiotensin II, since an increase 
in plasma levels towards the end of the study period 
compromised the correlation with time. Values of p<0.05 
were considered significant.
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RESULTS
Haemodvnamic Effects
Measurements of haemodynamic variables before and after 
treatment are given in Table 11.2. Decreases in systolic 
and diastolic pressures in the radial and pulmonary 
arteries together with a reduction in heart rate were 
evident 20 - 30 minutes after captopril, with maximal
effects between 45 and 50 minutes after drug intake. 
(Figure 11.1) Some recovery was noted by 60 minutes after 
dosing.
The percentage decreases in left ventricular filling 
pressure were similar to and well correlated with the 
decreases in systemic arterial pressure; both these 
variables also correlated with the decrease in heart rate 
(r values for correlations between 0.73 and 0.91; p<0.01). 
Cardiac index increased slightly from 2.0 +0.3 to 2.3 + 0.4 
1 itres/minute/m2./ 30 minutes after captopril, and 2.3 + 0.1 
litres/minute/m2., 60 minutes after the drug (p<0.05}.
Systemic vascular resistance fell markedly from 2973+558 to 
2357+699 dvnes.second.cm- 2. after 30 minutes and 1500 + 
470 dvnes.second.cm-5. after 60 minutes (p<0.01).
Three patients (patients 3, 4 and 5) showed evidence of
vasomotor syncope in the supine position, with a feeling of 
faintness and warmth associated with bradycardia, pallor, 
and sweating. Mean blood pressure fell by an average of 46% 
in this group, compared with 17% in the other patients. 
Pulmonary artery diastolic pressure also fell markedly (51%
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compared with 23%) , as did the heart rate (23% compared 
with 9%) . The haemodynamic results from a patient who 
showed evidence of vasomotor syncope is depicted in Figure 
11.2. Note the decline in pulmonary artery diastolic 
pressure before the abrupt onset of bradycardia and 
systemic hypotension. The overall timing of the fall in 
systemic arterial pressure was no different from the timing 
of the decline in pulmonary arterial diastolic pressures, 
with detectable falls occurring at 20 minutes. In contrast, 
in those patients who developed vasomotor syncope, a marked 
decline in left ventricular filling pressures, as reflected 
by pulmonary arterial diastolic pressure, preceded 
haemodynamic collapse.
Angiotensin II. Renin and Catecholamines
Plasma active renin concentration before captopril was high 
in 9 pat±-ents_and suppressed in one, a patient with marked
peripheral oedema. There was significant inverse
correlation between the serum sodium and renin (r- 
0.72;p<0.01). Although plasma concentrations of renin 
tended to be highest in those patients with the lowest 
cardiac output, the percentage decrease in systemic 
vascular resistance and increase in cardiac output after 
captopril were not well correlated with plasma 
concentrations of angiotensin II or renin before treatment 
(r=0.1-0.2). There was a closer relationship between the 
initial serum sodium concentration and the percentage 
change in systemic vascular resistance after captopril
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Figure 11.2 This represents the haemodynamic response 
to captopril in Patient 3, in whom vasomotor syncope 
developed 40 minutes after captopril administration.
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(r=0.5), but this was not statistically significant. Plasma 
concentrations of renin increased after captopril in 9 
patients but failed to increase in the patient with 
initially low levels. This patient had the highest initial 
arterial pressure, and was later observed to have 
suppressed levels of aldosterone also (patient 1). Plasma 
concentrations of angiotensin II fell progressively to 
reach a nadir about 40 minutes after drug intake (Figure
11.3) , a time that coincided with the greatest haemodynamic 
change. A sensitive index of angiotensin converting enzyme 
inhibition is the ratio of plasma concentrations of renin 
to angiotensin II. From this index, it is clear that the 
drug had an effect 15 minutes after administration (Figure
11.4) and that this coincided with the apparent onset of 
haemodynamic changes.
Plasma concentrations of noradrenaline also fell, despite 
the large reductions in arterial pressure. Plasma 
concentrations of adrenaline varied markedly, in- keeping 
with the pulsatile nature of adrenaline release. Large 
increases in plasma adrenaline were noted during syncope 
but arterial plasma noradrenaline failed to increase. One 
patient who developed marked bradycardia was given 1.2 mg 
atropine with a subsequent increase in heart rate and 
systemic and pulmonary pressures.
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Figure 11.3 This shows the individual responses in 
plasma concentrations of angiotensin II, renin, (the 
ratio of renin to plasma angiotensin II is shown in the 
inset), plasma noradrenaline, and plasma adrenaline.
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CHAPTER 12S SEVERE HYPOTENSION AFTER FIRST DOSE OF 
ENALAPRIL IN HEART FAILURE
INTRODUCTION
Enalapril was the second orally active converting enzyme 
inhibitor to become available for use in hypertension and 
heart failure. Occasional severe hypotension has been 
described after the first dose of captopril in patients 
with heart failure and hypertension. Syncope with captopril 
administration coincides with a rapid fall in angiotensin 
II concentration, which occurs usually within 30-45 minutes 
after oral dosage. Unlike captopril, enalapril requires 
conversion by the liver to the active metabolite 
enalaprilat, this delaying the onset of action.694,695 We 
report the effects of enalapril in a consecutive series of 
26 patients with cardiac failure, with particular reference 
to the time of onset of the hypotensive effect and its 
magnitude.
PATIENTS AND METHODS
Twenty-six patients were studied (mean age 59+4(SD) years) 
with moderate to severe heart failure (New York Heart 
Association Class II-IV; median III) of more than 6 months' 
duration and for which treatment with diuretics and digoxin 
had remained unchanged for at least a month. All patients 
received frusemide in a mean dose of 123 (SD 60) mg/day 
and, in addition, 4 were taking bendrofluazide 5-10 mg/day, 
and 7 amiloride 5-10 mg/day. All were also receiving
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digoxin (0.22 (SD 0.05) mg/day). All patients had a 
dilated, poorly functioning left ventricle on 
echocardiography. The aetiology of heart failure was 
ischaemic heart disease in 14, idiopathic dilated 
cardiomyopathy in 10, and severe residual impairment of 
left ventricular function after valve replacement in 2. No 
patient was noticeably hypertensive before treatment and 
all had systolic pressures above 90 mm Hg.
Before being given enalapril, the serum urea, creatinine 
and electrolytes, and plasma active renin (normal range 
10-50 mU/1) angiotensin II (normal range 5-35 pmol/l;53- 
368 pg/100 ml) concentrations were measured. Plasma
catecholamines and vasopressin values were also assayed in 
one patient. Diuretics were administered with the enalapril 
in the first 20 patients but withheld for 24 hours in a 
further 5, including cases 1 and 2. Blood pressure was 
recorded routinely before and 4 hours after the first dose 
of enalapril. Further readings were taken if the patient 
noted any symptoms. Mean blood pressure was calculated as 
(systolic - diastolic)/3 (+ diastolic). Patients were kept 
in bed for a minimum of 4 hours after the first dose of 
enalapril. Angiotensin II (Hypertensin; Ciba) was given by 
intravenous infusion when required.
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STATISTICS
Correlations were performed using the least squares 
technique for normally distributed data and Spearman's rank 
correlations for non-parametric data. The response to 
treatment was tested by Student's t test with prior log 
transformation of the data where indicated. A p value of 
<0.05 was considered significant.
RESULTS
Before enalapril, plasma sodium and plasma active renin 
concentrations were closely and inversely correlated 
(r=-0.75;p<0.001). The change in blood pressure with the 
first dose of enalapril was modestly correlated with the 
pre-treatment plasma active renin (r=-0.42;p<0.05) and 
angiotensin II (r=-0.59;p<0.01) concentrations (Figure 
12.1) but the correlation with serum sodium was not 
significant (r=0.34;NS).
In the first 20 patients, enalapril caused no adverse 
effects. Subsequently, after the first dose, 3 patients 
developed profound hypotension, bradycardia (Figure 12.2) 
and sweating. The falls in heart rate and mean blood 
pressure were significantly correlated (r=0.66;p<0.002). 
Table 12.1 shows the treatment and baseline recordings of 
3 patients who developed severe hypotension (cases 1-3) 
compared with the mean (and median where appropriate) 
values of the 23 patients who did not.
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The occurrence of syncope could not predicted by initial 
mean blood pressure (Figure 12.3), initial serum sodium 
(Figure 12.4), frusemide dose (Figure 12.5), or the 
creatinine/urea ratio (an index of prerenal uraemia). 
(Figure 12.6)
CASE HISTORIES OF PATIENTS WITH SYNCOPE 
Case Is
A 64-year-old man with a history of 2 myocardial 
infarctions was admitted with orthopnoea. His jugular 
venous pressure was raised and he had an enlarged liver and 
peripheral oedema. Diuretics were withheld for 24 hours and 
10 mg enalapril administered. Four hours later he abruptly 
developed syncope (Table 12.1). Head- down tilt and 
infusion of angiotensin II (6 ng/kg/minute) restored his 
blood pressure to 92/64 mm Hg but bradycardia persisted. 
Attempts to withdraw angiotensin resulted in further synco­
pal episodes until 24 hours afterwards, when it was 
stopped, the blood pressure remaining at 90/66 mm Hg and 
the heart rate at 62 beats/minute. Four hours after the 
onset of syncope a 12-lead electrocardiogram showed new 
anterior T wave inversion. The myocardial specific 
creatinine kinase MB fraction was mildly raised 18 hours 
later (239 IU, 8% of total creatinine kinase; normal range 
<160 IU, <6%). In the 24 hours after stopping the infusion 
of angiotensin II he passed 2.7 litres of urine (sodium 72 
mmol(mEq)/!, creatinine 2.4 mmol/l(27.1 mg/lOOml). Serum
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sodium fell to a nadir of 124 mmol(mEq)/I and creatinine 
rose to 297 umol/l(1.4 mg/100ml; see Table 12.1 for initial 
values). Forty-eight hours later the patient received 2.5 
mg enalapril without ill effect, his systolic pressure 
remaining above 80 mm Hg. In the following months, he had 
a good symptomatic response to the drug, with a reduction 
in diuretic requirements and improved exercise performance.
Case 2:
A 61-year-old man with a history of 3 myocardial 
infarctions was admitted with orthopnoea and dyspnoea. The 
jugular venous pressure was raised. Diuretics were withheld 
for 24 hours and he was given 5 mg enalapril. Two and a 
half hours later, however, he felt faint; blood pressure 
fell from 94/74 to 56/30 mm Hg and heart rate from 82 to 52 
beats/minute over 15 minutes. Blood samples showed that the 
previously high plasma angiotensin II concentration had 
fallen into the normal range, while the plasma active renin 
concentration showed a brisk rise (Table 12.2). Plasma 
noradrenaline concentration failed to rise in response to 
the fall in blood pressure but adrenaline and anti-diuretic 
hormone increased. Head-down tilt increased his pressure to 
78/42 mm Hg; heart rate remained at 56 beats/minute. After 
1.2 mg atropine given 15 minutes later, his blood pressure 
increased to 90/64 mm Hg and heart rate to 70/minute. After 
a further 24 hours of bed rest he was given 2.5 mg 
enalapril, without ill effect. Subsequently, he had a good
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symptomatic response, with an increase in exercise 
performance.
Case 3:
A 66-year-old man with a dilated cardiomyopathy was 
admitted with increasing dyspnoea. Jugular venous pressure 
was raised. Diuretics were not withheld. Two and a half 
hours after a 5 mg dose of enalapril, he became abruptly 
hypotensive with bradycardia (Figure 12.7). Plasma 
angiotensin II concentration had fallen from 58 to 18 
pmol/1 (609-189 pg/100 ml). After 1-2 mg atropine given 10 
minutes later, his blood pressure increased from 38/20 to 
58/40 mm Hg, and pulse rate from 38 to 50 beats/minute. An 
angiotensin II infusion (6 ng/kg/minute) partially restored 
his blood pressure to 90/74 mm Hg, although bradycardia 
persisted at 54 beats/minute. Attempts to stop the 
angiotensin II infusion resulted in a further episode of 
syncope. Diuretics were withheld for the next 4 days. 
Angiotensin II concentration measured 24 hours after the 
initial syncopal episode and during an infusion of 2 
ng/kg/hour was 189 pmol(1985 pg/100 ml), though blood
pressure and heart rate were incompletely restored (108/68 
mm Hg;64 beats/minute). Forty-eight hours after the initial 
syncope, 1 litre physiological saline was infused over 2 
hours, and angiotensin II discontinued, without further 
syncope. Over 48 hours of oliguria, his serum sodium 
concentration fell to 120 mmol(mEq)/I and serum creatinine 
value rose to 430 umol/l(4.9 mg/lOOml). A diuresis ensued
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after stopping angiotensin II (24-hour urine volume 3.7 
litres; sodium concentration 105 mmol(mEq)/l, creatinine 
1.8 mmol/l(20.4 mg/100ml). Three days later, 2.5 mg
enalapril was administered, without untoward effect. 
Subsequently, he had a fair clinical response in terms of 
symptoms and exercise performance.
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CHAPTER 13 S OBSERVATIONS ON THE ORAL DOSE OF CAPTOPRIL 
REQUIRED FOR HAEMODYNAMIC EFFECT
INTRODUCTION
The previous section demonstrated that 6.25 mg captopril 
given orally could cause an alarming fall in blood pressure 
in some patients, and the previous two chapters have shown 
that this group cannot be reliably identified. This raises 
the question "Is there a safe therapeutic window in which 
haemodynamic changes will occur but without syncope in 
subjects at high risk?"
PATIENTS
Two patients were studied, aged 63 and 58 years. Each had 
previously been given 6.25 mg captopril, causing marked 
hypotension and symptoms suggestive of incipient vasomotor 
syncope. At least one week had been allowed to elapse 
between this event before the present observations were 
made. The aetiology of heart failure was ischaemic heart 
disease in both. One was on frusemide 240 mg/day, the other 
on frusemide 200 mg/day, plus 5 mg bendrofluazide. Both 
received digoxin 0.25 mg/day. One had marked left 
ventricular failure, the other had evidence of both right 
and left ventricular failure, with the former 
predominating.
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METHODS
Patients were studied on bed rest, and medication was 
withdrawn for the day of study. A Swan-Ganz catheter was 
placed in the pulmonary artery for the measurement of 
pulmonary artery pressures 3 0 minutes before the study. 
Blood pressure was monitored by mercury sphygmomanometer 
every 15 minutes. Captopril was given every 2 hours, 
according to the following regime: 1 mg, 2 mg, 3 mg, 4 mg, 
etc, as tolerated. Any symptoms of hypotension or a fall in 
systolic arterial pressure of greater than 25% was 
considered a suitable end-point. Angiotensin II infusion 
was readied in case of need. Blood was taken prior to the 
study and 40 minutes after dosing or during any episode of 
marked hypotension for plasma levels of renin, angiotensin 
II, noradrenaline, adrenaline and anti-diuretic hormone.
RESULTS
No haemodynamic effect could be detected in either patient 
after 1 mg and 2 mg does of captopril. Both patients 
dropped their blood pressures markedly after 3 mg 
captopril. This was accompanied by feelings of faintness 
and a fall in pulmonary arterial pressures, pulmonary 
capillary wedge pressure and heart rate. At this time, 
plasma levels of angiotensin II were markedly suppressed, 
with a reciprocal rise in plasma renin. While plasma level 
of noradrenaline appeared to have fallen slightly, levels 
of adrenaline and anti-diuretic hormone were increased. 
(Tables 13.1 & 13.2)
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T A B L E  1 3 . 1
H A E M O D Y N A M IC  A N D  N E U R O E N D O C R IN E  E F F E C T S  O F  C A P T O P R I L  I N  A  P A T I E N T
DEVELOPING SYNCOPE AFTER 3MG OF CAPTOPRIL.
PATIENT 1
TIME Omins 4Omins 4Omins 40m:
BASELINE IMG 2 MG 3 MG
HEART RATE (bpm) 78 74 76 43
SYSTOLIC BP (mmHg) 124 118 116 64
DIASTOLIC BP (mmHg) 78 80 80 ?
PUL.ART.DIA.P(mmHg) 18 16 14 8
P.A.R.C. (uU/ml) 84 72 170 1,236
P.ANG.II (pmol/L) 27 21 25 ?
PARC/P.ANG.II 3.1 3.4 6.8 ?
P.NORADR. (nmol/L) 4.3 4.1 4.6 2.8
P.ADRENALINE (nmol/L) 0.3 0.3 0.3 5.3
P.A.D.H. (pg/ral) 1.3 1.2 1.2 3.7
BP = blood pressure. Pul. Art.Dia. = pulmonary arterial diastolic 
P = plasma. A.R.C. = active renin concentration.
Ang II = angiotensin II. Noradr = noradrenaline 
A.D.H. = anti-diuretic hormone
T A B L E  1 3 . 2
H A E M O D Y N A M IC  A N D  N E U R O E N D O C R IN E  E F F E C T S  O F  C A P T O P R I L  I N  A
PATIENT DEVELOPING SYNCOPE AFTER 
PATIENT 2
TIME Omins
BASELINE
HEART RATE (bpm) 86
SYSTOLIC BP (mmHg) 106
DIASTOLIC BP (mmHg) 74
PUL.ART.DIA. (mmHg) 36
P.A.R.C. (uU/ml) 154
P.ANG.II (pmol/L) 36
PARC/P.ANG.II 4.3
P.NORADR. (nmol/L) 6.7
P.ADRENALINE (nmol/L) 0.3
P.A.D.H. (pg/ml) 1.9
For abbreviations see table 13.1
3MG OF CAPTOPRIL.
4Omins 4Omins 35mins
IMG 2MG 3MG
83 83 52
104 106 58
80 76 ?
34 34 18
148 246 784
38 30 6
3.9 8.2 130.7
6.0 5.9 3.1
0.4 0.3 7.2
1.7 2.1 5.9
Both patients responded to the simple expedient of head- 
down tilt, and recovered fully in 5-10 minutes.
Both patients subsequently received several doses of 3 mg 
captopril, and although their blood pressures remained low, 
they did not develop symptomatic hypotension. After 48 
hours, the patients were allowed up. Their clinical course 
thereafter was very satisfactory.
Although no haemodynamic effect occurred with the 1 and 2 
mg doses of captopril, a small rise in plasma renin 
concentration was observed in both cases with the 2 mg dose 
of captopril, though no consistent fall in plasma 
angiotensin II occurred.
The ratio of plasma renin concentration to plasma 
angiotensin II increased, suggesting impaired negative 
feedback suppression of plasma renin by angiotensin II. 
This may reflect inhibition of locally synthesized 
angiotensin II, leading to increased renal renin secretion. 
Alternatively, it may indicate in the clinical setting a 
greater robustness of the renin assay.
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CHAPTER 14: CAPTOPRIL IN HEART FAILURE: A DOUBLE-BLIND
CONTROLLED TRIAL
Severe congestive cardiac failure entails a heavy burden of 
symptoms and carries a grave prognosis.
Captopril would be expected to have all the advantageous 
properties of conventional vasodilator agents in severe 
heart failure and also to have substantial additional 
benefits. Converting enzyme inhibition should overcome the 
possibly adverse direct renal effects of the renin- 
angiotensin system in severe heart failure as well as 
lowering secretion of anti-diuretic hormone and aldos­
terone.
Several open studies have indicated benefit from treatment 
with captopril; a double-blind trial is, however, critical 
in assessing the long-term effect of any drug in a disease 
with such prominent symptoms and fluctuating natural 
history. This study was one of the first three to report a 
beneficial effect of captopril in chronic heart failure696,697 
in a controlled trial. In addition to studying the effects 
of captopril on symptoms and exercise capacity in patients 
with heart failure, we also studied the effects on 
neuroendocrine activation, renal function, and the 
disturbed metabolism of heart failure.
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PATIENTS AND METHODS
Fourteen men and 6 women (mean age 62 years) with severe 
congestive heart failure (New York Heart Association Class 
III or IV) of more than 6 months' duration were studied. 
Thirteen had ischaemic heart disease, 4 congestive 
cardiomyopathy, and 3 severe left ventricular dysfunction 
associated with valvar regurgitation. All were receiving 
digoxin together with frusemide (mean dose 375 mg/day); 3 
were also receiving bendrofluazide 5 mg/day, and 2 others 
had been taking amiodarone 200 mg/day for more than a year. 
Six patients had atrial fibrillation. None had angina, 
significant respiratory disease, or serum creatinine 
concentrations >200 mol/1 (2.26 mg/lOOml). All gave written 
consent to the trial, which was approved by the hospital's 
ethical supervisory committee.
The study was in 4 phases, full patient assessment being 
performed at the end of each. Firstly, during a run-in 
phase of 2 weeks, treatment with digoxin, diuretics, 
potassium supplements, and amiodarone was stabilised and 
the patient made familiar with the procedures, including 
treadmill exercise. Secondly, captopril was introduced at 
a dose of 6.25 mg 3 times daily and titrated to a fixed 
thrice-daily dose for each patient (mean total dose 93.75 
mg;range 37.5-150 mg) for an open study of 6 weeks' 
duration. Thirdly, patients were randomly allocated 
double-blind to receive either the same dose of captopril 
as in the second phase or a matching placebo for 6 weeks.
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Fourthly, for a final 6 weeks, patients were crossed over 
double-blind to the alternative treatment to that given in 
the third phase. All treatment other than captopril was 
maintained without change throughout the third and fourth 
phases.
Symptoms were assessed according to the New York Heart 
Association classification, and by visual analogue scales 
for breathlessness, tiredness and ankle swelling. Exercise 
tolerance was tested with a modified Balke treadmill 
protocol in stages of 3 minutes. End- diastolic and 
end-systolic dimensions and fractional shortening were 
calculated from left ventricular M-mode echocardiographic 
monitoring. Twenty-four hour ambulatory 
electrocardiographic monitoring was performed using a 
Medilog I system. (See Methods - Chapter 7)
Venous blood samples were drawn at 8 am, the patients 
having fasted and remained supine overnight, 10 hours after 
the previous dose of captopril or placebo. Samples were 
assayed for serum concentrations of electrolytes, urea, 
creatinine, and for plasma concentrations of active renin, 
angiotensin II, aldosterone, cortisol, noradrenaline, and 
adrenaline. Blood pressure was measured between 2 pm and 4 
pm with a standard sphygmomanometer lying and after 2 
minutes standing; heart rate was recorded at the same time.
154
Total body potassium content was measured from endogenous 
40potassium, using the whole body counter; total body 
sodium, chlorine, calcium, phosphorus and nitrogen content 
were measured similarly after activation analysis.
Renal plasma flow and glomerular filtration rate were 
estimated with radioisotope clearance methods, using sodium 
iodohippurate (1311) and 99mtechnetiurn diethylenetriamine 
penta-acetic acid (DTPA). Urinary creatinine clearance over 
24 hours was also measured.
The studies requiring nuclear medicine techniques were only 
performed during the double-blind part of the study.
STATISTICAL METHODS
The results of 3 analyses are presented, each based on 
standard statistical methods with the data transformed to 
a logarithmic scale as appropriate. The first comparison 
was between the start and finish for the open study and the 
second between the ends of the phases of the double-blind 
study during which placebo or captopril was given. The 
final comparison used repeated measures analyses of 
variance to incorporate data from the start of the 
double-blind study together with data from the end of the 
placebo and captopril phases, and, in effect, this compared 
the changes during the 2 double-blind 6- week periods of 
treatment. The design of the study shows that this final
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analysis would be sensitive to any effect of the order of 
treatment allocation, and the results are not reported in 
cases where the order effect was significant at the 5% 
level.
RESULTS
Tables 14.1-14.4 give the results of all the tests 
undertaken.
CLINICAL OUTCOME
Of the 20 patients entered, 14 completed the study. Two 
died in the initial run-in phase, 2 during the open 
captopril phase, and one in the double-blind phase while 
taking placebo. The condition of a sixth patient with 
mitral incompetence improved considerably during the open 
captopril phase, and he was therefore withdrawn for valve 
replacement. The tables give detailed results only for the 
14 patients who completed the study, unless otherwise 
stated.
SYMPTOMS
Breathlessness, tiredness, and New York Heart Association 
classification were all significantly improved in the 
double-blind captopril phase of the study; by contrast, 
ankle swelling was not. (Table 14.1)
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TABLE 14.1
CLINICAL EFFECTS OF CAPTOPRIL COMPARED TO PLACEBO
SYMPTOMS
BASELINE
n = 14 
V.A.S.(mm)
- BREATHLESSNESS 52(27)
- TIREDNESS 48(25)
- ANKLE SWELLING 20(25)
CAPTOPRIL
OPEN
15(12)
26(20)
6(7)
New York Heart Association Class
- MEAN
- MEDIAN
- RANGE
WEIGHT (kg)
3.5
4
3-4
2.0
2
1-3
CAPTOPRIL PLACEBO
DOUBLE BLIND DOUBLE BLIND
66.8(14.7) 66.1(10.2)
16(17)
12(14)
6(8)
2.0
2
1-3
67.0(9.2)
34(22) 
28(28) 
8(14)
2.5
2
2-4
67.0(9.1)
p<0.02 
p<0.02
ns
p<0.02
ns
SYSTOLIC BP(mmHg) 118(20) 109(16) 110(18)
DIASTOLIC BP(mmHg) 79(14) 68(12) 64(13)
HEART RATE(bpm) 83(9) 79(10) 75(11)
130(27) p<0.001
83(16) p<0.001
79(11) *
EXERCISE TIME(secs) 336(228) 546(300) 549(318) 456(258) p<0.007
* = order effect significant at the 5% level 
VAS = visual analogue scores. BP = blood pressure
TABLE 14.2
THE EFFECTS OF CAPTOPRIL ON CARDIAC FUNCTION.
BASELINE CAPTOPRIL CAPTOPRIL PLACEBO
OPEN DOUBLE DOUBLE
BLIND ' BLIND
ECHOCARDIOGRAPHY 
LEFT VENTRICULAR
- DIMENSION (mm)
- END-DIASTOLE 67(8) 64(12) 64(10) 67(10) (p<0.06)
- END-SYSTOLE 56(11) 53(11) 52(10) 55(10) p<0.04
- FRACTIONAL SHORTENING 17.2(6.8) 18.3(5.9) 18.7(5.9) 17.3(5.6) n.s.
(%)
AMBULATORY ELECTROCARDIOGRAPHY
VENTRICULAR (in 24hours)
- EXTRASYSTOLES mean 3917 2353 1387 1897
median 187 107 121 199
range 3-24570 0-24299 0-10445 0-11416 p<0.05
- COUPLETS mean 82 26 8 14
median 2 1 0 3
range 3-750 0-357 0-82 0-103 (p<0.06)
- SALVOES mean 9 7 5 13
median 0 0 0 1
range 0-94 0-67 0-70 0-147 p<0.02
- TACHYCARDIA mean 9 5 4 7
median 0 0 0 1
range 0-94 0-67 0-49 0-86 p<0.05
TABLE 14.3
BIOCHEMISTRY AND TOTAL BODY COMPOSITION
BASELINE CAPTOPRIL CAPTOPRIL PLACEBO
OPEN DOUBLE DOUBLE
n = 14 BLIND BLIND
SERUM CONCENTRATIONS
- SODIUM (mmol/L) 140(5) 141(3) 140(3) 140(6) ns
- POTASSIUM (mmol/L) 3.4(0.7) 3.9(0.6) 3.9(0.4) 3.4(0.4) p<o.oo:
- CHLORIDE (mmol/L) 100(5) 101(7) 99 (5) 96(11) ns
- CALCIUM (mmol/L) 2.3(0.1) 2.3 (0.1) 2.3(0.1) 2.3(0.1) ns
- PHOSPHATE (mmol/L) 1.0(0.2) 1.1(0.2) 1.1(0.2) 0.9(0.1) p<0.02
- UREA (mmol/L) 9.3(5.7) 10.8(9.7) 11.1(8.4) 7.7(3.6) p<0.01
- CREATININE (umol/L) 116(40) 123(45) 133 (42) 113(32) p<0.02
-WHITE CELL
COUNT (X10 /L) 8.1(1.4) 7.0(6.5) 6.3(1.3) 7.4(1.1) ns
PLASMA CONCENTRATIONS
- ACTIVE RENIN (uU/ml)
- mean 168 383 405 262
- median 51 97 104 55
- range 20-1209 28-2287 46-2289 12-501 *
- ANGIOTENSIN II (pmol/L)
- mean 53 22 21 80
- median 36 22 17 31
- range 8-178 4-38 6-47 10-292 p<0.01
- ALDOSTERONE (pmol/L)
- mean 924 252 308 504
- median 336 196 224 280
- range 112-2100 56-924 56-1568 84-2072 ns
- NORADRENALINE(nmol/L)4.1(2.1) 3.0(2.0) 3.2(1.7) 5.1(2.6) p<0.05
- ADRENALINE (nmol/L) 0.2(0.3) 0.2(0.3) 0.3(0.2) 0.5(0.4) p<0.03
TOTAL BODY COMPOSITION
- SODIUM (mmol) ' 3195(437) 3195(447) 3200(367) ns
E/P (%) 104(11) 103(8) 104(7) ns
- POTASSIUM (mmol) 2596(443) 2667(111) 2543(135) p<0.03
E/P (%) 94(12) 97(14) 92(14)
- CHLORINE (mmol) 1604(263) 1627(245) 1600(239) ns
E/P (%) 100(7) 99 (6) 97(11)
- CALCIUM (mmol) 23311(3287) 23264(2905) 23441(3199) ns
E/P (%) 106(13) 104(11) 104(11)
- PHOSPHORUS (mmol) 15953(2397) 16303(2025) 16241(2200) ns
E/P = estimated/predicted
ADVERSE REACTIONS
Two patients developed morbiliform rashes within 2 weeks of 
starting captopril. Both were receiving doses at the upper 
limit for their level of renal function (captopril 300 
mg/day, with creatinine clearances 48 and 43 ml/minute). 
The rashes cleared on stopping captopril, and in both 
patients the drug was started again at lower doses, without 
relapse. Two patients had mild postural dizziness without 
demonstrable hypotension on starting captopril; symptoms 
resolved spontaneously. Total white cell count showed a 
slight but significant decline (p<0.05) during the open 
phase of captopril. (Table 14.2) A similar trend in the dou­
ble-blind phase was not significant. The lowest individual 
white cell count throughout the trial was 4000 x 106/1, with 
a normal differential count.
EXERCISE TESTING
Exercise time was significantly increased during double­
blind captopril treatment (Table 14.1)
WEIGHT
With the initiation of captopril in the open phase, mean 
(SD) body weight rose over the first week from 66.3 (2.5) 
kg to 67.5 (2.6) kg (n=18;p<0.05). This was largely due to 
distinct retention of fluid in 5 patients, 2 of whom 
required an increase in frusemide dosage. There were 
thereafter no significant differences in body weight 
between the mean values at the end of each phase of the
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study. (Table 14.1) Diuretics were fixed in the 4-week 
period prior to the double- blind part of the study. 
Diuretics were not changed during the double-blind study.
BLOOD PRESSURE AND HEART RATE
Both systolic and diastolic pressures, supine and standing, 
were lower during treatment with captopril; there was no 
postural fall in blood pressure in this study. Heart rate 
was not significantly changed in either posture. (Table 
14.1)
ECHOCARDIOGRAPHY
Both end-systolic and end-diastolic dimensions were reduced 
by captopril, although fractional shortening was not 
increased. (Table 14.2)
TWENTY-POUR HOUR AMBULATORY ECG MONITORING
The incidence of ventricular extrasystoles, couplets, 
ventricular salvoes, and ventricular tachycardia were all 
significantly lower with captopril. (Table 14.3)
SERUM ELECTROLYTES (Table 14.3)
Mean serum potassium on placebo and during the run-in 
period was low at 3.4 mmol l'1. Two patients were
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hyponatraemic with serum sodium of less than 128 mmol l'1. 
Captopril caused a significant increase in serum potassium 
levels; the increase was directly related to plasma active 
renin concentration in the placebo phase (r=0.61;p<0.05). 
Despite correcting hyponatraemia in some patients, mean 
serum sodium did not change. Serum chloride and calcium did 
not change with captopril therapy. However, serum phosphate 
was significantly higher on captopril therapy.
HORMONES
Plasma active renin concentration was elevated in the 
placebo phase and was positively correlated to plasma 
angiotensin II (r=0.92;p<0.001). Angiotensin II was, in 
turn, positively related to plasma aldosterone and plasma 
noradrena1ine.
With captopril therapy, plasma angiotensin II formation was 
suppressed, renin rose, while plasma aldosterone showed a 
statistically insignificant decline. Plasma noradrenaline 
and adrenaline also declined. (Table 14.3)
TOTAL BODY ELECTROLYTE COMPOSITION (Table 14.3)
Total Body Sodium
Absolute values and changes in total body sodium were not 
significantly correlated to plasma renin concentration. 
During the placebo phase, even in these oedema-free
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patients, total body sodium was increased for the group as 
a whole. During treatment with captopril, total body sodium 
was unchanged on captopril, whether considered either as an 
absolute value or as a ratio to predicted normal.
Total Body Potassium
During the placebo phase, total body potassium was depleted 
for the group as a whole. Those patients with abnormally 
high plasma renin and angiotensin II concentrations had 
lower total body potassium levels p<0.05) than did those 
with normal plasma renin. Serum potassium correlated 
linearly with total body potassium (r=0.82;p<005). 
Captopril caused a significant rise in total body 
potassium, the mean difference in total body potassium 
between the captopril and placebo double-blind phases being 
124 mmol. The increase in total body potassium was directly 
correlated with the highest plasma active renin 
concentration in the placebo phase (r=0.58;p<0.05).
Total Body Chlorine
During the placebo phase, total body chlorine was not 
significantly different from predicted at 992+12%. Whole 
body chlorine tended to be higher in those with normal 
plasma renin concentrations. These values were unaltered by 
captopril. Calculated extracellular fluid volume, even 
taking into account weight, tended to be lower in the low 
renin subgroup. Under the influence of captopril, there was 
a statistically insignificant de cline in mean
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extracellular fluid volume.
Whole Body Nitrogen. Calcium and Phosphorus
During the placebo phase, whole body nitrogen, calcium and 
phosphorus did not differ significantly from predicted, 
indicating no abnormality of body habitus to account for 
the changes in total body potassium and sodium. The amounts 
of these elements were unaltered by captopril.
EFFECTS OF CAPTOPRIL ON RENAL FUNCTION
Detailed results on renal function are presented in Figures 
14.1 and 14.2, & Table 14.4.
Serum urea, creatinine and phosphate increased 
significantly during the captopril phase of the study. 
Creatinine clearance fell with the administration of 
captopril, while radio-isotopically estimated glomerular 
filtration rate showed a similar but non-significant 
decline.
Effective renal plasma flow increased; therefore, 
calculated filtration fraction fell. Mean arterial pressure 
also fell and renal blood flow increased. Calculated reno­
vascular resistance declined.
During the placebo phase, glomerular filtration rate was 
directly related to effective renal plasma flow 
(r=0.95;p<0.001) , as expected. The change in glomerular
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TABLE 14.4
RENAL FUNCTION - THE EFFECTS OF CAPTOPRIL
n = 12 
G.F.R. (ml/min)
CREATININE CLEARANCE 
(ml/min)
BASELINE
62(22)
CAPTOPRIL
OPEN
56(20)
CAPTOPRIL
DOUBLE
BLIND
48(18)
56(21)
PLACEBO
DOUBLE
BLIND
53(19)
61(21)
E.R.P.F. (ml/min)
SERUM DIGOXIN (mmol/L) 1.3(0.1) 1.6(0.2)
G.F.R. = GLOMERULAR FILTRATION RATE 
E.R.P.F. = EFFECTIVE RENAL PLASMA FLOW
287(100) 
1.7(0.2)
241(72) 
1.4(0.1)
ns
p<0.01
p<0.05 
p<0.05
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Figure 14.1 Individual (solid line) and mean (open 
circle) changes in glomerular filtration rate, effective 
renal plasma flow, renal blood flow, and mean blood 
pressure between double-blind placebo and captopril 
phases.
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Figure 14.2 Individual (solid line) and mean (open 
circle) changes in serum creatinine and urea, filtration 
fraction, and renovascular resistance between double­
blind placebo and captopril phases.
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filtration rate with captopril was not related either to 
the percentage fall in mean blood pressure (Figure 14.3) or 
to blood pressure measured during either the placebo or 
captopril phase in this study. The patients in whom the 
greatest fall in glomerular filtration rate occurred were 
those in whom renal vascular resistance failed to decrease 
sufficiently to cause an adequate increase in effective 
renal plasma flow. (Figure 14.4)
No long-term natriuresis took place in our patients, since 
total body sodium did not change. This confirms the lack of 
natriuretic effect noted by others in open studies. That 
sodium balance was maintained in the face of the fall in 
glomerular filtration rate and blood pressure suggests that 
the natriuresis expected from the increase in renal blood 
flow was counterbalanced by the sodium-retaining effect of 
an overall fall in peripheral resistance and blood 
pressure. Despite this lack of long-term natriuresis, 
clinical improvement did occur, with a reduction of 
symptoms and improvement in exercise performance.
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CHAPTER 15s EFFECTS OF ENALAPRIL IN HEART FAILURES A 
DOUBLE-BLIND STUDY OF EFFECTS ON EXERCISE PERFORMANCE, 
RENAL FUNCTION, HORMONES AND METABOLIC STATE
INTRODUCTION
This study is similar in concept to the study described in 
Chapter 14, but included more detailed assessment of renal 
function in a slightly larger population of patients, with 
somewhat milder heart failure.
In addition to the assessments in Chapter 14, a much 
detailed investigation of the autonomic and neuroendocrine 
effects of angiotensin-converting enzyme therapy was 
carried out.
PATIENTS
We studied 20 patients with chronic heart failure caused by 
ischaemic heart disease (9) , congestive (dilated) 
cardiomyopathy (8), or severe left ventricular dysfunction 
after successful valve replacement (3) who were in New York 
Heart Association class II or IV. Mean (SD) duration of 
symptoms at entry was 18 (13) months.All had had symptoms 
for more than 3 months. Patients with serious concomitant 
disease or appreciable valvar regurgitation were excluded. 
All vasodilators were withdrawn at least one month before 
investigation and doses of frusemide (mean (SD) daily dose 
124 (57) mg/day) and digoxin (mean daily dose 0.22 (0.06
mg/day) were held constant. One patient refused frusemide
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and continued on bumetanide 3 mg/day. Four patients were 
also on amiloride 10-15 mg/day, 5 on potassium chloride 
(1.8-2.4 g/day), one on hydrochlorthiazide 100 mg/day, and 
one had been treated with amiodarone 400 mg/day for the 
previous 2 years; doses of these agents were also held 
constant through the trial.
STUDY DESIGN
Patients were assessed and were familiarised with study 
procedures, including repeated exercise tests, 4 weeks 
before the start of the study. They were then admitted for 
10 days for full initial assessment before being randomly 
allocated to enalapril 5 mg/day or matching placebo. Doses 
of enalapril (or matching placebo) were then doubled every 
2 weeks to a maximum of 40 mg once daily (9 am) if no 
adverse effect occurred. After 2 months, patients were 
readmitted, reassessed, and then started on the alternative 
treatment. Doses were again doubled every 2 weeks and 
patients were finally assessed after a further 2 months in 
the trial.
METHODS
For more detailed discussion of the methods, see Chapter 
7.Symptoms were evaluated by New York Heart Association 
score and by visual analogue scores for breathlessness, 
tiredness, and ankle swelling. Exercise capacity was 
measured by a modified Bruce protocol, with stages which 
lasted 3 minutes. Left ventricular internal dimensions were
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derived from M-mode echocardiography and systolic time 
intervals from the aortic root echocardiogram. Ambulatory 
electrocardiographic monitoring was performed for 48 hours 
with a Medilog-I system and the results were expressed as 
events per 24 hours. Repetitive extrasystoles were defined 
as 3 or more consecutive ventricular extrasystoles. Blood 
pressure was measured with a Hawksley random zero 
sphygmomanometer, and heart rate was taken from the apex 
beat 6 hours after dosing.The QT interval was calculated 
from the resting ECG.
Venous blood was drawn at 9 am, 24 hours after dosing, from 
the patients who had fasted (apart from water) , and had 
remained supine overnight. Further samples were taken at 1 
pm, 4 hours after usual therapy and drug or placebo, with 
the patient resting in the supine position, then after 5 
minutes standing, and subsequently immediately after a 
maximal exercise test.Samples were assayed for serum 
electrolytes, urea, and creatinine concentrations, and for 
plasma concentrations of active renin, angiotensin II, 
aldosterone, vasopressin, noradrenaline and adrenaline. A 
further sample was taken 5 minutes after exercise for 
potassium and catecholamines.
Tests of autonomic function were carried out 2-3 hours 
after drug or placebo administration.
Total body potassium was derived from endogenous 40K by
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means of a whole body counter, and total body sodium was 
similarly determined after neutron activation.Effective 
renal plasma flow and glomerular filtration rates were 
determined by single injection isotope techniques.
Creatinine clearance was calculated from a 24 hour urine 
collection and serum creatinine.
STATISTICAL ANALYSES
Possible order and period effects or both were assessed by 
comparison of the differences between observations for the 
enalapril and placebo phases for the 2 groups by means of 
2 sample t-tests. In cases were the order effect was not 
significant, we compared treatment effects by means of 
paired t-tests on the enalapril and placebo measurements 
and ignored the order of treatment.Correlations were 
calculated by Pearson's product-moment correlation 
coefficient and these were tested for significance by 
t-tests. The data were log transformed where appropriate.
For studies on neuroendocrine function the results of 3 
analyses are presented:
1) The actual values obtained during each treatment 
period were compared.
2) The response to physiological manoeuvres was compared 
within each treatment phase. For instance, the heart 
rate response during placebo was analysed, as was the
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heart rate response during the enalpril treatment 
phase.
3) The magnitude of the responses to physiological 
manoeuvres was then compared between treatment phases. 
Thus, the change in heart rate from lying to standing 
was compared during enalapril or placebo 
administration.
RESULTS
In 17 patients, the dose of enalapril was increased to a 
maximum of 40 mg/day, in 2 patients the dose was limited to 
20 mg/day, and in one to 10 mg/day because of symptomatic 
hypotension, which also occurred in 2 patients on 40 
mg/day. No severe hypotension was observed after the first 
dose in any patient. No patient failed to reach the maximum 
dose of placebo.Nineteen patients completed the study; one 
patient died suddenly during the placebo phase after 
showing an improvement in symptoms and exercise capacity on 
enalapril.
SYMPTOMS(Table 15.1)
New York Heart Association score improved (Figure 15.1) 
during treatment with enalapril. Breathlessness and 
tiredness also improved but ankle swelling, not a prominent 
complaint at the start of the study, was unchanged.
ADVERSE EFFECTS
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TABLE 15.1
CLINICAL EFFECTS OF ENALAPRIL COMPARED TO PLACEBO.
n = 19 
V.A.S.(mm)
- BREATHLESSNESS
- mean
- median
- range
- TIREDNESS
- mean
- median
- range
BASELINE
56
61
15-92
51
58
0-100
ENALAPRIL
24
7
0-89
29
13
0-88
PLACEBO
45
45
3-95
39
41
0-96
p<0.006
WEIGHT (kg) 66(11) 67(11) 67(11)
SYSTOLIC BP(mmHg) 117(22)
DIASTOLIC BP(mmHg) 75(12) 
HEART RATE(bpm) 79(12)
100(23)
62(11)
72(9)
121(24) p<0.0001
72(10) p<0.001
76(10) p<0.03
EXERCISE TIME(secs) 390(192) 642(144) 522(186) p<0.01
* = order effect significant at the 5% level 
V.A.S. = visual analogue scores 
BP = blood pressure
Figure 15.1 New York Heart Association functional class at 
baseline, after treatment with enalapril, and on placebo.
The difference between placebo and enalapril treatments 
was significant ( p < 0  05) by a modified x 2 test
Class Baseline Enalapril Placebo*
4 2 0 2
3 14 3 9
2 4 15 8
1 0 2 0
Mean score 2-9 21 2-7
*Qne death.
Weight increased in the first week on enalapril (0.4 
(0.8)kg;p<0.05), whereas there was no change after one week 
on placebo (-0.1(0.6) kg). One patient had weight gain with 
increased ankle swelling; the latter improved on continued 
therapy without alteration of diuretic dose. Weight was 
similar on placebo and enalapril at the end of both 2-month 
periods.
Adverse responses included hypokalaemia (serum potassium 
<3.5 mmol/1) in 8 patients on placebo; slight increases in 
transaminases, one patient on placebo (alanine transaminase 
62 U/l) and one on enalapril (60 U/l) ; and a pronounced 
increase in serum urea (6.8 mmol/1 to 12.0 mmol/1) and 
creatinine (127 umol/1 to 202 umol/1) in one patient on 
enalapril who also had postural hypotension (standing blood 
pressure on placebo 98/74 mm Hg, and on enalapril, 66/54 mm 
Hg) . No patient developed proteinuria or a blood dyscrasia.
Other possible adverse effects were a mild persistent dry 
cough in one patient on enalapril. Transient skin eruptions 
were noted in 3 patients on enalapril (one case each of 
varicose eczema and 2 cases of a macular rash of hands and 
feet) , and 2 on placebo (one case of varicose eczema and 
one of urticaria). In addition, one patient developed 
thoracic herpes zoster during enalapril therapy, from which 
she made an uncomplicated recovery. One patient, who had 
previously had a raised fasting blood glucose (8 mmol/1 at 
baseline), developed glycosuria and a further increase in
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his fasting blood glucose on enalapril (placebo 11.9 
mmol/1; enalapril 13.4 mmol/1), which he had received after 
placebo.
CLINICAL VARIABLES(Table 15.1)
Exercise Testing (Table 15.1)
Exercise performance improved onage by one treadmill
stage during enalapril treatment.
Blood Pressure and Heart Rate
Both systolic and diastolic blood pressure were 
significantly reduced on enalapril, and heart rate also 
declined. (Table 15.1)
Left Ventricular Function(Table 15.2)
Echocardiographic left ventricular systolic and diastolic 
dimensions were reduced by enalapril, although fractional 
shortening did not increase significantly.The ratio of 
pre-ejection period to left ventricular ejection time was 
also reduced, indicating an improvement in ventricular 
function.
Ambulatory Monitoring (Table 15.2)
Ventricular extrasystoles were significantly reduced (by 
50%) during enalapril treatment, but the reduction in 
repetitive extrasystoles was not statistically significant.
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TABLE 15.2
THE EFFECTS OF ENALAPRIL ON CARDIAC FUNCTION.
BASELINE
ECHOCARDIOGRAPHY 
LEFT VENTRICULAR
- DIMENSION (mm)
- END-DIASTOLE
- END-SYSTOLE
- FRACTIONAL SHORTENING
(%)
69(10)
58(12)
16(7)
667(204)- PEP/LVET (X1000)
AMBULATORY ELECTROCARDIOGRAPHY 
VENTRICULAR (in 24hours)
- EXTRASYSTOLES mean
median
range
- VENTRICULAR 
SALVOES
mean
median
range
1702
555
15-11045
4.6
1
0-41
ENALAPRIL PLACEBO
66(9) 
54(10) 
18(7)
69(9) p<0.004
58(12) p<0.003
17(6) ns
534(186) 631(172) p<0.03
1268
560
17-7827
3.9
1.5
0-35
2140
659
17-9130 p<0.05
4.7
1
0-58 ns
Effect of Enalapril on PTC
At baseline, QTC measured 438+30 milliseconds and did not 
change during placebo therapy at 434+36 milliseconds. 
However, during therapy with enalapril, QTC was reduced at 
415+44 milliseconds (p<0.05). QRS duration and the 
uncorrected QT interval were unchanged during any of the 
treatments.
Autonomic Function Testing(Table 15.3)
Baseline tests of autonomic function were abnormal, as 
outlined previously. Comparing placebo with enalapril, a 
greater fall in systolic blood pressure and rise in heart 
rate occurred after 2 minutes standing during enalapril 
therapy. The absolute levels of the penultimate heart rate 
and systolic blood pressure (ie the heart rate at the end 
of the last completed stage during the shorter of the two 
tests) were reduced by enalapril, but the change in each 
from rest to exercise was similar. The change in heart rate 
from rest to peak exercise was, in fact, greater during 
enalapril therapy.
Enalapril tended to normalise the heart rate response to 
the Valsalva manoeuvre, deep breathing, and the immediate 
heart rate response to standing.
Hormone Assays (Table 15.4-15.6)
At baseline, as expected and previously discussed, in
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TABLE 15.3
AUTONOMIC FUNCTION TESTS (also see tables 15.1-15.6)
BASELINE ENALAPRIL PLACEBO
HEART RATE RESPONSE TO
DEEP BREATHING (bpm) 6.4(2.9) 14.3(6.1) 7.3(2.7) p<0.001
VALSALVA RATIO (bpm) 1.03(0.09) 1.18(0.10) 1.05(0.06) p<0.005
15:30 RATIO (bpm) 0.98(0.03) 1.03(0.04) 0.99(0.02) p<0.05
TABLE 15.4 
BIOCHEMISTRY
n = 19
SERUM CONCENTRATIONS
SODIUM
POTASSIUM
MAGNESIUM
BICARBONATE
CHLORIDE
CALCIUM
PHOSPHATE
UREA
CREATININE
URATE
DIGOXIN
(mmol/L)
(mmol/L)
(mmol/L)
(mmol/L)
(mmol/L)
(mmol/L)
(mmol/L)
(mmol/L)
(umol/L)
(mmol/L)
(nmOl/L)
PLASMA CONCENTRATIONS
- ACTIVE RENIN (uU/ml)
- mean
- median
- range
- ANGIOTENSIN II (pmol/L)
- mean
- median
- range
- ALDOSTERONE
- mean
- median
- range
(pmol/L)
BASELINE
139(4)
3.8(0.3)
0.76(0.18)
30(3)
99(3)
2.3(0.1) 
1.13(0.20) 
6.4(2.0) 
100(24) 
0.46(0.10) 
1.5(0.7)
81
47
3-352
34
29
1-83
505
361
217-1336
- ANTI-DIURETIC HORMONE (pg/ml)
- mean 1.9
- median 1.6
- range 0.3-5.1
- NORADRENALINE
- ADRENALINE
(nmol/L) 3.2(1.4) 
(nmol/L) 0.3(0.1)
ENALAPRIL PLACEBO
138(4)
4.2(0.3) 
0.84(0.08) 
28 (3)
99(4)
2.3(0.3) 
1.19(0.15) 
8.0(2.4) 
110(31) 
0.48(0.09) 
1.8 (0.8)
139 (3)
3.7(0.3) 
0.82(0.08) 
29 (2)
99(4)
2.3(0.1) 
1.09(0.14) 
6.4(1.9) 
101(24) 
0.47(0.10) 
1.4(0.7)
ns
p<0.0001
p<0.05 
p<0.05 
ns 
ns
p<0.001
p<0.001
p<0.01
ns
p<0.01
695
406
3-2256
98
61
3-673 p<0.001
14
13
4-35
34
29
1-83 p<0.005
361
289
144-1408
578
325
181-3069 p<0.05
1.3
1.1
0.2—3.$ 
2.2(0.8) 
0.3(0.2)
2.2
1.5
0.5-7.8 
3.2(1.2) 
0.4(0.2)
p<0.02 
p<0.002
ns
VALUES ARE MEAN (STANDARD DEVIATION) UNLESS OTHERWISE STATED
TABLE 15.5
NEUROENDOCRINE EFFECTS OF ENALAPRIL 
DIURETIC AND DIGOXIN.
BASELINE
SUPINE FASTING
Heart Rate (bpm) 79(10)
Sys BP (mmHg) 119(26)
P.Potassium(mmol/L) 3.8 (0.3)
P.Sodium (mmol/L) 139(3) 
P.A.R.C. (uU/ml)
BEFORE AND AFTER TREATMENT 
ENALAPRIL PLACEBO
mean:median 
range
P.Ang.II (pmol/L) 
mean:median 
range
P.Aldo. (pmol/L) 
mean:median 
range
P.A.D.H (pg/ml) 
mean:median 
range
P.N.Adr (nmol/L) 
P.Adr (nmol/L)
SUPINE AFTER THERAPY 
Heart Rate (bpm)
Sys BP (mmHg) @@ 
P.Potassium(mmol/L)@@ 
P.Sodium (mmol/L) @ 
P.A.R.C. (uU/ml)'
mean:median @@ 
range 
P.Angll (pmol/L)
mean:median @@ 
range 
P.Aldo. (pmol/L)
mean:median @@ 
range 
P.A.D.H. (pg/ml) 
mean:median 
range 
P.N.Adr (nmol/L) 
P.Adr (nmol/L)
81: 47 
3-352
39: 31 
1-160
505:361
217-1336
1.9:1.6 
0.3-5.1 
3.2(1.4) 
0.3(0.1)
80(12)
117(22)
3.5(0.3)*** 
138(3)*
152: 91 
3-972**
55: 46 
1-134**
650:469
108-1949**
72 (9) 
104(25) 
4.3(0.3) 
138(3)
695:406
3-2256
14: 13 
4-35
361:289
144-1408
1.3:1.1 
0.2-3.6 
2.2 (0.8) 
0.3(0.2)
71(9)
99 (26)* 
4.2(0.4) 
137(3)*
2627:1512
3-9240***
9: 8 
1-18*
325:181
144-1516
78(10) 
122 (23) 
3.8(0.3) 
139(3)
98: 61 
3-673
34: 29 
1-83
578:325
181-3069
2.2:1.5 
0.5-7.8 
3.2(1.2) 
0.4(0.2)
83(14) 
124(24) 
***3.4(0.4) 
*138 (3) 
p<0.001
169: 94 
*5-1360
52: 47 
**1-126
578:469
72-2130
@@
2.2:1.9 1.4:1.2 2.0:1.9
0.3-5.9 0.2-3.6 0.7-5.8
3.9(1.4)** 2.5(1.0) ’*3.9(1.6)
0.4(0.2) 0.3(0.2) 0.5(0.4)
Comparisons have been made in three ways (see text for details)
1) actual values results shown in right hand column
2) Within treatment comparisons. * = p<0.05, ** = p<0.01, *** =
3) Between treatment comparisons. @ = p<0.05, @@ = p<0.01 
For abbreviations see table 9.1
WITH
p<0.01
p<0.001
p<0.001
ns
pco.001
p<0.005
p<0.05
p<0.02 
p<0.002
p<0.005
p<0.001
p<0.001
p<0.05
p<0.001
p<0.001
p<0.001
p<0.05 
p<0.005 
ns
p<0.001
-u
i
TABLE 15.6
• j NEUROENDOCRINE EFFECTS OF ENALAPRIL DURING STANDING AND EXERCISE.
BASELINE ENALAPRIL PLACEBO
STANDING (5 MINUTES)
Heart Rate -(bprn) 0 84(14) 77(10)** 83(13) p<0.01
Sys BP (mmHg) @0 118(19) 94(28)** **124 (24) p<0.001
P .Potassium(mmol/L) 3.6(0.3) 4.2 (0.3) 3.6(0.4) p<0.0001
P.Sodium (mmol/L) 138(3) 138(3) 138(3) ns
P.A.R.C. (UU/ml)
mean:median 183:103 2869:1820 165:96
range 4-1356 5-13510* 5-1025 pcO.OOl
P.Ang.II (pmol/L)
mean:median 54: 40 8: 8 59:55
range 7-156 2-16 4-150 pcO.OOl
P.Aldo. (pmol/L)
mean:median 686:505 289:217 686:433
range 108-2527 72-939 253-2419 pcO.OOl
P.A.D.H (pg/ml)
mean:median 2.2 :.2 .1 1.5:1.3 1.8:1.6
range 0.3-6.5 0.2-3.2 0.2-5.3 ns
P.N.Adr (nmol/L) 00 4.1(1.5) 3.6(1.4)*** 3.8(1.9) ns
P.Adr (nmol/L) 0.3(0.3) 0.3(0.2) 0.3(0.3) ns
IMMEDIATE POST-EXERCISE
Heart Rate (bpm) 00 121(17)*** 131(20)*** **126(13) ns
Sys BP (mmHg) 149(27)** 141(33)** **158(30) p<0.005
P.Pot. (mmol/L) 3.8(0.3)*** 4.5(0.4)** ***3.9(0.4) p<0.01
P .Sodium(mmol/L) 0 139(3)* 138(3) *139(3) p<0.05
P.A.R.C. (uU/ml) 
mean:median 00 219:183 3907:3034 192:122
range 4-1443** 7-14140** **7-862 p<0.001
P.Angll (pmol/L) 
mean:median 00 81:57 12:10 86:97
range 10-183** 1-33* **7-192 p<0.001
P.Aldo. (pmol/L) 
mean:median 
range
975:578
289-3032***
505:397
108-1408***
903:578
***433-2419 p<0.001
P.A.D.H. (pg/ml) 
mean:median 
range
7.5:3.4 
0.6-57***
4.4:3.8 
0.6-20.3**
4.7: 3.5 
**1.1-15.8 ns
P.N.Adr (nmol/L) 8.4(4.0)*** 9.9(5.7)*** ***9.4(5.9) ns
P.Adr (nmol/L) 0.5(0.5)** 0.5(0.3)** *0.5(0.5) ns
FIVE MINUTES AFTER EXERCISE 
P.Pot. (mmol/L) 00 3.2(0.5)** 4.2(0.6) **3.3(0.4) p<0.001
P.Sodium (mmol/L) 138(3) 138(3) 138(3) ns
P.N.Adr (nmol/L) 0 7.4(4.6) 5.2(2.!)* 8.0(3.8) p<0.01
patients with treated heart failure plasma levels of active 
renin, angiotensin II, aldosterone, noradrenaline, and 
anti-diuretic hormone were all significantly elevated and 
increased further after administration of the patient's 
usual therapy, consisting diuretic and digoxin.
No further increase in noradrenaline or other 
neuroendocrine variables was seen with standing. During 
exercise, patients with heart failure had further marked 
activation of all neuroendocrine systems.
After 8 weeks' therapy with enalapril, plasma angiotensin 
II levels were suppressed, as were plasma levels of 
aldosterone, noradrenaline and anti-diuretic hormone in the 
supine, fasting state and twenty-four hours after the last 
dose of enalapril. There was a reciprocal rise in plasma 
levels of active renin.
Four hours after a subsequent dose of enalapril together 
with diuretic and digoxin, there was a four-fold increase 
in plasma active renin, and a further significant 
suppression of plasma angiotensin II. In contrast to 
subjects at baseline and on placebo, there was a further 
fall in plasma aldosterone, despite the fact that a further 
dose of diuretic had been given. The rise in plasma 
noradrenaline seen after diuretic administration was also 
suppressed by enalapril.
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After 5 minutes standing, little change occurred in plasma 
levels of renin, angiotensin II or anti-diuretic hormone. 
This was also true of plasma noradrenaline during the 
baseline and placebo phases. However, there was a 
significant rise in plasma noradrenaline after standing 
during enalapril therapy. This paralleled the rise in 
noradrenaline seen during standing in normal 
subjects.
During exercise, there was a significant rise in plasma 
levels of active renin, angiotensin II, aldosterone, 
noradrenaline and anti-diuretic hormone, both in the 
baseline and placebo phases. The increase in angiotensin II 
during exercise was prevented by enalapril, and there was 
an enhanced increase in plasma concentrations of active 
renin. The increase in plasma levels of aldosterone, 
noradrenaline and anti-diuretic hormone during exercise 
were not inhibited by enalapril.
Five minutes after exercise, plasma levels of noradrenaline 
were significantly lower after enalapril compared to 
placebo and baseline.
Electrolytes (Ficrure 15.2)
At baseline and on placebo, mean serum potassium and 
magnesium were at the lower limit of normal. There was a 
significant increase in serum potassium and magnesium on 
enalapril.
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Initial serum potassium was inversely related (r=- 
0.53;p<0.05), and the rise in serum potassium on enalapril 
directly related (r=0.79;p<0.001), to the initial plasma 
renin concentration. (Figure 15.2)
No overall change in serum sodium occurred, nor was the 
fall in plasma sodium that occurred after diuretic therapy 
inhibited by enalapril. Two patients who developed postural 
hypotension (standing blood pressure on placebo 96/66 mm Hg 
& 108/88 mm Hg, falling to 72/56 mm Hg & 68/44 mm Hg, 
respectively, on enalapril), became hyponatraemic (serum 
sodium on placebo 139 mmmol/1 & 134 mmol/1, and on
enalapril 134 mmol/1 and 121 mmol/1, respectively). These 
patients showed an increase in plasma ADH, rather than the 
fall seen in other patients.Two patients had hyponatraemia 
corrected on enalapril, serum sodium rising from 129 mmol/1 
& 134 mmol/1 to 133 mmol/1 and 137 mmol/1, respectively. 
During the baseline and placebo phases, the administration 
of diuretic therapy led to an acute fall in serum 
potassium. This was prevented by enalapril.Standing had no 
significant effect on plasma electolytes. However, during 
exercise there was an acute increase in potassium during 
all phases of the study and a small increase in plasma 
sodium during baseline and placebo phases only.
Five minutes after exercise, plasma potassium had fallen 
below supine basal levels. This was prevented by enalapril.
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Serum bicarbonate fell during enalapril therapy, consistent 
with the correction of hypokalaemia. Serum chloride and 
calcium and urate were unchanged, but serum phosphate 
increased, consistent with a reduction in glomerular 
filtration rate.
Total Body Electrolytes (Table 15.7)
At baseline, total body potassium was low at 96+13% (mean 
+standard deviation) of predicted normal values (p<0.05), 
while total body sodium was elevated at 108+11% (p<0.01). 
Total body chlorine, nitrogen, calcium, phosphorus and 
oxygen content did not differ from predicted normal values.
During treatment with enalapril, total body potassium 
increased and total body sodium decreased, though neither 
change was statistically significant. However, the ratio of 
total body sodium to total body potassium was markedly 
altered. Total body potassium was negatively correlated to 
plasma active renin concentration measured at baseline 
(r=-0.64;p<0.01).Changes in total body potassium were 
related to initial plasma renin concentration 
(r=0.5;p<0.05). (Figure 15.3)
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TABLE 15.7
THE EFFECTS OF ENALAPRIL ON TOTAL BODY ELEMENTAL COMPOSITION
= 16
SODIUM
E/P
(mmol)
(%)
POTASSIUM (mmol) 
E/P (%)
POTASSIUM/SODIUM 
(%)
CHLORINE
E/P
(mmol)
(%)
CALCIUM (mmol) 
PHOSPHORUS (mmol)
NITROGEN
E/P
( g )
(%)
POTASSIUM/NITROGEN
(mmol/g)
OXYGEN (kg)
E = ESTIMATED P =
BASELINE
3385(621)
110(11)
2659(619) 
96(13)
79(12)
1760(392) 
109(16)
24025(4013)
16889(2939)
1632(323) 
106(16)
1.63(0.17) 
35.7(7.0) 
PREDICTED.
ENALAPRIL
3267(512)
106(11)
2787(635)
99(12)
86(11)
1751(278)
101(29)
PLACEBO
3390(575)
108(12)
2741(669)
97(13)
81(11)
1797(311) 
104(30)
23933(4218) 23445(4243)
16553(3134) 16738(2773)
1666(325)
108(19)
1.70(0.18)
36.4(6.6)
1619(311)
105(17)
1.68(0.16)
36.7(5.5)
p<0.01
ns
ns
ns
ns
ns
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Renal Function(Tables 15.8 & 15.9; Figures 15.4, 15.5 &
15.6)
In addition to measuring glomerular filtration rate and 
renal blood flow at baseline and at the end of each study 
periods, measurements were also taken at the end of the 
first week fo each double-blind period to help 
differentiate between short- and long-term effects on renal 
function.
During enalapril treatment, glomerular filtration rate 
measured isotopically was reduced and creatinine clearance 
also fell significantly, whereas effective renal plasma 
flow increased. The decline in glomerular filtration rate 
was reflected in a rise in serum urea and creatinine. The 
decline in glomerular filtration rate correlated with the 
decline in mean arterial pressure (Figure 15.3), but not 
with the baseline plasma angiotensin II. (Figure 15.4)
Glomerular filtration rate was significantly depressed 
after one week of treatment, with a further significant 
decline at 8 weeks (Table 15.9/ Figurel5.6). One week after 
withdrawal of enalapril, glomerular filtration rate had 
returned to normal. In contrast, renal blood flow was 
equally increased after one and 8 weeks of treatment and 
remained elevated after one week's withdrawal of therapy. 
Plasma angiotensin II was equally suppressed after one and 
8 weeks treatment with enalapril, and was no different one 
week and 8 weeks after withdrawal.
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TABLE 15.8
THE EFFECTS- OF CHRONIC ENALAPRIL THERAPY ON RENAL FUNCTION
MEAN ARTERIAL 
PRESSURE (mmHg)
G.F.R. (ml/min)
CREATININE CLEARANCE 
(ml/min)
E.R.P.F. (ml/min)
HAEMATOCRIT (%)
RENAL BLOOD
FLOW (ml/min)
BASELINE
94(16)
70(25)
69(29)
289(101)
42(5)
486(159)
RENAL VASCULAR RESISTANCE
((dynes/sec/cm )10 ) 16.3(5.9)
FILTRATION FRACTION 
(%) 25.8(5.2)
ENALAPRIL
78(21)
58(23)
65(24)
354(128)
39(3)
578 (226)
11.7(4.2)
17.0(4.8)
PLACEBO
94(15)
71(23)
72(23)
308(119) 
40(5)
514(208)
16.6(6.1)
23.4 (5.2)
p<0.001
p<0.0001
p<0.04
p<0.01
ns 
p<0.02 
p<0.005 
pcO.OOOl
G.F.R. = GLOMERULAR FILTRATION RATE 
E.R.P.F. = EFFECTIVE RENAL PLASMA FLOW
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Figure 15.6 Effects of enalapril on renal function 
(mean +standard deviation or median valu|g in the £gge 
of plasma angiotensin II). = p<0.05; =p<0.01; =
p<0.001
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CHAPTER 16S THE EFFECTS OF FRUSEMIDE AND ANGIOTENSIN- 
CONVERTING ENZYME INHIBITORS AND THEIR COMBINATION ON 
CARDIAC AND RENAL HAEMODYNAMICS IN HEART FAILURE
Diuretics have formed the mainstay of medical therapy for 
heart failure for the last 30 years. While the efficacy of 
long-term digoxin therapy for patients with heart failure 
remaining in sinus rhythm is still under debate698,699, 
angiotensin-converting enzyme inhibitors are now becoming 
accepted as effective second-line agents. However, there 
are important reasons for believing that 
angiotensin-converting enzyme inhibitors may not be 
valuable in the management of milder heart failure or as 
first-line agents,700 reinforced by the finding that sodium 
retention may occur in normal subjects given captopril 
alone.701
It is likely that the combination of a diuretic, usually a 
loop diuretic, and angiotensin-converting enzyme inhibitor 
will form the accepted therapy for moderate to severe heart 
failure in the foreseeable future. Little is known of the 
combined effects of these 2 types of agent on 
cardiovascular and renal function in patients with heart 
failure. Frusemide, a standard loop diuretic, might 
interact in at least 3 possible ways with 
angiotensin-converting enzyme inhibitors. Firstly, acute 
administration of frusemide causes renin release, a 
^phenomenon which appears independent of its other effects
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and is prostaglandin-dependent.702 Secondly, frusemide is a 
vaso-active compound, causing a decrease in venous tone703 
and a rise in renal blood flow704 when given acutely. These 
effects may also be inhibited by indomethacin.705,706 The 
effects on systemic vascular resistance and cardiac output 
seem more variable703,707 and may depend on the clinical 
setting in which heart failure occurs. Frusemide may also 
cause a redistribution in renal blood flow.708,709 Thirdly, 
due to the diuresis and fall in circulating volume, or 
possibly to local renal effects, it may stimulate the 
renin-angiotensin-aldosterone system, the sympathetic 
nervous system and plasma anti-diuretic hormone.705,710 This 
neuroendocrine response may result in a rise in systemic 
vascular resistance and left ventricular filling pressures, 
and a fall in cardiac output in the setting of left 
ventricular failure. It has previously been shown that 
angiotensin-converting enzyme inhibitors not only reduce 
plasma angiotensin II in patients with heart failure, but 
also reduce plasma levels of aldosterone, noradrenaline and 
anti-diuretic hormone. Accordingly, the cardiac, renal and 
neuroendocrine effects of orally administered frusemide in 
patients with heart failure before and after one week of 
therapy with enalapril were investigated.
PATIENTS
Written, informed consent was obtained from 12 patients 
(mean age 58 +11 years) with heart failure due primarily to 
left ventricular dysfunction. Two patients were women. The
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aetiology was ischaemic heart disease in 8 patients and 
idiopathic dilated (congestive) cardiomyopathy in 4. All 
patients had received digoxin and diuretics for at least 3 
months prior to investigation. The median dose of digoxin 
was 0.25 mg day'1 (range 0.125-0.375 mg day'1), and of 
frusemide 120 mg day'1 (range 80-240 mg day'1) . Eight 
patients were in New York Heart Association Class III and 
4 in Class IV. All patients were in sinus rhythm and were 
selected as having adequate recordings of aortic flow 
velocities by Doppler echocardiography from the cardiac 
apex.
All patients were commenced on a 100 mmol sodium and 40 
mmol potassium diet, with 2500 ml total fluid intake for 48 
hours prior to the study and for the 9 days of the study 
period. In order to achieve accurate dietary balance the 
patient was required to eat an identical diet each day for 
the duration of the study.
STUDY DESIGN
Patients were admitted to the ward and commenced on the 
above diet 48 hours before the study. Cardiac and renal 
haemodynamics were then studied in the presence or absence 
of a diuretic on separate days, at the same time of day, on 
days 3 and 4. Figure 16.1) Patients were then commenced on 
enalapril, and studies repeated in the presence of absence 
of a diuretic, on days 10 and 11.
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All studies were performed in the afternoon, after a light 
lunch, and commenced at midday. Patients were allocated in 
random order to receive frusemide (given at midday) in the 
usual oral dose or have it withheld till after the 6-hour 
study period (and then given at 6 pm). Plasma volumes were 
measured on the 5th day before administration of enalapril 
or frusemide. Patients then received 10 mg enalapril per 
day thereafter at 9 am with their usual dose of frusemide. 
On days 10 and 11, patients were again allocated in random 
order to receive or have withheld their usual daily dose of 
frusemide, while enalapril was continued. Plasma volume 
measurement was repeated on day 12, before the diet, and 
was terminated after giving enalapril only.
METHODS
Systemic Haemodvnamics
Measurements were taken 2 hours after the study period 
commenced, shortly after blood samples were taken for the 
effective renal plasma flow.
Heart rate was measured from the apex beat, and blood 
pressure using a Hawksley random zero sphygmomanometer. 
Mean arterial pressure was calculated as diastolic blood 
pressure +1/3 pulse pressure. Cardiac output was measured 
using continuous-wave Doppler echocardiography, recordings 
being taken from the cardiac apex. The outflow tract radius 
was taken as the aortic valve orifice according to the 
method of Ihlen et al (see Methods). Total vascular resist­
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ance was calculated using the formula: 80 (mean arterial 
pressure mm Hg) cardiac output (lmin"1) .
Urine Collections
Urine volumes were measured over 6 hours on each of the 
study days, starting at midday. Samples were taken for the 
estimation of urinary sodium and potassium. Urinary sodium, 
potassium and volume were also measured every 24 hours. 
Patients were weighed daily.
Plasma Volume
Plasma volume was estimated by measuring radioactivity 
before and 10 minutes after the injection of 125I-human serum 
albumin. Blood volume was calculated during non- diuretic 
and diuretic days using the haematocrit, assuming that red 
cell mass had not changed in the 48- hour study period.
Biochemistry
Blood was taken for electrolytes, urea and creatinine, at 
the start of the urine collection at the time of sampling 
for the effective renal plasma flow (ie, 105 minutes), and 
at the end of the urine collection. Blood was taken for 
estimation of plasma renin concentration and plasma levels 
of angiotensin II, aldosterone, noradrenaline and 
anti-diuretic hormone at 105 minutes only on each study 
day.
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STATISTICAL ANALYSIS
All values are expressed as mean and standard deviation 
unless otherwise stated. Data not following a normal 
distribution is expressed as mean, median and range. 
Differences between treatments were first analysed using 
analysis of variance. Only if this showed a difference was 
further analysis carried out using Student's t-test. A 
Bonferroni correction was used to adjust for the use of 
multiple t-tests.
RESULTS
The results are summarised in Figures 16.2-16.6, and Table 
16.1.
Systemic Haemodvnamics (Figure 16.2)
Heart rate, mean blood pressure, cardiac output and total 
vascular resistance were unchanged after oral frusemide. 
After one week, enalapril in the absence of concomitant 
frusemide therapy significantly reduced the blood pressure, 
total vascular resistance and heart rate but did not 
produce a significant increase in cardiac output. The 
addition of frusemide to enalapril resulted in a further 
reduction in blood pressure and total vascular resistance, 
but heart rate was again reduced compared to pre-enalapril 
values. Cardiac output increased significantly on the 
combination.
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Figure 16.2 Comparison of the effects of frusemide, 
enalapril and their combination on heart rate (HR), mean 
arterial pressure (MAP), cardiac output (CO), and total 
vascular resistance. Figures are mean +standard 
deviation. An over the error bar indicates an effect 
of enalapril, but between error bars signifies an effect 
of frusemide. *p<0.05;**p<0.02;***p<0.001.
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Renal Haemodvnamics (Figure 16.3)
The glomerular filtration rate was unaffected by frusemide 
alone, while increases in renal blood flow and the 
percentage of cardiac output to the kidney and the fall in 
filtration fraction did not achieve statistical 
significance. Renal vascular resistance was also 
unaffected.
After enalapril alone, renal blood flow increased 
significantly without a decline in glomerular filtration 
rate; consequently, the filtration fraction fell. Renal 
vascular resistance fell markedly and the proportion of 
cardiac output distributed to the kidney showed a non­
significant increase. The addition of frusemide to 
enalapril resulted in a further rise in renal blood flow 
and percentage distribution of cardiac output to the kidney 
and a further fall in renal vascular resistance and 
filtration fraction. However, glomerular filtration rate 
also fell.
Plasma Volume and Haematocrit (Figure 16.4)
Plasma volume increased by approximately 10% after one week 
of enalapril, while haematocrit fell. The decrease in blood 
volume after frusemide did not achieve statistical 
significance either before or after therapy with enalapril.
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Figure 16.3 Comparison of the effects of frusemide, 
enalapril and their combination on glomerular filtration 
rate (GFR), renal blood flow (RBF) , filtration fraction 
(FF) and the percentage of the cardiac output delivered 
to the kidneys (RBF/CO). Figures are mean +standard 
deviation. An * over the error bar indicates an effect 
of enalapril, but betwen error signifies
an effect of frusemide. p<0.05; p<0.01; p<0.001.
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Figure 16.4 Comparison of the effects of frusemide, 
enalapril and their combination on haematocrit and bloog 
volume. Figures are mean +standard deviation. An 
over the error bar indicates an effect of enalapril, but 
between error bars signifies an effect of frusemide.
p<0.05;**p<0.02; p<0.001.
Neuroendocrine Effects (Table 16.1)
Plasma concentrations of active renin, angiotensin II, 
aldosterone, anti-diuretic hormone and noradrenaline were 
all elevated in the absence of either frusemide or 
enalapril. Oral frusemide increased levels of each hormone.
Enalapril alone resulted in a significant reduction in 
plasma concentrations of angiotensin II, aldosterone, 
anti-diuretic hormone and noradrenaline, with a concomitant 
increase in plasma active renin concentrations. No increase 
in plasma concentrations of angiotensin II, aldosterone and 
noradrenaline were observed after frusemide. However, the 
increase in plasma active renin concentration and 
anti-diuretic hormone after frusemide were not inhibited by 
enalapril.
Serum Biochemistry (Figure 16.5)
Serum urea, creatinine, osmolality and sodium were 
unaffected by the acute administration of a further dose of 
frusemide. However, serum potassium fell acutely in 
response to frusemide.
After one week of enalapril, serum sodium and osmolality 
had fallen, while upward trends in serum potassium, urea, 
and creatinine were non-significant. Administration of 
frusemide with enalapril resulted in no significant changes 
in serum biochemistry.
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Table 1 Comparison o f I he effects o f frusemide, enalapril and their combination on plasma concentrations o f  active renin 
concentration (P A R C ), angiotensin II (P.Ang II), aldosterone (P .A ldo), noradrenaline ( NA)  and anti-diuretic hormone 
( ADH)
No frusemide F7ruscmidealone
Enalapril
alone
Enalapril
+
frusemide
PARC (//U ml*')
Mean 245 343 I822J 24341
Median 82 PcOOl 165 1050 P< 0-001 2796
Range 3 828 5 1210 11 6i(»0 55-7056
P.Ang.lI (pmol 1'')
Mean 103 136 lot 20t
Median 47 P<00l 84 9 NS 19
Range 5 392 11-398 2-22 2-28
P.Aldo (nmol I-1)
Mean 677 849 225f 220t
Median 466 P<001 520 187 NS 226
Range 262-1876 337-3326 90-392 100-392
P.NA (nmol 1~')
Mean 6-7 9-5 4 If 4-7J
Median 4-7 P<00l 71 3*0 NS 39
Range P9-25-0 2-5-39 1 1-2-13-3 1 4-13 5
ADH(pgml-1)
Mean 3-3 50 I 9f 3 8 NS
Median 3\3 PcOOl 6 3 1-9 P<00l 50
Range 0-5 6-7 0 6 12-3 0 2 -3-2 0-7-7-3
P values indicate a significant efTcct of frusemide. 
t.JAn effect of enalapril: +, PcO-Ol; P <0001.
Table 16.1 Comparison of the effects of frusemide, 
enalaparil and their combination on plasma 
concentrations of active renin concentration (PARC), 
angiotensin II (P. Ang II), aldosterone (P.Aldo), 
noradrenaline (NA) and anti-diuretic hormone (ADH).
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Figure 16.5 Comparison of the effects of frusemide, 
enalapril, and their combination on serum biochemistry. 
Figures are mean+standard deviation. An over the error 
bar indicates an effect of enalapril, but between error 
bars signfies an effect of frusemide. p<0.05;**p<0.01.
Urine Biochemistry (Figure 16.6)
In the absence of a diuretic, renal sodium and potassium 
excretion was low. With the administration of frusemide, 
urinary sodium and potassium content and concentration and 
the fractional excretion of these electrolytes filtered at 
the glomerulus increased. Urine volume and free water 
clearance increased while urine osmolality fell.
With enalapril alone, urine sodium content and 
concentration were unchanged, but urinary losses of 
potassium were reduced. With the administration of 
frusemide, the urinary content and concentration of sodium 
and potassium, urine volume and free water clearance were 
all reduced when compared to the effects of frusemide in 
the absence of enalapril.
Changes over the first week
Over the first week, 123+156 mmol sodium and 107+98 mmol 
potassium was retained, and weight increased by 2.3+2.1 kg. 
Three patients developed oedema (weight gain 3.2, 4.2 and 
6.1 kg) over the first week.
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Figure 16.6 Comparison of the effects of frusemide, 
enalapril and their combination on urine volume and 
biochemistry (Na, sodium;K, potassium). Figures are 
mean+standard deviation. An over the error bar 
indicates an effect of enalapril, but between error bars 
signifies an effect of frusemide. p<0.05;**p<0.01;
A A A „  ^ ap<0.001. —
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CHAPTER 17:THE EFFECTS OF CAPTOPRIL ON SERUM DIGOXIN AND 
URINARY UREA AND DIGOXIN CLEARANCES IN PATIENTS WITH 
CONGESTIVE HEART FAILURE
Since digoxin is largely excreted by the kidney unchanged, 
glomerular filtration rate is important in regulating the 
serum level of digoxin. Although the value of digoxin in 
patients with heart failure is still controversial, it is 
still commonly used and is standard therapy for those 
patients with atrial fibrillation, a common arrhythmia in 
this setting.
Angiotensin-converting enzyme inhibitors are now being 
prescribed frequently in patients with heart failure. While 
captopril increases renal blood flow in patients with 
congestive heart failure by preventing angiotensin 
II-mediated renal artery constriction, it reduces 
glomerular filtration rate. The latter might be predicted, 
as angiotensin II preferentially constricts efferent 
arterioles, thus maintaining glomerular hydrostatic 
pressure and glomerular filtration rate in the face of 
falling renal perfusion pressure.
Patients with congestive heart failure are prone to sudden 
death, presumably from arrhythmias, and these could be 
increased by the effects of digoxin. However, captopril has 
many other effects, including the correction of 
hypokalaemia, which might ameliorate the toxic effects of
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digoxin excess. We have previously demonstrated in 
double-blind studies that captopril can increase serum 
digoxin. The present study was undertaken to further 
characterise the mechanisms underlying this effect.
PATIENTS
Twelve patients (mean age 59+9 years), 10 men and 2 women 
with NYHA Class III or IV heart failure were studied. Eight 
had ischaemic heart disease and 4 had congestive 
cardiomyopathy. All were receiving digoxin (mean dose 
0.21+0.01 mg/day) for more than 3 months, together with 
frusemide (mean dose 127+49 mg/day). No patient had angina, 
significant respiratory disease, or serum creatinine above 
200 mol/1. All gave written consent to the trial, which was 
approved by the hospital's Ethical Supervisory Committee. 
Creatinine and digoxin clearance were estimated before and 
after captopril therapy (duration 3-8 weeks: mean 4 weeks).
METHODS
Creatinine and digoxin clearance were calculated from 6- 
hour urine collections, and venous samples were taken at 0, 
3 and 6 hours. These studies were peformed 6 hours after 
the last dose of digoxin. Fractional urinary excretion of 
urea and digoxin was calculated from the amount excreted in 
the urine, divided by the amount filtered at the glomerulus 
(that is, serum concentration x creatinine clearance) over 
the 6 hours of study.
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Digoxin was measured using fluorescence polarisation 
immunoassay, urine being diluted 1:10 with "blank" (non- 
digoxin-containing) serum. This assay is specific for 
digoxin and its cardioactive metabolites, digoxigenin and 
the mono- and bis-digitoxoside.
RESULTS
Before captopril, urea and creatinine clearance were 
correlated (r=0.67;p<0.02), as were urea and digoxin 
clearance (r=0.80;p<0.002) and creatinine and digoxin 
clearance (r=0.72;p<0.01). (Figures 17.1) Digoxin clearance 
was slightly greater than creatinine clearance, while both 
were greater than urea clearance. With captopril, urinary 
creatinine and digoxin clearance fell and a small rise in 
serum digoxin occurred. However, the fall in digoxin 
clearance was significantly greater than the fall in 
creatinine clearance (p<0.05). (Figure 17.1) Fractional 
urinary excretion of urea and digoxin declined on captopril 
suggesting that increased tubular reabsorption or reduced 
tubular secretion had taken place. (Table 17.1)
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TABLE 17.1
EFFECTS OF CAPTOPRIL ON URINARY DIGOXIN CLEARANCE
BASELINE CAPTOPRIL
SERUM DIGOXIN (mmol/L) 1.5(0.5) p<0.05 1.7(0.5)
URINARY DIGOXIN (ug) 41(11) ns 44(16)
CREATININE CLEARANCE (ml/min) 81(14) p<0 . 02 72(19)
UREA CLEARANCE (ml/min) 37(13) p<0 . 0 1 29(11)
DIGOXIN CLEARANCE (ml/min) 89(25) p<0 . 0 1 69(22)
FRACTIONAL EXCRETION OF
UREA (%) 1 1 1 (2 2 ) p<0.05 96(18)
DIGOXIN (%) 46(14) p<0.05 40(9)
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Figure 17.1 Correlation of creatinine clearance and digoxin 
clearance before (top panel) treatment with captopril 
 ^ (r=0.72;p<0.01). Correlation of creatinine clearance and digoxin 
clearance after (lower panel) treatment with captopril 
- : (r=0.84;p<0.002).
Solid line is line of correlation and broken line is the line of 
identity.
CHAPTER 18s THE EFFECTS OF SHORT-TERM CONVERTING-ENZYME 
INHIBITION ON RENAL TUBULAR FUNCTION AND ATRIAL NATRIURETIC 
PEPTIDE
INTRODUCTION
Previous studies have reported that the introduction of 
captopril or enalapril is associated with weight gain due 
to fluid retention. This is self-limiting in most instances 
and is reversed by longer-term therapy. (See Chapters 15,16 
& 17)
These findings are contrary to prior empirical thoughts on 
the subject. It was believed that improved renal blood flow 
and reduced angiotensin II, aldosterone and sympathetic 
activity would lead to a diuresis. However, a fall in 
glomerular filtration, arterial and atrial pressure could 
outweigh these influences.
The present study investigated the effects of enalapril on 
renal haemodynamics and tubular function.
PATIENTS
Written, informed consent was obtained from 20 patients 
(mean age 59+7 years) with heart failure due primarily to 
left ventricular dysfunction. Four patients were women. The 
aetiology was ischaemic heart disease in 12 patients and 
idiopathic dilated (congestive) cardiomyopathy in 8. All 
patients had received digoxin and diuretics for at least 3
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months prior to investigation. The median dose of digoxin 
was 0.25 mg day'1 (range 0.125-0.375 mg day"1), and of 
frusemide 120 mg day'1 (range 80-240 mg day'1) . Fourteen 
patients were in New York Heart Association Class III and 
6 in Class IV. Fifteen patients were in sinus rhythm.
All patients were commenced on a diet with a content of 100 
mmol sodium, 40 mmol potassium diet, and 2,500 ml total 
fluid intake for 48 hours prior to the study and for the 9 
days of the study. In order to achieve accurate dietary 
balance the patient was required to eat an identical diet 
each day for the duration of the study.
STUDY DESIGN
Patients were admitted to the ward and commenced on the 
above diet 48 hours before the study. Renal function was 
then studied in the presence of absence of a diuretic on 
separate days (days 3 & 4) . Patients were then commenced on 
enalapril, and studies repeated in the presence or absence 
of a diuretic on days 10 & 11.
All studies were performed in the afternoon, after a light 
lunch and commenced at midday. Patients were allocated in 
random order to receive frusemide (given at midday) in the 
usual oral dose, or have it withheld till after the 6-hour 
study period (and then given at 6 pm) . Patients then 
received 10 mg enalapril per day thereafter at 9 am with 
their usual dose of frusemide. On days 10 and 11, patients
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were again allocated in random order to receive or have 
withheld their usual daily dose of frusemide while 
enalapril was continued.
METHODS
Urine Collections
Urine volumes were measured over 6 hours on each of the 
study days, starting at midday. Samples were taken for the 
estimation of urinary sodium, potassium, magnesium, and 
phosphate. Urinary sodium, potassium and volume were also 
measured every 24 hours. Patients were weighed daily.
Biochemistry
Blood was taken for electrolytes, urea and creatinine at 
the start of the urine collection, at the mid-point, and at 
the end of the urine collection.
Atrial Natriuretic Peptide
Plasma atrial natriuretic peptide was measured before, 24 
hours after the administration of enalapril, and at the end 
of the study.
STATISTICAL ANALYSIS
All values are expressed as mean and standard deviation 
unless otherwise stated. Data not following a normal 
distribution is expressed as mean, median and range. 
Differences between treatments were first analysed using
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analysis of variance. Only if this showed a difference was 
further analysis carried out using Student's t-test. A 
Bonferroni correction was used to adjust for the use of 
multiple t-tests.
RESULTS
Clinical Outcome (Figure 18.1)
Weight increased by 1.7 kg over the first week, with a 
maximum around the fifth day after starting enalapril. Four 
patients subsequently required an increase in diuretic dose 
after the study in view of the development of new or 
worsening oedema.
The lowest measured blood pressure was on the second day 
after commencing enalapril. Blood pressure rose thereafter.
Atrial Natriuretic Peptide (Figure 18.1)
Plasma levels of atrial natriuretic peptide fell markedly 
24 hours after the administration of enalapril. Levels 
tended to rise over the duration of the study, accompanied 
by weight gain.
Serum Biochemistry (Table 18.1)
Serum sodium fell over the study period, while other 
electrolytes, urea, and creatinine were unchanged.
Creatinine Clearance (Table 18.2)
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T A B L E  1 8 . 1
NO
DIURETIC DIURETIC ACE
ACE+
DIURETIC
PLASMA
CONCENTRATION
SODIUM (mmol/L) 136(2) 137(2) 135(2) *135(3)
POTASSIUM (mmol/L) 3.8(0.2) 3.7(0.3) 3.8(0.2) 3.7(0.3)
UREA (mmol/L) 8.9(2.1) 8.1(1.6) 8.7(1.8) 9.0(1.8)
CREATININE (umol/L) 112(12) 113(14) 116(18) 116(21)
PHOSPHATE (mmol/L) 1.2(0.2) 1.1(0.2) 1.1(0.2) 1.2(0.2)
MAGNESIUM (mmol/L) 0.81(0.06) 0.78(0.04) 0.82(0.04) **0.83(0.0
OSMOLALITY (mOsm/L) 284(4) 284(6) *279(6) **279(4)
For comparisons before and after enalapril with and without diuretic 
* = p<0.05 ** = p<0.02
no symbol = not significant.
T A B L E  1 8 . 2
E F F E C T S  O F  S H O R T -T E R M  E N A L A P R I L  O N  U R I N E  C O M P O S I T I O N
NO ACE+
DIURETIC DIURETIC ACE DIURETIC
URINE VOLUME (mis) 
CONCENTRATION
251(50) 1040(140) 221(32) **836(130)
SODIUM (mmol/L) 16(8) 72(12) **11(4) 67(19)
POTASSIUM (mmol/L) 49(14) 29(6) ***30(10) ***16(2)
UREA (mmol/L) 325(64) 97(18) 322(80) 1 0 2 (2 2 )
CREATININE (umol/L) 12.3(3.4) 2 .8 (0 .4) 12.7(2.8) 3.2(0.3)
PHOSPHATE (mmol/L) 29(8) 6 (1 ) *2 2 (2 ) **4(1)
MAGNESIUM (mmol/L) 3.1(0.9) 1.7(0.3) **1.9(0 .6 ) **1 .1 (0 .2 )
OSMOLALITY (mOsm/L) 552(100) 315(24) 508(104) 320(40)
CREAT CL (mls/min) 73(14) 73(11) 67(12) *6 6 (1 1 )
UREA CL (mls/min) 28(8) 40(12) 24(8) *27(6)
UNaV (mmols) 3.8(1.6 ) 77.5(17.6) *2 .2 (0 .6 ) **55.1(11.8)
UKV (mmols) 11.3(3.2) 28.7(4.2) **6.4(2 .0 ) ****1 2 .9(2.6)
UP04V (mmols) 7.1(1.8 ) 6 .2 (0 .8 ) **4.5(0.8 ) ****3 .3(1.0)
UMgV (mmols) 0.7(0.2) 1.7(0.2) *0.4(0 .2 ) ****0.9(0 .2 )
FENa (%) 0.12(0.04) 2.45(0.42) **0.08(0.02) 1.93(0.66)
FEK (%) 15(10) 38(20) * 8 (4) **17(6)
FEUrea " (%) 38(6) 53(12) 34(8) 43(8)
FEP04 (%) 26(8) 24(6) *20(4) ****13(4 )
FEMg (%) 3.8(1.2) 9.3(2.4) *2 .2 (0 .6 ) **5.1(1.4)
Na/P04 • 0 .6 (0 .2 ) 12.7(2 .6 ) 0.5(0.2) *18.3(3.8)
Na/Mg • 5.1(1.0) 46.8(11.6) 6.3(1.9) *66.3(17.8)
Na/K . 0.4(0.2) 2 .8 (0 .8 ) 0.4(0 .2 ) **4.3(0.6)
For comparisons before and after enalapril with and without diuretic 
* = p<0.05 ** = p<0.02 *** = p<0.01 **** = p<0.001
no symbol = not significant.
All comparisons between the periods with and without diuretic were 
significant at p<0 . 0 0 1  apart from the following 
not significant: creatinine clearance, UP04V, FEP04. 
p<0.05 : potassium and magnesium concentration
urea clearance and FE Urea.
FE = FRACTIONAL EXCRETION Na = sodium. K = potassium 
P04 = phosphate. Mg = magnesium. CL = clearance.
This was lower after one week's treatment with enalapril, 
but the change was only significant for the combination of 
enalapril and diuretic.
Urine Volume (Table 18.2)
Urine volume increased after frusemide, as expected. After 
treatment with enalapril, urine volumes were reduced, but 
the change was again only significant when compared to 
baseline on the combination of frusemide and enalapril.
Urine Biochemistry (Table 18.2)
Urinary sodium, potassium and magnesium excretion were all 
increased by frusemide but phosphate was not. Urinary 
sodium, potassium, magnesium and phosphate excretion were 
all reduced by enalapril. This occurred both in the 
presence of and absence of frusemide. The fractional 
excretion of each of these electrolytes was also reduced by 
enalapril, suggesting increased tubular reabsorption. The 
ratio of sodium to phosphate increased on the combination 
of frusemide and enalapril compared to frusemide alone, 
suggesting increased proximal tubular reabsorption of 
sodium.
Over the 5 days between the 2 study periods, despite a 
constant sodium, potassium and fluid intake, weight 
increased (see above). A net positive balance of 187 ±133 
mmol sodium and 76+60 mmol potassium occurred.
192
CHAPTER 19S THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME 
INHIBITORS IN PATIENTS WITH ANGINA PECTORIS
INTRODUCTION
Patients suffering from angina pectoris and heart failure 
are difficult to manage and have a poor prognosis. In 
carefully selected patients, re-vascularisation may be of 
benefit but, due to poor ventricular function, age, and 
other associated problems, the operative morbidity and 
mortality is high.711 Moreover, it is controversial whether 
successful re-vascularisation can improve severely 
depressed left ventricular function.712-714
Medical therapy of angina and heart failure might include 
efforts to reduce pre- and afterload on the left ventricle, 
coronary vasodilatation, and limitation of heart rate 
response to exercise. Reduction in myocardial contractility 
is likely to be detrimental. Most calcium antagonists and 
beta-adrenergic receptor antagonists depress cardiac 
function and are contra- indicated in heart failure.715,716 
There is some controversial evidence that beta-adrenergic 
receptor antagonists may be of benefit in heart failure, 
but studies demonstrating success have started with long 
periods of dosing which would be sub-therapeutic for 
angina.717-719 Angiotensin converting enzyme (ACE) inhibitors 
exhibit several desirable properties resulting in venous 
and arterial dilatation and coronary vasodilatation, which 
theoretically should be of benefit in angina and heart
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failure.720'721 Some studies have shown that ACE inhibitors 
may reduce exercise-induced myocardial ischaemia in 
patients with angina,722,727 though others have been unable to 
confirm this.728,730 These studies have concentrated on 
patients with angina but without evidence of heart failure. 
It might be expected that patients with the combination of 
heart failure and angina would have more to gain in view of 
their often markedly elevated preload and afterload which 
is in a large part due to activation of the sympathetic 
nervous and renin-angiotensin systems.
Studies on animals have also suggested that ACE inhibitors, 
particularly captopril, reduce myocardial damage and 
arrhythmias during prolonged ischaemia and reperfusion.731'737
A double-blind placebo cross-over controlled trial of 
captopril compared to placebo in patients with heart 
failure and angina pectoris is reported here.
PATIENTS
We studied 14 men and 4 women who had heart failure, 
coronary artery disease and symptoms consistent with angina 
pectoris. The mean age was 63 +6 years.
All 18 had a history of one or more myocardial infarctions 
confirmed by enzyme and electrocardiographic changes and 
had symptoms consistent with Canadian Heart Association 
Class III. No patient had had a myocardial infarction
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within 3 months of the study. The median number of infarcts 
per patient was 2 (range 1-4). Three had anterior Q waves, 
indicative of infarction, 3 inferior and posterior changes, 
and 5 both inferior and anterior Q waves. Seven patients 
had left bundle branch block. Coronary artery disease was 
further confirmed by angiography in 14 patients. All 
patients were in sinus rhythm. Heart failure was confirmed 
by physical examination, the presence of radionuclide 
ventriculography and haemodynamic criteria. The left 
ventricular end-diastolic pressure was 23 +8 mm Hg in the 
14 patients who were catheterised. The median dose of 
frusemide was 120 mg/day (range: 40 - 240 mg/day), 10 were 
receiving digoxin (median dose: 0.25mg/day), 4 nitrates, 2 
nifedipine and 2 the combination of the above.
The presence of reversible myocardial ischaemia was based 
on a history of typical angina pectoris, with pain 
consistently induced by exercise and relieved by rest. 
Pre-existing electrocardiographic (ECG) abnormalities and 
treatment with digoxin rendered accurate interpretation of 
exercise-induced ECG changes impossible.
METHODS
Symptoms of breathlessness, fatigue and angina pectoris 
were assessed by visual analogue scores, and use of 
sublingual glyceryl trinitrate was recorded in a diary. 
Patients were also asked to state their preferred treatment 
in this double-blind trial.
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Heart rate was counted from the radial pulse and blood 
pressure determined using a Hawksley random-zero 
sphygmomanometer. Weight and venous pressure were measured 
and the presence of a third heart sound sought.
Venous blood was taken after 30 minutes of supine rest, and 
serum plasma concentrations of electrolytes, renin, 
angiotensin II and noradrenaline were measured.
Exercise capacity was determined using two special 
treadmill protocols. A "FAST" protocol was used in an 
attempt to induce maximal cardio-respiratory stress in the 
patient, and a "SLOW" protocol to more nearly simulate 
patient's everyday activity where patients are more likely 
to be limited by "peripheral" factors. Respiratory gas 
analysis was carried out using an Horizon Mobile Metabolic 
Cart (Sensormedics) to determine maximal oxygen 
consumption.
Rest and exercise left ventricular ejection fractions were 
determined by multiple uptake gated acquisition and a 
multi-crystal gamma camera during supine bicycle exercise. 
Exercise started at 25W and increased by 25W every 2 
minutes.
Ventricular arrhythmias were monitored for 48 hours in each 
phase by ambulatory ECG monitoring.
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STUDY DESIGN
After a 2-week run-in period to standardise therapy and 
familiarise patients with procedures, baseline assessments 
were carried out. Patients were given a test dose of 6.25 
mg of captopril in an open fashion to ensure no severe 
first-dose adverse reaction. If none occurred, patients 
were randomised to identical placebo or captopril (25 mg 
tid) in a double-blind fashion for a 2-week period. If the 
patient's symptoms remained unchanged and the standing 
systolic blood pressure was greater than 100 mm Hg, the 
dose of captopril was increased to 50 mg tid (or identical 
placebo) for a further 4 weeks. Patients were then 
reassessed and crossed over double-blind to receive the 
alternative therapy in an identical manner for a further 6 
weeks before final assessment.
STATISTICAL ANALYSIS
Order and period effects were excluded by comparing the 
differences between observations for the captopril and 
placebo phases using two-sample t-tests; results for the 
captopril and placebo phases were compared with Student's 
T-test with log transformation if appropriate. Where 
variables (such as exercise) were measured on more than one 
occasion, the Bonferroni correction was used to adjust for 
multiple t-tests. The Chi-squared test was applied to test 
for differences in distribution of discrete variables.
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RESULTS
Sixteen patients completed the study, one died suddenly at 
home. He did not report any increase in angina prior to 
his death. He was receiving placebo. One patient who was on 
nifedipine and nitrates developed a low arterial pressure 
(68/44 mm Hg) on the addition of captopril. Although he did 
not exhibit features of syncope or pre-syncope, he was 
withdrawn from the trial due to progressive hyponatraemia, 
uraemia, oliguria and weight gain. This resolved on 
stopping nifedipine and his blood pressure rose to 96/72 mm 
Hg. No other side-effects were noted. Five patients 
received 50 mg tid captopril and eleven 25 mg tid. 
Symptomatic responses appeared unrelated to the dose of 
captopril used.
Symptoms (Figures 19.1 & 19.2)
Visual analogue scores for breathlessness and fatigue were 
unchanged but, compared to placebo, scores for angina were 
worse on captopril. The consumption of sublingual nitrates 
was also increased. Nine patients preferred placebo, 4 had 
no preference but only 3 preferred captopril (p<0.05 
comparing captopril preference to other outcomes)
Clinical Signs
Resting heart rate and blood pressure were lower on 
captopril compared to placebo. Body weight was unchanged. 
Physical signs of heart failure at rest were not markedly 
changed.
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Biochemistry (Table 19.1)
Plasma potassium, urea and creatinine rose while plasma 
sodium was unchanged on captopril. Plasma renin 
concentration and plasma concentrations of angiotensin II 
and noradrenaline fell.
Treadmill Exercise Testing (Table 19.2)
At baseline, all patients stopped with symptoms of angina 
and breathlessness during the "FAST" protocol but only 10 
out of 18 during the "SLOW" test. Two stopped with 
breathlessness and 6 with fatigue during the latter 
protocol.
After statistical correction for multiple exercise tests, 
exercise duration was unaltered by the "SLOW" protocol but 
13 patients became limited by angina compared to 6 during 
the placebo phase (p<0.05). Exercise performance was 
significantly worse on captopril during the "FAST" protocol 
and patients always stopped due to breathlessness and 
angina. Maximum exercise heart rate was higher during the 
"FAST" compared to the "SLOW" protocol, but was unchanged 
by the introduction of captopril. Maximum systolic blood 
pressure was similar during "FAST" and "SLOW" protocols 
but was consistently lower during therapy with captopril. 
Recordings of diastolic blood pressure were also lower on 
captopril but these non-invasive estimates were considered 
technically unreliable and are not considered further.
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TABLE 19.1 TREADMILL EXERCISE TESTING
SUPINE
RESTING HEART RATE (bpm)
BASELINE
82+4
CAPTOPRIL
76+5
PLACEBO
80+3
P<
0.05
RESTING SYSTOLIC BP (mmHg) 128+10 119+14 126+11 0 . 0 1
RESTING DIASTOLIC BP (mmHg) 77+8 69+9 77+7 0 . 0 1
ERECT
RESTING HEART RATE (bpm) 84+4 81+6 83+5 ns
RESTING SYSTOLIC BP (mmHg) 127+9 105+16 125+8 0 . 0 0 1
RESTING DIASTOLIC BP (mmHg) 81+8 67+10 78+9 0 . 0 0 1
SLOW PROTOCOL
EXERCISE HEART RATE (bpm) 120+16 121+14 122+15 ns
EXERCISE SYSTOLIC BP (mmHg) 136+23 1 2 0 + 2 1 141+20 0 . 0 0 2
EXERCISE DOUBLE PRODUCT 16.3+5.1 14.9+4.1 17.2+4.5 0 . 0 1
EXERCISE TIME (minutes) 8 .7+3.1 9.6+2.4 10.9+3.3 ns
MAXIMUM OXYGEN CONSUMPTION 
(ml/kg/minute)
12.5+2.7 12.9+3.1 13.6+2.9 ns
FAST PROTOCOL
EXERCISE HEART RATE (bpm) 130+14 133+13 132+13 ns
EXERCISE SYSTOLIC BP (mmHg) 144+18 123+16 148+19 0 . 0 0 1
EXERCISE DOUBLE-PRODUCT 18.7+4.3 16.4+4.0 19.5+4.1 0 . 0 1
EXERCISE TIME (seconds) 234+22 213+18 255+24 0 . 0 1
MAXIMUM OXYGEN CONSUMPTION 
(ml/Kg/minute)
15.4+3.6 14.9+3.0 15.7+3.1 ns
**
BP = blood pressure 
bpm = beats per minute
** maximum oxygen consumption achieved was consistantly higher 
(p<0.05) on the fast protocol.
T A B L E  1 9 . 2  S U P I N E  B I C Y C L E  E X E R C I S E
BASELINE CAPTOPRIL PLACEBO p<
RESTING EJECTION FRACTION (%) 24+8 24+10 25+8 ns
EXERCISE HEART RATE (bpm) 118+19 122+17 124+20 ns
EXERCISE SYSTOLIC BP (mmHg) 137+19 132+16 140+13 0.05
EXERCISE DOUBLE PRODUCT 16.2+3.7 16.1+2.8 17.4+3.9 ns
EXERCISE EJECTION FRACTION (%) 19+5 17+7 17+6 ns
EXERCISE TIME (seconds) 221+36 257+28 232+24 ns
BP = blood pressure
Respiratory Gas Analysis
Maximal oxygen consumption was consistently greater with 
the shorter "FAST" protocol. Maximal oxygen consumption did 
not vary between placebo and captopril phases.
Radionuclide Ventriculography (Table 19.3)
Left ventricular ejection fraction fell during exercise, 
consistent with myocardial ischaemia. Resting and exercise 
left ventricular ejection fractions were unaltered by 
captopril as was the exercise-induced change. There was a 
statistically insignificant trend to improved exercise 
performance during captopril therapy. Eight patients 
stopped with angina, 6 of whom also complained of 
breathlessness and 6 with leg fatigue during placebo, and 
10 with angina, 3 of whom also complained of 
breathlessness, and 4 with leg fatigue on captopril. 
Exercise heart rate was similar on captopril and placebo, 
but exercise systolic blood pressure was lower. Comparing 
exercise tests on captopril and placebo, there was a 
significant difference between the change in exercise 
performance when supine bicycle exercise (+11% in favour of 
captopril) and either upright treadmill protocol was used 
(-12% and -17%;p<0.05). The reduction in peak exercise 
systolic blood pressure on captopril was also less marked 
in the supine position (p<0.05).
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T A B L E  1 9 . 3  B I O C H E M I S T R Y
n = 16
BASELINE CAPTOPRIL
SERUM SODIUM (mmol/L) 137+5 136+3
SERUM POTASSIUM (mmol/L) 3.5+0.6 4.0+0.4
SERUM UREA (mmol/L) 7.7+3.6 8 .9+5.4
SERUM CREATININE (umol/L) 113+24 121+19
n = 9
PLASMA ACTIVE RENIN CONCENTRATION (uU/ml)
MEAN
MEDIAN
RANGE
298
144
5-1040
2118
2294
14-5234
PLASMA ANGIOTENSIN II (pmol/L)
MEAN 118 21
MEDIAN 70 17
RANGE 12-308 2-29
PLASMA NORADRENALINE (nmol/L)
MEAN 6.4 4.4
MEDIAN 6.1 3.9
RANGE 2.5-13.4 1.4-8.9
PLACEBO 
136+3 
3.4+0.7 
7.4+4.0 
112+18
214
112
5-720
89
42
10-288
6.5
5.9
1.9-12.7
P<
ns
0.01
0.05
ns
0.001
0.001
0.05
Ambulatory Electrocardiographic Monitoring (Table 19.4)
The frequency of isolated ventricular extrasystoles and 
salvoes was reduced, but the decline in ventricular 
function was not statistically significant.
Comparison of Patients by clinical preference
Patients receiving concomitant therapy with nifedipine 
(n=3) all preferred placebo and had more severe angina on 
captopril. The combination of nitrates and captopril (5 
patients) did not exhibit the same deleterious effects. 
Those patients who had a large fall in systolic blood 
pressure on captopril also did worse. Of the 9 patients who 
had a stated preference for placebo, the resting diastolic 
arterial pressure fell by a mean of 23%, while of 3 who 
preferred captopril it fell by only 4%. Baseline plasma 
active renin concentrations tended to be higher in the 
former group (median value 162 uU/1 v 10 uU/1). Among the 
14 patients who had angiography, 8 had coronary stenoses in 
vessels supplying actively contracting regions at rest 
(group A) . Six had stenoses only in vessels supplying 
regions with severe wall motion abnormalities (group B) . 
Six of eight patients in group A preferred placebo and two 
had no preference, while only two of six patients in group 
B preferred placebo, and one had no preference.
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TABLE 19.4 AMBULATORY MONITORING 
(EVENTS OVER 48 HOURS)
BASELINE CAPTOPRIL PLACEBO p<
VENTRICULAR EXTRASYSTOLES
MEAN 4628 3478 5088
MEDIAN 1144 686 1424
RANGE 126-19 ,728 0-13,084 342-16,024 0.05
VENTRICULAR SALVOES
MEAN 24 14 28
MEDIAN 6 2 6
RANGE 0-128 0-102 0-164 0.05
VENTRICULAR TACHYCARDIA
MEAN 6 3 4
MEDIAN 1 0 0
RANGE 0-42 0-24 0-32 ns
CHAPTER 20S MORTALITY IN HEART FAILURES CLINICAL VARIABLES 
OF PROGNOSTIC VALUE AND THE IMPACT OF 
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Chronic heart failure is a condition of varied aetiology 
that imposes a heavy burden of symptoms, confers a very 
poor prognosis,738*740 and affects 4% of the population under 
the age of 75 years.741 Once an in-hospital diagnosis of 
heart failure has been made, the annual mortality is likely 
to be 40% or more,738'740 though the prognosis seems to be 
slightly better in those patients not referred to hospital 
and who, presumably, have milder disease.
The most frequently reported mode of death in patients with 
heart failure seems to be sudden,739,740,742 presumably caused 
by ventricular arrhythmias743 which are common.738,744,745 
Many738,746,747 but not all748* 750 workers suggest that these 
arrhythmias are powerful independent prognostic indicators 
for mortality. Whether they are of primary importance or 
merely reflect the extent of left ventricular dysfunction 
is unclear at present.738,747,750 One retrospective case-control 
study suggested no reduction in mortality with 
procainamide,751 though anecdotal comment has suggested a 
possible benefit with amiodarone.752 Another prospective 
study suggested that arrhythmias in patients with heart 
failure are resistant to treatment.753 "Vasodilator" 
treatment on the other hand has been shown to improve 
outcome.754,755
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We investigated the importance of arrhythmias, ventricular 
function, treatment, functional capacity, and biochemical 
indices in predicting outcome in a large series of patients 
with heart failure followed prospectively in an open study.
PATIENTS
The patients presented in Chapter 10 are a sub-set from 
this larger population who had more detailed studies on 
their metabolic and neuroendocrine profile carried out. One 
hundred and fifty two patients in whom a diagnosis of heart 
failure was established on clinical, radiological, and 
echocardiographic grounds were recruited. All were 
symptomatically stable but in New York Heart Association 
Classes II-IV (mean+SD) 2.8(0.8). The mean (±SD) age was 59 
(9) years, 84% were male, and the mean (±SD) duration of 
heart failure was 18 (19) months (all >3 months).
One hundred and four had received digoxin for more than one 
month before entry to the study and all were receiving 
frusemide in a mean (SD) daily dose of 127 (85) mg/day. No 
patients were on potassium-sparing diuretics but 47 were on 
potassium chloride supplements (median dose 1800 mg/day).
The diagnosis was ischaemic heart disease in 93, idiopathic 
congestive (dilated) cardiomyopathy in 28, residual left 
ventricular dysfunction after successful valve replacement 
in 16, secondary to hypertension in 9, and alcohol-related 
cardiomyopathy in 6. Patients in whom angina was an
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appreciable complaint at rest or during exercise were 
excluded. The absence of coronary artery disease was always 
confirmed by coronary angiography; coronary artery disease 
was diagnosed either at coronary angiography or after 
myocardial infarction with typical history and 
electrocardiographic and enzyme changes.
Patients were allocated to angiotensin-converting enzyme 
inhibitors or amiodarone on an open basis for clinical 
reasons on the order of the attending physician or in the 
context of a clinical trial. Selection of patients was not 
systematic and criteria varied over the period of 
observation. Patients were therefore not necessarily 
selected for angiotensin-converting enzyme inhibitors or 
treatment with amiodarone on the basis of severity of heart 
failure or the presence of arrhythmias. This reflects the 
uncertainty of the clinical value of these drugs during 
much of the observation period. Amiodarone was started at 
600 mg a day in most cases, with a mean (±SD) daily 
maintenance dose of 183(54) mg/day (range 100-400 mg/day).
METHODS
New York Heart Association scores were determined in the 
light of exercise performance. Heart rate was measured from 
the apex beat and blood pressure was recorded with a 
Hawksley random zero sphygmomanometer.
A 12-lead electrocardiogram was recorded before a graded
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treadmill test using a modified Bruce protocol. Forty- 
eight hour ambulatory monitoring was also performed with a 
Medilog I system, and the results were analysed with a 
Pathfinder Analyser under constant visual monitoring. 
Ventricular tachycardia was defined as >3 consecutive 
ventricular extrasystoles at >120 beats/minute.
M-mode echocardiography was performed with the patients in 
the left lateral position.
Blood was taken for measurement of serum sodium, potassium, 
and creatinine concentrations on at least 2 and up to 5 
occasions at different times of day and an average value
was taken. The median number of samples taken was 3. Blood
was taken for measurement of serum digoxin concentration at 
least 6 hours after the last dose.
DEFINITIONS OF MODES OF DEATH
The mode of death was ascertained either from the
deceased's relatives, from the family practitioner, or from 
the observations of the hospital staff. Where death was 
believed to be from cardiac causes, it was classified as 
death from pulmonary oedema, cardiogenic shock, or sudden 
(defined as death without reporting a change in symptoms to 
lay or medical persons in the 24 hours before death). 
Sudden death was also divided into cases that had or had 
not indicated some gradual chronic deterioration of
symptoms of heart failure in the months before death.
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STATISTICAL ANALYSIS
Means (±SD) are given for the study group and treatment 
subgroups. Means of subgroups were compared by two- sample 
t-tests. The log-rank test was used to compare survival 
rates in the treatment subgroups. Cox's proportional 
hazards model was used to correct for and identify 
important co-variates. A stepwise routine was used to 
identify the best subset of predictors. Both forward and 
backward stepping was used to protect against the omission 
of important predictors. Pearsons' product moment 
correlation coefficients were calculated to investigate 
inter-relations between the prognostic indicators and the 
other variables. Estimated survival curves were 
subsequently constructed for each treatment and for each of 
the variables independently related to outcome. This was 
done by fixing at median values all variables that carried 
independent predictive information other than the one 
tested.
RESULTS
Clinical Outcome
The mean follow up time was 21 (12) months, during which 63 
patients (41%) died. Forty-seven (75%) of the deaths were 
sudden, though in 12 (26%) patient's clinical deterioration 
was noted at the follow-up clinic in the months before
death. Five patients died in cardiogenic shock after
recurrent myocardial infarction, and 2 died after
cerebrovascular accidents. One patient died after
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mesenteric artery occlusion, one soon after peripheral 
vascular surgery, one from chronic lymphatic leukaemia and 
associated respiratory infection, and one from rectal 
carcinoma. Only 5 (8%) deaths were considered to be caused 
by intractable left ventricular failure. Four patients 
presented with sustained ventricular tachycardia during 
follow up. None was on anti- arrhythmic treatment at the 
time. Although treatment with procainamide in 2 cases, 
tocainide in one case, and amiodarone in one case, was 
started, all four subsequently died.
Prevalence of Arrhythmias
The mean frequency of ventricular extrasystoles over 24 
hours was 4321 (median value 1375, range 0-24,299). 
Seventy-nine per cent of patients had couplets or salvoes 
of ventricular extrasystoles on ambulatory monitoring (mean 
15, median 5, range 0-768 per 24 hours). Sixty one per cent 
of patients had one or more episode of ventricular 
tachycardia with a mean overall frequency of 7 (median 
value 2, range 0-201) in 24 hours.
Baseline Characteristics
The mean initial heart rate was 88 (14) beats/minute and 
mean arterial pressure was 91 (14) mm Hg. Forty-five
patients (30%) had left bundle branch block. The mean 
concentration of serum sodium was 136 + 10 mmol/1, of serum 
potassium 3.8 (0.4) mmol/1, and of serum creatinine 117
(27) umol/1. The mean end-diastolic left ventricular
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dimension was 6.7 (0.8) cm and end-systolic dimension was 
5.7 (0.9) cm. The resulting fractional shortening was 15.3 
(6.5).
Changes in Treatment
During follow up, 11 patients were started on nitrate 
treatment, one on prazosin, and 3 on hydralazine. In 18 
patients an increase in diuretic treatment was required, 
and in 6 patients who were taking angiotensin-converting 
enzyme inhibitors the dose of diuretic was reduced because 
of postural hypotension. As mentioned above, 4 patients 
were treated with anti-arrhythmic agents for sustained 
ventricular tachycardia at a time other than entry to the 
study. Nineteen patients were taking potassium-sparing 
diuretics: amiloride in 14 (10-20 mg/day) and
spironolactone in 5 (25-50 mg/day) . Only 3 of these were in 
the group treated with angiotensin- converting enzyme 
inhibitors.
Comparison of Treatment Subgroups
Those treated with amiodarone were well matched in all 
respects with those who did not receive this treatment. 
(Table 20.1) Those subjects treated with angiotensin- 
converting enzyme inhibitors (Table 20.2) had significantly 
worse New York Heart Association scores, tended to have 
shorter exercise times, more episodes of ventricular 
tachycardia, and required significantly more frusemide and 
digoxin. Patients taking digoxin (Table 20.3) had worse New
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T a b l e  2 0 1
• NO A M I O D A R O N E  A M I O D A R O N E
n = 1 11 41
A G E  ( y e a r s ) 6 0 + 1 0 5 8  + 8
S E X (% m a 1 e s ) 8 2 % 8 8 %
N Y H A 2 . 8 + 0 . 8 2 . 9 + 0 . 9
C . A . D . (%) 6 0% 6 6%
E X E R C I S E  T I M E 7 . 5 + 4 . 8 7.4 + 4. 6
(m i n s )
M . A . P .  (m m H g ). 91 + 14 92 + 14
F . S . (%) 1 5 . 6 + 6 . 8 1 4 . 6 + 5 . 7
L E F T  B B B (%) 3 2% 2 4 %
S E R U M  S O D I U M 137 + 5 1 3 7 + 4
(m m o 1 / L )
S E R U M  P O T A S S I U M 3 . 8 + 0 . 4 3 . 9 + 0 . 4
(m m o 1 / L )
V E N T R I C U L A R
E X T R A S Y S T O L E S 4 2 6 1 4 4 6 2
(/ 2 4 h r s ) r a n g e 6 - 2 4 2 9 9 7 - 1 7 3 4 5
V E N T R I C U L A R 1
T A C H Y C A R D I A 4 . 8 11.4
(2 4 h r s ) r a n g e 0 - 6 7 0 - 2 0 1
A C E  I N H I B I  T O R (n ) 43 18
D I G O X I N ( n ) 74 30
F R U S E M I D E ( m g / d a y ) 1 2 8 + 9 3 1 2 2 + 6 1
V A L U E S  A R E  M E A N  + S T A N D A R D  D E V I A T I O N  OR R A N G E  G I V E N  IN B R A C K E T S  (
AC E  = A N G I O T E N S I N  C O N V E R T I N G  E N Z Y M E
N Y H A  = N E W  Y O R K  H E A R T  A S S O C I A T I O N  F U N C T I O N A L  C L A S S
C . A . D .  = C O R O N A R Y  A R T E R Y  D I S E A S E
M . A . P .  = M E A N  A R T E R I A L  P R E S S U R E
F .S . = E C H O C A R D I O G R A P H I C  L E F T  V E N T R I C U L A R  F R A C T I O N A L  S H O R T E N I N G  
B B B  = B U N D L E  B R A N C H  B L O C K
Table 20.2
N O  A C E  I N H I B I T O R ACE I N H I B I T O R
n = 91 61
A G E ( y e a r s ) .  5 9 + 1 0  5 9 + 8
S E X (% m a 1 e s ) 8 9% 7 5%
N Y H A  ' 2 . 6  + 0 . 7  p < 0 . 0 1  3 . 1 + 0 . 8
C . A. D . ( % ) 6 5% 5 6%
E X E R C I S E  T I M E  8 . 0 + 4 . 5  6 . 6 + 5 . 0
(mi ns )
M . A . P . (m m H g ) 93 + 1 5 88 + 1 3
F . S . (% ) 1 6 . 1 + 6 . 3  1 4. 3 + 6.7
L E F T  B B B (%) 3 2 %  2 7 %
S E R U M  S O D I U M  1 3 7 + 8  1 3 6 + 6
(mmo1/L)
S E R U M  P O T A S S I U M  3 . 9 + 0 . 4  3 . 7 + 0 . 4
( m m o l / L )
V E N T R I C U L A R
E X T R A S Y S T O L E S  4 1 2 1  4 5 9 2
( / 2 4 h r s ) r a n g e  0-2 1 8 0 4  0 - 2 4 2 9 9
V E N T R I C U L A R
T A C H Y C A R D I A  4 . 4  10
( 2 4 h r s )  r a n g e  0 - 3 8  0 - 2 0 1
A M I O D A R O N E (n ) 23 18
D I G O X I N ( n )  49 p < 0 . 0 5  55
F R U S E M I D E ( m g / d a y ) 1 0 1 + 5 4  p < 0 . 0 0 1  1 6 3 + 1 0 6
V A L U E S  A R E  M E A N  + S T A N D A R D  D E V I A T I O N  OR R A N G E  G I V E N  IN B R A C K E T S  (
A C E  = A N G I O T E N S I N  C O N V E R T I N G  E N Z Y M E
N Y H A  = N E W  Y O R K  H E A R T  A S S O C I A T I O N  F U N C T I O N A L  C L A S S
C . A . D .  = C O R O N A R Y  A R T E R Y  D I S E A S E
M . A . P .  = M E A N  A R T E R I A L  P R E S S U R E
F .S . = E C H O C A R D I O G R A P H I C  L E F T  V E N T R I C U L A R  F R A C T I O N A L  S H O R T E N I N G  
B B B  = B U N D L E  B R A N C H  B L O C K
Table 20.3
N O  D I G O X I N  D I G O X I N
n = 48 104
A G E ( y e a  r s ) 59 + 11 6 0 + 9
S E X ( % m a l e s ) 8 9 % 80%
NYHA' 2 . 5  + 0. 7 p < 0 . 03 3 . 0 + 0 . 8
C . A . D . (%) 5 0% 67 %
E X E R C I S E  T I M E  
(mi ns )
8 . 0 + 4 . 5 7 . 0 + 4 . 7
M . A . P . (m m H  g ) 93 + 13 90 + 15
F . S . ( % ) 1 6 . 6 + 6 . 3 1 4 . 8 + 6 . 5
L E F T  B B B (%) 3 7 % 29%
S E R U M  S O D I U M  
( m m o l / L )
1 38 + 5 136 + 5
S E R U M  P O T A S S I U M  
( m m o 1 / L ) 
V E N T R I C U L A R
4 . 0 + 0 . 4 3 . 8 + 0 . 4
E X T R A S Y S T O L E S 3 4 5 2 4 692
( / 2 4 h r s  ) r a n g e  
V E N T R I C U L A R
6 - 2 1 8 0 4 7 - 2 4 2 9 9
T A C H Y C A R D I A 4. 7 7.6
( 2 4 h r s ) r a n g e 0 - 3 8 0 - 2 0 1
A M I O D A R O N E ( n ) 1 1 30
A CE  I N H I B I  T O R (n ) 6 p < 0 . 01 55
F R U S E M I D E ( m g / d a y ) 93 + 58 1 4 3 + 9 2
V A L U E S  A R E  M E A N  + S T A N D A R D  D E V I A T I O N  OR R A N G E  G I V E N  IN B R A C K E T S  (
A C E  = A N G I O T E N S I N  C O N V E R T I N G  E N Z Y M E
N Y H A  = N E W  Y O R K  H E A R T  A S S O C I A T I O N  F U N C T I O N A L  C L A S S
C . A . D .  = C O R O N A R Y  A R T E R Y  D I S E A S E
M . A . P .  = M E A N  A R T E R I A L  P R E S S U R E
F . S .  = E C H O C A R D I O G R A P H I C  L E F T  V E N T R I C U L A R  F R A C T I O N A L  S H O R T E N I N G  
B B B  = B U N D L E  B R A N C H  B L O C K
York Heart Association scores than those not on digoxin.
Predictors of Prognosis
Several variables were found to be of prognostic value by 
Cox's proportional hazards model. (Table 2 0.4) Stepwise 
regression with Cox's proportional hazards model showed 
that, in order of importance, ventricular extrasystoles 
(p<0.0001), amiodarone treatment (p<0.001), mean blood 
pressure (p<0.001), and a diagnosis of coronary artery 
disease (p<0.001) were of important independent prognostic 
value. Initial serum potassium concentration (p<0.02) and 
exercise time (p<0.03) were found to be of some additional 
independent predictive value.
Predictive Value
Amiodarone treatment seemed to improve the prognosis 
(p<0.01) (Figure 20.1); this reduction in mortality was 
largely caused by a decline in the occurrence of sudden 
death, as 45% of those not treated with amiodarone died 
suddenly compared with 15% of those treated with amiodarone 
during the follow up period. While angiotensin-converting 
enzyme inhibitors had no overall beneficial effect on 
mortality (Figure 2 0.2), the frequency of sudden death was 
less (21% v 37%) ;p<0.05) . There were 6 (10%) deaths (see 
above) caused by vascular events in the group on 
angiotensin-converting enzyme inhibitors but only 3 (3%) in 
the group not treated with angiotensin-converting enzyme 
inhibitors (NS). Treatment with digoxin (Figure 20.3) and
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Table 20.4
P R E D I C T O R S  OF P R O G N O S I S  O N  U N I V A R I A T E  A N A L Y S I S  
V E N T R I C U L A R  E X T R A S Y S T O L E S  (2 4 H R S ) p < 0 . 0 0 0 1
M E A N  A R t E R I A L  P R E S S U R E  ( m m H g )  p < 0 . 0 0 0 1
S E R U M  P O T A S S I U M  ( m m o l / L )  p < 0 . 0 0 0 1
S E R U M  S O D I U M  ( m m o l / L )  p < 0 . 0 0 0 1
E X E R C I S E  T I M E  ( m i n u t e s )  p<0.,0001
N Y H A  S C O R E  p < 0 . 0 0 0 1
A M I O D A R O N E  T H E R A P Y  p < 0 . 0 1
E C H O  E N D - S Y S T O L I C  D I M E N S I O N  (cm) p < 0 . 0 1
E C H O  F R A C T I O N A L  S H O R T E N I N G  (%) p < 0 . 0 1
L E F T  B U N D L E  B R A N C H  B L O C K  ’ p < 0 . 0 1
E C H O  E N D - D I A S T O L I C  D I M E N S I O N  (cm) p < 0 . 0 2
D I A G N O S I S  OF C O R O N A R Y  A R T E R Y  D I S E A S E  p < 0 . 0 6
V E N T R I C U L A R  T A C H Y C A R D I A  ( / 2 4 h o u r s )  p < 0 . 0 6
A G E ( y e a r s )  p < 0 . 0 7
F R U S E M I D E  D O S E  ( m g / d a y )  p < 0 . 1
D U R A T I O N  OF S Y M P T O M S  p < 0 . 7
H E A R T  R A T E  ( bp m)  p < 0 . 8
C A P T O P R I L  T H E R A P Y  p = 0 . 9 3
D I G O X I N  T H E R A P Y  p = 0 . 9 9
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diuretic dose did not alter the overall prognosis or the 
frequency of sudden death before or after adjustment for 
the co-variates. Separate analysis of those patients 
undergoing a change in treatment showed no alteration in 
prognosis. Potassium supplements did not affect prognosis.
Relation of Ventricular Extrasvstoles to other measured 
variables
Ventricular extrasystoles were correlated with the 
frequency of more complex ventricular extrasystoles 
(r=0.66;p<0.0001) and were also associated with a worse New 
York Heart Association score (p<0.001). However, no 
association was noted with the use of digoxin or with the 
concentrations of serum digoxin (0.8-23 nmol/1) (all of 
which were in the therapeutic range <2.6 nmol/1). Exercise 
time (r=-0.45;p<0. 001) , serum potassium (r=- 0.38;p<0. 001) , 
and left bundle branch block (r=0.35;p<0.001) were the best 
predictors of the frequency of ventricular arrhythmias.
Comparison of Risk Factors in Diagnosis Subgroups
Those subjects with heart failure caused by coronary artery 
disease had a significantly lower blood pressure than those 
without coronary artery disease (89 (12) v 94 (16) mm
Hg;p<0.01) and a lower frequency of ventricular arrhythmias 
(3950 v 4875/24 hours;p<0.02) . The duration of symptoms 
before entry was also shorter (12.9 (14.7) v 25.7 (21.1) 
months;p<0.01). In other respects, including ventricular 
function (fractional shortening 15.5 (6.3)% v 15.0 (6.8)%,
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exercise time (7.5(4.6) v 7.4 (4.9) minutes), and serum 
potassium (3.9 (0.4) v3.8 (0.4) mmol/1) they were similar 
to patients in other diagnostic groups.
Relation of Mean Arterial Pressure to other measured 
Variables
The set of variables with the best independent relation to 
mean arterial pressure was serum sodium (r=0.54;p<0.001), 
New York Heart Association score (r=- 0.41;p<0.001), and 
end-diastolic left ventricular dimension (r=-0.29;p<0.01)
Relation of Serum Potassium and Exercise Time to other 
measured Variables
Only serum sodium (r=0.40;p<0.001) was found to have a 
significant and independent relation to serum potassium. 
Exercise time was best related on stepwise regression to 
New York Heart Association score (r=-0.79;p<0.0001) and 
fractional shortening (r=0.31;p<0.001).
Estimated Survival Curves
The estimated survival curves for amiodarone versus no 
amiodarone treatment again suggested significant 
improvement in survival with amiodarone (Figure 2 0.4). The 
estimated survival curves still suggested no pronounced 
beneficial effect with angiotensin-converting enzyme 
inhibitors (Figure 2 0.5), but also suggested no deleterious 
effect with digoxin use. The estimated survival curves for 
prognostic indicators suggested that clinically meaningful
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Figure 20.4 Estimated survival function
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separation could be made on the basis of the frequency of 
ventricular extrasystoles (Figure 2 0.6), a diagnosis of 
coronary artery disease (Figure 20.7), mean arterial 
pressure (Figure 20. 8), exercise time (Figure 20.9), and 
serum potassium (Figure 20.10).
212
% 
su
rv
iv
or
s
Figure 20.6 E s t i m a t e d  survival function
100 
90- 
80- 
70- 
60- 
50- 
40-
30-
2 0 -
1 0 -
0 -
3
OO
o to 
o o
00 o 
o to 
o o 
o o 
o • 
oo o
© = 240 V.E.S./24 hours 
o= 2,400 V.E.S./24 hours
o tt
o •
o tt
O tfl
00
o t
o ©
o t
o tto <
o
o
oo
o
oo
o
oo
o
oo
oo
oo
o
o
o
00
t©©
ooo
00
oo
ooo
o
ooo
ooo
ooo
0000
000000000
0000
ooooo
i— r
0
t — i— r
12
T — T
18 24 30 36
Time (months)
I Survival figure 20.7
100-1
80-
60-
W -
20 -
OO ••
O •
00 •
o 00 
O 0 
O o 
o 
00 
o 
o 
o 
o
e No C.A.D.
0 C.A.D.
O
o
o
o
OO
o
o
o
00
00
00
00
00
o
o
c
00
000
o
ooo
00
oo
00
00
0000
00
00
OCOOOOO
00
0000
00
0 12 18 2*1 30 36
Time (months)
Figure 20.8 Estimated survival function
lOO-i®09
90-
80-
70-
60-
50-
40-
30-
2 0 -  
1 0 -  
0
09
• 0 = MAP 70mmHgo
OO 09
o •
00 0 
o •
MAP 120mmHg
O 9
O ©
O 99
00 •
O 0
O 99
0 9
O •
O •
o m►
o 99
O 999
o 9
o 9
o 9
o 99
o 99
o 999
o 99
00 99
OO @9
00 9
OO @
O ©
O 0
O
0 99
o ©oo
0000
00
o
oo
oo
00 9 
O 99
OOP 9
0000 ©® 
OOO Q
OOOOOO
COOOQOOOO
OOOOOO
i— r— t— i— i— i— i— i— i— j— i— i— p
o 6 12 18 24 30 36
Time (months)
Pi
00
90
80
70
60
50
40
30
20
10
0
20.9 - Estimated survival function
3#
O •
OO#
o  •• o = exercise time 3 mins
o •#
°£ %  • = exercise time 12 mins
00 • o «® 
o • o • 
o • 
o •
00 • 
o 
o o
o  •
o •
o #oo #
o 
o
o #o &
CD CO
o #
o ©
o ©
o 
o 
o 
00 
00 
o oo 
o 
o
o ©
0000 ©
00
00 
00 
00
OO 9 900000
n m m
oooooooooooooco
oooooooooo
I— I— I— I— I— I— I— 1— I— I— I— I— I— I
3 6 12 18 24 30 36
Time (months)
% 
su
rv
iv
or
s
Figure 20.10 Estimated survival function
100-.
90-
80-
70-
60-
50- 
40- 
30- 
20 -  
10-  
. 0-
©
oV»» o = serum K+ 3mmol/lo o
o ®S . • = serum K+ ^.5mmol/l
o ©
o ©$o •o •»00 •
o •o i
o
o00
ooo
oo
ooo
o ©
O €
O O
OO ©
O ©Oo 
o
o ©
o €©
O ©O ©
o ©
00 o
o •o • •
o ©•
00ooo
000o
o
00
rrrrrm
0000
ooooooooooooooooooooooooooooooooooo 
t— r— r— i— i— i— i— i— i— i— i— i— t
0 6 12 18 24 30 36
Time (months)
GLASGOW 
UNIVERSITY
l ib r a r y
NEURO-ENDOCRINE ACTIVATION AND INHIBITION IN HEART 
FAILURE
JOHN GEORGE FRANKLIN CLELAND M.B.Ch.B., M.R.C.P. (UK) 
VOLUME TWO
(Containing the Discussion and References)
THESIS FOR DOCTOR OF MEDICINE
SUBMITTED TO THE UNIVERSITY OF GLASGOW
FROM THE DEPARTMENT OF CARDIOLOGY, WESTERN INFIRMARY 
GLASGOW
SUBMITTED IN MARCH 1991.
COPYRIGHT:- JOHN G.F. CLELAND 1991
intro:1
PUBLICATIONS BASED ON MATERIAL WHICH FORMS THIS THESIS
1. Cleland JGF, Dargie HJ, Ball SG, Robertson JIS. The 
use of captopril in the management of cardiac failure. 
Scot Med J. 1984; 29: 129-130
2. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson 
JIS, Morton JJ, East BW, Robertson I, Murray GD, 
Gillen G. Captopril in heart failure. A double blind 
controlled trial. Br Heart J 1984; 52: 53 0-535.
3. Cleland JGF, Dargie HJ, Roberston JIS, Ball SG,
Hodsman GP. Renin and Angiotensin responses to posture 
and exercise in elderly patients with heart failure. 
Eur Heart J. 1984; 3: (suppl E) 9-11.
4. Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie 
H: Angiotensin II levels, haemodynamics and 
sympathoadrenal function after low-dose captopril in 
heart failure. Am J Med 1984; 77: 880-886.
5. Cleland JGF, Dargie HJ, Robertson JIS. Angiotensin 
converting enzyme inhibition in heart failure. Br J 
Clin Pharm. 1984; 18: 157s-160s.
6. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP,
Morton JJ, East BW, Robertson I, Ford I, Robertson 
JIS: Effects of enalapril in heart failure: a double
blind study of effects on exercise performance, renal 
function, hormones, and metabolic state. Br Heart J 
1985; 54: 305-312.
7. Cleland JGF, Dargie HJ, East BW, Robertson I, Hodsman 
GP, Ball SG, Gillen G, Robertson JIS, Morton JJ. Total 
body and serum electrolyte composition in heart 
failure: the effects of captopril. Eur Heart J 1985; 
6: 681-688.
8. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton
JJ, Robertson JIS, Ford I: Severe hypotension after
first dose of enalapril in heart failure. Br Med J
1985; 291: 1309-1312.
9. Richards AM, Cleland JGF, Tonolo G, McIntyre GD,
Leckie BJ, Dargie HJ, Ball SG, Robertson JIS: Plasma
atrial natriuretic peptide in cardiac impairment. Br 
Med J 1986; 293: 409-412.
10. Cleland JGF, Dargie HJ, Gillen G, Roberston I, East
BW, Ball SG, Morton JJ, Robertson JIS. Captopril in
heart failure a double-blind study of the effects on 
renal function. J Cardiovasc Pharm. 1986; 8: 700-706.
11. Cleland JGF, Dargie HJ, Henderson E. Arrhythmias in
heart failure: effects of amiodarone. Br J Clin
Practice. 1986; 40: 31-34.
intro:2
12. Cleland JGF, Pettigrew A, Dargie HJ, Gillen G, East 
BW, Robertson JIS, Robertson I. The effect of
captopril on serum digoxin and urinary digoxin
clearance in heart failure. Am Heart J 1986; 112: ISO- 
135.
13. Richards AM, Tonolo G, Cleland JGF, McIntyre GD,
Leckie BJ, Dargie HJ, Ball SG, Robertson JIS. Plasma 
atrial natriuretic peptide concentrations during 
exercise in sodium replete and deplete normal man. 
Clin Sci 1987; 72: 159-164.
14. Cleland JGF, Dargie HJ, Robertson I, Robertson JIS, 
East BW: Total body electrolyte composition in 
patients with heart failure: a comparison with normal 
subjects and patients with untreated hypertension. Br 
Heart J 1987; 58: 230-8.
15. Cleland JGF, Dargie HJ. Angiotensin converting enzyme 
inhibitors: their current role in thhe management of 
heart failure. Cardiology in Practice 1987; 5: 18-32.
16. Cleland JGF, Dargie HJ. Ventricular dysrhythmias 
during exercise in patients with heart failure: the 
effect of amiodarone. Eur Heart J 1987; 8: 65-69.
17. Cleland JG, Dargie HJ: Heart failure, renal function 
and angiotensin converting enzyme inhibitors. Kidney 
International 1987; 31(Suppl. 20): S-220-S-228.
18. Dargie HJ, Cleland JGF, Leckie BJ, Inglis CG, East BW, 
Ford I: Relation of arrhythmias and electrolyte 
abnormalities to survival in patients with severe 
chronic heart failure. Circulation 1987; 75 (Suppl 
IV): IV-98.
19. Cleland JGF, Dargie HJ, Findlay IN, Wilson JT. 
Clinical haemodynamic and anti-arrhythmic effects of 
long-term treatment with amiodarone of patients in 
heart failure. J. 1987; 57: 436-445.
20. Cleland JGF, Dargie HJ, Ford I. Mortality in heart 
failure: clinical variables of prognostic value. Br 
Heart J 1987; 58: 572-582
21. Cleland JGF, Dargie HJ.. Arrhythmias, catecholamines 
and electrolytes. Am J Cardiol 1988; 62: 55-60.
22. Cleland JGF, Gillen G, Dargie HJ: The effects of
frusemide and angiotensin-converting enzyme inhibitors 
and their combination on cardiac and renal 
haemodynamics in heart failure. Eur Heart J 1988; 9: 
132-141.
23. Cleland JGF. Neuroendocrine activation in heart 
failure. Curr Opinion in Cardiology 1989; 4: S39-S45.
24. Cleland JGF. ACE inhibitors in mild heart failure: 
first-line or second line therapy. Eur Heart J* 1990; 
11: 51-57.
intro:3
TABLE OF CONTENTS
PART ONES HISTORICAL INTRODUCTION
CHAPTER ONE PAGE
HISTORICAL PERSPECTIVES
section i) renin and angiotensin 1
section ii) aldosterone 3
section iii) angiotensin-converting 
enzyme inhibitors 3
section iv) renin inhibitors 4
section v) summary 5
CHAPTER TWO
PHYSIOLOGICAL CONTROL OF THE COMPONENTS OF THE RENIN- 
ANGIOTENSIN-ALDOSTERONE SYSTEM
section i) renin 6
section ii) angiotensinogen 22
section iii) angiotensin I 22
section iv) angiotensin-converting enzyme 23
section v) angiotensin II 23
section vi) aldosterone 33
section vii) summary 35
CHAPTER THREE
ANIMAL MODELS OF NEUROENDOCRINE ACTIVATION IN I
FAILURE
section i) introduction 36
section ii) renin-angiotensin-aldosterone
system 37
section iii) atrial natriuretic peptide 42
section iv) anti-diuretic hormone 43
section v) sympathetic nervous system 43
section vi) conclusions 45
CHAPTER FOUR
NEUROENDOCRINE ACTIVATION IN HUMAN HEART FAILURE
46
CHAPTER FIVE
CARDIOVASCULAR ADAPTATIONS IN HEART FAILURE
section i) preload 50
section ii) afterload 50
section iii) Frank-Starling principle 52
section iv) extrinsic factors affecting
myocardial contractility 54
section v) heart rate 56
section vi) myocardial hypertrophy 57
section vii) regional blood flow 58
section viii)summary 64
intro:4
CHAPTER SIX
VASCULAR TONE IN HEART FAILURE: THE NEUROENDOCRINE- 
THERAPEUTIC INTERFACE
section i) introduction 66
section ii) historical perspectives 67
section iii) "direct"-acting vasodilators 68
section iv) vasodilators acting through
inhibition or activation
neuroendocrine systems 71
section v) conclusion 76
PART TWO •• METHODS AND RESULTS
CHAPTER SEVEN
METHODS
section i) assessment of symptoms 77
section ii) measurement of blood pressure
and heart rate 78
section iii) 12-lead electrocardiogram 79
section iv) exercise testing in
heart failure 80
section v) assessment of left ventricular
function 82
section vi) ambulatory ECG monitoring 86
section vii) measurement of renal function 87
section viii)plasma volumes 91
section ix) whole body composition 91
section x) testing the autonomic
nervous system 96
section xi) biochemistry 98
CHAPTER EIGHT
THE METABOLIC CONSEQUENCES OF HEART FAILURE AND THE 
INFLUENCE OF NEUROENDOCRINE ACTIVATION 
section i) introduction 108
section ii) patients 110
section iii) methods 111
section iv) statistical analysis 111
section v) results 112
CHAPTER NINE
COMPARISON OF AUTONOMIC AND NEUROENDOCRINE FUNCTION IN 
NORMAL SUBJECTS AND PATIENTS TREATED FOR CHRONIC HEART
FAILURE.
section i) introduction 117
section ii) patients 118
section iii) methods 119
section iv) statistical analysis 120
section v) results 121
intro:5
CHAPTER TEN
RELATION OF ARRHYTHMIAS, ELECTROLYTES AND 
NEUROENDOCRINE ABNORMALITIES TO SURVIVAL IN PATIENTS 
WITH SEVERE CHRONIC HEART FAILURE
section i) introduction 125
section ii) patients 126
section iii) methods 128
section iv) statistical analysis 130
section v) results 131
CHAPTER ELEVEN
HAEMODYNAMICS, ANGIOTENSIN II LEVELS AND 
SYMPATHOADRENAL FUNCTION AFTER LOW-DOSE CAPTOPRIL IN 
PATIENTS WITH SEVERE HEART FAILURE.
section i) introduction 136
section ii) patients 137
section iii) methods 137
section iv) statistical analysis 138
section v) results 139
CHAPTER TWELVE
SEVERE HYPOTENSION AFTER FIRST DOSE OF ENALAPRIL IN 
HEART FAILURE
section i) introduction 142
section ii) patients 142
section iii) methods 142
section iv) statistical analysis 144
section v) results 144
CHAPTER THIRTEEN
OBSERVATIONS ON THE ORAL DOSE OF CAPTOPRIL REQUIRED 
FOR HAEMODYNAMIC EFFECT
section i) introduction 149
section ii) patients 149
section iii) methods 150
section iv) results 150
CHAPTER FOURTEEN
CAPTOPRIL IN HEART FAILURE: 
TRIAL
section i) 
section ii) 
section iii) 
section iv) 
section v)
A DOUBLE-BLIND CONTROLLED
introduction
patients
methods
statistical analysis 
results
152
153 
153 
155 
157
intro:6
CHAPTER FIFTEEN
EFFECTS OF ENALAPRIL IN HEART FAILURE: A DOUBLE-BLIND 
STUDY OF THE EFFECTS ON EXERCISE PERFORMANCE, RENAL 
FUNCTION, HORMONES AND METABOLIC STATE.
section i) introduction 163
section ii) patients 163
section iii) methods 164
section iv) statistical analysis 166
section v) results 167
CHAPTER SIXTEEN
THE EFFECTS OF FRUSEMIDE AND ANGIOTENSIN-CONVERTING 
ENZYME INHIBITORS AND THEIR COMBINATION ON CARDIAC AND 
RENAL HAEMODYNAMICS IN HEART FAILURE.
section i) introduction 176
section ii) patients 177
section iii) study design and methods 179
section iv) statistical analysis 181
section v) results 181
CHAPTER SEVENTEEN
THE EFFECTS OF CAPTOPRIL ON SERUM DIGOXIN AND URINARY 
UREA AND DIGOXIN CLEARANCES IN PATIENTS WITH 
CONGESTIVE HEART FAILURE
section i) introduction 185
section ii) patients 186
section iii) methods 186
section iv) statistical analysis 186
section v) results 187
CHAPTER EIGHTEEN
THE EFFECTS OF SHORT-TERM CONVERTING-ENZYME INHIBITION 
ON RENAL TUBULAR FUNCTION AND ATRIAL NATRIURETIC
PEPTIDE.
section i) introduction 188
section ii) patients 188
section iii) study design and methods 189
section iv) statistical analysis 190
section v) results 191
CHAPTER NINETEEN
THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 
IN PATIENTS WITH HEART FAILURE AND ANGINA PECTORIS
section i) introduction
section ii) patients
section iii) study design and methods
section iv) statistical analysis
section v) results
193
194
195
197
198
intro:7
CHAPTER TWENTY
MORTALITY IN HEART FAILURE: CLINICAL VARIABLES OF
PROGNOSTIC
section
section
section
section
section
: VALUE AND THE IMPACT OF ANGIOTENSIN
; INHIBITORS
i) introduction 202
ii) patients 203
iii) study design and methods 204
iv) statistical analysis 206
v) results 206
PART THREE: DISCUSSION AND CONCLUSIONS
CHAPTER TWENTY ONE
NEUROENDOCRINE ACTIVATION IN HEART FAILURE
section i) renin and angiotensin II 213
section ii) aldosterone 218
section iii) the sympathetic nervous system 219
section iv) anti-diuretic hormone 220
section v) atrial natriuretic peptide 223
section vi) neuroendocrine effects of diuretics
in heart failure 224
section vii) neuroendocrine response
to standing 225
section viii)neuroendocrine response
to exercise 226
CHAPTER TWENTY TWO
THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
ON NEUROENDOCRINE ACTIVATION IN HEART FAILURE.
section i)
section
section
section
section
section
section
section
section
ii)
iii)
iv)
v)
vi)
vii)
plasma active renin 
concentration 230
angiotensinogen 230
angiotensin I 231
angiotensin-converting enzyme 231 
angiotensin II 232
aldosterone 232
section x)
section xi)
section
section
the sympathetic nervous system 233
viii)anti-diuretic hormone 234
ix) interaction of diuretics and converting 
enzyme inhibitors on neuroendocrine 
systems in heart failure 235
effects of angiotensin converting
enzyme inhibitors on the neuroendocrine 
response to changes in posture 
heart failure 236
effects of angiotensin converting
enzyme inhibitors on the neuroendocrine 
response to exercise
in heart failure 237
xii) atrial natriuretic peptide 239
xiii)summary 239
CHAPTER TWENTY THREE
METABOLIC CHANGES IN HEART FAILURE 
section i) serum sodium 
section ii) serum potassium
241
243
intro:8
section iii) serum bicarbonate 245
section iv) serum chloride 246
section v) serum calcium and phosphate 246
section vi) blood glucose 246
section vii) serum urate 247
section viii)total body sodium 247
section ix) total body potassium 248
section x) total body nitrogen,
calcium and phosphorus 251
section xi) total body chlorine 252
section xii) total body oxygen 252
section xiii)summary 253
CHAPTER TWENTY FOUR
METABOLIC CHANGES IN HEART FAILURE: THE CONSEQUENCES 
OF ANGIOTENSIN-CONVERTING ENZYME INHIBITION
section i) serum sodium 255
section ii) serum potassium 257
section iii) serum bicarbonate 258
section iv) serum chloride 258
section v) serum calcium and phosphate 259
section vi) blood glucose 259
section vii) serum urate 259
section viii)total body sodium 259
section ix) total body potassium 261
section x) total body nitrogen,
calcium and phosphorus 263
section xi) total body chlorine 264
section xii) total body oxygen 264
section xiii)summary 264
CHAPTER TWENTY FIVE
section
i)
ii)
RENAL FUNCTION IN HEART FAILURE: THE EFFECTS OF
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 
section  the renal haemodynamic consequences of 
cardiac failure 2 66
the effect of angiotensin converting 
enzyme inhibitors on renal function in 
heart failure 2 68
section iii) acute studies on the renal haemodynamic 
effects of angiotensin converting 
enzyme inhibitors 2 68
medium-term studies on the effects of 
ACE inhibitors on renal function in 
heart failure 2 69
chronic effects of angiotensin 
converting enzyme inhibitors on renal 
haemodynamics in heart failure 272 
interaction of angiotensin converting 
enzyme inhibitors and diuretics on 
renal haemodynamics 
in heart failure 275
long-term effects of angiotensin 
converting enzyme inhibition on 
renal sodium handling 
in heart failure 278
section iv)
section v)
section vi)
section vii)
intro:9
influence of angiotensin converting 
enzyme inhibitors on renal tubular 
function in heart failure 279
effects of angiotensin converting
enzyme inhibition on 
renal digoxin handling 282
effects of angiotensin converting
enzyme inhibitors on the distribution 
of intra-renal blood flow in patients 
with heart failure 283
summary 284
CHAPTER TWENTY SIX
AUTONOMIC FUNCTION IN HEART FAILURE: THE EFFECTS OF 
ANGIOTENSIN CONVERTING ENZYME INHIBITION
section i) autonomic dysfunction 
in heart failure 286
section ii) tests reflecting 
parasympathetic activity 289
section iii) tests reflecting 
sympathetic activity 291
section iv) effects of enalapril therapy 293
section v) effects of enalapril on QTc 298
section vi) summary 299
CHAPTER TWENTY SEVEN
SYMPTOMS
section i) symptoms in heart failure 300
section ii) the effect of angiotensin converting
enzyme inhibitors in
patients with heart failure 306
CHAPTER TWENTY EIGHT
EXERCISE PERFORMANCE 311
CHAPTER TWENTY NINE
ARRHYTHMIAS, HEART FAILURE AND ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS
section i) introduction 319
section ii) survival in heart failure: the 
death
mode of 
320
section iii) prognosis in heart failure 322
section iv) factors predicting prognosis in heart
failure 323
section v) effect of angiotensin converting enzyme
inhibitors on arrhythmias 328
section vi) effect of treatment on 
prognosis 330
section vii) summary 333
section viii 
section ix) 
section x)
section xi)
intro:10
CHAPTER THIRTY
ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ISCHAEMIC
HEART DISEASE
section i) chronic heart failure 335
section ii) angina 335
section iii) unstable angina 340
section iv) acute myocardial infarction 340
section v) cardiogenic shock 344
section vi) conclusions 344
CHAPTER 31
CONCLUSION 346
intro:11
LIST OP TABLES
TABLES CHAPTER 7
7.1 New York Heart Association Functional Classification
7.2 Visual Analogue Scores
7.3 Treadmill Protocols
7.4 Reactions Examined During In-Vivo Neutron Activation 
Analysis
TABLES CHAPTER 8
8.1 Comparison of Total Body Potassium in Normal Subjects 
and in Patients with Hypertension and Heart Failure
8.2 Comparison of Measurements in Patients with 
Hypertension and Heart Failure
8.3 Total Body Oxygen in Patients with Hypertension and 
Heart Failure
8.4 Comparison of Measurements in Patients with Heart 
Failure and with Normal or High Renin Concentrations
TABLES CHAPTER 9
9.1 Neuro-endocrine Effects of Dynamic Exercise. Resting 
Values Before and After Diuretic. Comparison to Normal 
Subjects
9.2 Neuro-endocrine Effects of Dynamic Exercise. Light 
Exercise. Comparison to Normal Subjects
9.3 Neuro-endocrine Effects of Dynamic Exercise. Strenuous 
Exercise. Comparison to Normal Subjects
TABLES CHAPTER 10
10.1 Pre-Treatment Comparison of Patients Subsequently 
Receiving Amiodarone or Not
10.2 Pre-Treatment Comparison of Patients Subsequently 
Receiving ACE Inhibitors or Not
10.3 Univariate Analysis of Factors Related to Survival
TABLES CHAPTER 11
11.1 Clinical Characteristics
11.2 Haemodynamic Data
TABLES CHAPTER 12
12.1 Comparison of Patients With and Without Hypotension on 
First Administration of Enalapril
intro:12
12.2 Plasma Hormone Concentrations in Case 2 Before and 
After Enalapril
TABLES CHAPTER 13
13.1 Haemodynamic and Neuro-endocrine Effects of Captopril 
in a Patient (1) Developing Syncope after 3mg of 
Captopril
13.2 Haemodynamic and Neuro-endocrine Effects of Captopril 
in a Patient (2) Developing Syncope after 3mg of 
Captopril
TABLES CHAPTER 14
14.1 Clinical Effects of Captopril Compared to Placebo
14.2 The Effects of Captopril on Cardiac Function
14.3 Biochemistry and Total Body composition. Captopril v 
Placebo
14.4 Renal function - The Effects of Captopril
TABLES CHAPTER 15
15.1 Clinical Effects of Enalapril v Placebo.
15.2 Effects of Enalapril on Cardiac Function
15.3 Autonomic Function Tests. Enalapril v Placebo.
15.4 Serum Biochemistry. Enalapril v Placebo.
15.5 Neuro-endocrine Effects of Enalapril Before and After 
Treatment with Diuretic and Digoxin.
15.6 Neuro-endocrine Effects of Enalapril During Standing 
and Exercise
15.7 Effects of Enalapril on Total Body Elemental 
Composition
15.8 Effects of Chronic Enalapril Therapy on Renal Function
15.9 Comparative Effects of Short- and Long-Term
Administration of Enalapril on Renal Function in 
Patients with Heart Failure
TABLES CHAPTER 16
16.1 Comparison of the Effects of Frusemide, Enalapril and 
their Combination on Neuroendocrine Variables.
TABLES CHAPTER 17
17.1 Effects of Captopril on Urinary Digoxin Clearance
intro:13
TABLES CHAPTER 18
18.1 Effects of Short Term Enalapril on Serum electrolytes.
18.2 Effects of Short Term Enalapril on Urine Composition.
TABLES CHAPTER 19
19.1 Treadmill Exercise Testing. Captopril v Placebo
19.2 Supine Bicycle Exercise. Captopril v Placebo
19.3 Serum Biochemistry and Neuro-endocrine Effects of 
Captopril in Patients with Heart failure and Angina
19.4 Ambulatory ECG Monitoring
TABLES CHAPTER 2 0
20.1 Comparison of Amiodarone and Non-Amiodarone Treated 
Groups
20.2 Comparison of ACE Inhibitor and Non-ACE Inhibitor 
Treated Groups
20.3 Comparison of Digoxin and Non-Digoxin Treated Groups
20.4 Predictors of Prognosis on Univariate Analysis
intro:14
LIST OF FIGURES
FIGURES CHAPTER 8
8.1 Relation Between Plasma Active Renin Concentration and 
Total Body Potassium in Patients with Heart Failure
8.2 Relation Between Plasma Active Renin Concentration and 
Mean Blood Pressure in Patients with Heart Failure
8.3 Relation Between Plasma Active Renin Concentration and 
Serum Sodium in Patients with Heart Failure
8.4 Relation Between Plasma Active Renin Concentration and 
Serum Potassium in Patients with Heart Failure
8.5 Relation Between Total Body Potassium and Serum 
Potassium in Patients with Heart Failure
FIGURES CHAPTER 9
9.1 Tests of Parasympathetic Reflex Function, Comparison 
of Normal Subjects and Patients with Heart Failure
FIGURES CHAPTER 10
10.1 Cumulative Proportion Surviving. Ventricular 
Extrasystoles
10.2 Cumulative Proportion Surviving. Exercise Time
10.3 Cumulative Proportion Surviving. Serum Sodium
10.4 Cumulative Proportion Surviving. Plasma Noradrenaline
10.5 Cumulative Proportion Surviving. Amiodarone Treatment
10.6 Cumulative Proportion Surviving. Plasma Active Renin 
Concentration
10.7 Cumulative Proportion Surviving. Fractional Shortening
10.8 Cumulative Proportion Surviving. Serum Potassium
10.9 Correlations Between Ventricular Extrasystole 
Frequency and Measures of Neuro-endocrine Activity, 
Arterial Pressure, Exercise Time, and Serum 
Electrolytes.
10.10 Relationship Between Plasma Active Renin Concentration 
and Plasma Noradrenaline
10.11 Correlations Between Plasma Active Renin Concentration 
and Plasma Noradrenaline against Serum Electrolytes, 
Arterial Pressure and Exercise Time.
10.12 Correlations Between Serum Electrolytes and Arterial 
Pressure and Total Body Electrolytes
intro:15
10.13 Relationship Between Plasma Active Renin Concentration 
and Total Body Potassium
10.14 Relationship Between Ventricular Extrasystoles and 
Total Body Potassium
10.15 Cumulative Proportion Surviving. ACE Inhibitor 
Treatment
FIGURES CHAPTER 11
11.1 Individual Responses of Mean Arterial Pressure,
Pulmonary Artery Diastolic Pressure and Heart Rate to 
Acute Administration of Captopril
11.2 Acute Haemodynamic Response to Captopril in Patient 3.
11.3 Individual Responses in Plasma Concentrations of
Angiotensin II, Renin, Plasma Noradrenaline and
Adrenaline to Acute Administration of Captopril
11.4 Plasma Concentrations of Angiotensin II, Renin, Plasma 
Noradrenaline and Adrenaline to Acute Administration 
of Captopril in Patient 3
FIGURES CHAPTER 12
12.1 Relationship Between Log Plasma Angiotensin II and 
Fall in Mean Blood Pressure after Enalapril
12.2 Relationship Between Fall in Mean Blood Pressure and 
fall in heart rate after Enalapril
12.3 Relationship Between Initial Mean Blood Pressure 
Change in Mean Blood Pressure after Enalapril
12.4 Relationship Between Serum Sodium and Change in Mean 
Blood Pressure after Enalapril
12.5 Relationship Between Frusemide Dose and Change in Mean 
Blood Pressure after Enalapril
12.6 Relationship Between Creatinine/Urea Ratio and Change 
in Mean Blood Pressure after Enalapril
12.7 (Case 3) Changes in Systolic and Diastolic Blood 
Pressure and Heart Rate after 5mg of Enalapril
FIGURES CHAPTER 14
14.1 Individual and Mean Changes in Glomerular Filtration 
Rate, Effective Renal Plasma Flow, Renal Blood Flow 
and Mean Blood Pressure with Captopril Therapy.
14.2 Individual and Mean Changes in Serum Creatinine and 
Urea, Filtration Fraction and Reno-vascular Resistance
intro:16
with Captopril Therapy.
14.3 Poor Relationship Between Percentage Change in Mean 
Blood Pressure and Percentage Change in Glomerular 
Filtration Rate with Captopril Therapy.
14.4 Relationship Between Percentage Change in Effective 
Renal Plasma Flow and Percentage Change in Glomerular 
Filtration Rate During Treatment with Captopril 
Therapy.
FIGURES CHAPTER 15
15.1 New York Heart Association Functional Class at 
Baseline and After Enalapril or Placebo.
15.2 Relationship Between the Increase in Serum Potassium 
on Enalapril and the Baseline Plasma Renin 
Concentration
15.3 Relationship Between the Increase in Total Body 
Potassium on Enalapril and the Baseline Plasma Renin 
Concentration
15.4 Relationship of the Percentage Change in Mean Blood 
Pressure and the Percentage Fall in Glomerular 
Filtration Rate During Treatment with Enalapril
15.5 Relationship of the Decline in Glomerular Filtration 
Rate on Enalapril to the Initial Plasma Angiotensin II 
concentration
15.6 Effects of Enalapril on Renal Function
FIGURES CHAPTER 16
16.1 Diagrammatic Outline of the Study.
16.2 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Systemic Haemodynamics.
16.3 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Renal Function.
16.4 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Haematocrit and Blood Volume.
16.5 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Serum Biochemistry.
16.6 Comparison of the Effects of Frusemide, enalapril and 
their Combination on Urine Volume and Biochemistry.
FIGURES CHAPTER 17
17.1 Correlation of Creatinine Clearance and Digoxin 
Clearance Before and After Captopril
intro:17
FIGURES CHAPTER 19
19.1 Visual Analogue Scores for Breathlessness, Tiredness 
and Angina
19.2 Glyceryltrinitrate consumption. Captopril v Placebo 
FIGURES CHAPTER 20
20.1 Cumulative Proportion Surviving. Amiodarone
20.2 Cumulative Proportion Surviving. ACE Inhibitors
20.3 Cumulative Proportion Surviving. Effect of Digoxin
20.4 Estimated Survival Function. Effect of Amiodarone
20.5 Estimated Survival Function. Effect of ACE Inhibitors
20.6 Estimated Survival Function. Ventricular Extrasystoles
20.7 Estimated Survival Function. Coronary Artery Disease
20.8 Estimated Survival Function. Mean Arterial Pressure
20.9 Estimated Survival Function. Exercise Time 
20.lOEstimated Survival Function. Potassium
intro:18
ACKNOWLEDGMENTS
I wish to thank the following without whose help the 
studies presented herein could not have been 
completed.
Dr Henry J Dargie and Dr JIS Robertson who provided 
valuable guidance and advice. Dr Iain Morton, Dr 
Brenda Leckie and Professor Stephen Ball who gave 
generous technical assistance with the biochemical 
assays. Mr Gerry Gillan for his help with radio­
isotopic measures of renal and cardiac function. Dr 
Ian Roberston and Dr Bill East for performing the 
measurements of whole body composition. Ms Esther 
Henderson and Sister Kay Mcleod for their technical 
assistance and help in organising the studies. Dr Iain 
Ford for his statistical advice and Ms Elaine 
Lipscombe for her secretarial help.
DEDICATION
To My Mother and My Wife without who waited patiently 
for the completion of this work.
intro:19
SUMMARY
The idea of vasodilator therapy for heart failure has been 
toyed with for almost one hundred years, possibly more. In 
the mid-twentieth century nitrates attained a definite role 
in the management of acute pulmonary oedema. There is 
little doubt that vasodilators can improve central
haemodynamics acutely. However, during the 1970's 
investigators started to apply physiological principles of 
preload and afterload reduction to the management of 
chronic heart failure. The results were largely 
disappointing, either because tolerance occurred to the 
vasodilator actions of the drugs, or because vasodilatation 
is an ineffective mode of treatment for chronic heart 
failure. When work on this thesis started disillusionment 
was setting in regarding the efficacy of chronic
vasodilator therapy for patients with heart failure.
Although increases in plasma renin were first demonstrated 
in heart failure almost 50 years ago, there are few studies 
which have investigated the haemodynamic and metabolic 
correlates of renin-angiotensin-aldosterone system
activation in detail. The present work indicates that 
patients with heart failure have a depletion of total body 
potassium and an excess of total body sodium when compared 
to normal subjects or patients with mild untreated 
hypertension. This depletion in potassium is not related to 
a reduction in lean body mass. Within the group of patients 
with heart failure elevated plasma concentrations of active 
renin were associated with a lower arterial pressure, lower 
serum concentrations of sodium and potassium and more
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marked depletion of total body potassium. Arterial pressure 
appears to be an important determinant of renin secretion 
in heart failure. Although the electrolyte disturbances are 
probably largely a consequence of increased plasma 
concentrations of renin and angiotensin II, mediated 
through aldosterone and antidiuretic hormone, depletion of 
serum sodium and potassium may further stimulate renin 
secretion.
The renin-angiotensin, sympathetic and parasympathetic 
nervous systems are closely integrated. Angiotensin II can 
stimulate sympathetic activity in several ways, but can 
also reduce parasympathetic activity. The present work 
confirms that patients with heart failure have elevated 
sympathetic activity at rest, but reduced parasympathetic 
and sympathetic reflex activity as has been previously 
shown. This thesis also shows that at maximal exertion 
patients with heart failure have evidence of reduced 
sympathetic activity compared to normal subjects, and that 
this is related to the intensity rather than duration of 
exercise.
In view of the disturbances in haemodynamic function, 
autonomic activity and cellular metabolism in heart failure 
it is not surprising to find a high frequency of 
arrhythmias. These arrhythmias are directly related to 
plasma concentrations of renin and noradrenaline, though 
whether this is a causal relationship or by association 
with the severity of ventricular dysfunction is 
controversial. The present study found a poor relationship
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between the severity of ventricular dysfunction and the 
frequency of arrhythmias in a group of patients with 
generally poor ventricular function.
Using two double-blind cross-over studies the angiotensin- 
converting enzyme inhibitors captopril and enalapril were 
shown to improve symptoms and exercise performance over a 
6-8 week period. The study on captopril constituted one of 
the first placebo-controlled investigations in the 
literature to establish the efficacy of angiotensin- 
converting enzyme inhibitors in chronic heart failure. The 
paper on enalapril established that this was a class 
effect. These studies demonstrated that angiotensin- 
converting enzyme inhibitors could correct hypokalaemia and 
total body potassium depletion, but did not have a major 
impact on serum or total body sodium. Angiotensin- 
converting enzyme inhibitors also reduced plasma levels of 
noradrenaline, suggesting reduced sympathetic activity, and 
improved parasympathetic reflex responsiveness. Not 
surprisingly angiotensin-converting enzyme inhibitors also 
reduced the frequency of ventricular arrhythmias.
\
Studies were performed to investigate the effects of 
angiotensin-converting enzyme inhibitors on renal function 
in greater detail, and their interaction with frusemide. 
These indicated that introduction of angiotensin-converting 
enzyme inhibitor led to a reduced diuresis, plasma volume 
expansion and a fall in serum sodium. Urinary potassium 
losses were reduced and serum potassium unaltered in the 
short term. Renal blood flow tended to increase and
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glomerular filtration rate to fall; these effects were 
enhanced by concomitant administration of frusemide. 
Studies on renal tubular function indicated increased 
proximal tubular water and sodium reabsorption as the 
likely cause for the reduced diuresis in response to 
frusemide. Longer term studies indicate that angiotensin- 
converting enzyme inhibitors cause a consistent fall in 
glomerular filtration rate and increase in renal blood flow 
while the filtration fraction is reduced towards normal. 
Withdrawal of the angiotensin-converting enzyme inhibitor 
leads to a rapid return of glomerular filtration to 
baseline levels, but renal blood flow appears elevated for 
some time after withdrawal, suggesting structural change in 
the vasculature or prolonged tissue enzyme inhibition.
Heart failure and angina pectoris commonly co-exist but the 
effects of angiotensin converting enzyme inhibitors had not 
been studied previously in such patients. The present study 
indicates that captopril may reduce the angina threshold. 
The reduction in coronary perfusion pressure appears to 
offset the potential beneficial effects on myocardial 
oxygen consumption of the reduction in preload and 
afterload. However, the frequency of ventricular 
arrhythmias was also reduced in this study.
Finally an attempt was made to determine if angiotensin- 
converting enzyme inhibitors had had a beneficial effect on 
prognosis in patients with heart failure. This was an open 
non-randomised evaluation. Computer modelling was used to 
try and correct for differences in the distribution of
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adverse prognostic factors between those receiving an 
angiotensin-converting enzyme inhibitor and those not. A 
non-significant trend to improved prognosis in those 
receiving captopril or enalapril was noted. However, there 
was an excess of vascular deaths in the group treated with 
an angiotensin-converting enzyme inhibitor, but small 
numbers make these findings of uncertain significance.
Angiotensin-converting enzyme inhibitors are a new modality 
for the treatment of chronic heart failure. The work 
presented in this thesis has helped establish their 
usefulness and limitations, and demonstrated that they are 
more than mere vasodilator agents. The reason for their 
efficacy remains to be established. Perhaps it is because 
they induce haemodynamic tolerance infrequently. However, 
correction of intra-cellular electrolyte disturbances and 
autonomic dysfunction could be at least as important.
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PART THREE DISCUSSION AND CONCLUSIONS
CHAPTER 21S NEUROENDOCRINE ACTIVATION IN HEART FAILURE 
RENIN AND ANGIOTENSIN II
In the absence opf an angiotensin converting enzyme 
inhibitor, renin and angiotensin II are closely related. 
According to our studies, approximately two-thirds of 
patients will have resting renin-angiotensin system 
activity above the normal range for our laboratory, while 
of 84 patients tested, only one had a suppressed plasma 
renin. Furthermore, the group of patients who exhibited
plasma renin within the laboratory "normal" limits still
had a mean plasma active renin concentration greater than 
that for a matched group of normal subjects. There is
little doubt that diuretics play a major role in
maintaining elevated plasma renin and angiotensin II in 
heart failure. However, in another sense, diuretics may 
reveal the underlying activity of systems that otherwise 
would be suppressed by the fluid overload that occurred due 
to the heart failure itself. Thus, the diuretic-treated 
patient may resemble more closely patients who are actively 
developing heart failure. In patients with untreated heart 
failure who achieve a compensated state without resort to 
diuretics, neuroendocrine activity, especially the 
renin-angiotensin system, may not be increased.
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Patients with an activated renin-angiotensin system are 
characterised by lower mean arterial pressure, lower serum 
sodium and potassium concentrations, and a more activated 
sympathetic nervous system. Though there was a trend to 
more severe heart failure, as assessed by functional class, 
exercise performance, and diuretic dose, these were not 
significantly different between those with and without an 
activated renin-angiotensin system.
Examining the problem in a different way, regarding, 
perhaps more appropriately, the renin-angiotensin 
activation as a continuous variable, multiple regression 
analysis revealed 3 variables which carried independent 
predictive value for plasma active renin concentrations 
(Chapter 11) . Plasma active renin varied linearly and 
directly with plasma noradrenaline, inversely with serum 
potassium concentration, and inversely with mean arterial 
pressure. These three values accounted for 75% of the 
variation in plasma renin (r2 value). Although serum sodium 
was fairly closely related to plasma renin concentration, 
on multiple regression analysis this could be displaced by 
arterial pressure and potassium. However, it is not clear 
if these relationships are causal or merely associated. The 
relationship between plasma noradrenaline and renin is to 
be expected. As described in Chapter 2, the juxtaglomerular 
apparatus is richly innervated by sympathetic nerve fibres 
and increased sympathetic nerve activity may release renin 
directly. Sympathetically-mediated constriction of the
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afferent arteriole may also contribute to an indirect 
increase in renin secretion.
The relationship between serum potassium concentration and 
plasma renin may be an equally complex interaction. In 
animal experiments, when potassium is infused into the 
afferent arteriole, plasma renin is suppressed. (Chapter 2) 
A low serum potassium in our patients could have stimulated 
plasma renin or at least had a facilitatory effect on 
activation by other stimuli. Other researchers have also 
found that potassium depletion is poorly related to 
diuretic therapy in heart failure but is strongly related 
to plasma aldosterone.756 An activated renin-angiotensin 
system is therefore likely to lead to hypokalaemia. There 
is potential within this system for positive feedback,, 
with hypokalaemia causing further activation of the 
renin-angiotensin system and aldosterone, which itself will 
cause further hypokalaemia. However, hypokalaemia tends to 
reduce aldosterone secretion.757
A low mean arterial pressure will activate the renin- 
angiotensin system, not only directly by reducing renal 
perfusion pressure but also indirectly, by activating the 
sympathetic nervous system through baroreceptors in the 
carotid and aortic arches.
The kidney responds predominantly not to the serum sodium 
concentration but to the sodium composition of the early
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distal tubular fluid, as sensed at the macula densa. In 
heart failure, of course, the composition of renal tubular 
fluid varies enormously in relationship to the diuretic 
dose. For instance, a hyponatraemic patient with heart 
failure under basal conditions will produce a small volume 
of highly urea-concentrated but salt-poor urine. The amount 
of sodium at the macula densa is likely to be small and 
this should activate the renin-angiotensin system. However, 
when the patient is given a diuretic much larger volumes of 
urine of low urea concentration but high sodium content are 
produced. This should inactivate the renin-angiotensin 
system but, in contrast, further activation of the 
renin-angiotensin system was found under these 
circumstances. However, frusemide may cause renin release 
by other mechanisms mediated through bradykinin, 
prostaglandins, and the sympathetic nervous system.
It is not clear why hyponatraemia should be associated with 
renin-angiotensin system activation. However, serum sodium 
was found to be directly related to mean arterial pressure. 
Serum sodium concentration may be a marker for arterial 
hypovolaemia, with anti-diuretic hormone forming a possible 
link;758 the low renal perfusion pressure and more avid water 
retention during the diuretic-free period then produce the 
association between low serum sodium and high plasma renin 
concentration. Alternatively, hyponatraemia may be a 
consequence of angiotensin II-mediated stimulation of 
anti-diuretic hormone, high plasma concentrations leading
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to an impaired ability of the kidney to formulate a 
hypotonic urine. Loss of the renal medullary concentration 
gradient, a possible consequence of raised proximal tubular 
reabsorption in the very low distal tubular flow, markedly 
reduced flow in the vasa recta as renal blood flow 
declines, or the effects of loop diuretics on the ascending 
limb of the loop of Henle and medullary core gradient, may 
all lead to an impaired ability of the kidney to form a 
dilute urine.
The only patient in whom plasma active renin concentration 
was not elevated also exhibited plasma noradrenaline levels 
which were only mildly elevated. This patient was receiving 
200 mg frusemide/day, which was above the mean dose for the 
other patients in the study. The patient had a normal serum 
sodium and had essential hypertension. During exercise, he 
failed to activate the plasma renin-angiotensin system, 
although plasma noradrenaline rose appropriately. Acute 
challenge with frusemide also failed to cause a rise in 
plasma renin. Addition of enalapril in doses of up to 40 
mg/day also failed to increase the plasma concentrations of 
active renin. He therefore appeared to have a totally 
inactivated renin-angiotensin system. This individual 
nonetheless showed apparent improvement during controlled 
studies of enalapril for his heart failure, and his blood 
pressure also fell during treatment with enalapril.
Although caution should be exercised in interpreting data
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from one patient, it does emphasize the fact that 
renin-angiotensin system activation is not necessarily 
activated by diuretic therapy. This patient was not on 
potassium-sparing diuretics or potassium supplements, and, 
despite a large dose of frusemide, was not hypokalaemic, 
indicating the importance of the renin- angiotensin system 
in inducing hypokalaemia. Lastly, it suggests that the 
hypotensive and beneficial clinical effects of enalapril 
are not entirely mediated by the renin-angiotensin system, 
at least not as reflected in the plasma.
ALDOSTERONE
Aldosterone is secreted by the adrenal cortex and seems 
largely regulated by the concentration of angiotensin II, 
ACTH, and the concentration of sodium and potassium in the 
plasma. We found a close relationship between angiotensin 
II and aldosterone (Chapter 16), and this is likely to be 
the main stimulus to aldosterone secretion in heart 
failure. Although sodium may have direct effects on 
aldosterone secretion, quite large changes are necessary to 
produce any effect, and this seems unlikely to be of great 
importance. In heart failure, serum potassium is low and 
this should lead to a decrease in aldosterone secretion, an 
effect which is obviously overcome by angiotensin II. 
Adrenocorticotrophic hormone is probably not of great 
importance in regulating aldosterone in heart failure, 
although we have not personally examined this question. 
Adrenocorticotrophic hormone stimulation of aldosterone is
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transient and not maintained with continued administration 
of ACTH. Atrial natriuretic peptide also appears to inhibit 
aldosterone secretion but we did not examine this in the 
present studies.759 However, this effect does not appear to 
be of major importance in patients with heart failure.760 
Reduced catabolism of aldosterone due to impaired hepatic 
function may also contribute to increased plasma 
concentrations. 761»762
THE SYMPATHETIC NERVOUS SYSTEM
Compared to normal age- and sex-matched controls, patients 
with heart failure have elevated levels of plasma 
noradrenaline and adrenaline. Though there is still some 
controversy over the source of venous catecholamines in 
heart failure, nonetheless they appear to reflect overall 
sympathetic activity fairly well.
In the 84 patients in whom we measured plasma noradrenaline 
under basal conditions, plasma noradrenaline was most 
closely related to plasma renin concentration and severity 
of heart failure as assessed by NYHA classification. This 
explained 58% of the variability in plasma noradrenaline (r2 
value). If plasma renin concentration is excluded from the 
analysis then the single strongest predictor of plasma 
noradrenaline was the mean arterial pressure. A low 
arterial pressure therefore which is also associated with 
a poor prognosis in heart failure was associated with high 
levels of sympathetic activity.
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The stimulus to increased sympathetic activity in heart 
failure has not been entirely elucidated. The above 
findings certainly support a role for baroreceptors in the 
carotid and aortic arches that are influenced by changes in 
the arterial pressure. These high pressure resistance sites 
appear to be working in a physiologically normal direction 
(that is, a loss of effective circulating volume leads to 
a tendency for cardiac output and blood pressure to 
decline, precipitating, in turn, fluid retention and 
vasoconstriction to restore blood pressure). However, 
arterial baro-receptor activity may be more closely related 
to transmural arterial tension, rather than to the arterial 
pressure itself. The variability in arterial distensibility 
and in the arterial cross- sectional diameter, which, 
according to Laplace's law, would also markedly influence 
arterial transmural tension in heart failure, may account 
for the fact that there was not a better relationship 
between arterial pressure and plasma noradrenaline levels.
The increase in circulating plasma noradrenaline in heart 
failure seems largely derived from the cardiac and renal 
circulations, while reduced renal clearance of plasma 
noradrenaline will also elevate plasma levels.
ANTI-DIURETIC HORMONE
Two of the effects of anti-diuretic hormone on the kidney 
in heart failure should be to produce a small volume of 
urine of high urea concentration. This is exactly what is
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found in the urine of patients with heart failure when 
diuretics are withheld.
In addition to its important role in producing an anti­
diuresis in the diuretic-free phase in cardiac failure, 
anti-diuretic hormone may also be a potent vasoconstrictor. 
However, when vasopressin antagonists have been given to 
patients with heart failure, little haemodynamic response 
is observed generally, although occasionally acute 
hypotension may occur.
It is of some interest that during acute severe hypotension 
induced by a first dose of an angiotensin- converting 
enzyme inhibitor, we observed paralysis of both the 
renin-angiotensin system and the sympathetic nervous 
system, but adrenaline and anti-diuretic hormone both 
increased. Anti-diuretic hormone may be of greater 
haemodynamic significance during converting enzyme 
inhibition, and perhaps also in those patients who have a 
markedly low plasma osmolality.
We found elevated levels of anti-diuretic hormone in 
patients with heart failure, compared to normal subjects. 
Normally, anti-diuretic hormone is strongly influenced by 
the plasma osmolality. As plasma osmolality falls, 
anti-diuretic hormone should be suppressed. However, in 
heart failure, where plasma osmolality is generally low, 
the anti-diuretic hormone levels are elevated, indicating
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a breakdown in the normal relationship.763 Angiotensin II may 
stimulate anti-diuretic hormone secretion, and a strong 
correlation between the two was found in our studies of 
patients with heart failure who were not receiving ACE 
inhibitors. It is possible that angiotensin II might lower 
the osmotic stimulus threshold for anti-diuretic hormone 
release or stimulate its release by centrally-mediated 
mechanisms.764 However, the relationship may be even more 
complex. Although plasma concentrations of anti-diuretic 
hormone generally declined during chronic ACE inhibitor 
therapy, anti-diuretic hormone eventually rose in those 
patients who developed low arterial pressures and pre-renal 
uraemia, despite the fact that angiotensin II had been 
markedly suppressed. Thus, a reduction in arterial baro- 
receptor activity may release anti-diuretic hormone from 
tonic inhibition.765 A low arterial pressure may therefore 
be a common stimulus to angiotensin II and anti-diuretic 
hormone secretion in heart failure, or may sensitise 
anti-diuretic hormone release to angiotensin II.
A fall in right atrial pressure could stimulate anti­
diuretic hormone release, though this only pertains to 
patients with heart failure over-treated with diuretics. 
However, there is accumulating evidence that afferent 
and/or efferent pathways in atrial reflexes are reduced in 
cardiac failure. Impaired afferent or efferent expression 
of the effects of raised atrial pressure on suppression of 
anti-diuretic hormone secretion could also be important.766
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ATRIAL NATRIURETIC PEPTIDE
Atrial natriuretic peptide is elevated in patients with 
cardiac failure. Concentrations vary directly with mean 
right atrial pressure and are also weakly related to plasma 
active renin concentration in patients with heart failure.767
This concurs with others studies, suggesting a close 
relationship between transmural atrial, in particular right 
atrial, pressures. Atrial natriuretic peptide has many 
effects, including the ability to relax vascular smooth 
muscle, inhibit vasoconstriction induced by angiotensin II 
and noradrenaline, and reduce secretion of renin, 
aldosterone and anti-diuretic hormone.759 However, as the 
name suggests, its primary physiological function appears 
to be to promote natriuresis and diuresis as right atrial 
pressure rises. This potentially useful reflex in cardiac 
failure unfortunately appears to be impaired.760 Although 
markedly elevated levels of atrial natriuretic peptide are 
observed, clearly a sufficient diuresis does not ensue. It 
is not yet clear if the relationship between plasma 
concentrations of atrial natriuretic peptide and atrial 
pressure in heart failure is different from what might be 
observed in a normal heart. Studies in animals suggest that 
the raised levels of atrial natriuretic peptide are still 
having some effect. Injection of antibodies to atrial 
natriuretic peptide leads to an anti-diuresis.768 The 
relative resistance of the kidney in heart failure to the 
effects of atrial natriuretic peptide could be due to
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receptor down- regulation, antagonism by the 
renin-angiotensin or sympathetic nervous system, or due to 
the relatively low arterial perfusion pressure.
NEUROENDOCRINE EFFECTS OF DIURETICS IN HEART FAILURE
Some investigators have suggested that the renin- 
angiotensin system is not activated in untreated heart 
failure, though such studies have not included comparison 
with normal controls. Administration of diuretics to such 
patients results in a decline in plasma noradrenaline and 
an increase in plasma renin.
Studies on the effects of intravenously-administered 
frusemide to patients with heart failure have also 
demonstrated acute increases in renin, noradrenaline, and 
anti-diuretic hormone. This was accompanied surprisingly by 
a rise in atrial pressures and an increase in vascular 
resistance. All these effects had disappeared by 4 hours in 
one study, rather surprising in view of the associated 
diuresis and volume contraction.769,770
Our studies were carried out in patients with chronic 
stable heart failure receiving long-term diuretic therapy. 
A further dose of oral frusemide led to further increases 
in plasma concentrations of renin, angiotensin II, 
aldosterone, anti-diuretic hormone, and noradrenaline. This 
was attended by an acute fall in plasma concentrations of 
potassium and sodium.
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Frusemide can stimulate plasma renin release acutely by a 
variety of mechanisms. Sympathetic activation by diuretics 
has been previously described in hypertension and is 
probably due to volume depletion. 771 The late activation of 
renin is probably a sympathetically- mediated phenomenon. 
The rise in plasma anti-diuretic hormone may be secondary 
to the increase in angiotensin II or to a fall in plasma 
osmolality, as reflected by the fall in sodium and 
potassium. The fall in sodium and potassium may also play 
a role in the release of renin in response to the diuretic.
NEUROENDOCRINE RESPONSE TO STANDING
We compared the neuroendocrine responses to standing in 
normal subjects and patients with heart failure. We 
observed no further activation of the renin-angiotensin- 
aldosterone system or anti-diuretic hormone in patients 
with heart failure, while a small increase only in renin 
and aldosterone occurred in normal controls. In contrast, 
plasma noradrenaline increased distinctly in normal 
subjects but failed to do so in patients with heart 
failure. This is in accordance with other studies which 
have suggested that basal sympathetic activity is increased 
in heart failure but that sympathetic responses are 
blunted. Heart rate, another index of sympathetic reflex 
activity, failed to rise in a normal fashion on assumption 
of the erect posture in patients with heart failure. Other 
investigators have found that upright posture activates the
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renin-angiotensin system but most of these studies have 
been performed with a tilt table where reflex activation 
may be more intense than that due to standing.772
Patients with heart failure may have a blunted increase in 
sympathetic activity during standing due to their 
relatively high venous and arterial tone. Cardiac output 
normally falls on standing up as venous pooling occurs in 
the legs. A potential fall in blood pressure is averted by 
baroreflex activation, an increase in sympathetic activity, 
and peripheral vasoconstriction. In patients with heart 
failure, high atrial pressures and venous constriction 
combine to prevent cardiac output falling in the upright 
position, preventing the need for a reflex increase in 
sympathetic activity. The failure of sympathetic activity 
to increase may in turn account for the lack of an increase 
in renin during standing.
An alternative explanation is that the sympathetic nerve 
terminal in heart failure may suffer from one or more 
biochemical defects, leading to decreased reflex 
responsiveness and a reduction in noradrenaline release to 
the plasma.
NEUROENDOCRINE RESPONSES TO EXERCISE
We compared the clinical and neuroendocrine responses of a 
maximal exercise test in patients with heart failure to 
that of normal subjects exercised to the same absolute
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workload and to their maximum exercise capacity. The 
maximum exercise protocol for the normal subjects had been 
specifically designed so that they exercised for a similar 
time to the patients with heart failure, thus preventing 
effects due to the duration of exercise.
Exercise provoked an approximately 30% increase in mean 
plasma concentrations of renin, angiotensin II and 
aldosterone, while concentrations of noradrenaline and 
anti-diuretic hormone more than doubled during a maximum 
exercise test in the patients with heart failure.
The neuroendocrine response to exercise in patients with 
heart failure must be interpreted with extreme caution. 
Under basal conditions, neuroendocrine activation is 
greater in patients with heart failure than in normal 
controls. During exercise at the same workload, activation 
of the renin-angiotensin system and anti- diuretic hormone 
are more intense in subjects with heart failure. 
Sympathetic activity, as reflected by plasma noradrenaline, 
is still less intense in normal subjects than that seen in 
patients with heart failure but the relative increase is as 
great in normal subjects. Heart rate at the same workload 
is higher in patients with heart failure, an indirect index 
of sympathetic activity, as is the absolute increase from 
rest. Comparing maximum exertion in normal subjects and 
controls (exercised for the same duration, but different 
intensity), normal subjects had a much more intense
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activation of all neuroendocrine systems compared to 
patients with heart failure. Absolute plasma levels of 
noradrenaline, adrenaline, and anti-diuretic hormone were 
higher at maximum exercise in normal subjects. Although 
absolute levels of renin-angiotensin system activity were 
lower in normal subjects at maximum exercise, the 
percentage increase was greater than that found in patients 
with heart failure.
Activation of the sympathetic nervous system during 
exercise is partly centrally mediated, increases in 
sympathetic activity occurring in anticipation of exercise 
but also probably dependent on input from mechano-receptors 
in joints and muscles. Increased circulating noradrenaline 
during exercise seems largely derived from exercising 
muscles, perhaps associated with beta-2receptor-mediated 
peripheral vasodilation. Cardiac and renal noradrenaline 
release both increase during exercise and this is enhanced 
in heart failure. 773*774 Transient reductions in arterial 
oxygen tension during exercise would also enhance 
sympathetic function at a given level of baro-receptor 
activity.775 Finally, the heart is richly supplied with 
afferent sympathetic fibres. Alterations in filling 
pressures may reflexly stimulate sympathetic activity.
Patients with heart failure had a sustained increase in 
plasma noradrenaline after exercise when compared to normal 
subjects. This may have important implications for
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post-exercise arrhythmias and post-exercise hypokalaemia.
The increase in renin during exercise could be due to 
activation of renal sympathetic efferents. However, 
although plasma noradrenaline increased by a broadly 
similar amount in patients with heart failure and normal 
controls exercised to the same workload, plasma renin only 
increased in those with heart failure. An alternative 
explanation is that renal ischaemia develops during maximal 
exercise as blood is diverted to exercising muscle. This 
would explain why renin increased in both groups during 
intense exercise. A reduction in tubular sodium delivery 
during exercise could also have stimulated renin secretion.
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CHAPTER 22s THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME 
INHIBITORS ON NEUROENDOCRINE ACTIVATION IN HEART FAILURE
Angiotensin-converting enzyme inhibitors have complex 
haemodynamic and metabolic effects, not only because they 
inhibit the formation of angiotensin II which interferes 
with many other neuroendocrine systems but also because 
they inhibit other enzymes such as bradykininase, and may 
affect prostaglandin metabolism.
PLASMA ACTIVE RENIN CONCENTRATION
Freed from the negative feedback of angiotensin II, plasma 
active renin concentration rises. Even though large amounts 
of renin may appear in the circulation, this has no active 
role as the sole effect of this enzyme is to convert 
angiotensinogen to angiotensin I. The amount by which renin 
increases is highly variable, and may be useful as an 
indicator of the underlying stimulation to renin excretion 
in the absence of negative feedback from angiotensin II. 
Some authors have suggested that the increase in plasma 
renin in response to an ACE inhibitor predicts a good 
clinical response.776
ANGIOTENSINOGEN
Angiotensinogen formed in the liver is under the positive 
feedback influence of angiotensin II. Chronic reduction in 
angiotensin II leads to a decreased synthesis of the 
substrate for renin.
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ANGIOTENSIN I
After converting enzyme inhibition, angiotensin I 
accumulates, but this molecule probably has little 
biological effect. However, as angiotensin I accumulates, 
even a small amount of free converting enzyme may cause 
further rapid synthesis of angiotensin II. Large amounts of 
angiotensin I in the circulation also cause problems as 
they may cross-react with the angiotensin II assay, giving 
falsely high concentrations of angiotensin II. Formulae 
should either be adjusted to take this into account, 
depending of the specificity of the antibody in the 
radio-immunoassay. Alternatively, the angiotensin I and II 
may be separated using high performance liquid 
chromatography. (See Methods)
ANGIOTENSIN-CONVERTING ENZYME
In response to blockade of the converting enzyme, total 
levels of the enzyme go up. Eighty per cent or more 
occupation of the enzyme's binding sites by an inhibitor is 
required before any suppression of angiotensin II takes 
place. These considerations must be kept in mind when 
dosing with ACE inhibitors. However, it should be mentioned 
that some authors have found that low doses of converting 
enzyme inhibitors, which probably suppress angiotensin II 
for a few hours per day only may still have beneficial 
effects on patients with cardiac failure. These studies 
were not well controlled, and await confirmation.777
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ANGIOTENSIN II
Angiotensin II is, of course, suppressed after 
administration of a converting enzyme inhibitor. In our 
long-term study on captopril we took blood samples 10 hours 
after the last dose of chronically administered drug. It 
was apparent that there was some breakthrough, though 
incomplete, in converting enzyme inhibition. In the study 
on enalapril the samples which were taken under basal 
conditions were 24 hours after the last dose of enalapril, 
and again there appeared to be some breakthrough from 
converting enzyme inhibition, although this was to a much 
lesser extent that in the study on captopril. Further 
angiotensin II suppression occurred 4 hours after the next 
dose of enalapril. Increases in angiotensin I and the 
converting enzyme itself during chronic ACE inhibition make 
it likely that larger doses of inhibitors are required to 
suppress angiotensin II completely during long-term 
studies.
ALDOSTERONE
Initially, on introduction of a converting enzyme 
inhibitor, aldosterone falls rapidly to low levels. 
However, after several months of treatment, aldosterone 
levels rise, although not back to baseline. The associated 
rise in serum potassium with chronic therapy could 
stimulate aldosterone release and is probably responsible. 
However, during the enalapril study when a further dose of 
enalapril was given, a further fall in aldosterone levels
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was observed. This apparent marked sensitivity of 
aldosterone to angiotensin II could be explained by a 
sensitising role of potassium or by an up-regulation of 
angiotensin II receptors in response to the generally low 
prevailing levels of angiotensin II. This rise in 
aldosterone during chronic converting enzyme inhibition 
should probably be viewed as a useful safety valve, 
preventing excessive accumulation of potassium and 
dangerous hyperkalaemia. Certainly, hyperkalaemia is 
commonly noted when converting enzyme inhibitors and 
aldosterone antagonists are used together.
THE SYMPATHETIC NERVOUS SYSTEMS
In both acute and chronic studies with converting enzyme 
inhibitors, plasma noradrenaline concentrations fell. Less 
marked effects on plasma adrenaline were noted, though the 
apparent lack of effect may be due to the difficulties in 
measuring plasma adrenaline accurately. The reasons for the 
decline in sympathetic activity may be several. An 
improvement in cardiac failure would reduce the stimulus to 
the sympathetic nervous system. Alternatively, angiotensin 
II has been shown to have direct stimulatory effects on 
sympathetic nerve terminals. Changes in the composition and 
properties of the arterial wall could also account for some 
of the long-term changes in sympathetic activation by 
altering the relationship between arterial pressure and 
baroreceptor activation.
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The reduction in sympathetic activity is all the more 
surprising as it occurs in the setting of a fall in mean 
arterial pressure, apparently one of the major stimuli to 
the increase in sympathetic activity in heart failure.
It is remarkable that even when severe hypotension occurred 
after initial doses of a converting enzyme inhibitor, 
plasma noradrenaline failed to rise, although plasma 
adrenaline still responded. It is possible that this 
paralysis of sympathetic nerve function was an effect of 
angiotensin II suppression. However, it appears that 
sympathetic paralysis may be a general feature of patients 
who faint. Adrenal medullary responses may be mediated 
through parasympathetic efferents and therefore may respond 
differently.
ANTI-DIURETIC HORMONE
As expected, anti-diuretic hormone, which may be largely 
under the influence of angiotensin II in patients with 
heart failure, was reduced during converting enzyme 
inhibition. Although anti-diuretic hormone levels generally 
fell during converting enzyme inhibition, increases were 
seen in patients who developed hypotension, whether acute 
or chronic. In those patients who developed very low blood 
pressures during long-term converting enzyme inhibition, 
the increase in anti-diuretic hormone was associated with 
hyponatraemia.
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THE INTERACTION OF DIURETICS AND CONVERTING ENZYME 
INHIBITORS ON THE NEUROENDOCRINE SYSTEM IN HEART FAILURE
Released from the negative feedback of angiotensin II, the 
already elevated concentrations of plasma active renin 
demonstrate an exaggerated rise after frusemide. The rise 
in angiotensin II and aldosterone normally observed after 
administration of frusemide was inhibited. Although the 
rise in plasma noradrenaline after the diuretic was 
suppressed, the rise in anti- diuretic hormone was not.
It should be noted that in a short-term interactive study 
(Chapter 16) that patients had gained weight. There was 
also evidence of blood volume expansion and reduced urine 
volumes in response to diuretic. The suppression of the 
rise in plasma noradrenaline under these circumstances 
could be due not only to the loss of the direct effects of 
angiotensin II on the sympathetic nerve terminal but also 
a failure of blood volume to contract sufficiently to act 
as an afferent stimulus to the sympathetic nervous system. 
However, data from longer term studies (Chapter 15) also 
show a failure of plasma noradrenaline to increase after 
frusemide, despite the fact that body weight was similar 
before and after converting enzyme inhibition. Although 
plasma anti-diuretic hormone was reduced by enalapril in 
the absence of a diuretic, the rise after the 
administration of frusemide was not. This was reflected by 
a reduction in free water clearance when enalapril and
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frusemide were administered together. The stimulus to the 
increase in anti-diuretic hormone is not clear, but may 
well have been the reduction in blood pressure with the 
combination of diuretic and ACE inhibitor. Anti- diuretic 
hormone increases during hypotension in otherwise normal 
subjects.778 It also increases in response to syncope induced 
by the administration of an ACE inhibitor, when other 
neuroendocrine systems appear paralysed. We also noted that 
in those subjects who developed postural hypotension and 
hyponatraemia during chronic converting enzyme inhibition 
anti-diuretic hormone levels increased, unlike their 
counterparts without this problem. Anti-diuretic hormone 
may be a vasoconstrictor under these circumstances 
providing some protection from severe falls in blood 
pressure.
THE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON 
THE NEUROENDOCRINE RESPONSE TO CHANGES IN POSTURE
The rise in plasma renin during standing was slightly, 
though not markedly, enhanced by chronic enalapril therapy. 
The rise in plasma angiotensin II was completely 
suppressed, as was the rise in plasma aldosterone. The 
reflex increase in plasma noradrenaline in response to 
standing was restored in patients with heart failure during 
chronic treatment with enalapril and was comparable to that 
seen in normal subjects. Thus, the reductions in plasma 
noradrenaline after ACE inhibition observed in the supine 
position were lost on standing.
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The reasons for the restoration of the increase in 
noradrenaline on standing have not been fully elucidated. 
Sympathetic responses could have returned to normal as 
heart failure improved. The reduction in angiotensin II may 
have induced changes in sympathetic nerve terminals, 
allowing noradrenaline stores to replete. However, as blood 
pressure fell more during standing after enalapril, the 
stimulus to the sympathetic nervous system may have been 
greater. This increase in reflex sympathetic responsiveness 
was reflected by a significant rise in heart rate on 
standing after converting enzyme inhibitor, which was not 
seen in patients with heart failure prior to this.
The increase in anti-diuretic hormone during standing was 
variable, but those patients who had the greatest postural 
fall in blood pressure showed a prominent rise in 
anti-diuretic hormone. Thus, the fall in blood pressure 
again is the most likely stimulus to anti- diuretic hormone 
secretion on standing.
THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR ON 
NEUROENDOCRINE RESPONSES TO EXERCISE.
During exercise, plasma renin rose markedly during 
treatment with enalapril, presumably because of the loss of 
angiotensin II feedback. Even during maximal converting
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enzyme inhibition, there was some slight increase in 
angiotensin II during exercise which did achieve 
statistical significance. Although pre-exercise aldosterone 
was suppressed, the relative rise in aldosterone during 
exercise was identical on enalapril compared to placebo. 
This suggests that other factors such as the rise in serum 
potassium with exercise may be important in controlling 
aldosterone secretion under these circumstances. The rise 
in plasma noradrenaline, in heart rate, and in 
anti-diuretic hormone during exercise appeared unaffected 
by converting enzyme inhibitors. Others have suggested that 
ACE inhibitors may reduce cardiac sympathetic activation 
during exercise and reduce plasma noradrenaline at a given 
workload.779'781 The present study could have missed a small 
effect as patients were all exercised to their maximum 
capacity. Enalapril improved exercise performance which 
could have introduced a consistent bias in our results.
During long-term enalapril therapy, plasma noradrenaline 
levels declined more rapidly after exercise when compared 
to the placebo period. This is much more akin to the 
catecholamine response observed in normal subjects. It may 
account for the prevention of post- exercise hypokalaemia 
observed during enalapril therapy and may also have 
contributed to a reduction in arrhythmias observed with 
chronic enalapril therapy.
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ATRIAL NATRIURETIC PEPTIDE
Assays for atrial natriuretic peptide were not available at 
the outset of most of the studies presented here. In one 
small study acute administration of an ACE inhibitor caused 
a fall in plasma levels, while atrial natriuretic peptide 
levels rose over the subsequent week as weight gain 
occurred in response to the introduction of an ACE 
inhibitor. This is consistent with the effects of ACE 
inhibitors on atrial pressures. This reduction in atrial 
natriuretic peptide is one mechanism which might cause 
fluid retention immediately after giving an ACE inhibitor. 
Longer-term studies have suggested that ACE inhibitors may 
reset the relationship between atrial natriuretic peptide 
and atrial pressure such that, for a given pressure, a 
higher plasma level of peptide is present.782
SUMMARY
In this section we have outlined not only the 
neuroendocrine responses of patients with chronically 
treated cardiac failure but have also defined the response 
of these systems to a variety of everyday stimuli. 
Angiotensin-converting enzyme inhibitors appear effective 
in suppressing angiotensin II in all these situations. 
Aldosterone is generally suppressed, except during 
exercise, perhaps indicating an important role for 
potassium, which also increases during exercise, as a 
stimulus for aldosterone secretion under these
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circumstances. The decline in sympathetic nervous system 
activity is consistent between studies, though whether this 
is due to an improvement in the heart failure or a specific 
effect of reducing angiotensin II is unclear. Activation of 
the sympathetic nervous system during standing is blunted 
in patients with heart failure but this is reversed by ACE 
inhibition. The increase in sympathetic nervous activation 
during exercise appears unaffected by angiotensin 
converting enzyme inhibitors in our studies. However, 
increased sympathetic nervous activity due to the 
administration of diuretics is blocked.
Anti-diuretic hormone appears suppressed by converting 
enzyme inhibitors with the patient in the supine position 
under "basal" conditions, but appears to rise in response 
to diuretics and exercise.
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CHAPTER 23: METABOLIC CHANGES IN CARDIAC FAILURE
INTRODUCTION
This chapter will concentrate on the effects of heart 
failure on serum electrolytes and total body elemental 
composition.
Serum Sodium
Comparing patients with heart failure to normal controls or 
patients with hypertension, patients with heart failure had 
a lower serum sodium. Hyponatraemia was confined to those 
patients with an elevated plasma renin. Patients who did 
not have an elevated basal plasma renin had exactly the 
same mean serum sodium as hypertensive patients and normal 
controls. The link between hyponatraemia and an elevated 
plasma renin is complex, and it is unclear which of these 
is the dependent response. The effects of diuretic agents 
on renin release by the juxtamedullary apparatus may be 
important.785,786 The effect of sodium at the macula densa 
must be complex as distal tubular delivery of sodium must 
vary widely before and after dosing with diuretics while 
plasma renin remains elevated in both circumstances. 
Anti-diuretic hormone, which may be largely under the 
control of angiotensin II in this setting, could have 
promoted dilutional hyponatraemia. Thus, activation of the 
renin-angiotensin system may be the primary event in the 
induction of hyponatraemia.
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Although the use of diuretics probably contributes greatly 
to the development of hyponatraemia, the relationship 
between diuretic dose and plasma renin or hyponatraemia was 
poor. This may reflect differences between patients in the 
absorption or renal effects of diuretics. Diuretics may 
induce hyponatraemia by impairing the ability of the kidney 
to produce a hypotonic urine, that is, they produce, 
directly or indirectly, a greater natriuresis than 
aquaresis. Other potential mechanisms that may induce 
hyponatraemia in heart failure include altered renal 
haemodynamics, enhanced thirst, or total body potassium 
depletion.790,791 Interference with renal prostaglandin 
synthesis greatly increases the risk of developing 
hyponatraemia in patients with heart failure792,793
In addition to the strong link between plasma renin and 
serum sodium, hyponatraemic patients also had higher levels 
of angiotensin II, aldosterone, noradrenaline and 
anti-diuretic hormone. We found only a weak correlation 
between serum sodium levels and serum urea and creatinine, 
suggesting that hyponatraemia is not merely caused by a 
decline in renal function in heart failure. Serum sodium 
was strongly correlated with serum chloride, again 
indicating some deficiency in function at the level of the 
loop of Henle, probably diuretic- induced. Serum sodium and 
potassium also correlate fairly well in patients not 
receiving potassium-sparing diuretics. Again, activation of 
the renin-angiotensin- aldosterone system and anti-diuretic
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hormone may constitute the common link.
Comparing subjects with heart failure to those with 
hypertension, patients with heart failure have an expanded 
extracellular fluid volume and increased total body sodium. 
This confirms that hyponatraemia under such circumstances 
is due to excessive water retention rather than sodium 
depletion.
We found that serum sodium tended to fall acutely after 
frusemide administration in chronically diuresed patients, 
there being a one millimole fall in serum sodium 4 hours 
after oral dosing. This was associated with further 
activation of neuroendocrine systems. We found no effect of 
posture but exercise caused a small but significant 
increase in serum sodium concentration, despite further 
activation of neuroendocrine systems.
Serum Potassium
In comparison to subjects with hypertension and normal 
controls, patients with treated heart failure who were not 
on potassium-sparing diuretics (though some were receiving 
potassium supplements), had markedly lower serum 
concentrations of potassium. Potassium depletion was 
associated with markedly elevated levels of plasma renin 
and aldosterone but was poorly related to the dose of 
frusemide. Patients who were hypokalaemic were more likely 
to be receiving potassium supplements which therefore
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appeared to have remarkably little effect on serum 
potassium in this setting. Diuretic agents are the likely 
cause of hypokalaemia in our patients but the relationship 
is not direct; it is mediated through aldosterone. Only 
t h o s e  p a t i e n t s  w h o  a c t i v a t e  t h e  
renin-angiotensin-aldosterone system develop hypokalaemia. 
It is possible that increased sympathetic activity could 
have driven potassium from the extracellular to the 
intracellular compartment in addition. Indeed, despite a 
reduction in total body potassium, intracellular potassium 
was relatively preserved compared to serum potassium in 
patients with heart failure.
Concentrations of serum bicarbonate were higher in patients 
with heart failure, as might be expected in the presence 
of hypokalaemia, but bicarbonate concentrations were 
similar in normal and high renin subgroups, despite 
significant differences in serum and total body potassium. 
A long-term increase in serum bicarbonate and alkalosis may 
be less important in the regulation of the 
intra-/extracellular potassium ratio in treated heart 
failure, though it may have a short-term regulatory role.
In response to orally administered diuretic, we noted a 
fall in serum potassium of 0.3-0.4 mmol/1 over the 
subsequent 2-4 hours. This was associated with increased 
renin-angiotensin system and sympathetic nervous activity, 
both of which may have contributed to this. Though posture
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had no significant effect on serum potassium, exercise 
resulted in a rise in serum potassium but this was less 
than in normal subjects either exercising at the same 
workload or at maximal exercise. However, marked falls in 
serum potassium were seen in the post-exercise period in 
patients with heart failure. This was associated with a 
prolonged period of elevated sympathetic activity.
These acute changes in serum potassium activity undoubtedly 
represent shifts between the intra- and extracellular 
space. They could readily be accounted for by the noted 
variations in sympathetic activity. Alternatively, 
intracellular acidosis developing readily in the patient 
with heart failure due to the reduced skeletal muscle blood 
flow could also have altered the exchange of hydrogen and 
potassium ions across the cell membrane.
Intracellular potassium stores are depleted in heart 
failure. This may limit the rise in serum potassium during 
exercise, thereby exaggerating post-exercise hypokalaemia. 
Additionally, depleted intracellular stores of potassium 
may accept more avidly extracellular potassium under the 
influence of the sympathetic nervous system.
Serum Bicarbonate
This has been discussed above briefly. Patients with heart 
failure appear to have a mild extracellular alkalosis, 
perhaps representing a deficiency in the hydrogen-potassium
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exchange across the cell membrane, or changes in the sodium 
and hydrogen ion exchange in the distal convoluted tubule.794
Serum Chloride
The chloride ion may well be the primary ion on which 
frusemide has its action in the loop of Henle. Sodium is 
excreted in conjunction with it to maintain cation- anion 
balance. The two were closely correlated throughout our 
studies.
Serum Calcium and Phosphate
We did not carry out a controlled comparison of these 
electrolytes between normal subjects and subjects with 
heart failure. However, the values did not seem to differ 
from the normal laboratory range.
Glucose
Although overt diabetes mellitus was excluded from many of 
our studies, it became apparent that impaired glucose 
metabolism was common. Several patients developed overt 
diabetes mellitus during the course of the study. Although 
the age group studied is one in which a relative high 
prevalence of glucose intolerance would be expected, this 
was probably exacerbated by diuretic therapy. Reports of 
ACE inhibitors causing increased insulin sensitivity 
indicates that the renin-angiotensin system may play a role 
in induction of glucose intolerance.795
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Serum Urate
Serum urate was generally elevated beyond the normal range, 
although we did no direct comparative studies. This is a 
further side-effect of diuretic therapy.
Several patients experienced gout during the course of 
these studies. Allopurinol may readily prevent this problem 
but should probably be prescribed in reduced doses in view 
of the impaired renal function in patients with heart 
failure. It should be noted that adverse responses to the 
combination of allopurinol and ACE inhibitors have been 
recorded, patients developing eosinophilia.
TOTAL BODY ELEMENTAL COMPOSITION 
Total Body Sodium
Total body sodium was elevated in patients with cardiac 
failure, despite the fact that the patients specifically 
studied for elemental analysis were oedema-free. Only a 
small part of this sodium excess could be accounted for by 
an increase in sodium in the extracellular space, as 
derived from measurements of the extracellular fluid volume 
and serum sodium concentration. This suggests that either 
sodium must be trapped in the intracellular space or in 
bone matrix. However, when we measured total body calcium 
and phosphorus, the best indices of bone mass, the trend 
towards an excess in patients with heart failure was not 
significant. Thus, it is likely that there is an excess of 
intracellular sodium in patients with cardiac failure. This
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may represent a defect in sodium-potassium ATPase due to 
impaired nutritional supply, particularly to skeletal 
muscle, or due to neuroendocrine changes, or to digoxin.796
In myocardial tissue, an excess of intracellular sodium may 
potentiate the inotropic effect of calcium. Indeed, this is 
one of the effects of digoxin.797 An increase in vascular 
wall sodium may also contribute to vascular stiffness in 
heart failure and may account for some of the delayed 
response to converting enzyme inhibitors.
Total body sodium was elevated in patients with heart 
failure, both with and without elevated plasma renin 
levels, though it tended to be highest in those with 
suppressed plasma renin.
Serum sodium and total body sodium did not correlate well. 
This may be in part due to the large and variable amount of 
sodium present in bone.
Total Body Potassium
Our present studies clearly show that total body potassium 
depletion does occur in patients with heart failure treated 
with digoxin and diuretics. Others have argued that 
potassium depletion in such patients is due to cachexia and 
a loss of protein (nitrogen mass) #798*799 our study 
demonstrates that this is not the case and in fact the 
tendency for higher body calcium and nitrogen suggests that
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adipose tissue may be preferentially lost in subjects with 
heart failure with a relative preservation of lean body 
mass. Indeed, the percentage of body weight consisting of 
fat has been shown to be lower in elderly patients with 
heart failure than in age-matched controls.800 James et al799 
have argued that potassium depletion in cachectic patients 
is due to a loss of cellular nitrogen mass with 
preservation of collagen nitrogen mass, and that this 
accounts for the fall in potassium in relation to nitrogen 
in wasting disease. They did not, however, specifically 
study patients with heart failure. Although Burkinshaw and 
Morgan801 noted a fall in potassium in relation to nitrogen 
in heart failure, they too were unable to distinguish
between relative changes in collagen and cellular nitrogen 
because their control groups differed markedly from the 
study group. Our groups were well matched for height, 
weight, age, and sex, and also had very similar total body 
nitrogen. If cell mass had been lost, nitrogen values
should have fallen, even if collagen nitrogen mass was 
preserved. Further support for a true depletion of
potassium rather than a change in cellular mass comes from 
the demonstration that the total body potassium deficit can 
be corrected without a change in total body nitrogen by the 
use of angiotensin-converting enzyme inhibitors, presumably 
by suppressing angiotensin II-mediated aldosterone 
secretion. However, amiloride and spironolactone have not 
been shown to correct long-term total body potassium
deficits in patients with heart failure.802,803
249
Others have reported a poor, non-linear, relation between 
serum potassium and total body potassium. In our series, 
where diagnosis was tightly defined and treatment well 
documented and uniform, we found a good and apparently 
rectilinear relation between serum and total body potassium 
(expressed as a percentage of predicted normal) over the 
measured range. Multiple blood sampling may have improved 
this relationship (serum potassium was measured at least 
twice and on up to 5 occasions) , as diurnal variation in 
potassium concentration as shown above is likely to be 
exaggerated by diuretic therapy. Total body potassium would 
not have been expected to respond in such a rapid manner.
Diuretic treatment, though associated with potassium 
depletion, is probably not the direct cause. When patients 
with high and patients with normal or low plasma active 
renin concentrations were compared, only the former were 
significantly potassium deplete, though the diuretic dose 
was very similar in the 2 groups. Even after appropriate 
corrections for nitrogen, the depletion of potassium in the 
group of patients with normal plasma renin was not 
significant. When the sodium-potassium ratio was examined, 
this was markedly increased in patients with heart failure 
compared to normal subjects or subjects with hypertension, 
being most markedly elevated in those subjects with an 
activated renin-angiotensin system.
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Total Body Nitrogen. Calcium, and Phosphorus
Nitrogen is largely present in the protein of skeletal 
muscle and the viscera, tissues which are particularly rich 
in potassium. Our studies demonstrate that patients with 
heart failure have higher than expected total body nitrogen 
compared to predicted normal values. Patients with heart 
failure also tended to have higher levels than patients 
with hypertension, though this did not achieve statistical 
significance. The increase in nitrogen values was 
especially marked in those subjects who had normal or low 
plasma renin levels. It has been suggested that lean body 
mass declines with the onset of cardiac failure. Our study 
suggests that, if this is so, then the fall in either body 
water or adipose tissue mass is greater. This is further 
supported by the finding that total body calcium is above 
normal predicted levels, though again not statistically 
greater than in patients with untreated hypertension. The 
ratio of calcium to phosphorus was altered in patients with 
heart failure, perhaps reflecting an effect of diuretics on 
bone metabolism.804,805 We found little difference in total 
body calcium or phosphorus in patients with and without an 
activated renin-angiotensin system.
These data suggest that the patients with heart failure may 
have been originally significantly heavier than normal 
controls or hypertensive subjects but that, with time, they 
had lost body mass, mostly adipose tissue, with relative 
preservation of skeletal muscle and bone. Cardiac cachexia
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probably represents an extreme form of what we observed in 
this study.
Total Body Chlorine
Total body chlorine appeared slightly higher in cardiac 
failure with or without an activated renin-angiotensin 
system when compared with expected values or hypertensive 
patients, though this did not reach statistical 
significance. Chloride is largely present in the 
extracellular space and there is no evidence that this 
situation is altered in cardiac failure. As extracellular 
chloride concentrations are reduced in heart failure, the 
calculated extracellular fluid volume was increased, 
despite the fact that the patients studied were 
oedema-free. It is not clear whether a further increase in 
the dose of diuretic would have corrected this. Further 
diuresis may merely deplete the intravascular volume 
causing pre-renal uraemia, without correcting extracellular 
fluid volume overload.
Total Body Oxygen
Surprisingly, total body oxygen, which is an index of total 
body water, appeared to be depleted in patients with 
cardiac failure, both compared to hypertensive subjects and 
to expected values. Even when corrected for body weight, 
total body oxygen was still lower in the heart failure 
group. As extracellular water was in excess, this suggests 
that intracellular dehydration may be present. This could
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explain some of the apparent intracellular potassium 
deficit. Intracellular potassium concentrations may be less 
reduced than the absolute amount of intracellular 
potassium. Likewise, loss of intracellular water may have 
reduced body weight in the heart failure subjects, 
accounting for some of the changes seen in nitrogen, 
calcium and phosphorus composition.
Intracellular dehydration could be an effect of diuretic 
therapy. Alternatively, water may have followed potassium 
out of the cell in order to maintain intracellular 
isotonicity. Total body oxygen was no different in high and 
low/normal renin subsets. As potassium was only deplete in 
the high renin subset this does suggest that this group of 
patients is still relatively potassium deplete.
SUMMARY
Patients with heart failure treated with diuretics have 
marked abnormalities, not only in the electrolyte 
composition of the extracellular fluid but also the 
intracellular environment. We have presented evidence that 
such patients still have an expanded extracellular space 
but apparently intracellular dehydration. Although I have 
presented evidence for both an extra- and intracellular 
potassium deficit in patients with heart failure, because 
of the evidence for intracellular dehydration, potassium 
concentrations may not have changed so dramatically in the 
whole group. Nonetheless, the evidence still suggests that
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a true reduction in intracellular potassium concentrations 
as well as amount exists in patients with heart failure and 
high renin concentrations.
Oedema-free patients still appear to have sodium excess and 
in view of the reduction in extracellular sodium 
concentration and only slight increase in extracellular 
volume, this supports the hypothesis that an excess of 
intracellular sodium exists in heart failure.
I have also shown that our patients did not have a relative 
reduction in lean body mass and suggest that weight loss 
due to heart failure may be due predominantly to a 
reduction in body water or adiposity. The relative 
importance of the heart failure state itself, diuretics, 
and activation of the renin- angiotensin system await 
further study.
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CHAPTER 24s METABOLIC CHANGES IN CARDIAC FAILURES THE 
CONSEQUENCES OF ANGIOTENSIN-CONVERTING ENZYME INHIBITION
Serum Sodium
In 2 well controlled studies, I have demonstrated that ACE 
inhibitors do not materially affect mean serum sodium in 
patients with heart failure. This is in contrast to some 
cited papers on this subject.806,807 However, many other 
investigators have noted a failure of converting enzyme 
inhibitors to correct hyponatraemia,808,809 and that 
angiotensin converting enzyme inhibitors may actually cause 
hyponatraemia sometimes.810,811
Packer et al 807 demonstrated a consistent rise in serum 
sodium from the 3rd - 4th day after introduction of an ACE 
inhibitor in a large number of patients with heart failure. 
However, the study was not performed in a controlled 
fashion.
In studies performed during the first week of converting 
enzyme inhibition, we have consistently shown in a 
population not selected on the basis of pre-existing serum 
sodium concentration, a tendency for serum sodium to fall. 
This occurred in the setting of renal sodium retention, 
blood volume expansion and weight gain, indicating 
dilutional hyponatraemia. This may have occurred in 
response to a fall in mean arterial pressure and an acute 
decline in glomerular filtration. Also, a decline in atrial
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natriuretic peptide could have been responsible for sodium 
retention while an increase in anti-diuretic hormone may 
have reduced free-water clearance. In contrast, over 6-8 
weeks we saw no change in mean serum sodium. However, 
detailed study of the patients revealed some interesting 
variations. Several patients who were initially 
hyponatraemic had this corrected with long-term enalapril. 
These patients tended to have a good clinical response 
without developing excessively low blood pressures or 
symptoms of postural hypotension. In contrast, another 
group of patients actually acquired hyponatraemia during 
the course of the study. These patients also showed 
clinical improvement with an ACE inhibitor but developed 
postural hypotension and more prominent increases in serum 
urea and creatinine. Interestingly, in these patients 
plasma anti-diuretic hormone actually increased during ACE 
inhibition, with more marked increases being seen on 
standing. Hyponatraemia in the setting of long- term ACE 
inhibition occurred without an increase in body weight or 
total body sodium which is in contrast to the early onset 
hyponatraemia.
The increase in anti-diuretic hormone is presumably in 
response to reductions in blood pressure in both early and 
late hyponatraemia. Angiotensin converting enzyme 
inhibitors do not appear to prevent the acute fall in serum 
sodium after the administration of diuretics.
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Serum Potassium
Although angiotensin-converting enzyme inhibition would be 
expected to correct hypokalaemia, not all studies agree 
that serum potassium changes, although, interestingly, some 
of these studies do note that dangerous hyperkalaemia 
developed when ACE inhibitors and potassium-sparing 
diuretics (particularly spironolactone) were combined.812 Our 
studies show no acute effects of an ACE inhibitor on serum 
potassium, despite marked renal potassium retention. The 
associated weight gain and fluid retention may account for 
this in part. We noted an increase in blood volume one week 
after instituting enalapril in our patients. However, if 
all the weight gain was extracellular we would have 
expected to observe a 5 mmol/1 increase in serum potassium 
in the first week of therapy. Obviously, an increase in 
intracellular potassium must have taken place. It is not 
clear whether the increase in intracellular potassium 
reflected an increase solely in concentration or if a 
simultaneous increase in intracellular water took place. 
However, even in the early phase of ACE inhibition, the 
acute fall in serum potassium after diuretic administration 
is inhibited. This is not only associated with suppression 
of the renin-angiotensin system but also the sympathetic 
nervous system, and suggests that acute diuretic-induced 
hypokalaemia may be attributed to activation of one or both 
of these systems.
During long-term angiotensin converting enzyme inhibition,
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mean serum potassium rises on average 0.5- 0.6 mmol/1. This 
is accompanied by a smaller increase in serum magnesium 
which may also be partially under the control of 
aldosterone. During long-term ACE inhibition, not only is 
basal serum potassium increased but the diuretic-induced 
fall in potassium is blocked and the rise in serum 
potassium during exercise is maintained without any 
exaggerated fall in serum potassium in the post-exercise 
period. Sympathetic activity at peak exercise was similar 
in patients before and after ACE inhibition, but plasma 
noradrenaline fell more rapidly after exercise during 
treatment with an ACE inhibitor. This may account for the 
correction of post-exercise hypokalaemia by enalapril.
Serum Bicarbonate
In conjunction with the correction of hypokalaemia, serum 
bicarbonate fell towards normal and this may suggest also 
that a relative intracellular hydrogen ion excess was 
corrected.
Serum Chloride
Serum chloride levels did not change with chronic ACE 
inhibition. On analysing subsets, chloride ion tended to 
follow a similar pattern to the sodium ion.
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Serum Calcium
This was unaltered by converting enzyme inhibition. The 
effects of ACE inhibitors on ionised calcium were not 
specifically examined. Changes could have occurred in view 
of the change in serum bicarbonate.
Serum Phosphate
Serum phosphate rose consistently during chronic ACE 
inhibition. This probably reflects a decline in glomerular 
filtration rate, although the possibility that this may 
also reflect subtle changes in renal tubular phosphate 
handling cannot be excluded.
Serum Urate
We saw no effect of ACE inhibitors on serum uric acid. 
Plasma Glucose
No consistent change in plasma glucose occurred during ACE 
inhibition. There was no evidence of amelioration of 
diuretic-induced hyperglycaemia.
Total Body Sodium
In an uncontrolled study, we demonstrated renal sodium 
retention during the first week of ACE inhibition. This was 
accompanied by water retention and weight gain. This early 
sodium retention was confirmed by double- blind studies 
when fluid retention and weight gain were also noted in the 
first 1-2 weeks after initiating ACE inhibitor. This early
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sodium retention probably represents compensatory reflexes 
which attempt to preserve the mean arterial pressure during 
ACE inhibition. We noted evidence for increased proximal 
tubular reabsorption of sodium. An increase in anti­
diuretic hormone and decline in atrial natriuretic peptide 
probably contribute to water and sodium retention.
In a controlled study, total body sodium was measured 6 
weeks after the introduction of captopril. In this study 
there was no evidence that sodium balance had been altered 
in either direction. In a second study using enalapril, 
total body sodium decreased by about 100 mmol but this did 
not achieve statistical significance, nor was weight 
reduced.
It was notable in the enalapril study that symptoms such as 
postural hypotension were more common than in the study 
with captopril, and this may have reflected differences in 
sodium balance between the two studies.
Thus, ACE inhibitors initially cause sodium and water 
retention as noted above, which is limited by the 
improvement in cardiac function and the decline in plasma 
aldosterone, and perhaps angiotensin II and sympathetic 
nervous activity. During longer term ACE inhibition, the 
sodium "set point" appears to be altered, those reflexes 
enhancing renal sodium reabsorption decline813 and a 
natriuresis takes place, reversing the initial sodium
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retention. One mechanism for this may be a relative 
increase in atrial natriuretic peptide relative to the 
atrial pressure that has been observed. Another possibility 
is that the composition of the vascular wall may change, 
altering the relationship between arterial pressure and 
baroreceptor tone. It seems likely that this change from 
sodium retention to sodium excretion takes place between 
1-2 months after initiation of therapy. Longer term ACE 
inhibition may lead to a net natriuresis, though this 
remains to be documented. The occurrence of postural 
hypotension many months after the institution of ACE 
inhibitor therapy would support such an idea.
Symptomatic improvement of heart failure with ACE 
inhibitors may be observed soon after instituting therapy, 
while exercise performance is demonstrably improved within 
6 weeks. Thus, a natriuresis cannot be held solely 
responsible for the clinical benefits of ACE inhibitors, 
though they may enhance the long-term benefit. However, the 
fact that sodium retention is limited and reversed by ACE 
inhibitors may allow the beneficial effects of vasodilation 
to be displayed.
Total Body Potassium
Although serum potassium did not rise in the first week 
after ACE inhibition, renal potassium retention was 
prominent. During longer term ACE inhibition, we saw a 
consistent rise in total body potassium. This was directly
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related to the initial extent of potassium depletion and to 
the initial activity of the renin- angiotensin-aldosterone 
system. This rise in total body potassium could not be 
accounted for by the rise in extracellular potassium which 
would only account for a 10-20 mmol increase in total body 
potassium. Intracellular potassium deficits must have been 
corrected.
The potassium deficits do not appear to be artefactual. The 
apparent potassium depletion could be corrected by an ACE 
inhibitor, the greatest rise in potassium being in those 
already potassium deplete. The relationship between 
potassium depletion and the renin-angiotensin- aldosterone 
system and the fact that the increase in potassium during 
ACE inhibitor therapy was directly related to pre-treatment 
renin also support the presence of a true potassium 
deficit.
Perhaps more striking than the increase in total body 
potassium was the change in the ratio of sodium to 
potassium which initially had been distinctly abnormal in 
patients with cardiac failure. Chronic ACE inhibition 
resulted in a significant increase in potassium in relation 
to sodium.
The increase in intracellular potassium may be important 
for several reasons. Presumably correction of deficits in 
the intracellular environment could improve cell metabolism
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generally. Studies using nuclear magnetic resonance 
spectroscopy have suggested that the muscles of patients 
with heart failure may have a resting acidosis which 
worsens rapidly, even during light exercise. Restoration of 
intracellular potassium deficits could reduce intracellular 
hydrogen ion concentration and may delay the onset of 
exercise- induced intracellular falls in Ph. During 
exercise, serum potassium increases, potassium being 
released from the exercising muscle.814 In the post-exercise 
period, this resolves rapidly, partly due to the high 
levels of sympathetic activity induced by exercise. In the 
presence of potassium depletion and sustained sympathetic 
activity observed in patients with heart failure, dangerous 
hypokalaemia may develop.815 Repletion of muscle potassium 
may act as a buffer to stimuli which cause an acute decline 
in serum potassium.816 Potassium deficits could also be 
partly responsible for the high incidence of arrhythmias 
observed in patients with heart failure. The myocardium may 
be protected from potassium depletion.817 However, even if 
this is true it may not render it immune from the effects 
of potassium depletion elsewhere in the body. The presence 
of hypokalaemia and normal intra- myocyte potassium 
concentrations may be more unstable than if intra- and 
extracellular concentrations were reduced in concert.
Total Body Nitrogen, Calcium and Phosphorus
Total body calcium, phosphorus and nitrogen did not change 
during these studies. However, in both the study with
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captopril and enalapril, an upward trend in total body 
nitrogen was observed. Clinical improvement, followed by 
improved mobility, may have had a training effect resulting 
in an increased skeletal muscle mass.
Total Body Chlorine
Total body chlorine was unchanged during long-term ACE 
inhibitor therapy. In studies both with captopril and 
enalapril, there was a downward trend in extra-cellular 
fluid volume which did not reach statistical significance, 
the magnitude of this effect being about 0.5 litres.
Total Body Oxygen
Total body oxygen, an index of body water, was unaltered by 
ACE inhibitors. This is consistent with the lack of change 
in weight. However, the downward trend of total body sodium 
and extracellular fluid volume in association with an 
unchanged total body oxygen suggests that intracellular 
rehydration may have occurred.
SUMMARY
I have defined the effects of converting enzyme inhibitors 
on serum electrolytes. Though the effects on serum 
potassium are consistent, at least during long- term 
converting enzyme inhibition, the effects on serum sodium 
are highly variable. In addition to simply raising serum 
potassium, ACE inhibitors can prevent acute falls in 
potassium in response to diuretics and in the post-exercise
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period. This could be a result not only of inhibition of 
the renin-angiotensin system but also of secondary effects 
on the sympathetic nervous system.
Angiotensin converting enzyme inhibitors also have 
important effects on total body elemental composition. 
Total body sodium did not change for up to 2 months after 
starting an ACE inhibitor, suggesting that a natriuresis 
had not contributed directly to the benefits observed. 
Intracellular potassium deficits are at least partially 
corrected, as is the ratio of total body sodium to 
potassium. These changes in cell metabolism could 
contribute to the improvement in well-being and exercise 
performance experienced by patients established on ACE 
inhibitors.
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CHAPTER 25: RENAL FUNCTION IN HEART FAILURE: THE EFFECTS OF 
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
THE RENAL HAEMODYNAMIC CONSEQUENCES OF CARDIAC FAILURE
As cardiac output falls, so too does renal blood flow818-821 
In early heart failure, this is evident only during 
exercise,819,822 while at rest renal blood flow, glomerular 
filtration rate and filtration fraction are normal. With 
worsening cardiac function, renal haemodynamics become 
relatively fixed, with a decline in renal blood flow and 
glomerular filtration rate. The portion of the total 
cardiac output distributed to the kidney also declines. 
Characteristically, glomerular filtration declines less 
than the renal blood flow, hence filtration fraction rises. 
Renal blood flow may be further compromised by arrhythmias 
commonly seen in heart failure.823
In experimental heart failure in animals, there is also a 
redistribution of blood flow, with a relative reduction in 
cortical, compared to medullary, flow. This results in a 
diversion of blood to the juxta- medullary nephrons, whose 
loops of Henle and associated vasa recta delve deep into 
the medulla and are responsible for counter-current 
exchange. These mechanisms may be important in maintaining 
sodium-poor, urea-rich urine, characteristic of heart 
failure. Such data as exists suggests that redistribution 
of renal blood flow in favour of the medulla also exists in 
humans, though most studies on renal function have been
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carried out on patients treated with diuretics.824'827 In 
addition to the fall in cardiac output, other factors that 
may affect renal blood flow in heart failure include an 
increase in sympathetic nerve activity,828,829 angiotensin II, 
and atrial natriuretic peptide. Increased sympathetic 
activity could lead to afferent arteriolar constriction and 
a fall in renal blood flow and glomerular filtration. An 
increase in angiotensin II will lead to both afferent and 
efferent arteriolar constriction, with the predominant 
effect on the latter. This will lead to a decline in renal 
blood flow but with a relative preservation of glomerular 
filtration and an increase in filtration fraction.
Atrial natriuretic peptide may increase glomerular 
filtration and renal blood flow, but, like several other 
actions of this peptide, its effects appear to be over­
ridden by other factors.830,831
Angiotensin II may have other intra-renal effects, 
including contraction of the glomerular mesangium, 
alterations in the intra-renal distribution of blood flow, 
and contraction of the vasa recta, which are discussed in 
Chapter 2.
Finally, especially in the context of 
angiotensin-converting enzyme inhibition, that renal blood 
flow and glomerular filtration rate fall steeply as the 
blood pressure falls below the auto- regulatory threshold.
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THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON
RENAL FUNCTION IN HEART FAILURE
On reviewing the literature on the effects of 
angiotensin-converting enzyme inhibitors on renal 
haemodynamics, the picture is somewhat confusing. Perhaps 
this is because of the complex nature of the problem. The 
effects of angiotensin-converting enzyme inhibitors on 
renal function depend on the duration of therapy, on the 
renal perfusion pressure, and on the prior state of 
activation of the renin-angiotensin system. Furthermore, 
angiotensin-converting enzyme inhibitors do not only 
suppress the formation of angiotensin II but also have 
complex effects on other systems.
ACUTE STUDIES ON THE RENAL HAEMODYNAMIC EFFECTS OF 
ANGIOTENSIN CONVERTING ENZYME INHIBITORS
On reviewing the acute studies, Creager et al832 noted an 
increase in renal blood flow 1-2 hours after captopril, no 
change in glomerular filtration rate, and an increase in 
urinary sodium excretion. Similarly, Faxon et al833 reported 
an increase in renal blood flow, 30-90 minutes after 25-100 
mg captopril, while glomerular filtration rate was 
unchanged. A "substantial" natriuresis was reported. Powers 
et al834 reported an increase in renal blood flow 24-48 hours 
after starting captopril, with no change in glomerular 
filtration rate, weight or sodium excretion. In contrast,
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Mujais et al835 noted a fall in renal blood flow 1-2 hours 
after 25 mg captopril; renovascular resistance fell, but 
not sufficient to compensate for the fall in arterial 
pressure. Glomerular filtration rate fell markedly, as did 
filtration fraction and sodium excretion. After one week of 
therapy and during long- term therapy, these effects were 
reversed.
MEDIUM-TERM STUDIES ON THE EFFECTS OF ACE INHIBITORS ON 
RENAL FUNCTION IN HEART FAILURE
On reviewing the medium-term studies (less than 10 days), 
a somewhat different picture emerges. Pierpoint et al836 
noted sodium retention and hyponatraemia developing in the 
first 3 days after starting captopril; glomerular 
filtration rate was unaffected. Kubo et al837 noted a rise 
in renal blood flow one week after initiating captopril 
that was most marked in patients with high baseline plasma 
renin. Infusion of aprotinin, a kallikrein inhibitor, to 
suppress any increase in bradykinin after administration of 
captopril, failed to diminish the increase in blood flow. 
Dzau and Hollenberg838 found an increase in renal blood flow 
and glomerular filtration rate 5 days after starting 
captopril in a group of patients with hyponatraemia. One 
group of patients had diuretics withdrawn for a 5- day 
period and showed similar haemodynamic changes. In those 
patients treated with diuretics and captopril, body weight 
declined and serum sodium concentration increased, while
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those who received captopril alone increased their body 
weight and serum sodium did not change. Packer et al839 also 
observed a correction of hyponatraemia with captopril which 
began 48 hours after starting therapy. However, Nicholls810 
et al reported a fall in serum sodium concentration over 
the first week of therapy in conjunction with a fall in 
urinary sodium excretion, implying inappropriate water 
retention. Fitzpatrick also reported a fall in serum sodium 
concentration and renal sodium retention in the first few 
days of treatment with enalapril, while glomerular 
filtration rate was unchanged.811
Our studies support the view that renal blood flow 
increases, both in absolute amount and as a proportion of 
the total cardiac output in response to the introduction of 
an angiotensin-converting enzyme inhibitor. Glomerular 
filtration rate tends to decline in the first few days of 
treatment with an angiotensin- converting enzyme inhibitor, 
and this is attended by a fall in urinary sodium excretion 
and a reduction in free water clearance and serum sodium 
concentration. Some of these patients developed new 
peripheral oedema. Sodium and water retention were most 
marked during the initial decline in arterial pressure. As 
sodium and water retention progressed, arterial pressure 
increased and a new balance was achieved at an expanded 
blood volume over the following 1-2 weeks.
We also noted a significant increase in weight after one
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week of therapy with enalapril in a double-blind study. One 
patient developed frank worsening of his oedema. This 
subsided without the need to change the dose of diuretics 
over a 2-week period. Other double-blind placebo-controlled 
studies have also noted weight increases, necessitating an 
increase in diuretics on introduction of an
angiotensin-converting enzyme inhibitor.840 It is surprising 
that this problem is not more widely recognised clinically. 
This perhaps reflects the fact that many patients start 
angiotensin- converting enzyme inhibitors at a time when 
diuretic doses are being adjusted for other reasons and 
that symptoms may improve after introduction of an 
angiotensin-converting enzyme inhibitor despite fluid 
retention as long as it is not of a limited extent.
In the short-term studies on enalapril, we examined the 
interaction of diuretics and angiotensin-converting enzyme 
inhibitors on renal function. This demonstrated a 
significant interaction of frusemide and enalapril on renal 
haemodynamics. It is not clear whether other investigators 
have controlled for this effect. Patients with marked falls 
in arterial pressure and patients with pre-renal uraemia 
may behave differently also. Thus, therapeutic interactions 
and differences in the population under study could account 
for the discrepancies in the studies on renal haemodynamics 
mentioned in this section.
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CHRONIC EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITION
ON RENAL HAEMODYNAMICS IN HEART FAILURE
Glomerular Filtration Rate
Apart from our double-blind, placebo-controlled, crossover 
studies, there are only 2 other studies which have 
investigated the long-term effects of angiotensin- 
converting enzyme inhibitors on glomerular filtration rate 
in heart failure.835,841 These open evaluations both showed a 
tendency for glomerular filtration rate to rise with 
sustained treatment. They make no comment as to the timing 
of their studies in relationship to diuretic dose. In 
contrast, in our controlled studies we showed a consistent 
decline in glomerular filtration rate, whether measured by 
isotopic methods, by 24-hour urinary creatinine clearance, 
or by the measurement of serum urea and creatinine.
The cause of the decline in glomerular filtration rate has 
several possible explanations. Firstly, a fall in renal 
perfusion pressure without a change in efferent arteriolar 
tone to maintain glomerular hydrostatic pressure could 
result in a fall in glomerular filtration rate. However, 
the fall in renovascular resistance and a rise in renal 
blood flow suggest this explanation is incomplete. It is 
more likely that a reduction in angiotensin II, with a loss 
of efferent arteriolar tone, would lead to a fall in 
renovascular resistance and glomerular hydrostatic pressure 
together, and this would result in a decline in glomerular
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filtration rate. Angiotensin II also has complex effects on 
the mesangium, but as most of these would appear to 
depress, rather than increase, glomerular filtration rate, 
this also seems an unlikely mechanism for the reduction in 
glomerular filtration rate during ACE inhibition.
Renal Blood Flow
Our studies concur with other studies of the long-term 
effects of angiotensin-converting enzyme inhibitors on 
renal blood flow. Renal blood flow not only rises but the 
proportion of cardiac output distributed to the kidney 
appears to increase.
The rise in renal blood flow with the fall in glomerular 
filtration rate suggests that it was predominantly efferent 
arteriolar tone that was reduced. However, afferent 
arteriolar tone may have been reduced also which would 
account for the beneficial renal haemodynamic effects of 
angiotensin-converting enzyme inhibitors observed in some 
studies of patients with pre-renal uraemia.841
This is consistent also with the finding that the fall in 
renal vascular resistance after an angiotensin- converting 
enzyme inhibitor was inversely related both to the initial 
angiotensin II and the initial plasma noradrenaline 
concentrations.
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Filtration Fraction
Filtration fraction is the ratio of glomerular filtration 
rate to effective renal plasma flow and it is normally 
increased in cardiac failure. Our studies suggest that the 
renal "hallmark" of angiotensin- converting enzyme 
inhibitors is a decline in filtration fraction. However, 
the filtration fraction is complexly related to renal 
perfusion pressure and afferent and efferent arteriolar 
tone. No good relationship was found between other 
variables and the decline in filtration fraction. The 
decline in filtration fraction may represent a haemodynamic 
spectrum, one end being represented by a marked decline in 
glomerular filtration rate, with relatively little change 
in renal blood flow, the other end of the spectrum being a 
maintenance of glomerular filtration rate, with a marked 
rise in renal blood flow. Both patterns were observed in 
our studies, leading to a decline in filtration fraction.
The decline in filtration fraction is likely to reduce the 
oncotic pressure of fluid passing into the proximal renal 
tubules and could reduce proximal tubular salt and water 
reabsorption.
INTERACTION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND
DIURETICS ON RENAL HAEMODYNAMICS IN HEART FAILURE
During the long-term study on enalapril, we noted 
consistent declines in isotopically measured glomerular 
filtration rate which were highly consistent with the 
decline in 24-hour creatinine clearance. Fortunately, at 
the outset of this study we had addressed the question of 
timing of diuretic administration and had decided that all 
patients should be established on a twice-daily diuretic 
dose. Thus, all patients had their renal function assessed 
radio-isotopically in the presence of both an 
angiotensin-converting enzyme inhibitor and diuretic. 
However, in the study on captopril some patients were on 
once-daily and some on twice-daily diuretic regimes, in 
conjunction with 3 times/day captopril. We noted that those 
patients who were on twice-daily diuretic regimes and 
therefore had their renal isotope studies performed during 
concomitant angiotensin-converting enzyme inhibitor and 
diuretic therapy had a much greater decline in glomerular 
filtration rate. Those patients who received an 
angiotensin-converting enzyme inhibitor without additional 
diuretic therapy had relatively little decline in 
glomerular filtration rate. We therefore undertook 
short-term studies on enalapril to investigate this 
further. This confirmed that the decline in glomerular 
filtration rate was much greater when an 
angiotensin-converting enzyme inhibitor and diuretic were
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used concomitantly. The study also suggested that all the 
haemodynamic effects of an angiotensin- converting enzyme 
inhibitor were exaggerated by a diuretic. Thus, the decline 
in mean arterial pressure, total vascular resistance and 
filtration fraction were all greater on the combination, as 
was the rise in cardiac output, renal blood flow, and that 
proportion of the renal blood flow diverted to the kidney.
The decline in glomerular filtration rate may be attributed 
to a fall in angiotensin II-mediated efferent arteriolar 
tone and a further fall in renal perfusion pressure, 
resulting in a fall in glomerular hydrostatic pressure. 
Frusemide also appears to have vasodilator properties, 
perhaps mediated through the prostaglandin systems.842"846 
This study suggests that frusemide may reduce efferent 
arteriolar tone which is normally masked by a rise in 
angiotensin II.
In a study with enalapril, we studied renal haemodynamics 
at baseline, one week after the introduction of drug or 
placebo in a double-blind fashion and then 8 weeks after 
introduction, one week after a change-over to the 
alternative treatment, and again at 8 weeks after the 
change in treatment. We were thus able to examine the 
subacute and chronic effects of angiotensin-converting 
enzyme inhibitors on renal function and the effects of 
withdrawal of this treatment.
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Plasma angiotensin II was equally suppressed during tests 
of renal function after one and 8 weeks of enalapril, 
despite the different doses of the drug. The glomerular 
filtration rate, mean arterial pressure and the filtration 
fraction were less depressed after one week's treatment 
than after 8 weeks' therapy. The rise in renal blood flow 
was similar at one and 8 weeks' treatment.
There are several explanations for these findings. Firstly, 
in our patients, weight increased in the first week after 
treatment. Fluid retention could have supported mean 
arterial pressure, either by expanding blood volume or by 
increasing vascular stiffness. This maintenance of mean 
arterial pressure could have preserved the glomerular 
filtration rate, and enhanced renal blood flow.
Many other possible explanations exist, including time- 
dependent effects on endothelial renin-angiotensin systems 
which we would not be able to detect. However, we know that 
angiotensin-converting enzyme inhibitors have powerful 
effects on sodium and potassium metabolism and a decline in 
vascular wall sodium might occur more slowly, eventually 
leading to a greater vasodilator capacity.
On withdrawing enalapril, which we did in a controlled 
fashion in 10 subjects, we noted that glomerular filtration 
rate returned to normal within one week but mean arterial 
pressure remained reduced and renal blood flow elevated,
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despite plasma angiotensin II concentrations rising to 
pre-treatment levels.
It is possible that endothelial-converting enzyme is 
inhibited for longer periods than circulating levels but 
metabolic changes and changes in vessel wall composition 
are likely to occur over longer periods of time and may 
account for this apparent maintenance of some of 
enalapril's effects.
LONG-TERM EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME 
INHIBITION ON RENAL SODIUM HANDLING IN HEART FAILURE
No significant change in sodium balance occurred over a 6-8 
week period. The technique available should have been able 
to detect changes of more than 100 mmol, even though a 
large amount of sodium is relatively locked in bone matrix. 
As body weight and mean serum sodium concentration were 
unchanged also, this supports the view that no diuresis had 
occurred over the study period.
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INFLUENCE OF CONVERTING ENZYME INHIBITORS ON RENAL TUBULAR
FUNCTION IN CARDIAC FAILURE
Proximal Tubular Function
In salt-replete normal humans during a water diuresis, 
there is evidence that angiotensin II in pressor doses 
increases proximal tubular sodium reabsorption. However, 
captopril had no effect on sodium excretion in these 
subjects.847 Also Ichikawa et al suggested that proximal 
tubular fluid reabsorption is reduced during 
angiotensin-converting enzyme inhibition in rats with heart 
failure induced by left ventricular infarction.848 However, 
these data cannot easily be extrapolated to human subjects 
with heart failure, who are usually on diuretics and in 
whom substantial falls in blood pressure can occur.
I have experimented with lithium clearance methods to 
estimate proximal tubular function in heart failure but my 
initial experience with this method suggested that it was 
unsatisfactory. Firstly, lithium can either suppress or 
enhance renin production.849 Secondly, we found that 
frusemide substantially effected lithium clearance, an 
effect that has been previously noted in sodium-deplete 
normal volunteers.850 Although we have not excluded the 
possibility that frusemide itself has an effect on proximal 
tubular function, this is not consistent with the present 
theories of frusemide's action on the renal tubule.
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Phosphate clearance methods have been advocated as measures 
of proximal tubular re-absorptive851 and we have
demonstrated that in patients with heart failure frusemide 
has little effect on phosphate clearance. We examined the 
effects of one week of therapy with a converting enzyme 
inhibitor on phosphate clearance in patients with cardiac 
failure. The amount of phosphate found in the urine was 
expressed as a percentage of that filtered at the 
glomerulus, based on creatinine clearance, and this was 
used as an index of proximal tubular reabsorption. On 
introduction of an angiotensin-converting enzyme inhibitor 
to chronically diuresed patients, we noted, in conjunction 
with the reduction in urine volumes and sodium 
concentration, an increase in proximal tubular 
reabsorption. Thus, early sodium retention in response to 
a converting enzyme inhibitor appears to be due to 
increased proximal tubular sodium reabsorption, perhaps 
associated with an acute decline in glomerular filtration 
rate and therefore the amount of sodium filtered at the 
glomerulus. As blood pressure is restored, glomerular 
filtration rate and proximal tubular reabsorption will tend 
to return to baseline levels. The reasons for the increase 
in proximal tubular reabsorption are not clear. Very high 
levels of angiotensin II (probably higher than levels found 
even in severe heart failure) can cause a natriuresis, 
reduction of which could promote sodium reabsorption. Lower 
concentrations of angiotensin II appear to cause sodium 
retention and this reduction should enhance sodium
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excretion.847 A decline in filtration fraction and 
sympathetic activity would be expected to increase sodium 
excretion also. However, other mechanisms, such as the fall 
in arterial pressure and atrial natriuretic peptide, may 
overcome the above. Although a decline in plasma 
noradrenaline was observed reflecting overall sympathetic 
activity, it is possible that renal sympathetic activity 
increased in response to the fall in arterial pressure. An 
increase in renal sympathetic activity could have caused 
renal sodium retention. However, when prazosin and 
captopril are used in combination, renal sodium retention 
is not prevented. 857
The mechanism of action by which atrial natriuretic peptide 
induces natriuresis is yet to be fully elucidated. It may 
inhibit the sodium-retaining effects of angiotensin II on 
the proximal tubule852,853 and may directly reduce proximal 
tubular reabsorption854, and certainly appears to have 
effects on the collecting duct.855,856
Distal Tubular Function
Aldosterone has powerful effects on sodium/potassium 
exchange in the distal tubule. The acute suppression of 
angiotensin II causes a marked fall in aldosterone. 
Suppression of aldosterone cannot have an over-riding 
effect on tubular sodium handling at the onset of 
angiotensin-converting enzyme inhibition. It may take
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several days for the renal effects of an elevated 
aldosterone to wane. Though urinary potassium excretion 
declines abruptly after starting an angiotensin- converting 
enzyme inhibitor, so too does urinary sodium, therefore 
this may not be mediated by aldosterone. During long-term 
therapy with converting enzyme inhibitors, potassium rises 
due to the chronic suppression of aldosterone secretion. 
This in turn leads to some stimulation of aldosterone 
production which serves to limit the extent of potassium 
retention. Suppression of aldosterone probably limits the 
extent of sodium retention, and may have an important role 
in reversing initial fluid retention.
EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITION ON 
RENAL DIGOXIN HANDLING
Serum digoxin rose during long-term treatment with 
captopril. Possibly due to the accompanying rise in serum 
potassium and the rather low initial serum levels of 
digoxin, no serious consequences were found in association 
with this problem.
In an open study on 12 patients, we specifically examined 
urea, digoxin and creatinine clearance before and one month 
after captopril in patients with treated heart failure. 
Although all 3 declined, urea and digoxin clearance 
declined more than creatinine clearance. Fractional
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excretion of urea and digoxin filtered at the glomerulus 
therefore declined, indicating greater tubular reabsorption 
or reduced tubular secretion of these compounds during 
treatment with captopril in patients with heart failure.
EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON THE 
DISTRIBUTION OF INTRA-RENAL BLOOD FLOW IN PATIENTS WITH 
CARDIAC FAILURE
A gradient exists from outer cortex to inner cortex, with 
the filtration rate of the outer cortical nephrons being 
lower than that of the middle and deep cortical nephrons in 
both the rat and the dog. Redistribution of renal blood 
flow from the outer renal cortex to juxta- medullary 
nephrons may be a further important haemodynamic change 
occurring in heart failure leading to sodium retention. 
These functional changes are accompanied by a rise in renin 
content in the kidney which is relatively greater in the 
juxta-medullary nephrons. There is some evidence that 
captopril may reverse these haemodynamic abnormalities.
The deep cortical nephrons may be less responsive to 
changes in sodium balance. The superficial nephrons appear 
to have a greater ability to increase sodium excretion, 
whereas the deeper nephrons have a greater capability for 
sodium retention.
No information is available in human subjects with heart
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failure but in humans with hypertension and in experiments 
on rats, captopril, like frusemide, appears to correct the 
maldistribution of renal blood flow, diverting more blood 
to the outer renal cortex.
Angiotensin II, either by its effects on the efferent 
arteriole or by direct effects, may slow blood flow through 
the vasa-recta which descend deep into the renal medulla. 
Initially, this slowing of blood flow through the vasa- 
recta will enhance counter-current exchange mechanisms, 
maintaining urea excretion despite the fall in glomerular 
clearance. More marked increases in angiotensin II will 
lead to afferent arteriolar constriction and a more 
profound reduction in medullary blood flow. Uraemia may 
then occur.
SUMMARY
The effects of angiotensin-converting enzyme inhibitors on 
renal function are complex. They cannot be viewed as 
entirely beneficial. In the early stages of heart failure, 
angiotensin II may be useful in maintaining glomerular 
filtration rate and urea excretion. Even in more profound 
heart failure the acute effects of angiotensin-converting 
enzyme inhibitors on renal function seem more deleterious 
than beneficial, sodium retention and an acute decline in 
glomerular filtration being prominent effects. However, in 
the longer term, despite a continuing slight reduction in
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glomerular filtration, angiotensin-converting enzyme 
inhibitors do appear to enhance renal sodium excretion. The 
importance, if any, of the increase in renal blood flow and 
changes in intra-renal blood flow distribution have yet to 
be determined. The medium-to-long-term effects of
angiotensin-converting enzyme inhibitors on the kidney 
appear to be fairly neutral. In the setting of
vasodilatation, this "neutral" role of the kidney in sodium 
homeostasis after angiotensin-converting enzyme inhibition 
may be important.
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CHAPTER 26s AUTONOMIC FUNCTION IN HEART FAILURES THE 
EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITION
Although the primary defect in the syndrome of heart 
failure is pump malfunction, the consequences of this 
defect leads to dysfunction in many other body systems. 
Indeed, it is probably essential for the evolution of heart 
failure that the vascular resistance is raised and that the 
blood flow to the kidney and skeletal muscle is depressed. 
This increase in vascular resistance is mediated not only 
by hormones such as angiotensin II, but also by the 
autonomic nervous system. However, neither can be 
considered in isolation. The sympathetic nervous system may 
not only stimulate the release of renin but angiotensin II 
may have vagolytic effects and modulate sympathetic 
activity. Angiotensin II and the sympathetic nervous system 
may have powerful interactive roles, especially on the 
venous systems. 254»259
AUTONOMIC DYSFUNCTION IN HEART FAILURE
The pattern of autonomic dysfunction in heart failure is 
well characterised. Parasympathetic tone is reduced in 
patients with heart failure, while sympathetic activity, 
under resting conditions, is increased.858-863 This autonomic 
imbalance may account for some of the characteristic 
features of heart failure such as tachycardia and 
arrhythmias, in addition to the increase in vascular tone.
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Although basal sympathetic activity is increased in heart 
failure, sympathetic reflexes are characteristically 
blunted. For example, although resting heart rate is 
increased, heart rate does not increase on standing.864
The stimulus to increased sympathetic activity in heart 
failure is derived probably from high pressure 
baroreceptors that sense a relative reduction in arterial 
pressure or, at least, arterial wall tension.865 Very high 
levels of sympathetic activity may be observed in pulmonary 
oedema but may be related more to stress and anxiety than 
to ventricular filling pressure.866 However, stimulation of 
atrial stretch receptors can depress renal efferent 
sympathetic nerve activity.73,78 In heart failure, reduced 
atrial compliance and morphological changes in the 
receptors themselves lead to reduced sensitivity.867'869 Thus, 
a reduction in tonic inhibition of sympathetic nerve 
activity may be lost in heart failure. Finally, angiotensin 
II may have a facilitatory role on sympathetic nerve 
activity.254,259 The reasons for the defect in sympathetic 
reflex responsiveness in heart failure are complex. The 
number of cardiac neurones may be reduced in patients with 
idiopathic cardiomyopathy and with Chaga's disease.870 These 
abnormalities are probably fixed and unlikely to be 
restored by any therapeutic manoeuvre. Sympathetic nerve 
terminals within the heart are also abnormal, with evidence 
for defects in noradrenaline synthesis and turnover.426,427
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Finally, down-regulation or uncoupling of adreno-receptors 
may reduce end-organ responses.430'432
The increase in sympathetic activity may have other 
important effects on the cardiovascular system. Excessive 
sympathetic tone may cause further myocardial damage. Some 
authors advocate the use of beta-receptor blocking agents 
for the management of ischaemic and non- ischaemic 
cardiomyopathy, suggesting direct beneficial myocardial 
effects. Beta-blockers could also reduce plasma renin.80 
Less is known of the origin of parasympathetic dysfunction 
in heart failure. Angiotensin II has vagolytic effects,294'298 
while digoxin is a parasympathomimetic871'876 Resting 
parasympathetic tone appears to be low, while the increase 
in heart rate in response to atropine is reduced, as is the 
bradycardia in response to an increase in blood pressure. 
860 This apparent loss of parasympathetic reflux response 
could be due to an actual or functional loss of cardiac 
innervation or autonomic defect in end-organ response. 
However, animal models of heart failure suggest that the 
sinoatrial node reacts normally to direct stimulation of 
the vagus nerves, suggesting that the efferent limb of the 
reflex is not impaired. 877 This suggests there must be a 
mechanism which interferes with the afferent and/or central 
modulation of parasympathetic activity.
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TESTS REFLECTING PARASYMPATHETIC ACTIVITY
Normally, the heart rate varies continuously. This depends 
upon an intact parasympathetic nerve supply and therefore 
this beat-to-beat variation can be abolished by atropine 
but is uninfluenced by propranolol. (See Methods) Heart 
rate variability on ambulatory monitoring is reduced in 
patients with heart failure.878 Deep breathing at 6 
breaths/minute is a convenient and reproducible technique, 
deep inspiration resulting in an increase in heart rate. 
The heart rate variation is exaggerated by deep breathing, 
presumably due to more pronounced variations in venous 
return and inactivation of cardiopulmonary reflexes in 
response to larger changes in intra-thoracic pressure. In 
heart failure, where venous and intra-cardiac pressures are 
elevated, this effect is diminished. Consequently, 
autonomic reduction of the STIMULUS to variations in 
parasympathetic tone, rather than autonomic defect in 
detection or transduction of the signal, could explain this 
abnormality in heart failure.
During the strain period of the Valsalva manoeuvre, the 
blood pressure drops and the heart rate rises as venous 
return to the heart is impeded. Peripheral arterial 
constriction occurs in response to the fall in blood 
pressure. After release, the blood pressure rises, 
overshooting its resting value as cardiac output increases 
against the raised peripheral resistance; the heart slows. 
Again, the heart rate responses can be blocked by atropine,
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but not by propranolol. (See Methods) In heart failure, 
cardiac output and blood pressure are maintained during the 
Valsalva manoeuvre as venous return does not decline. No 
overshoot of blood pressure nor fall in heart rate occurs 
on release of strain. This failure of parasympathetically 
mediated slowing of the heart rate could be due primarily 
to autonomic nervous system reflex dysfunction, but the 
lack of blood pressure overshoot means there is no primary 
parasympathetic stimulus in heart failure anyway.
During the change from lying to standing, a rapid increase 
in heart rate occurs, which is maximal about the 15th beat 
after standing, a relative overshoot bradycardia then 
occurs, maximal about the 30th beat. This response is also 
mediated by the vagus nerve. This test is dependent upon 
changes in venous return, a relative maintenance of which 
during the upright posture may account for the abnormality 
in heart failure.
Using the tests employed, it is difficult to say whether 
the defects in parasympathetic reflexes are due to an 
intrinsic defect in the reflex arc or are due to a 
reduction in the afferent stimuli due to changes in venous 
haemodynamics. However, other studies have demonstrated a 
reduced heart rate response to atropine in subjects with 
heart failure due to idiopathic dilated cardiomyopathy. As 
resting parasympathetic tone is reduce in heart failure, 
one might expect that the change in heart rate after
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atropine should be reduced, but not the absolute level 
achieved. This suggests that other factors such as 
defective sinus node function, reduced sensitivity to the 
prevailing sympathetic tone, or the pharmacological effects 
of digoxin, may play a role. Indeed, all our subjects were 
on digoxin.
Reduced parasympathetic control of heart rate may be 
important. Several investigators have suggested that loss 
of heart rate variability, a sign of reduced 
parasympathetic activity, may herald serious ventricular 
arrhythmias.879 Also, diabetic patients with autonomic 
dysfunction appear to have a higher risk of sudden death.880
TESTS REFLECTING SYMPATHETIC NERVOUS DYSFUNCTION: 
COMPARISON OF NORMAL SUBJECTS WITH PATIENTS WITH HEART 
FAILURE
Basal sympathetic nervous activity in heart failure is 
probably increased, as noted above. Sympathetic nervous 
activity may be further excited by the rise in angiotensin 
II, and by further contractions in plasma volume as a 
result of diuretic therapy.
We observed a significant increase in plasma noradrenaline 
after the administration of diuretic in patients with heart 
failure, and although we have no direct comparative 
information, other studies have shown this to be true in 
patients with hypertension given intravenous frusemide.881
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On standing, venous pooling of blood causes a fall in blood 
pressure, which is normally rapidly corrected by venous and 
arterial constriction. The heart rate is also increased 
after 2 minutes of standing. These responses are largely 
dependent upon an intact sympathetic nervous system and are 
accompanied by an increase in plasma noradrenaline. Our 
results confirm these findings. In heart failure, the rise 
in heart rate and plasma noradrenaline on standing are 
blunted. This is probably due to a lack of venous
compliance which prevents peripheral pooling of blood. 
Thus, cardiac output does not appear to fall on standing in 
patients with heart failure, while some have reported an
increase in cardiac output associated with a fall in
systemic vascular resistance. 882*883
Although studies of autonomic reflexes in cardiac failure 
are of some interest, as the heart, the target organ for 
the disease under study, is the major determinant of the 
reflex, the results must be interpreted with a great deal 
of caution. Again, it is difficult to distinguish to what 
extent abnormal reflexes are due to cardiac malfunction and 
what are due to intrinsic alterations in sympathetic
activity.
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EFFECTS OF ENALAPRIL THERAPY
Tests of autonomic function in normal subjects, salt- 
replete and -deplete, have failed to reveal an effect of 
ACE inhibitors on sympathetic reflexes,884,885 but do suggest 
an effect on parasympathetic autonomic reflexes. In 
contrast, one study in subjects with heart failure 
suggested the reverse.589 However, this study was not 
placebo-controlled and improvements in the response to the 
Valsalva manoeuvre did occur, although the author dismissed 
them.
During long-term therapy with enalapril, basal supine heart 
rate was reduced, most probably due to a reduction in 
sympathetic drive, as suggested by the decline in plasma 
noradrenaline, although an increase in parasympathetic tone 
may also have occurred. The increase in supine heart rate 
and plasma noradrenaline that occurred later in the day, 
after diuretics, was also inhibited by enalapril.
However, on standing, systolic blood pressure fell more on 
enalapril compared to placebo, and this was accompanied by 
a significantly greater increase in heart rate and plasma 
noradrenaline on assumption of the upright posture. The 
changes in heart rate and plasma noradrenaline on standing 
during long-term enalapril therapy were similar to those in 
normal controls. Though this may suggest a return of 
autonomic function to normal, it could also indicate that 
a greater stimulus to sympathetic afferents occurred after
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enalapril therapy. Sequestration of blood in the 
peripheral veins and consequently a greater fall in blood 
pressure could have contributed to the "improvement" in 
this sympathetic reflex after treatment with enalapril. 
Additionally, a greater fall in atrial pressure could 
activate renal sympathetic efferents.
The heart rate and blood pressure response to isometric 
exercise and cold pressor testing were unchanged by 
enalapril.
Systolic blood pressure was reduced at all levels of 
exercise during enalapril therapy. Heart rate, measured at 
the same stage of exercise, was lower during enalapril 
therapy, though the peak exercise heart rate was slightly 
faster. Plasma noradrenaline measured at the end of 
exercise was not changed by enalapril therapy. It is 
difficult to interpret these observations as patients 
exercised significantly longer on enalapril. A reduction in 
heart rate or sympathetic activity measured at the same 
stage of exercise could therefore be appropriate to the 
percentage of maximal exercise capacity rather than be due 
to a reduced sympathetic responsiveness. Thus, we were not 
able to confirm reduced sympathetic activation during 
exercise as has been suggested by others.886 Other 
investigators have studied cardiac sympathetic activity by 
measuring coronary sinus catecholamine levels and the 
transmyocardial (coronary) changes both at rest and during
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exercise.887 These studies are in agreement that, at rest and 
during exercise, long-term treatment with an ACE inhibitor 
reduces cardiac sympathetic activity. However, it is 
possible that ACE inhibitors increase renal sympathetic 
activity during exercise and that renal excretion of 
catecholamines is also reduced.
However, although we were not able to demonstrate any 
differences in plasma noradrenaline immediately after 
exercise, plasma noradrenaline did seem to fall more 
rapidly after exercise in patients treated with enalapril. 
This parallels the changes found in normal subjects and is 
contrasted with the sustained high levels of plasma 
noradrenaline seen in patients with heart failure not 
receiving an ACE inhibitor.
Therefore, although resting sympathetic activity appeared 
to be reduced during treatment with enalapril, the 
improvements noted in some sympathetic reflexes must be 
interpreted with caution.
Tests of parasympathetic function were generally improved 
by long-term therapy with enalapril in patients with heart 
failure. A sudden increase in parasympathetic tone due to 
a loss of the vagolytic action of angiotensin II may also 
be responsible for the sudden fall in heart rate seen 
during hypotension after the first dose of an ACE 
inhibitor. There are several possible explanations for
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these effects on sympathetic and parasympathetic function:
1) Angiotensin II might itself cause the derangement in 
parasympathetic and sympathetic functions seen in heart 
failure. Angiotensin II is known to inhibit parasympathetic 
activity and also facilitate cardiac sympathetic 
noradrenaline release. Chronically elevated sympathetic 
activity may cause adrenergic receptor down-regulation or 
uncoupling. Angiotensin II could then give rise to the 
picture of elevated basal sympathetic activity, but reduced 
sympathetic responsiveness.
Angiotensin-converting enzyme inhibitors, by suppressing 
angiotensin II, could also increase parasympathetic tone. 
There is considerable evidence that this is the case in 
animal experimental models.
A decrease in angiotensin II might lead to a fall in basal 
sympathetic activity and thus to up-regulation of 
adrenergic receptor sensitivity. A reduction in angiotensin 
II might conserve cardiac stores of noradrenaline also. 
Thus, a reduction in angiotensin II could lead to reduced 
basal activity but an increased response to physiological 
stress. This is probably highly desirable.
2) An improvement in autonomic function may have been a 
non-specific response to the improvement in heart failure. 
For instance, an increase in cardiac vagal afferent
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activity mediated by ventricular baroreceptors may result 
from a reduction in diastolic filling pressures.72,73 Changes 
in contractile force and ventricular compliance may also 
affect autonomic function.
3) The improvement in the tests might reflect effects upon 
the arterial system. Changes in arterial wall tension 
rather than the pressure itself may be the primary stimulus 
to baroreflexes as arterial wall tension is directly 
proportional to the pressure and the radius of the artery. 
Therefore, if blood pressure falls and the artery dilates, 
transmural wall tension may be unchanged; a dilated, more 
compliant, arterial system may then reduce the stimulus of 
a fall in blood pressure to the baroreceptors. We have only 
examined autonomic reflexes during chronic angiotensin 
converting enzyme inhibition. Changes in vascular wall 
composition may occur during long-term treatment which 
could have profound implications for activation of the 
sympathetic nervous system and ultimately renal sodium 
handling.
4) Increased venous compliance could have increased the 
stimulus to the afferent limb in those tests in which 
peripheral pooling of blood provides the stimulus to the 
cardio-pulmonary receptors. The effects of upright posture, 
Valsalva manoeuvre, and deep breathing in particular could 
be affected by this mechanism.
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5) There may be changes in the baroreceptor or efferent 
organs themselves.
6) Digoxin is known to stimulate parasympathetic activity, 
which may have been unmasked by suppression of angiotensin 
II. Digoxin may have other effects on patients with heart 
failure, including a reduction in plasma renin, direct 
vasoconstriction, direct sensitisation of baroreceptors, 
and indirect sensitisation of ventricular baroreceptors by 
digoxin's positive inotropic effects.873 However, as digoxin 
therapy was unchanged throughout this study and the 
increase in serum digoxin small during enalapril therapy, 
it is unlikely that any of the above could be relevant to 
the changes observed during chronic enalapril therapy.
EFFECTS OF ENALAPRIL ON QTC
The baseline QT interval was prolonged in those patients 
with heart failure; approximately 80 milliseconds greater 
than in the control group. The underlying myocardial 
disease, alterations in the balance of cardiac sympathetic 
tone, and reduced serum potassium could have accounted for 
this. The one patient who was on amiodarone was excluded 
from this part of the study but did have a markedly 
prolonged QT interval. A large component of the QT 
prolongation was due to an increase in the QRS width, 
though only one patient had complete left bundle branch 
block. This was corrected for by subtracting the QRS width
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from the QT interval to give the JT interval. The JT 
interval was found also to be greater than the mean value 
for normal subjects. Though enalapril did not alter the 
uncorrected QT interval significantly, heart rate fell 
during treatment with enalapril, leading to a reduction in 
QTc. This was due to a reduction in the JTc interval rather 
than an alteration in QRS width. This shortening of QTc may 
have been due to the reduction in cardiac volumes, changes 
in autonomic tone, and the rise in serum potassium. The 
implications of this will be discussed further on in the 
section on arrhythmias.
SUMMARY
In summary, changes in most sympathetic and parasympathetic 
reflexes are observed during chronic converting enzyme 
inhibition. In general, these reflexes are improved, 
resembling more closely responses seen in normal subjects. 
However, it is difficult to be certain that these changes 
represent a restoration of normal physiology. Many, if not 
all, of the improvements could represent a pharmacological 
response to vasodilator therapy.
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CHAPTER 27: SYMPTOMS
Over the last 5 years angiotensin-converting enzyme 
inhibitors have evolved from a promising therapeutic 
intervention into an established treatment for heart 
failure. The series of experiments in this thesis reflects 
the progress in our understanding of heart failure, the 
renin-angiotensin system, and of the use of converting 
enzyme inhibitors over this period. While many questions 
regarding the use of angiotensin- converting enzyme 
inhibitors in heart failure have been answered, I believe 
we have still only a crude understanding of their 
mechanisms of action and their optimal use.
SYMPTOMS IN HEART FAILURE
The mechanism(s) of the induction of symptoms in heart 
failure is/are incompletely understood. Exercise 
performance relates poorly to resting, peak exercise, or 
the change in atrial pressures in patients with heart 
failure.888,889 The same is true of left ventricular ejection 
fraction, while initial reports of a relationship between 
right ventricular ejection fraction and exercise duration 
have not been confirmed.890'892 Exercise cardiac output does 
correlate fairly well with exercise duration889,889 but a 
causal relationship has not been demonstrated. The peak 
achieved cardiac output could reflect the output required 
for that level of exercise, the patient stopping for 
reasons unrelated to cardiac output itself. It is clear
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that many patients with heart failure stop exercising 
before respiratory indices such as the "anaerobic" 
threshold and the "V02 Max" have been reached, suggesting 
that maximum cardiac performance has not been achieved. 
Certainly, breathlessness in chronic cardiac failure seems 
poorly related to most measurements of cardiac 
haemodynamics, either at rest or during exercise.
However, the possibility of a disorder of cardio- pulmonary 
haemodynamics being the root cause of breathlessness should 
not be rejected too easily. The duration of heart failure 
and the relative change of haemodynamic variables from rest 
to exercise must play some role in the induction of 
symptoms. For instance, the patient with previously normal 
left ventricular function developing a large myocardial 
infarction, with a rise in left ventricular filling 
pressures, might very well develop pulmonary oedema, with 
a left atrial pressure of 20-25 mm Hg. Patients with heart 
failure often tolerate left atrial pressures of 30-40 mm Hg 
without evidence of pulmonary oedema. Changes in pulmonary 
capillary permeability, the quality of the interstitial 
pulmonary tissues, and changes in pulmonary lymphatic 
drainage, may all operate to the patient's advantage in 
heart failure, at least at rest. Patients may develop these 
protective mechanisms to differing degrees. This is 
exceedingly difficult to take into account in haemodynamic 
studies.
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During exercise, a rise in circulating lactate occurs at 
much lower workloads than in normal subjects.893,894 This 
tendency to produce a metabolic acidosis may lead to an 
increase in ventilation which in turn will reduce arterial 
carbon dioxide tensions (pC02) and return hydrogen ion 
concentration towards normal.895 A change in the relationship 
between exercise workload and ventilation could then lead 
to the sensation of breathlessness. This must only be part 
of the story as at maximal exertion ventilation and blood 
lactate levels are far higher in normal subjects than in 
patients with heart failure.896 Moreover, some authors have 
failed to find a fall in arterial pC02 despite a relative 
increase in ventilation in patients with heart failure, 
which suggests that there may be an increase in the 
physiological dead-space due to ventilation/perfusion 
mis-match in such patients.896
A pulmonary rather than a cardiac abnormality could be the 
underlying cause of symptoms in heart failure. Firstly, 
despite an increase in ventilation which should raise 
end-tidal and alveolar oxygen tensions, arterial oxygen 
tension p02 remains constant in patients with heart 
failure.890,897 This implies a widening of the 
alveolar-arterial oxygen gradient, and the possibility of 
a pulmonary diffusion block. Opinions are divided as to 
whether a fall in arterial pC02 occurs.890,898 If one accepts 
that pC02 falls during exercise in heart failure then this 
implies that a diffusion block to oxygen or
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ventilation-perfusion mis-match exists. If one accepts the 
evidence that pC02 is unaltered, then a diffusion block is 
likely. Any obstruction to diffusion would have to be 
moderately severe as the transit rate of blood through the 
pulmonary capillaries is likely to be reduced in heart 
failure. Extravasation of fluid due to a change in 
capillary pressure, a change in capillary permeability, 
reduced lymphatic clearance and possibly chronic changes 
which lead to thickening of the tissue barrier between the 
alveoli and the capillary blood will reduce the diffusing 
capacity for oxygen. Another potential pulmonary mechanism 
related to breathlessness and exertion in heart failure is 
an increase in airways resistance.899,900 Bronchial 
hyper-responsiveness to the inhalation of methacholine, a 
muscarinic receptor agonist, in patients with heart failure 
has been documented. The reasons for this response are 
unclear but an increase in bronchial mucosal blood flow 
caused by methacholine may increase the thickness of the 
bronchial wall and reduce bronchial calibre. Alternatively, 
a chronic reduction in vagal activity could lead to 
receptor super-sensitivity. The effects of methacholine can 
be reversed by inhalation of methoxamine but not by 
optimising diuretic therapy.900 Interestingly, hypocapnia is 
a broncho-constricting stimulus which is thought to be 
mediated through muscarinic receptors.901 Alterations in lung 
"stiffness" could also contribute to symptoms of 
breathlessness by activating juxta-pulmonary capillary 
receptors.902 However, decreased lung compliance does not
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correlate with the degree of breathlessness.903,904
Of course, many patients are limited by symptoms other than 
breathlessness during exercise, predominant among these is 
fatigue. Though skeletal muscle blood flow is impaired at 
rest in more severe cases of heart failure, it is reduced 
during exercise.905,906 Femoral vein oxygen saturations are 
reduced to very low levels, and this seems to correlate 
with fatigue. This suggests that an inadequate blood supply 
to exercising muscle may be the origin of fatigue and the 
limiting factor for exercise. A reduced oxygen supply will 
lead to tissue hypoxia, acidosis, local lactate 
accumulation, and a depletion of high-energy 
phosphates.907,908,910 As skeletal muscle blood flow is 
dependent on the cardiac output, this may be the reason why 
cardiac output, minute oxygen consumption, and exercise 
performance, are related. Relative regional vascular 
resistance must also govern what proportion of the cardiac 
output supplies skeletal muscle. However, some relative 
increase in limb vascular tone is probably necessary in 
heart failure to prevent exertional hypotension, with a 
consequent fall in cerebral perfusion and syncope. A 
reduction in limb vascular tone may also be undesirable if 
it is not diverted to exercising muscle. This appears to be 
a problem with some vasodilator agents.911
Another probable contributory factor to the symptoms of 
heart failure is that most patients are not only unhealthy
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but also unfit. Training programmes can improve patients' 
exercise performance and improve symptoms of fatigue and 
breathlessness.912,913 Interestingly, peak exercise cardiac 
output increases after a period of training, again 
suggesting that it is not cardiac output per se that is 
limiting exercise in heart failure. Changes in skeletal 
muscle metabolism and perhaps vascular tone induced by the 
relative immobility of the patient may make a major 
contribution to exercise performance.
Finally, the problem which probably confounds success in 
discovering the origin of symptoms in heart failure more 
than any other is the relationship between the type of 
exertion and symptoms. Exercise that requires bursts of 
exertion at high workload are commonly terminated by 
breathlessness, while those that involved prolonged low- 
level exertion are terminated by fatigue.914 Measurement of 
gas exchange during a short period of high-level stress 
demonstrates that the patient makes a maximal 
cardio-respiratory effort. In contrast, during protocols 
which involve much slower increases in speed and incline, 
many patients do not achieve maximal cardio-respiratory 
stress or cross the so-called anaerobic threshold. Of 
course, what is low-level exercise for some patients with 
heart failure represents a maximum effort for others. Most 
studies suffer from studying patients using only one 
exercise protocol. Inevitably, the same protocol requires 
different forms of exertion for different patients.
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Thus, from studies on respiratory gas exchange, there does 
appear to be a closer relationship between breathlessness 
and maximal cardiac stress when compared with the symptom 
of fatigue. Though there is little information in this 
area, it is likely that changes in fatigue are most closely 
associated with changes in the peripheral circulation and 
skeletal muscle metabolism. In particular, changes in 
skeletal muscle potassium and energy stores in the form of 
ATP and ADP.908,909
THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN 
PATIENTS WITH HEART FAILURE
We have confined ourselves to the study of more severely 
symptomatic patients with heart failure. Studies in milder 
degrees of heart failure have also been encouraging,915 
though the use of converting enzyme inhibitors without 
diuretics in heart failure remains highly 
controversial.916,917 In our studies, breathlessness was the 
symptom most consistently improved.
As demonstrated by ourselves in an acute study, and by 
others in long-term studies,918 converting enzyme inhibitors 
favourably affect cardiac haemodynamics in heart failure, 
increasing cardiac output and reducing left ventricular 
filling pressure. However, symptoms may not improve for
306
several months after instituting an ACE inhibitor, and 
certainly appear to continue to improve with time.919,920 In 
contrast, there is relatively little difference between the 
acute and chronic haemodynamic effects of ACE inhibitors in 
the majority of patients.918 Therefore, central haemodynamic 
changes alone fail to explain the reduction in 
breathlessness with ACE inhibitors.
A potential beneficial effect of ACE inhibitors upon 
ventilation/perfusion mis-match or bronchial hyper­
reactivity has not yet been observed, though neither has it 
been specifically investigated as far as I am aware. 
Angiotensin-converting enzyme inhibitors can have pulmonary 
effects such as cough. Using the capsacein test this can be 
observed in up to 15% of cases.921 However, no relationship 
between cough sensitivity and beneficial effect has been 
noted.
The effects of angiotensin-converting enzyme inhibitors on 
skeletal muscle blood flow during exercise are subject to 
controversy.922'925 Some have observed no effect, others an 
improvement. Some suggest that an increase in skeletal 
muscle blood flow is only observed in those who improve and 
that the relationship is causal. However, this line of 
argument is not tenable. Skeletal muscle blood flow could 
have been higher because the patient exercised for longer.
307
It is likely that "training" effects are important in the 
genesis of the beneficial effects of ACE inhibitors. The 
restriction in activity enforced by the patient's 
breathlessness must have a "detraining" effect, as with any 
sedentary life-style. This is reflected in evidence of 
impaired muscle strength and impaired muscle metabolism in 
cardiac failure.926 Improvements in peripheral muscle 
metabolism have been noted after starting patients with 
heart failure on captopril. However, the mechanism which 
allows the patient to "retrain" while receiving an ACE 
inhibitor is unknown. Perhaps minor improvements induced by 
central or peripheral haemodynamic effects allow the 
patient to tolerate more exercise, setting up a beneficial 
spiral. Another possible mechanism of improvement in 
patients with heart failure is the induction of a 
natriuresis by the ACE inhibitor. Cowley et al have shown 
that increasing the diuretic is as effective in improving 
symptoms and exercise performance as adding an ACE 
inhibitor.927 The effects of studying long-term sodium 
metabolism are, of course, exceedingly difficult. However, 
using in-vivo activation analysis, we were unable to 
demonstrate any negative sodium balance in the first 6-8 
weeks after starting an ACE inhibitor, although a 
beneficial effect on the sodium/potassium ratio was 
observed. In contrast, in the first week after starting a 
converting enzyme inhibitor, if diuretics were left 
unchanged, sodium balance is positive. Milder degrees of 
sodium retention during addition of an ACE inhibitor appear
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compatible with simultaneous clinical improvement. However, 
more severe degrees of sodium retention may lead to 
clinical deterioration in the patient's heart failure, with 
increasing ankle swelling, breathless, and fatigue.
Finally, a psychological effect of ACE inhibitors leading 
to an increase in physical activity and a secondary 
training effect has not been excluded.928 This would be 
difficult to do in patients with heart failure. An 
improvement in symptoms is at least as likely to improve 
psychological well-being as the converse. Studies in 
hypertension have shown improvements in psychological 
status during treatment with ACE inhibitors.929 Much, if not 
all, of this effect may be due to withdrawal of other 
therapies such as beta-blockers. However, it is possible 
that diuretics have subtle effects on the psyche and that 
these may be ameliorated by ACE inhibitors.
Ankle swelling was not a prominent feature in the patients 
in our studies. In patients who were already severely 
symptomatic, it was felt unethical not to try and optimise 
their diuretic dose. It was unlikely that we would observe 
any improvement in ankle swelling in these studies, and, 
indeed, this proved to be the case, though a certain number 
of patients did show temporary increases in ankle swelling.
Not all studies have confirmed an improvement in symptoms
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in patients with heart failure treated with converting 
enzyme inhibitors.930,931 Of course, some differences are to 
be expected due to random sampling, but, of note, our study 
in patients who had heart failure and angina and one 
further study which specifically studied patients with 
ischaemic heart disease, failed to show symptomatic 
benefit. In our study, we demonstrated deterioration in the 
symptom of angina. This was associated with a failure of 
exercise performance to improve. Breathlessness and fatigue 
were also unchanged. It is probable that resting 
haemodynamics were improved in these patients but exercise 
haemodynamics may well have been unchanged due to the 
further impairment of left ventricular function due to 
myocardial ischaemia. One of the implications from the 
study on angina is that changes in exercise haemodynamics 
and metabolism may be more important than those at rest.
In summary, the origin of symptoms in heart failure and the 
reason for the beneficial effects of ACE inhibitors on 
exercise are probably multi-factorial. Major methodological 
problems in the assessment of symptoms have retarded 
progress to date.
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CHAPTER 28: EXERCISE PERFORMANCE
In two separate double-blind placebo-controlled studies, I 
have demonstrated that ACE inhibitors improve the exercise 
performance of patients with congestive heart failure. This 
concurs with other studies which incorporated larger number 
of subjects but used a single-leg design.932 Using a 
cross-over design, as in our studies, not only are the 
number of comparisons per patient doubled but, as the 
patient is compared with him/herself, inter-individual 
variability is reduced. Thus, it is likely that a 
cross-over study design has several times the power of a 
single-leg study to demonstrate differences in patients 
with heart failure. The syndrome called heart failure 
varies markedly from patient to patient in terms of the 
pattern and inter- relationships of symptoms, signs, and 
central and peripheral haemodynamics. Therefore, a 
cross-over study design may considerably enhance the 
ability to detect clinically important differences in this 
heterogenous population. A further problem with large scale 
studies designed to test for improvement in symptoms and 
exercise performance is that irrelevant differences may be 
discovered. Small improvements requiring a large study 
population to detect change are unlikely to impress either 
the patient or clinician. Likewise, a treatment that 
benefits symptoms in only one patient in ten is unlikely 
to have a major impact on the management of heart failure. 
Controlled trials are necessary in heart failure as the
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placebo response may be very marked, and this is an 
argument in favour of cross-over study designs, but the 
need for very large studies to demonstrate a change in 
symptoms or exercise performance is ethically and 
economically questionable. Large studies are valuable in 
determining an effect on progression of disease and 
mortality. Double-blind cross-over studies do have 
problems. They may produce carry-over effects from one 
treatment phase to the other, or the patient's underlying 
condition may improve or deteriorate. However, "order" and 
"period" effects were not noted in our studies. The impact 
of patients dropping out of the study in a cross-over study 
design will be much greater as each individual represents 
a higher proportion of the overall study and much more data 
are "lost". In order to reduce the likelihood of 
"drop-outs", treatment phases have to be relatively short, 
though we had a very low drop-out rate with treatment 
periods of up to 2 months, with a total study duration of 
4 months. As with any study design, there are flaws, but 
the use of cross-over studies is best as long as very 
long-term effects are not being studied.
Single-blind studies have also examined the time-course of 
the effect of ACE inhibitors on exercise performance. 
Serial exercise testing has shown a progressive improvement 
in exercise performance, significant differences appearing 
at about 5 weeks and increasing up to at least 3 months.933 
Our studies demonstrating improved exercise performance at
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6-8 weeks are entirely compatible with this. However, it 
was impossible to distinguish whether improved exercise 
tolerance was due to a reduction in fatigue or 
breathlessness, though symptom scores for the patients 
day-to-day experience suggested that breathlessness was 
more improved than fatigue. The application of multiple 
exercise protocols could have been helpful in determining 
if ACE inhibitors had a greater impact on one particular 
limiting symptom during exercise testing.
As discussed in the section on symptoms, what limits 
exercise in patients with heart failure is still largely 
unknown. Therefore, the mechanism by which ACE inhibitors 
improve exercise has not been determined.
It does appear that an additional natriuresis was not the 
cause of improved exercise performance as there was no 
change in total body sodium status at 6-8 weeks' treatment 
with an ACE inhibitor, when exercise performance had 
clearly improved. This was further confirmed by a lack of 
change in the patients' weight.
In the introduction to this thesis, I argued that evidence 
that vasodilator agents improved patients with chronic 
heart failure was lacking. Accordingly, it cannot be 
assumed that ACE inhibitors have brought about benefit due 
to vasodilatation. However, arteriolar dilators reduce 
arterial and renal perfusion pressure which may cause
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sodium retention, possibly, though not necessarily, by 
activating the renin-angiotensin system. Likewise, 
venodilatation may reduce atrial pressures and reduce 
atrial natriuretic peptide, leading to sodium retention. 
Indeed, we have demonstrated this with ACE inhibitors. 
Angiotensin converting enzyme inhibitors cause arteriolar 
and venous dilatation, and early in the course of therapy 
may also reduce sodium excretion. However, by interrupting 
the production of angiotensin II, with all its 
consequences, ACE inhibitors limit the intensity of sodium 
retention and eventually reverse it, restoring the status 
quo. Angiotensin converting enzyme inhibitors may even 
cause a net diuresis if given for long periods of time. It 
is not entirely clear if this is merely an effect of 
aldosterone suppression or a more subtle resetting of the 
sodium "set-point". The combination of vasodilatation and 
inhibition of secondary sodium retention may be what makes 
ACE inhibitors uniquely effective among vasodilator 
agents.
Structural changes in the arterial wall which occur in 
heart failure could also be reversed by ACE inhibitors,934,935 
improving exercise blood flow, while ACE inhibitors prevent 
the rise in angiotensin II seen during exercise and may 
moderate the increase in sympathetic activity. However, the 
effects of ACE inhibitors on skeletal muscle blood flow 
during exercise are controversial. Certainly, increases in 
limb blood flow are not impressive generally.936'939 Some
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authors have suggested that it is only those patients in 
whom exercise limb blood increases that demonstrate an 
increase in exercise performance. However, again the 
problem arises, does an increase in exercise performance 
induce a high limb blood flow or the inverse? Angiotensin 
converting enzyme inhibitors could have improved exercise 
performance by a "training" effect, though the mechanism 
which initiates it is unclear. An improvement in general 
well-being could be a factor. Improvement in central 
haemodynamics may be enough to allow slightly more 
exercise, too small to detect with our techniques, but 
which leads to a positive feedback.
Changes in skeletal muscle metabolism are well described in 
heart failure, which are probably in a large part due to 
"disuse".940 An additional effect may be due to 
under-perfusion, leading to an early intracellular acidosis 
and loss of high energy phosphates.941 Finally, we have 
suggested that a true intracellular deficit of potassium 
exists in heart failure, which could impair skeletal muscle 
performance. Angiotensin converting enzyme inhibitors may 
affect all of these.
Just as all studies have not demonstrated an improvement in 
symptoms with ACE inhibitors, nor have they all 
demonstrated an improvement in exercise performance. Again, 
most notably those studies that specifically looked at 
ischaemic heart disease and heart failure have failed to
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show consistent benefits. In our study of ischaemic heart 
disease and angina, we employed 2 exercise protocols. While 
the longer exercise protocol, which incorporated more 
gradual increases in speed and incline, showed little 
difference with and without an ACE inhibitor, the shorter 
exercise protocol showed a definite reduction in exercise 
tolerance with an ACE inhibitor. It was notable that, with 
the shorter exercise protocol, patients were more likely to 
stop with angina and breathlessness, and that the time to 
angina was reduced with an ACE inhibitor. During the slower 
protocol, patients' exercise performance was essentially 
unaltered, but patients were significant more likely to 
stop due to angina pectoris while taking captopril. It is 
possible that induction of sub- clinical (silent) ischaemia 
may cause a deterioration in ventricular function during 
exercise in some patients with heart failure and coronary 
disease which will offset any improvement in central or 
peripheral haemodynamic or metabolic effects of the ACE 
inhibitor.
Although one might expect to see improvements in exercise 
performance in conjunction with a reduction in symptoms, 
the two need not necessarily go together. Most patients 
rarely exert themselves above 70% of their maximal 
capability during daily activity. The patient with heart 
failure may well restrict his activity such that 
breathlessness is never really a problem, though he is 
aware that his capacity for exercise is reduced. A maximal
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exercise test, especially when used in conjunction with 
respiratory gas exchange, is not only useful in determining 
the patient's maximal effort capacity but also in 
estimating the "anaerobic threshold". Such measurements 
give a guide to the level of exercise at which the patient 
may comfortably exercise for longer periods. Exercise 
protocols which involve much slower increases in speed and 
gradient probably more nearly represent the patient's 
normal daily activity.
It should be emphasized that the exercise test used in 
these studies was a graded treadmill exercise test. 
Although exercise performance increased only by a minute or 
two, this probably obscures a more important improvement 
as, for the majority of patients, this meant increasing the 
exercise workload by one stage. On a linear scale, this 
would represent a more substantial improvement in exercise 
time.
All exercise protocols involve both subjective and 
objective components. Other investigators have used tests 
such as the 6-minute walking test (the maximal distance a 
patient can walk in a straight line in 6 minutes) , and 
tests which rely on the patient walking a fixed distance.942 
These are very useful when sufficient uncrowded space is 
available, as it is a more natural form of exercise than 
treadmill or bicycle exercise. Many patients have great 
difficulty in co-ordinating their activity during treadmill
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exercise, in which case fixed time or distance tests may be 
the only ones possible. However, space and the requirement 
for physiological monitoring render treadmill exercise 
preferable in many cases, Bicycle exercise has advantages 
over the use of the treadmill as the patient's head and 
body are held relatively still. This may again be helpful 
during physiological monitoring. Also, the patient's weight 
is supported by the saddle during bicycle exercise, perhaps 
reducing differences between patients of different body 
mass. However, a relatively small muscle group is 
exercised, (British) patients are unfamiliar with this sort 
of exercise, calf fatigue is a more frequent limiting 
symptom, and maximum oxygen consumption and the likelihood 
of passing the "anaerobic" threshold are less than with 
treadmill exercise. These various exercise protocols and 
modes of exercise should be considered complementary, 
giving different sorts of information, rather than 
information which is either worse or better.
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CHAPTER 29: ARRHYTHMIAS, HEART FAILURE AND ACE INHIBITORS
INTRODUCTION
The diagnosis of heart failure has long been known to carry 
a poor prognosis, but the symptoms of heart failure due to 
valvular disease are now eminently treatable, and the 
prognosis can be improved by intervention. To date, medical 
treatment of heart failure primarily due to myocardial 
failure has been less successful, indicating that accurate 
diagnosis is necessary for prediction of outcome.
Recent studies and new treatments aimed at reducing 
morbidity in patients with heart failure have once again 
highlighted the appalling mortality associated with this 
condition. There are 3 questions central to the discussion 
of prognosis in heart failure. Firstly, is it right to 
prolong life in patients with heart failure? It could be 
considered that when a patient's symptoms had become of 
sufficient severity that he may wish to be allowed to die 
with as little suffering as possible. If there is no 
effective remedy for the patient's symptoms, it could be 
argued that it may be "unkind" to prolong his life. 
Secondly, can we predict those at greatest risk? Thirdly, 
is there any treatment that will influence prognosis? 
Effective therapy for symptoms of heart failure could 
reduce life expectancy or extend it. Therapy other than 
that required to improve symptoms may be needed to improve 
prognosis.
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SURVIVAL IN HEART FAILURE: THE MODE OF DEATH
In our study of heart failure, we found that 75% of 
patients died suddenly. This is a greater proportion than 
reported in other studies but probably represents 
differences in the mode of reporting.943 It should be noted 
that a quarter of the patients in the present study showed 
progressive deterioration in their heart failure prior to 
dying suddenly. In many studies of cardiac failure these 
patients would have been classified as dying of progressive 
cardiac failure. However, none of them had acute pulmonary 
oedema immediately prior to death, nor were they noted to 
be hypotensive for prolonged periods resulting in organ 
failure. They had required increased treatment to control 
their symptoms but their final demise was sudden. If the 
majority of patients die suddenly before reaching 
"end-stage" heart failure then treatment for prognostic 
reasons alone is worthwhile.
There is little information on the exact cause of sudden 
death in patients with heart failure. In patients 
incidentally undergoing ambulatory ECG monitoring, not 
necessarily with cardiac failure, the common mode of sudden 
death has been ventricular tachycardia followed by 
ventricular fibrillation.944 In 2 patients who were admitted 
due to deterioration in their cardiac failure, death 
occurred during ECG monitoring in our study. Ventricular 
tachycardia degenerating into ventricular fibrillation was
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noted in both cases. Ischaemic heart disease was common in 
our patients, the risk of death due to sudden deterioration 
in myocardial function due to myocardial ischaemia or 
infarction, or due to a pulmonary embolus or a 
cerebrovascular event, must be relatively high. Indeed, a 
cardiovascular thromboembolic event was the second most 
common cause of death in our series. However, the evidence 
that anti- coagulants alter the incidence of embolic events 
or overall outcome in heart failure is controversial.945,946 
However, the very low incidence of death due to intractable 
heart failure should be noted. It is true that we have 
taken a very rigid definition of death due to heart failure 
but as this is readily documented, and with adequate 
guidelines should be reproducible from centre to centre, we 
strongly advocate that other researchers adopt this 
definition of heart failure death. With the advent of 
combined thiazide and loop diuretics, and angiotensin 
converting enzyme inhibitors, death due to intractable 
heart failure has become uncommon in my experience. The 
commonest mode of death in most studies of heart failure is 
that of sudden death. This is in contrast with the results 
of the CONSENSUS study from the Scandinavian countries 
where the majority of patients died from progressive heart 
failure. However, they chose a group of patient with very 
severe heart failure and they may well therefore be a 
self-selected group, very resistant to arrhythmias, 
producing an abnormal bias towards death due to severe 
heart failure. Alternatively, as they chose a group of
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patients who were already completely immobilised by their 
heart failure, death may have been ascribed to their heart 
failure, even though the terminal event was sudden. It is 
much easier to document the mode of death in patients with 
milder degrees of cardiac failure where symptoms have been 
controlled initially. An important feature of the CONSENSUS 
study was the improvement in functional status as well as 
in survival. This dual benefit argues strongly that it is 
right to apply this treatment to patients with severe heart 
failure.
A report from the Captopril Multi-Centre Research Group has 
suggested that ACE inhibitors reduce mortality in 
moderately severe heart failure primarily by reducing the 
incidence of sudden death.
PROGNOSIS IN CARDIAC FAILURE
The prognosis of cardiac failure is related to the severity 
of symptoms. Our group of patients with moderately severe 
heart failure had a 41% mortality after a mean follow-up 
time of 21 months. Adjusting for the length of follow-up, 
this gives us approximately a one-year survival of 70% and 
2-year survival of 50%. This is in keeping with other 
studies of patients with similar degrees of heart failure, 
but notably worse than in a series reporting cases of 
milder heart failure.947
322
FACTORS PREDICTING PROGNOSIS IN CARDIAC FAILURE
In order of importance, the frequency of ventricular 
extra-systoles, non-treatment with amiodarone, low mean 
arterial pressure, and a diagnosis of coronary artery 
disease, were associated with a poor prognosis, with each 
of these variables proving extra-predictive information 
independently of the others. Initial serum potassium 
concentration and treadmill exercise time also carried 
further weak but independent prognostic information.
Several other recent studies in populations of patients 
with heart failure with varying diagnoses have recorded 
conflicting results regarding the most reliable independent 
indicators of prognosis.948'950 Some suggest that ventricular 
arrhythmias are the most powerful independent 
indicators948,951'952 but others have not confirmed this.950,953'954 
It may be that ventricular arrhythmias merely reflect the 
extent of left ventricular dysfunction.943,950'951,955 These 
different views may be a reflection of different study 
populations with arrhythmias and heart failure caused by 
idiopathic cardiomyopathy showing a good relation with the 
extent of left ventricular dysfunction in some studies956 but 
not in others.950 In patients with ischaemic heart disease 
and left ventricular dysfunction, arrhythmias seem poorly 
related to the extent of dysfunction.943,952 Some studies 
suggest that indices of cardiac function and severity of 
symptoms are helpful in predicting the prognosis of
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patients with heart failure.946,954,957 Left bundle branch 
block,951,958 serum sodium concentration,949,959 mean arterial 
pressure,957 exercise performance,960 and central venous 
plasma noradrenaline concentrations949 have also been found 
to be useful in some studies. But for each of these indices 
there are other studies which have not found any predictive 
value for these variables.961*963
The present study clearly demonstrated the frequency of 
ventricular extra-systoles is strongly associated with a 
poor prognosis in patients with chronic heart failure 
caused by left ventricular dysfunction. That death is due 
to ventricular arrhythmias cannot be proved in a study like 
this one but the high frequency of sudden death and low 
frequency of death caused by intractable heart failure 
suggests that the great majority of deaths in such patients 
are a result of arrhythmias. The lack of a significant 
relation between more complex ventricular arrhythmias and 
mortality may reflect the relatively short period over 
which the electrocardiogram was recorded. A more protracted 
period of monitoring may have shown the true frequency of 
complex arrhythmias.
The present study suggests that arrhythmias are more 
closely related to functional class and exercise 
performance than to indices of resting left ventricular 
performance. Severe ventricular dysfunction was present in 
the majority of patients in the present study. The lack of
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a wide spectrum of cardiac dysfunction would make it 
difficult to find a relationship with arrhythmias.
Lack of a relationship between prognosis and M-mode 
echocardiographic measurements of left ventricular function 
should be interpreted with caution also, especially when 
comparing different subjects with ventricles that have been 
damaged by ischaemia. Several studies which have monitored 
resting haemodynamics invasively also suggest a poor 
relationship between mechanical dysfunction and prognosis.946 
A relatively poor relationship between exercise performance 
and left, but perhaps not right, ventricular haemodynamic 
function, has also been documented.964,965 The relationship 
between exercise performance and prognosis may suggest that 
it is a better overall index of cardiac performance.960
Those patients treated with amiodarone appeared to have a 
better prognosis. The baseline characteristics of those 
receiving amiodarone differed little from those who did not 
and significant differences remained in the survival 
curves, even after correction for confounding variables. 
Amiodarone appeared to have a particularly strong effect in 
reducing sudden death, and it is likely that it exerts its 
beneficial effect through its anti- arrhythmic action. 
However, amiodarone also has anti- ischaemic effects and it 
is possible that a reduction of ischaemia-induced 
arrhythmias occurred.966,967 This may have implications, not 
only for those patients with coronary atherosclerosis but
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also in patients with congestive cardiomyopathy who may 
have had sub- endocardial ischaemia without epicardial 
coronary artery obstruction.968
A low mean arterial pressure was also found to be of 
prognostic significance, as has been noted by others.957 
Plasma renin and catecholamines are known to be inversely 
related to blood pressure in heart failure,969 and recent 
studies have suggested that concentrations of plasma 
noradrenaline and plasma renin are of prognostic 
significance in heart failure.9490ur study also demonstrates 
the inverse relationship between blood pressure and serum 
sodium, as would be expected in patients with high 
concentrations of plasma renin and noradrenaline. Low blood 
pressure appears also be a marker of clinically more severe 
heart failure because it is associated with a worse New 
York Heart Association score and poorer exercise 
performance.
Patients with coronary artery disease had a poorer 
prognosis than other diagnostic groups, as in some but not 
all other studies.970 The poorer prognosis appears related 
to sudden death rather than re-infarction. Transient focal 
ischaemia may have caused arrhythmias, even though angina 
was not a feature of this study group. The shorter duration 
of symptoms prior to inclusion in the study, lower mean 
blood pressure, and lower incidence of arrhythmias in those 
with coronary artery disease, should also be noted.
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The effect of vasodilator agents on prognosis remains 
controversial, while angiotensin converting enzyme 
inhibitors appear to have beneficial effects on 
prognosis.972,974*975 However, we were unable to demonstrate any 
effect on overall prognosis associated with the use of 
either digoxin or angiotensin converting enzyme inhibitors, 
nor did the dose of diuretic exert any powerful effect. The 
group treated with ACE inhibitors had worse heart failure 
however and the statistical analysis may not have 
compensated for this difference. Certainly, no 
deterioration in prognosis was noted as in some trials of 
inotropic agents in patients with heart failure. In our 
study, the incidence of sudden death was significantly 
reduced in those on ACE inhibitors; this may have been 
attributable to the correction of hypokalaemia and 
hypomagnesaemia and intracellular potassium depletion, 
beneficial haemodynamic effects, and a reduction in 
sympathetic nervous activity.976,977 The statistically 
insignificant increase in the frequency of vascular events 
suggests that ACE inhibitors should be used with caution in 
patients with known critical arterial stenoses. Potential 
deleterious effects of digoxin and higher doses of 
diuretics may have been masked by the use of amiodarone and 
captopril.
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THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON 
ARRHYTHMIAS
We have demonstrated in 3 studies that there were 
reductions in both simple and complex ventricular 
arrhythmias during treatment with ACE inhibitors in 
patients with heart failure. This effect does not really 
constitute an "anti-arrhythmic" effect as the reductions 
were only of the order of 20-40%. This reduction in cardiac 
arrhythmias has also been noted by others.976
Published animal experimental work is confined to the 
post-infarction state where experiments in the rat and pig 
have demonstrated a reduction in re-perfusion arrhythmias. 
979,980 However, these effects may not be related to 
converting enzyme inhibition. There is some evidence that 
effects differ between ACE inhibitors and also that 
prostaglandin metabolism may be important in mediating 
these effects.979 Captopril, by virtue of its sulphydryl 
group, may have other effects. The ability of this part of 
the molecule to act as a proton donor may help to maintain 
glutathione in the reduced state.979 This could lead in turn 
to increased production of endothelium-derived relaxant 
factor and a reduction in free radical damage. However, the 
doses of drug given in animal experiments were often many 
times those that would be administered to man.
Hypokalaemia was more closely related to the frequency of 
ventricular extrasystoles than has been previously
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suggested. Though a causal relationship cannot be 
confirmed, the association may have been increased by the 
use of digoxin since hypokalaemia may enhance digoxin 
binding. In contrast, we were unable to demonstrate an 
effect of therapeutic concentrations of digoxin on the 
frequency of arrhythmia, perhaps because of wide 
inter-individual susceptibility or to a counter- balancing 
of an improvement in left ventricular function.
The foregoing studies do suggest that ACE inhibitors can 
alter the QTc interval. As indicated above, it is 
unnecessary to invoke a primary anti-arrhythmic effect of 
ACE inhibitors. Angiotensin converting enzyme inhibitors 
reduce cardiac volumes, cardiac sympathetic activity and 
angiotensin II, while improving the metabolic profile of 
the patient and cardiac parasympathetic control. It would 
be surprising if this constellation of effects did not 
improve arrhythmias. However, it is not clear which factor, 
if any, is most important, and may vary from patient to 
patient. As arrhythmias were also reduced in patients with 
clear evidence of reversible ischaemia and heart failure 
despite evidence that ischaemia was not improved, it does 
suggest that ACE inhibitors do not exert their beneficial 
effect on arrhythmias by preventing focal ischaemia. It is 
still possible that ACE inhibitors may improve myocardial 
perfusion in a more subtle fashion.
The demonstration of improvement in "simple" arrhythmias is
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not sufficient. Evidence of a reduction in malignant 
arrhythmias such as sustained ventricular tachycardia and 
the incidence of sudden death is required before 
anti-arrhythmic action can be deemed clinically useful. It 
is possible that on-going studies into the effects of ACE 
inhibitors will clarify the importance of this reduction in 
arrhythmias.
THE EFFECT OF TREATMENT ON PROGNOSIS
As we have noted above, the CONSENSUS study demonstrated a 
reduction in death due to progressive heart failure. This 
is an important finding but I have argued that it may not 
be relevant to the majority of patients with heart failure. 
The reasons why ACE inhibitors retard the progress of heart 
failure is unclear. Simple reduction in preload and 
afterload could reduce cardiac volumes and improve cardiac 
function. Alternatively, levels of angiotensin II 
sufficient to cause myocyte necrosis in animal experiments 
may be found in patients with heart failure.981 Reduction of 
the direct toxic effects of angiotensin II on myocytes 
could preserve cardiac function. We have also noted very 
high circulating levels of noradrenaline in some patients 
which could potentiate myocyte damage also.982,983 Beneficial 
effects of ACE inhibitors on free radical- mediated damage 
and on the intercellular matrix are also theoretically 
possible.984 Therefore, there are good reasons why ACE 
inhibitors could retard progression of heart failure. In 
patients with less severe heart failure, the Captopril
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Multi-Centre study reported retrospectively a reduction in 
sudden death.985 Though this requires confirmation it does 
imply that therapy to improve symptoms in patients with 
moderate heart failure may also favourably affect 
prognosis. Sudden death could be prevented by favourable 
effects of ACE inhibitors on arrhythmias or preservation of 
myocardial blood flow. Preservation of cardiac function is 
likely to be important also. The present study suggests 
that amiodarone may specifically reduce the incidence of 
sudden death. Though this awaits confirmation, it does 
suggest that arrhythmias may be an important cause of 
sudden death.
In contrast, class I anti-arrhythmic agents appear to be 
contra-indicated in patients with heart failure. A 
retrospective study of procainamide failed to show any 
benefit. The CAST study incorporated many patients who had 
evidence of heart failure and ventricular ectopy.986 Patients 
receiving active therapy had a worse outcome than those 
receiving placebo. Class I anti-arrhythmic agents appear to 
suppress arrhythmia less effectively in the presence of 
severe left ventricular dysfunction and have more 
pro-arrhythmic effects.987,988 Class I anti- arrhythmic agents 
also have deleterious haemodynamic effects.
Agents such as beta-blockers and verapamil also have 
negative inotropic effects and are generally unsuitable in 
patients with heart failure, although there is conflicting
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evidence of benefit with beta-blockers.
Agents that alter beta-adrenergic tone, such as xamoterol, 
also have the potential to adversely affect prognosis, at 
least in patients with severe heart failure. Though 
xamoterol may improve heart function in milder heart 
failure, in patients with severe heart failure and very 
high levels of sympathetic activity a decline in 
ventricular function may be observed.
Though diuretics have been implicated in the neuroendocrine 
and metabolic disturbance associated with heart failure, 
there is no direct evidence linking them to a worse 
prognosis. Obviously, in patients with acute pulmonary 
oedema they may be life-saving, while in the patient who is 
over-treated they are going to be deleterious. However, as 
patients with worse heart failure will require more 
diuretic and have a worse prognosis, it is difficult to 
implicate directly diuretic therapy in the prognosis of 
heart failure.
The advent of implantable defibrillators has given a 
further mode of arrhythmia treatment in patients with heart 
failure. Preliminary evidence does suggest that in patients 
with poor ventricular function and a high incidence of 
ventricular arrhythmia such devices may improve prognosis.989 
This implies that control of arrhythmias is important but 
that proper selection of the patients and the therapeutic
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agent is required. The criteria for such selection remain 
to be established.
SUMMARY
Angiotensin-converting enzyme inhibitors have a beneficial 
effect on survival in patients with heart failure, which is 
probably partly due to a reduction in sudden death. This is 
in contrast to class I anti- arrhythmic agents which have 
more potent anti-arrhythmic effects but depression cardiac 
function. However, improving cardiac function alone may not 
be protective, as increased mortality due to inotropic 
therapy has been reported. Beneficial effects on 
arrhythmias, albeit small, associated with improved cardiac 
function, improved autonomic control and correction of 
potassium depletion, are all likely to play a role in the 
observed benefit with angiotensin converting enzyme 
inhibitors.
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CHAPTER 30: ACE INHIBITORS IN ISCHAEMIC HEART DISEASE
It has been established beyond reasonable doubt over the 
last 6 years that ACE inhibitors improve symptoms, exercise 
performance and haemodynamics in patients with moderate or 
severe heart failure. The CONSENSUS study demonstrated that 
ACE inhibitors could not only reduce mortality in patients 
with very severe heart failure but also retard or prevent 
progression of the condition. Some have argued that if ACE 
inhibitors prevent progression of heart failure in severe 
cases then it may also do this in cases of mild heart 
failure. This has generated much speculation over a role 
for ACE inhibitors in mild heart failure or asymptomatic 
left ventricular dysfunction. An increasing number of these 
are likely to have angina pectoris as the dominant symptom.
What then is the role of ACE inhibitors in the management 
of ischaemic heart disease? The answer is distinctly 
beneficial for some syndromes, ineffective for others, and 
possibly harmful for some.
The role of ACE inhibitors in ischaemic heart disease may 
be considered under the following headings:
1) Chronic heart failure
2) Stable angina
3) Unstable angina
4) Acute myocardial infarction
5) Cardiogenic shock
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CHRONIC HEART FAILURE
The majority of patients included in studies of chronic 
heart failure have coronary artery disease as the basis for 
their myocardial dysfunction. It is therefore highly 
probable that the majority of patients with heart failure 
due to ischaemic heart disease benefit from ACE inhibitors. 
However, not all studies show benefit with ACE inhibitors 
in heart failure, and it may be that some patients, 
possibly those with additional reversible ischaemia due to 
epicardial artery disease, fail to improve.
ANGINA
Daly first demonstrated an anti-anginal effect of ACE 
inhibitors in a study using single doses of captopril in 
patients with high blood pressure and angina.990 A further 
recent study has also suggested an anti-anginal effect of 
captopril in patients with angina and hypertension after 
medium- to long-term therapy.991 However, a series of studies 
investigating the possible anti-anginal effects of ACE 
inhibitors in patients with angina but without marked 
hypertension failed to show any difference from 
placebo.992*995 The present study, comparing placebo and 
captopril in patients with heart failure and angina treated 
with diuretics, suggested that captopril may actually 
exacerbate the symptoms of angina and increase nitrate 
consumption. Exercise performance was reduced in this
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study, thus increased mobility did not account for the 
deterioration in symptoms.
How then do we account for the disparity of the effect of 
ACE inhibitors in these 3 groups of patients? 
Theoretically, ACE inhibitors could alter anginal symptoms 
in a number of ways.
Potential Effects on Myocardial Oxygen Demand 
In patients with heart failure, ACE inhibitors reduce the 
resting heart rate but they have no marked effect on 
exercise heart rate. Therefore, they are unlikely to alter 
the ischaemic threshold by this mechanism.
A reduction in afterload could also reduce myocardial 
oxygen consumption by lowering the systolic wall tension 
and therefore stroke work and cardiac efficiency. 
Potentially, patients with hypertension have most to gain 
by this mechanism, though patients with heart failure and 
an elevated systemic vascular resistance could also 
benefit.
A decrease in preload may decrease myocardial oxygen demand 
by decreasing diastolic wall tension. Importantly, in the 
dilated ventricle, even in the absence of obstructive 
epicardial coronary artery disease, an increase in preload 
may cause subendocardial ischaemia. It is well known that
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the balance between myocardial oxygen supply and demand is 
precarious in the failing heart. I have demonstrated that 
captopril and enalapril can reduce ventricular dimensions 
in patients with heart failure and that this is accompanied 
by a decrease in preload.
Myocardial oxygen consumption could also be reduced by 
reducing myocardial contractility. An anti-ischaemic effect 
of ACE inhibitors by this mechanism is not generally 
recognised and, indeed, might be considered unfortunate by 
some. However, angiotension II does have positive inotropic 
effects, though these are largely obscured by the 
concomitant increase in afterload as a result of arterial 
constriction. Angiotensin converting enzyme inhibitors, by 
reducing angiotensin II levels, could have a mild negative 
inotropic effect. There is a further mechanism by which ACE 
inhibitors could reduce the inotropic state of the 
ventricle. It has been demonstrated both in patients with 
heart failure and hypertension that ACE inhibitors can 
reduce the concentration of noradrenaline in the coronary 
sinus, suggesting that ACE inhibitors reduce cardiac 
sympathetic activity.998
There are multiple reasons why ACE inhibitors can and 
probably do reduce myocardial oxygen demand. However, in 
the present study angina frequency and GTN consumption 
increased. This was not due to an increase in patient 
activity as the maximal achieved oxygen consumption and
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exercise performance deteriorated, with angina more 
frequently limiting exercise during the "slow" test.
Myocardial Oxygen Supply
Angiotensin II, anti-diuretic hormone, and increased 
sympathetic activity may increase coronary artery tone in 
heart failure.996 Angiotensin converting enzyme inhibitors 
have been infused into the coronary artery and this results 
in coronary vasodilatation and an increase in coronary 
blood flow.997'1002 However, in studies where ACE inhibitors 
have been administered systemically, the fall in coronary 
vascular resistance is counter-balanced by a reduction in 
perfussion pressure, resulting in little change in coronary 
blood flow. Most of these studies have been conducted in 
the supine position. As it is likely that coronary 
perfusion pressure falls in the upright position, coronary 
blood flow may also fall. However, the effect of ACE 
inhibitors on coronary blood flow are even more complex. 
Angiotensin converting enzyme inhibitors reduce cardiac 
sympathetic activity which could reduce coronary artery 
tone. Coronary blood flow is closely matched to myocardial 
oxygen requirements leading to auto-regulatory changes in 
coronary tone. A reduction in afterload and preload could 
then lead to an appropriate fall which is economically 
desirable. Angiotensin II also appears to have differential 
effects upon large and small coronary arteries, the 
constrictor effect being sustained on the large conductance 
vessels but undergoing tachyphylaxis in the small distal
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vessels and perhaps the coronary collateral supply. This is 
the converse of the effect of nitrates. 1003,1004 Suppression of 
angiotensin II in this situation could cause a coronary 
"steal" effect.
It should always be remembered that angina is rarely a 
problem of global myocardial oxygen supply and that focal 
ischaemia is the rule rather than the exception.
Clinical Studies of Angina and ACE Inhibitors 
There are now many studies investigating the effects of ACE 
inhibitors in angina. In general, those studies which have 
reported the effects on exercise-induced angina or 
pacing-induced angina in the supine position, usually with 
single doses of an ACE inhibitor, have reported some 
improvement. 1004,1005 There are now 6 studies which have 
investigated the effect of multiple dose ACE inhibitors on 
exercise-induced angina in the upright position. In 4 
studies, patients with angina as the sole complaint were 
studied, and none of these studies demonstrated significant 
benefit with an ACE inhibitor.992'995 One study in patients 
with hypertension and angina has suggested significant 
improvement.991 The present study in patients with angina and 
heart failure has suggested a significant deterioration in 
angina. At first sight it may be difficult to reconcile the 
differences but the key is probably the effects on coronary 
perfusion pressure. In hypertensive patients, a reduction 
in cardiac loading conditions may reduce myocardial oxygen
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requirements without an undue reduction in coronary 
perfusion pressure. In normotensive subjects with angina 
the effects of reducing coronary perfusion pressure are 
probably balanced by the reduction in myocardial oxygen 
demand. In heart failure, the marked reduction in coronary 
perfusion pressure with the combination of diuretics and 
ACE inhibitors, may lead to deterioration. This is 
especially likely to occur if coronary stenosis is present 
in an artery supplying myocardium with a relatively normal 
function.
UNSTABLE ANGINA
I am unaware of formal studies in this field and would 
recommend caution. The patient with hypertension and 
unstable angina would be most likely to benefit both 
theoretically and on the scanty evidence available.
ACUTE MYOCARDIAL INFARCTION
Myocardial infarction leads to an acute activation of the 
sympathetic nervous system, the renin-angiotensin system, 
and anti-diuretic hormone. In patients sustaining a large 
myocardial infarction sustained increases are seen.
Animal work in this area has suggested that ACE inhibitors 
may reduce myocardial damage occurring as a result of 
coronary artery occlusion and re- perfusion. 1006'1009 Apart
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from the reduction in myocardial oxygen demand due to 
altered loading conditions, there are 4 proposed beneficial 
mechanisms. Firstly, ACE inhibitors in general may reduce 
cardiac sympathetic overflow which could be protective. 
However, captopril, by virtue of its sulphydryl group, 
could have additional protective effects. The attached 
sulphydryl group may scavenge free radicals which are felt 
to cause myocardial damage at the time of re- perfusion. 
The sulphydryl group may also maintain or enhance the 
production of endothelial-dependent relaxing factor. 
Angiotensin converting enzyme inhibitors could also have a 
role in preventing coronary stenosis occurring at the site 
of plaque rupture by preventing smooth muscle 
proliferation. Angiotensin converting enzyme inhibitors may 
also cause accumulation of bradykinin by inhibiting its 
catabolism, which in turn may have cardio-protective 
effects.
Initial animal work has indicated beneficial effects of ACE 
inhibitors, in particular, captopril, on post- infarction 
myocardial dysfunction and mortality. Human studies have 
been conducted in patients with acute myocardial infarction 
to determine if captopril could reduce the severity of 
re-perfusion damage when used in conjunction with 
thrombolytic therapy.1010 In some centres this was associated 
with worrying hypotension. However, these initial studies 
used relatively high doses of intravenous captopril. 
McAlpine et al used smaller oral doses of captopril (3.125
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mg titrated up over a period of hours to 12.5 mg)1011 This 
resulted in beneficial haemodynamic effects and a 
significant suppression of angiotensin II, even with the 
smallest dose of captopril. Severe hypotension did not 
occur. Another study (Di Pasquale - personal communication) 
demonstrated that captopril could reduce the frequency of 
complex ventricular arrhythmias after myocardial 
infarction. Others have suggested that an acute reduction 
in plasma noradrenaline may indicate a beneficial effect of 
ACE inhibitors as the concentration of noradrenaline in 
plasma has been related to prognosis after myocardial 
infarction.
Longer-term controlled studies have initiated ACE 
inhibitors some days or weeks after myocardial infarction. 
These have generally shown a small but significant 
reduction in cardiac volume. It is still unclear whether 
this represents purely a haemodynamic effect of continued 
ACE inhibition or genuine ventricular remodelling. Studies 
are awaited to determine if the effects on ventricular 
function can still be seen one or more months after 
withdrawal of the ACE inhibitor. More recently, Lamas and 
co-workers1013 have demonstrated that in patients who had a 
moderately severe myocardial infarction, exercise tolerance 
deteriorates in the post-infarction period. In a 
double-blind placebo-controlled study, they demonstrated 
that this could be prevented by introduction of captopril. 
While changes in ventricular volumes are of interest to the
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cardiologist, this latter aspect may have more relevance 
for the patient. However, it is far too early to generally 
recommend ACE inhibitors in the immediate post-infarction 
period or, indeed, for asymptomatic ventricular 
dysfunction. The outcome of large, multi-centre controlled 
studies such as SOLVD (Study on Left Ventricular 
Dysfunction) and SAVE (Survival and Ventricular 
Enlargement) may give us more information on how important 
this aspect of therapy is.
Animal experimental work has demonstrated that ACE 
inhibitors can reduce the severity and duration of 
ventricular arrhythmias during coronary re-perfusion.1006 
Again, there is a suggestion that there may be differences 
between ACE inhibitors, with an additional role for the 
sulphydryl group. However, other studies comparing ramipril 
and captopril in rats have suggested a reduction in 
ventricular fibrillation only with the former. Perhaps the 
differences occurred only by chance. Perhaps it is 
suggested that animal models of myocardial infarction are 
highly. operator- dependent.1014
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CARDIOGENIC SHOCK
Lipkin reported 3 patients suffering from cardiogenic shock 
who were subsequently administered captopril.1015 
Administration of captopril, starting at a dose of 1 mg and 
gradually increasing to 6.25 mg, resulted in a favourable 
haemodynamic response, with a fall in left ventricular 
filling pressures, a rise in cardiac output and urine flow, 
with the maintenance of arterial pressure. Although these 
preliminary results are optimistic, wider experience is 
required before the use of ACE inhibitors can be generally 
recommended in this condition. It is imperative that left 
ventricular filling pressures are documented for proper 
management of these patients. Only those with a marked 
elevation in left ventricular filling pressure are likely 
to benefit from an ACE inhibitor.
CONCLUSIONS
The ideal anti-anginal agent with which to treat patients 
with heart failure and angina is yet to be discovered. 
Amiodarone, diltiazem, nicardipine, xamoterol, and nitrates 
all have their advocates. Calcium antagonists and 
converting enzyme inhibitors often produce marked 
hypotension when used in combination in patients with heart 
failure and are to be used with great caution. Xamoterol 
may be very useful as long as the heart failure is not too 
severe. Amiodarone, by reducing the frequency of 
ventricular arrhythmias and its marked anti-anginal
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potency, must be considered one of the best drugs in this 
situation. In moderate doses, side-effects, even over 
prolonged periods of time, are few. Nitrates may be useful 
but tolerance is a problem, even in the patient with heart 
failure.
When contemplating the use of ACE inhibitors in ischaemic 
heart disease the first problem is to define the question 
more precisely. Many treatments for myocardial infarction 
are inappropriate for the management of angina, and many 
treatments for angina are inappropriate for heart failure. 
There is little doubt that ACE inhibitors have had a major 
beneficial impact upon heart failure induced by coronary 
artery disease. The treatment of acute myocardial 
infarction with ACE inhibitors is a current area of 
research but cannot be recommended clinically yet. For 
patients with angina, ACE inhibitors do seem to have some 
beneficial effects in hypertensive patients but they do not 
appear to reduce the severity of angina in normotensive 
patients or patients with heart failure. However, the 
patient with heart failure and angina may still benefit 
from the introduction of an ACE inhibitor. The present 
study suggests that the frequency of ventricular 
arrhythmias may be reduced and there is always the 
possibility, still theoretical, that progressive 
ventricular dysfunction may be ameliorated.
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CHAPTER 31S CONCLUSION
The idea of vasodilator therapy for heart failure has been 
toyed with for almost one hundred years, possibly more. The 
results were largely disappointing, either because 
tolerance occurred to the vasodilator actions of the drugs, 
or because vasodilatation is an ineffective mode of 
treatment for chronic heart failure. This all appeared to 
change with the discovery that angiotensin converting 
enzyme inhibitors were effective in the treatment of 
chronic heart failure, or so it might seem.
However, activation of the renin-angiotensin system in 
heart failure indicates not only a haemodynamic disturbance 
but also profound metabolic disturbances throughout the 
body. Moreover, the renin-angiotensin system has secondary 
effects on the sympathetic and parasympathetic nervous 
systems that may have consequences not only for vascular 
resistance and cardiac function but also heart rhythm 
control.
Angiotensin converting enzyme inhibitors are able to 
reverse or ameliorate many of the endocrine, neural and 
metabolic consequences associated with renin-angiotensin 
system activation in heart failure and improve prognosis. 
It is likely that these effects make a significant 
contribution to the benefits of angiotensin converting 
enzyme inhibition. Indeed, as drugs with more profound 
haemodynamic effects have made little impact in the 
management of heart failure, the metabolic effects may be 
of greater importance.
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